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Abstract 
The  main  aim  of  this  research  was  to  explore  the  potential  of  the  isothermal 
microcalorimeter  to  detect  bacteria  in  mixed  cultures;  applied  to  investigate  the 
antagonistic effect of commercial probiotics against pathogens and each other; and also 
the prebiotic potential of a substrate. Gastric tolerance of commercial probiotic products 
was also investigated with an improvement on current methods.  
An initial mixed culture study with Pseudomonas aeruginosa, Staphylococcus aureus 
and Escherichia coli in the microcalorimeter showed that the microcalorimeter could 
detect their growth in mixed cultures;  S. aureus was always outcompeted in growth. 
Antagonistic  activity  of  probiotic  strains,  Lactobacillus  acidophilus,  Bifidobacterium 
lactis, Bifidobacterium bifidum or commercial probiotic products against P. aeruginosa, 
E. coli, S. aureus and the clinically important gut pathogen, Clostridium difficile was 
demonstrated  in  the  microcalorimeter  and  was  shown  to  be  pH-dependent  using 
neutralized and unmodified cell free culture supernatant (CFS) produced by the probiotic 
strains. But concentrated CFS of the probiotics also inhibited the pathogenic species in a 
non  pH-dependent  manner,  likely  due  to  specific  antimicrobial  substances  or 
bacteriocins. The result also demonstrated that probiotic strains could compete with each 
other in growth when put together. The prebiotic potential of inulin was demonstrated 
with  the  microcalorimeter  using  faecal  slurry  and  pure  probiotic  strains.  Gastric 
tolerance assay of commercial probiotic products in porcine gastric fluid, SGF (acidified 
NaCl solution) and FaSSGF (acidified NaCl solution with biorelevant amounts of bile 
salt,  pepsin  and  lecithin)  mimicking  the  fed  and  fasted  states  showed  significant 
differences between the products and fluids.  
In conclusion, the research showed that the microcalorimeter is a useful in vitro tool for 
detecting bacterial growth in mixed cultures and studying functional characteristics of 
probiotics  and  prebiotics;  overcoming  some  of  the  limitations  of  the  conventional 
methods.  
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Chapter 1 Introduction 
1.1 Overview 
Probiotics are bacteria related to those found naturally in the human gut. It is claimed 
that ingesting probiotics could have beneficial effects in several biomedical conditions: 
diarrhoea,  constipation,  colitis,  flatulence,  gastroenteritis,  gastric  acidity, 
immunostimulation,  hypercholesterolemia,  hepatic  encephalopathy  and  carcinogenesis 
(Gibson and Roberfroid, 1995). The belief that these positive effects of probiotics can be 
attained is based on the knowledge of beneficial effects of intestinal microbiota (Fuller, 
1991). The mechanism by which their beneficial effects could be achieved has been 
proposed to include production of antimicrobial substances, competition for adhesion 
receptors, competition for nutrients and stimulation of immunity (Fuller, 1991, O'Toole 
and Cooney, 2008, Bermudez-Brito et al., 2012). 
There  is  a  large  market  for  probiotics  worldwide.  In  Western  Europe  alone,  the 
consumer market for probiotic food is more than 1.4 billion euros (Saxelin, 2008). A 
global sale of probiotics amounted to $24.23 billion in 2011 and has been forecasted to 
rise steadily (Pedretti, 2013). The commercial growth of probiotics is largely attributed 
to their claimed health benefits.  
To  have  a  potential  health  benefit  in  a  host,  probiotics  require  certain  functional 
characteristics apart from satisfying safety and technological characteristics (Sanders and 
Huis  in't  Veld,  1999,  FAO/WHO  2001,  Kailasapathy  and  Chin,  2000,  Iannitti  and 
Palmieri, 2010). The functional characteristics  required include their adhesion to gut 
cells, ability to modulate immune responses and production of antimicrobial compounds 
(Sanders  and  Huis  in't  Veld,  1999,  FAO/WHO  2001,  Kailasapathy  and  Chin,  2000, 
Ouwehand et al., 2002). These functional characteristics could be absent in some strains, 
which satisfy safety characteristics and could also  be compromised during industrial 
production (Gismondo et al., 1999, Annuk et al., 2003). Apart from these functional 
characteristics, it is important that probiotic products have sufficient numbers of viable 
cells and must be resistant to gastrointestinal barriers to bring about beneficial health 
effects (Sanders and Huis in’t Veld, 1999, FAO/WHO 2001, Minelli and Benini, 2008, 
Champagne et al., 2011).   25 
In vitro methods for characterizing most of these functional properties are conducted 
using conventional culture techniques (Charteris et al., 1998, Annuk et al., 2003, Mishra 
and Prasad, 2005, Masco et al., 2007, Kotsou et al., 2008, Bao et al., 2010, Tham et al., 
2012). Methods based on conventional culture techniques are labour intensive and time 
consuming. For instance, for the determination of the antagonistic effect or antimicrobial 
production of potential probiotics, the probiotic species or their bioproducts are cultured 
together with pathogenic species, and changes in population determined by plating out 
(Annuk et al., 2003, Trejo et al., 2006, Schoster et al., 2013). When complexity of the 
gut  is  simulated  through  use  of  faecal  components  or  multi  probiotic  species  and 
pathogenic species are encountered, the workload increases due to the need for multiple 
sub-cultures to distinguish growth inhibition amongst the species (Tejero-Sarinena et al., 
2013). This may require further biochemical assays for identification of species which 
could  take  several  days  or  require  the  use  of  molecular  techniques,  in  which 
identification is also a multi-step process requiring specialized reagents, equipments, 
trained  personnel,  and  sometimes  unable  to  distinguish  viable  and  non-viable  cells 
(Spiegelman et al., 2005, O'Mahony and Papkovsky, 2006, Nagarajan and Loh, 2014).  
Thus,  in  the  assessment  of  some  functional  characteristics,  probiotics  may  be 
encountered  as  mixed  cultures:  with  themselves  or  with  pathogenic  organisms.  In 
microbiological  assays  where  differential  enumerations  of  multiple  species  are 
encountered, such assays could be tedious, requiring multiple subcultures and techniques 
(Spiegelman et al., 2005, Schmidt et al., 2007).  
The work reported in this thesis explored the use of isothermal microcalorimetry to study 
some  characteristics  of  probiotics,  particularly  the  antagonistic  effect  of  probiotics; 
where probiotics are encountered as mixed cultures and there was a need to differentially 
detect them in mixed cultures to determine their relationship with other species. Other 
functional aspects of probiotics were characterised using isothermal microcalorimetry. 
Isothermal microcalorimetry is a technique based on the principle of measurement of 
heat and can be used for real-time monitoring of growth of bacteria. In an appropriate 
medium, bacteria utilize the energy sources provided for respiration and fermentation to 
form new cellular materials. These metabolic processes are heat evolving or consuming 
resulting in the exchange of heat energy to or from the environment and this can easily 
be detected by the microcalorimeter. It is a very simple, sensitive and fast technique, and   26 
analyses heterogeneous systems non-destructively. Although it is not a very common 
technique among microbiologists, it is an established method that has been successfully 
applied in various disciplines for the detection and characterization of bacteria and other 
microorganisms mostly in pure culture (Zhao et al., 2000, O'Neill et al., 2003, Gaisford 
et al., 2009, Xing et al., 2011) and complex polymicrobial systems (Beaubien et al., 
1987, Braissant et al., 2010b, Bravo et al., 2011). However its potential use for the study 
of differential growth of systems consisting of defined multiple species of bacteria has 
been just explored (Vazquez et al., 2014). Its use for characterizing  potential  health 
benefits of probiotics has also not been pursued. It must be mentioned that the capacity 
of  isothermal microcalorimetry  to  discriminate  between  species  of  bacteria  has  been 
established  (Newell,  1980).  It  was  therefore  hypothesized  in  this  work  that  such 
discrimination could be used for the dectection of growth in mixed bacterial cultures for 
the study of some functional properties of probiotics. 
This introductory chapter provides relevant background information to probiotics, the 
principle of isothermal microcalorimetry and its application to microbial systems. For 
the understanding of the scope of this research, which focuses on probiotics and their 
association to human health, some ecological considerations on the gut microbiota are 
also given. 
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1.2 Gut microbiota-the source of probiotics 
1.2.1 Composition of the human gut microbiota 
The  human  gastrointestinal  (GI)  tract  (Figure  1.1),  sub-divided  into  the  mouth, 
oesophagus, stomach, small intestine and large intestine harbours a complex ecosystem 
consisting of trillions (approximately 10
13 to 10
14) of microbes (Ley et al., 2006a) with 
approximately 500 to 1000 bacterial species (Xu and Gordon, 2003) and an estimated 
weight between  200 g and 1 kg (Gibson and Williams, 1999,  Liddell, 2014). These 
microbes, together with those that inhabit the skin and mucosa of human outnumber the 
human cells by a factor of ten (Hooper and Gordon, 2001, Dethlefsen et al., 2006) and 
have a collective genome termed microbiome (Ley et al., 2006a, Ley et al., 2008). The 
human gut microbiota contains at least 100-fold more genes as the human genome and is 
often referred to as the hidden metabolic 'organ' of the body due to its enormous impact 
on  ones  wellbeing,  including  ones  metabolism,  physiology,  nutrition  and  immune 
function (Ley et al., 2006a, Guinane and Cotter, 2013). 
 
Figure 1.1. Anatomy of the human gastrointestinal tract showing the amount of bacteria in each 
region, figure adapted from (NIH. September 2013. Colonoscopy. [online]. Available from: 
http://catalog.niddk.nih.gov/ImageLibrary/detail.cfm?id=1450 [ Accessed 7 May 2014] ) 
The  human  gut  microbiota  contains  three  dominant  bacterial  phyla  distributed 
throughout the gut: the Gram-positive Firmicutes, the Gram-negative Bacteroidetes, and   28 
the Gram-positive Actinobacteria. The Firmicutes consist of over 200 genera including 
Lactobacillus, Bacillus, Clostridium and Mycoplasma (Vrieze et al., 2010). This phylum 
has  been  identified  as  the  most  prevalent  in  the  human  gut.  The  Bacteroidetes  also 
consists of about 20 genera and include Bacteroides, Prevotella and Porphyromonas 
making  up  9  to  42%  of  total  bacteria  in  the  gut  (Dore  and  Corthier,  2010).  The 
Actinobacteria,  also  a  dominant  phylum  of  the  gut  microbiota,  consists  of 
Bifidobacterium  and  Colinsella-Atopobium  (Dore  and  Corthier,  2010,  Vrieze  et  al., 
2010).  
Although these microbes are distributed throughout the gut, their relative  numbers in 
different parts of the gut differ. This is because of the variations of the physiological 
condition along the GI tract. The variations are mainly pH, redox potential, transit time, 
presence of proteolytic enzymes and bile (Macfarlane and Macfarlane, 2004, McConnell 
et al., 2008b). The luminal pH influences bacterial concentration in each section of the 
gut. Generally, a low pH kills most bacteria whilst the redox potential is influenced by 
the bacterial concentration in each of the GI sections. High bacterial concentrations are 
responsible  for  lower  redox  potentials  (Sousa  et  al.,  2008).  Transit  time  as  earlier 
mentioned can influence bacterial activity. Movement of digestive material through the 
stomach  and  the  small  intestine  is  relatively  quick,  with  mean  transit  time  of 
approximately 4 to 6 h coupled with the presence of gastric acid, bile, pancreatic and 
intestinal secretions makes the establishment of microbes in this region of the gut very 
difficult (Gorbach et al., 1967, Savage, 1977) whereas the flow of digestive material in 
the  colon  is  markedly  slow  (with  mean  transit  time  of  approximately  60  to  70  h) 
facilitating the establishment of a complex microbial ecosystem (Macfarlane et al., 1997, 
Macfarlane and Macfarlane, 2004). 
The mouth has around 10
7-10
9 bacteria per ml of saliva with approximately 10 times 
more anaerobic bacteria than aerobic (Ross, 1971, Evaldson et al., 1982). Aas et al., 
(2005) has estimated 700 different species of bacteria in the mouth with 9 bacterial phyla 
and 1 archaeal phylum. Streptococcus is the most dominant genus in the mouth (Drasar 
et al., 1969a, Aas et al., 2005). Pei et al., (2004) has also established that there are 95 
species of bacteria from 6 phyla in the oesophageal mucosa.  
The  normal  concentration  of  bacteria  in  the  stomach  is  between  10
1-10
3  CFU/
  mL 
(Finegold,  1969,  O'Hara  and  Shanahan,  2006).  This  lesser  population  as  mentioned   29 
previously  is  due  to  the  lower  gastric  pH  of  the  stomach  and  the  relatively  faster 
movement  of  digestive  material  through  the  stomach  making  the  establishment  of 
microbes in this region of the gut very difficult (Savage, 1977). However when food is 
ingested,  the  gastric  pH  increases  and  bacterial  population  increases  to  10
4–10
8 
CFU/mL. The pH falls down again once food mixes with the gastric juice, and only the 
acid-resistant bacteria and those that are able to associate with the epithelial surfaces 
survive (Drasar et al., 1969a). In the stomach the rate of passage of microbes exceeds 
their rate of multiplication (Savage, 1977). A 16S rRNA survey  by Bik et al., (2006) 
found  128  bacterial  species  from  8  phyla,  which  they  suggested  could  be  residents 
(Helicobacter pylori was the only definite resident) or ingested strains (Bik et al., 2006). 
Most of the bacteria in the stomach are predominately Gram-positive and aerobic. The 
most  commonly  isolated  genera  of  bacteria  in  the  stomach  include  Streptococcus, 
Staphylococcus and Lactobacillus (Finegold, 1969, Savage, 1977). Yeasts are also often 
isolated (Drasar et al., 1969a).   
Bacterial population in the small intestine (from the end of the stomach to the beginning 
of the colon) is estimated to be approximately 10
4 to 10
7 CFU/mL with an increasing 
population of anaerobic bacteria (Hayashi et al., 2005). The microbiota of the duodenum 
is known to resemble that of the stomach whereas, that of the ileum resembles that of the 
colon. In the duodenum, the bacterial concentration is around 10
3–10
4 CFU/mL and the 
major species are aerobic and Gram-positive bacteria. The microbial population of the 
duodenum  includes  Lactobacillus,  Streptococcus,  Staphylococcus,  and  anaerobic 
Veillonella.  Anaerobic  bacteria  can  be  isolated  in  the  duodenum  but  in  very  low 
concentrations. Very few microorganisms are found in the jejunum and the upper ileum. 
Organisms  present  in  this  area  of  the  small  intestine  include  Lactobacillus  and 
Enterococcus. In the distal ileum, bacterial concentrations are much higher and Gram-
negative  bacteria  are  known  to  outnumber  the  Gram-positive  organisms.  Anaerobic 
bacteria  present  in  high  concentrations  include  Bacteroides,  Bifidobacterium, 
Fusobacterium  and  Clostridium.  In  addition,  Streptococcus  (Streptococcus  faecalis), 
Staphylococcus,  Lactobacillus,  Clostridium  perfringes,  Veillonella  and  occasionally 
Escherichia  coli  can  be  isolated  (Drasar  et  al.,  1969a,  Drasar  and  Shiner,  1969b, 
Gorbach et al., 1967, Gorbach, 1971, Thadepalli et al., 1979).  
The colon is the most densely colonized part of the gut. Its bacterial population is around 
10
11  to  10
12  CFU/mL  containing  approximately  800  species  representing  9  bacterial 
phyla and 1 archaeal phylum (Ley et al., 2006a). The high bacterial population in this   30 
region of the gut can be credited to the almost neutral pH as a result of the neutralisation 
of the contents of the bowel by the juice of the intestine as well as the decreased rate of 
movement of the contents in the large intestine (Savage, 1977, Macfarlane et al., 1997). 
This part of the GI tract primarily functions as a site for reabsorption of water from 
chyme, with less mixing and propulsive movements; functioning as a reservoir. The 
sluggish rate of movement of the luminal contents in the colon exceeds the doubling 
times of bacteria hence they proliferate (Savage, 1977). The main bacterial population 
present in this section of the GI tract is that of oxygen-intolerant anaerobic bacteria of 
various types (Gorbach, 1971) reflecting the fact that the oxygen concentration in the 
colon is very low (Roediger, 1980, Quigley, 2013). It is estabalished that the anaerobes 
outnumber the facultative anaerobes by a factor of 10
3 to 10
4 in the colon (Gorbach, 
1971).  The  prevalent  species  isolated  include  Bacteroides,  Bifidobacterium  and 
Eubacterium  (Gorbach  et  al.,  1967,  Hill  and  Drasar,  1975).  Also  anaerobic  Gram-
positive  cocci,  Clostridium,  Enterococcus  and  other  species  of  Enterobacteriaceae, 
Diphtheroides, coliforms, Staphylococcus, Lactobacillus, Spirochetes, yeasts, Proteus, 
Pseudomonas, Bacillus subtilis, Actinomyces, Borrelia, Fusobaterium and Clostridium 
species have also been found (Moore et al., 1969, Moore and Holdeman, 1974, Hill and 
Drasar, 1975, Moore et al., 1975, Savage, 1977). 
Overall, Bacteroides species have been noted to account for nearly 32% of all organisms 
isolated from the GI microbiota. Some studies have pointed to the fact that the Gram-
negative  rods  belonging  to  the  Bacteroides  fragilis  group  are  numerically  the 
predominant  organisms  and  account  for  up  to  30%  of  total  anaerobes  (Moore  and 
Holdeman, 1974, Macy and Probst, 1979). Bifidobacteria have also been reported to 
account for up to 25% of the total cultivable gut flora (Mitsuoka, 1984). It has also been 
claimed that the bifidobacteria are the dominant species of the microbiota of healthy new 
born infants (Long and Swenson, 1977, Kawase et al., 1983, Heine, 1996) but then the 
bifidobacteria  population  decreases  progressively  as  the  infant  ages  (Thompson-
Chagoyan et al., 2007).  
It must be mentioned that much of the information regarding the composition of the gut 
microbiota  has  come  from  studies  that  used  culture-based  techniques  (Guarner  and 
Malagelada, 2003a). As a result, a thorough description of the human gut microbiota has 
not been established yet (Quigley, 2013) since several bacteria (more than 30%) that can 
be  seen  and  counted  by  direct  microscopic  examination  of  faecal  samples  are  not   31 
recoverable  by  culture-based  techniques  (Holdeman  et  al.,  1976,  Guarner  and 
Malagelada,  2003a).  However  the  advent  of  non-culture  based,  high-throughput 
sophisticated  methodologies  is  now  facilitating  the  detailed  description  of  the 
composition of the human gut microbiota in a way that has never been possible before 
(Quigley, 2013). 
1.2.2 Significance  
The gut microbiota are known to play vital roles in the human body. They are known to 
contribute towards human nutrition by synthesizing and secreting vitamins in excess of 
their own needs, which are absorbed as nutrients by humans (Hill, 1997). Evidence of 
this has been demonstrated with the requirement of supplementation with vitamins B and 
K for rodents reared in a sterile environment (germ free rodents) consuming standard 
chow compared with conventional rodents (Savage, 1986). They are also responsible for 
fermenting parts of the diet, which are not digested in the upper part of the digestive 
system. The products of carbohydrate fermentation of these bacteria are mainly short-
chain  fatty  acids  (SCFA),  essentially  acetate,  propionate  and  butyrate  and  other 
metabolites  such  as  lactate,  pyruvate,  ethanol  and  succinate  (Cummings,  1981, 
Macfarlane and Macfarlane, 1997). The products of fermentation manipulate intestinal 
motility, aiding in digestion and peristalsis (Dass et al., 2007) as well as contribute to the 
energy requirement of the host (Saulnier et al., 2009). Acetate is a primary substrate for 
cholesterol synthesis (Ukai et al., 1976, Wong et al., 2006). It is metabolised in the 
kidney,  heart,  and  muscles  (Lindeneg  et  al.,  1964).  Butyrate  is  metabolised  by  the 
colonic epithelium where it serves as its major energy source (Cummings, 1981). It is 
known for its prevention of colon cancer by stimulating apoptosis and modulating the 
immune system (Roberfroid et al., 2010). Propionate, a gluceogenic substrate, is also 
important in glucose and lipid metabolism (Reshef et al., 1967). It inhibits cholesterol 
synthesis in hepatic tissue (Wong et al., 2006). 
The  gut  microbiota  also  contribute  towards  metabolism  of  xenobiotic  compounds 
including  drugs  (Ilett  et  al.,  1990).  While  this  has  had  toxicological  implications  of 
drugs, it has also been exploited pharmaceutically for applications such as site specific 
delivery and prodrug approach (McConnell et al., 2008a, Sousa et al., 2008).   32 
The gut microbiota also functions to protect the gut against colonization by pathogens 
(Fuller,  1991).  This  is  achieved  by  competitive  exclusion  such  as  occupation  of 
attachment  sites,  consumption  of  nutrient  sources  and  production  of  antimicrobial 
compounds (Sekirov et al., 2010). This protective function has been demonstrated by the 
fact that germ free animals are more susceptible to infections than their conventional 
counterparts. This difference was shown by infections caused by Salmonella enteritidis 
(Collins and Carter, 1978) and Clostridium botulinum (Moberg and Sugiyama, 1979). In 
humans, this has been evidenced from infections with Clostridium difficile characterised 
by  pseudomembranous  colitis  after  antibiotic  treatment  which  is  reversed  by 
administration of faecal enemas from healthy adults (Schwan et al., 1984, Fuller, 1991).  
The  gut  microbiota  also  play  important  role  in  the  development  of  tissues  like  the 
caecum and development of both the intestinal mucosal and systemic immune systems 
(Macpherson and Harris, 2004, Sekirov et al., 2010). This again has been demonstrated 
in studies in which germ free animals showed deficits in local and systemic lymphoid 
structures;  poorly  formed  spleens  and  lymph  nodes  and  smaller  Peyer’s  patches 
(Macpherson and Harris, 2004). 
The gut microbiota has been known to be important in diseases such as inflammatory 
bowel disease, allergies, obesity, diabetes, non-alcoholic fatty liver diseases, cancers and 
other metabolic and degenerative disorders (Savage, 1977, Ley et al., 2005, Dethlefsen 
et al., 2006, Dore and Corthier, 2010).  
1.2.3 Acquisition 
Shortly after birth, microorganisms colonize the human gut, which is initially known to 
be  sterile.  These  microorganisms  are  derived  from  the  mother’s  faecal  and  vaginal 
microbiota,  maternal  milk  (West  et  al.,  1979,  Perez  et  al.,  2007)  as  well  as  the 
environment. It is thought that colonization starts during the process of childbirth. Some 
researchers have suggested that colonization is complete after 1 week, reaching levels of 
10
11 bacteria per gram of stool (Hooper and Gordon, 2001, Bjorksten, 2006, Dore and 
Corthier, 2010). Vrieze et al., have also mentioned that the microbiota changes after the 
initial colonization as a result of changes in diet and that an individual’s microbiota is 
fully matured at 4 years (Vrieze et al., 2010).    33 
It  has  been  proposed  that  the  type  of  delivery:  vaginal  verses  caesarean,  hygiene 
(Adlerberth et al., 2006), geographical location (Fallani et al., 2010); all play significant 
roles in the dynamics of colonization. For example, it is known that births by caesarean 
section are associated with high colonization by Klebsiella, Enterobacter and clostridia 
(Conroy et al., 2009) which are organisms usually found in the hospital surroundings and 
are  acquired  from  the  air,  equipment,  nursing  staff,  the  mother  and  other  infants 
(Tennyson and Friedman, 2008). On the other hand, vaginal birth is often associated 
with  a  higher  colonization  by  bifidobacteria  (Chen  et  al.,  2007a)  which  is  acquired 
mainly from maternal flora. Tennyson and Freidman (2008), have suggested that the 
longer the birth process, the greater the exposure of the maternal bacteria to the infant. 
The type of feeding of infants also affects the colonization pattern. Formula fed infants 
have shown an increased amount of clostridia and Bacteroides compared to breastfed 
infants (Conroy et al., 2009) who have high amounts of bifidobacteria (Tennyson and 
Friedman,  2008).  Tennyson  and  Friedman  have  also  established  that  after  the 
introduction of solid food, the intestinal microbiota of both breastfed and formula fed 
infants becomes similar.  
The  gut  microbiota  of  humans  evolves  during  different  stages  of  life,  from  infancy 
through adulthood to old age. The transformation from infant to adult-type microbiota 
has been proposed to be triggered by numerous host and external factors; stabilizing 
thereafter  until  the  7
th  decade  albeit  there  will  be  inconsequential  fluctuation  of  the 
established colonisers of the individual (Brown et al., 2007, Ley et al., 2006b). There are 
also  significant  fluctuations  in  disease  states  and  during  treatments  with  drugs.  For 
example, short term treatment with a single dose of an oral antibiotic has led to changes 
of the composition of the gut microbiota for as long as 4 weeks before returning to the 
original composition (Dethlefsen et al., 2008b). 
The  ultimate  composition  of  the  gut  microbiota  of  an  individual  is  known  to  be 
determined  by:  his  or  her  physiology,  colonisation  history,  environment  and  genetic 
makeup (Gordon et al., 2009). Some of these factors are more important than others. For 
example, the  genetic makeup  of  an  individual is  more  important  in  determining  the 
composition of his or her microbiota than the environment. Zoetendal et al., (2001), were 
able to establish that the microbiota of identical twins living separately was similar than 
the  microbiota  of  unrelated  individuals.  In  contrast,  a  couple  living  in  the  same   34 
environment  with  similar  dietary  habits  did  not  show  similarity  in  their  microbiota 
making environment a less important factor in gut colonisation.  
The microbiota diversity and distribution has been related with certain conditions and 
diseases.  However,  there  is  generally  a  huge  variability  of  microbiota  between 
individuals (Ley et al., 2006b, Zoetendal et al., 2006) and this variability  sometimes 
complicates  studies  attempting  to  establish  the  relationships  between  disease  or  host 
health and specific gut microbial population.  
1.2.4 Homeostasis and Dybiosis 
Even though the microbiota of the gut may vary considerably from one individual to 
another, the dynamics and homeostasis of the gut microbiota may be considered specific 
for  a  given  individual.  Thus,  the  composition  of  the  microbiota  can  be  said  to  be 
consistent  in  an  individual  over  time.  Under  normal  physiological  conditions,  the 
dominant  phyla  are  stable  throughout  an  individual’s  life.  Even,  dominant  species, 
specific to an individual will remain dominant throughout life (Zoetendal et al., 1998, 
Vanhoutte et al., 2004). However, the same cannot be said for individual strains, as not 
much  research  has  been  done  in  this  area.  Although,  the  environment,  presence  of 
exogenous substrates and diet may cause changes in the microbiota of an individual as 
mentioned earlier, these changes are sometimes not remarkable and even if they tend to 
be, they only occur over a short period and sometimes has no impact on the individual. 
For example, a modified microbiota caused by the use of antibiotics can see a return to 
the  normal  dominant  profile  within  a  month  without  causing  a  pathological  state 
(Dethlefsen et al., 2008a, De La Cochetiere et al., 2005). Thus, the microbiota of each 
individual has got a resilience factor that allows it resist changes induced by stress (De 
La Cochetiere et al., 2005, Dore and Corthier, 2010). It has been implied that genotype 
could  play  a  role  in  resilience  of  the  microbiota  and  also  in  the  development  and 
structuring  of  the  microbiota  and  this  has  been  linked  to  the  fact  that  the  faecal 
microbiota profile of monozygote twins are similar than the microbiota of an unrelated 
individual (Zoetendal et al., 2001, Dore and Corthier, 2010). However, excessive stress 
could disturb the equilibrium of an individual’s microbiota, resulting in an irreversible 
perturbation (Dore and Corthier, 2010). The threshold above which one’s microbiota   35 
loses its ability to return to its original balance has however not been clearly defined 
(Dore and Corthier, 2010).  
Dysbiosis is the term used when the composition of the microbiota of the gut is thrown 
out of a state of equilibrium (due to excessive stress) leading to a state of imbalance, 
which could consequently affect a host metabolically or immunologically (Round and 
Mazmanian, 2009). The microbiota has been described as a balanced composition of 
different  classes  of  bacteria  consisting  of  symbionts,  commensals  and  pathobionts 
(Round and Mazmanian, 2009). Symbionts are those bacteria of the microbiota, which 
have health promoting effect. Commensals are those that have neither health promoting 
nor depreciating effect and pathobionts are those bacteria of the gut, which have the 
potential to cause diseases (Round and Mazmanian, 2009). A balanced composition of 
these different classes of bacteria in the GI is responsible for the known health effects of 
the microbiota (Figure 1.2; Roberfroid et al., 2010). In dysbiosis, it has been proposed 
that there is either a reduction in the number of symbionts or an increase in the number 
of pathobionts (Round and Mazmanian, 2009). 
 
Figure 1.2. A scheme describing the hypothesis of a balanced microbiota of an adult proposed by 
Gibson and Roberfroid, (1995) and revised by Roberfroid et al., (2010). The figure shows the number 
of CFU/g of faeces of major phyla/genera. The bacteria are divided into three groups: those groups 
that have harmful or pathogenic influences on human health (located on the left), those that have 
beneficial effects (located on the right), and those that may have both (located on both sides, also 
contain genera/species yet to be classified). Obtained from Roberfroid et al., (2010).   36 
Dysbiosis could be caused by, for example, excessive lifestyle of host, host genetics, 
medical practices: overuse of antibiotics and vaccination (Round and Mazmanian, 2009). 
It is believed that certain diseases are the result of dysbiosis. Diseases that have been 
linked  to  dysbiosis  include  celiac  disease  (De  Palma  et  al.,  2010),  type  2  diabetes 
(Larsen et al., 2010), obesity (Ley et al., 2005, Ley et al., 2006b, Turnbaugh et al., 2009, 
Zhang  et  al.,  2009),  IBD  (Tannock,  2008,  Seksik,  2010)  and  chronic  diarrhoea 
(Swidsinski et al., 2008). Table 1.1 lists some members of the microbiota that are known 
to increase or reduce in diseases associated with dysbiosis. 
Table 1.1. Diseases associated with dysbiosis and members of the microbiota implicated  
 
Human disease  Abundance   Reduction 
Celiac disease  Gram-negatives, Bacteroides-
Prevotella, 
Escherichia coli 
Gram-positives, 
Bifidobacterium, Clostridium 
histolyticum 
and C. liteseburense, 
Faecalibacterium prausnitzii 
Inflammatory bowel 
diseases 
Enterobacteriaceae, Bacteroidetes, 
Enterococcus, 
Clostridium difficile, Escherichia 
coli, Shigella flexneri,  
Mycobacterium paratuberculosis, 
Listeria monocytogenes and 
paramyxovirus 
Firmicutes, Eubacterium 
rectale, Bacteroides fragilis, 
B. vulgatus, Ruminococcus 
albus, R. callidus, R. bromii, 
and Fecalibacterium prausnitzi 
 
Obesity  Firmicutes  Bacteroidetes, Bifidobacterium, 
Staphylococcus aureus 
Type 2 diabetes  ß-Proteobacteria, Bacteroides, 
Parabacteroides 
Firmicutes, Clostridium, 
Bifidobacterium, Bacteroides 
vulgatus 
Chronic diarrhoea  Enterobacteriaceae, Eubacterium 
cylindroides, Clostridium 
histolyticum, and Clostridium 
lituseburense.  
Eubacterium rectale, 
Bacteroides and 
Faecalibacterium prausnitzii  
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Despite the inter-individual variation of the microbiota, a number of recurring features 
have  also  been  mentioned  to  generally  characterise  dysbiosis  (Walker  and  Lawley, 
2013).  For  example,  the  overall  diversity  of  the  microbiota  is  known  to  reduce. 
Likewise, irrespective of the disease state, there are also reductions in the population of 
obligate anaerobic members of the Firmicutes, and a corresponding increased population 
of facultative anaerobes, especially members of the Enterobacteriaceae family of the 
Proteobacteria phylum which consists of a number of strict and opportunistic pathogens 
such as Salmonella spp., Shigella spp., Klebsiella spp., Proteus spp. and E. coli (Walker 
and Lawley, 2013).  
1.3 Probiotics 
Since it is a balanced composition of one’s microbiota that is responsible for the known 
health effects of the microbiota (Round and Mazmanian, 2009), there has been much 
interest  in  deliberately  manipulating  the  normal microbiota  to  accrue  health  benefits 
through using “probiotics”. Probiotics are bacteria related to those found naturally in the 
human gut, notably those supposedly found in the gut of breastfed infants because they 
are known to be significant in contributing towards the health effects of the microbiota 
(Iannitti  and  Palmieri,  2010).  When  ingested,  they  are  claimed  to  prevent  or  treat 
dysbiosis  by  changing  the  ecology  of  the  gut  microbiota  towards  a  healthier 
composition. Its concept dates back to over 100 years when the Russian Nobel laureate, 
Elie Metchnikoff linked the longevity of Bulgarian peasants to their consumption of a 
fermented milk product that contained lactic acid bacteria. He therefore suggested that 
ingesting  these  “useful  microbes”  could  replace  harmful  microbes  and  consequently 
have beneficial effects for man (Metchnikoff, 1908). During the time of Metchnikoff’s 
discovery, a French paediatrician, Henry Tissier also noticed that children with diarrhoea 
had  lower  number  of  peculiarly  Y-shaped  bacteria  “bifid  bacteria”  in  their  stools 
compared with healthy children who had an abundant amount of those bacteria (Tissier, 
1906). Tissier therefore suggested that these bacteria could be given to patients with 
diarrhoea  to  treat  them.  Even  though  these  two  scientists  introduced  the  concept  of 
probiotic, the term was only coined in 1965 by Lilly and Stillwell (Lilly and Stillwell, 
1965) to describe substances secreted by one organism, which stimulated the growth of 
another.  This  description  has  however  been  rephrased/  redefined  a  number  of  times 
(Fuller, 1989, Fuller, 1991, Havenaar and Huis In't Veld, 1992, Guarner and Schaafsma, 
1998)  but  the  World  Health  Organisation  (WHO)  and  Food  and  Agricultural   38 
Organization  of  the  United  Nations  (FAO)  have  jointly  adopted  the  definition  of 
probiotics  as  “live  microorganisms,  which,  when  administered  in  adequate  amounts, 
confer a health effect on the host.” Recently, the International Scientific Association for 
Probiotics  and  Prebiotics  (ISAPP),  have  made  minor  grammatical  correction  to  the 
definition as “live microorganisms that, when administered in adequate amounts, confer 
a health effect on the host” (Hill et al. 2014). Microorganisms used as probiotics are 
usually  species  of  lactic  acid  bacteria  and  bifidobacteria.  They  generally  include 
members of the genera Lactobacillus and Bifidobacterium. Also, members of the genera 
Streptococcus and Enterococcus and Lactococcus spp., Bacillus spp. and some yeast, for 
example Saccharomyces boulardii, have been identified as probiotics (Salminen et al., 
1998,  FAO/WHO  2001,  Iannitti  and  Palmieri,  2010).  These  organisms  are  generally 
applied in food (yogurt, cheese, fermented milk products) or used as dietary supplements 
(for example, capsules, tablets, powders and solutions).  
1.3.1 Properties of probiotics 
For an organism to be considered a probiotic, and used in food, the WHO/FAO guideline 
stipulates that it should be safe and non-pathogenic. It must survive passage through the 
digestive  tract  and  be  capable  of  proliferation  in  the  gut.  Which  according  to  the 
guideline, means they must be “resistant to gastric juices and be able to grow in the 
presence of bile under conditions in the intestines, or be consumed in a food vehicle that 
allows it to survive passage through the stomach and exposure to bile.” Apart from these 
properties,  it  is  also  proposed  that  all  probiotics  either  included  in  food  or  used  as 
supplement  must  also  reduce  pathogenic  adherence  and  be  able  to  adhere  to  cells, 
persist, multiply and produce acids, peroxides and bacteriocins that are antagonistic to 
pathogenic  adherence  and  should  co-aggregate  to  form  a  normal  balanced  flora  and 
demonstrate health benefits. They must also be amenable to industrial processes and 
remain viable in a product throughout its shelf life (Collins and Gibson, 1999, Gismondo 
et al., 1999, Kailasapathy and Chin, 2000, Iannitti and Palmieri, 2010).  
1.3.2 Health benefits of probiotics 
Given  the  significant  effect  of  the  gastrointestinal  microbiota  on  human  health  and 
disease, probiotic consumption has been linked to a number of health benefits. These   39 
health  benefits  can  be  categorized  into  nutritional  and  therapeutic  as  likened  to  the 
benefits  of  the  normal  microbiota.  Nutritionally,  they  are  believed  to  improve 
digestibility  by  breaking  down  complex  carbohydrates,  (which  are  otherwise  non-
digestible) producing absorbable substrates and energy, also secreting -D galactosidase, 
which metabolize lactose into glucose and galactose (Shah, 2007). They are also known 
to  synthesize  and  excrete  vitamins,  which  are  used  by  man  (Rossi  et  al.,  2011). 
Therapeutically, they are known to prevent and alleviate complains of the GI tract and 
other  ailments.  For  instance,  ingestion  of  probiotics  has  been  shown  to  prevent  the 
occurrence of diarrhoea (Saavedra, 2000). The mechanism by which this is achieved has 
been suggested to be by competitive exclusion (Steer et al., 2000); they are thought to 
inhibit the adhesion of pathogens to intestinal mucosa and produce SCFA, organic acids, 
peroxides, and other antimicrobials, which kill off pathogens. In constipated patients, 
these, SCFA can stimulate intestinal peristalsis which help in normal bowel movement 
(Arunachalam,  1999).  Probiotics  are  claimed  to  reduce  cancer  risk  by  reducing  the 
concentration of cancer-promoting enzymes and/or putrefactive (bacterial) metabolites in 
the gut (Goldin and Gorbach, 1984, El-Nezami et al., 2000, Oatley et al., 2000). They 
are also believed to prevent or alleviate allergies and atopic diseases in infants (Majamaa 
and Isolauri, 1997, Kalliomaki et al., 2001, Isolauri et al., 2000, Rosenfeldt et al., 2003), 
prevent  respiratory  tract  infections  (common  cold,  influenza)  and  other  infectious 
diseases  as  well  as  help  in  the  treatment  of  urogenital  infections  (Rio  et  al.,  2002, 
Hatakka et al., 2001, Reid, 2001b, Marelli et al., 2004). They are also known to improve 
autoimmune diseases like arthritis (Malin et al., 1997). Certain probiotics are believed to 
stimulate the immune system; they increase mucosal antibody production, boost pro-
inflammatory cytokine expression, and enhance host defensin production (Sokolnicka, 
2000). They are also considered to have a hypocholesterolemic effect and reduce the risk 
of ischemic heart diseases (Naruszewicz et al., 2002, Agerholm-Larsen et al., 2000). A 
good account of  health benefits of probiotics are reviewed in  these articles: Goldin, 
1998,  Saarela  et  al.,  2000,  Kailasapathy  and  Chin,  2000,  Ouwehand  et  al.,  2002, 
Salminen et al., 2005, Parvez et al., 2006, de Vrese and Schrezenmeir, 2008, Saulnier et 
al., 2009, Masood et al., 2011. 
Although the claimed effects of probiotics are endless due to their relation with the gut 
microbiota, there are however differing degrees of evidence supporting their purported 
benefits.  Nonetheless,  there  is  also  some  clinical  evidence  to  suggest  that  specific 
probiotics can be effective in the treatment of some dysbiosis-related diseases. Table 1.2   40 
summarizes some studies on diseases which probiotics have been shown to evidentially 
alleviate.  
Table 1.2. Proven health effects of probiotics 
 
Disease  Probiotic  Study  Outcome  Reference 
Diverticular 
disease 
VSL#3 
(Probiotic of 
different strains 
of 
Bifidobacterium 
and 
Lactobacillus) 
To determine whether 
probiotic could prevent 
reccurence of disease and 
alter the colonic bacteria 
to metabolize balsalazide  
into 5-ASA and 4-
aminobenzoil--alanine 
Probiotic in combination 
with anti-inflammatory 
drug was found better in 
treatment and preventing 
relapse of Diverticular 
disease than single use. 
(Tursi et 
al., 2007) 
Irritable 
bowel 
syndrome 
(IBS) 
L. plantarum 
L. reuteri 
S. boulardiii 
To determine whether 
probiotic could improve 
symptoms of IBS 
Flatulence, abdominal 
pain, pain frequency and 
overall symptoms of IBS 
improved for most of the 
probiotics studied. 
(Guslandi, 
2007) 
Inflammator
y bowel 
disease 
(IBD) 
B. longum 
 
 
S. boulardii 
Synbiotic of B. longum 
and prebiotic (inulin-
oligofructose) given to 
patients with Ulcerative 
colitis                              
Probiotic added to 
baseline therapy in 
Crohn’s disease 
Improved inflammation 
in Ulcerative colitis 
patients. 
 
Improved intestinal 
permeability but not 
complete normalization 
of the disease. 
(Furrie et 
al., 2005) 
 
 
(Vilela et 
al., 2008) 
Colon 
cancer  
 
L. rhamnosus 
LC705 (LC705) 
Propionibacteri
um 
freudenreichii 
ssp shermanii 
JS (PJS) 
To examine whether the 
administration of LC705 
and PJS could decrease 
the activity of faecal -
glucosidase, -
glucuronidase, and 
urease 
LC705 and PJS were 
associated with a 
decrease in -glucosidase 
activity. 
(Hatakka 
et al., 
2008)   41 
Table 1.2. Proven health effects of probiotics (continued) 
 
Disease    Probiotic  Study  Outcome  Reference 
Diarrhoea 
 
 
Lactobacillus 
GG 
B. bifidum and 
S.thermophilus 
VSL#3 
Bifilac 
(synbiotic) 
Different studies involving 
the use of these probiotics 
or synbiotic to evaluate 
their efficacy in reducing 
the frequency and duration 
of diarrhoea induced by 
rotaviral infection 
All studied probiotic or 
synbiotic reduced the 
rate of rotavirus-
associated diarrhoea by 
reducing either the 
volume or frequency of 
diarrhoea. 
(Saavedra, 
2000) 
(Dubey et 
al., 2008) 
(Narayanap
pa, 2008) 
H. pylori 
eradication 
L. acidophilus 
HY2177, L. 
casei HY2743, 
B. longum 
HY8001 and 
Streptococcus 
thermophilus B-
1 
These probiotics (delivered 
in yoghurt) was added to a 
Proton Pump Inhibitor 
(PPI)-based triple therapy 
to determine whether the 
probiotic could increase 
success in eradication of 
H. pylori 
Probiotic was shown to 
increase success of H. 
pylori eradication 
(Kim et al., 
2008) 
Bacterial 
vaginosis 
L. rhamnosus 
GR-1 and L. 
reuteri RC-14 
To find out if the 
probiotics could help in 
curing urogenital infection 
when taken concomitantly 
with single dose tinidazole 
There was an improved 
cure of the infection 
from 50% to 87.5% 
cure. 
(Martinez et 
al., 2009) 
Allergic 
disease 
L. reuteri ATCC 
55730 
To investigate if probiotic 
could decrease the 
incidence of eczema of 
infants with a family 
history of allergic disease 
by giving mothers in their 
36 gestational week and 
their babies the probiotic 
until 12 months old. 
Infants had less IgE 
associated eczema at 2 
years. Authors 
concluded that infants 
could possible have a 
reduced risk of 
developing respiratory 
allergic disease later on 
in life.  
(Abrahamss
on et al., 
2007)   42 
1.3.3 Antipathogenic activity of probiotics against potential pathogens 
It is believed that the primary  effect of probiotics in man is their ability  to prevent 
pathogenic colonization (Fuller, 1991, Lu and Walker, 2001, Reid et al., 2001a). Certain 
features of probiotics have been shown to decrease pathogenic attack in man and these 
features  include  the  ability  to  increase  mucin  production  and  reduce  intestinal 
permeability (Caballero-Franco et al., 2007, Ewaschuk et al., 2008), strengthening the 
defence of man. Apart from these features, some probiotics are also thought to have 
some surface proteins that adhere onto the cell surfaces of its host and these prevent 
pathogenic  bacteria  from  attaching  to  the  same  surfaces.  For 
example, Lactobacillus crispatus has surface proteins (S-layer proteins) that are able to 
prevent the adhesion of Escherichia coli O157:H7 and Salmonella (Chen et al., 2007b).  
Probiotics are also thought to compete for nutrients with pathogens and stimulate host's 
immunity. They are believed to produce antimicrobial compounds that are capable of 
inhibiting pathogens. The antimicrobial compounds include SCFA and organic acids, 
predominantly,  acetate,  butyrate,  propionates  and  lactate.  These  generate  an  acidic 
environment  that  inhibits  pathogens.  They  are  also  believed  to  synthesize  specific 
proteins and peptides (bacteriocins) with inhibitory effect against some pathogens (Reid 
et al., 1990, Mishra and Lambert, 1996, Yildirim and Johnson, 1998). Table 1.3 shows 
the specific peptide and inhibitory spectrum respectively of some probiotics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   43 
Table 1.3. A list of probiotics and the specific peptide (with antimicrobial properties) they produce 
 
Probiotic  Peptide/ Protein  Properties/Inhibitory Spectrum  Reference   
B. bifidum 
NCFB 1454 
Bifidocin B  Active within pH 2 to 10. Stable at 121
oC and -20
oC. 
Sensitive to several proteolytic enzymes (protease IV, 
pronase E, protease XVII, proteinase K, trypsin, alpha-
chymotrypsin, papain, and pepsin) but resistant to 
catalase, peroxidase, lipase, lysozyme, cellulase, 
ribonuclease A, and amylases. Resistant to organic 
solvents and heat. Active against Listeria, 
Enterococcus, Bacillus, Lactobacillus, Leuconostoc, 
and Pediococcus species. 
(Yildirim 
and 
Johnson, 
1998) 
B. lactis BB-
12 
Bifilact BB-
12 
No activity at pH 3, -20
oC or 121
oC. Considerable 
biological activity retained at pH 4 and 7 but reduced at 
pH 9. Sensitive to pepsin and trypsin, but resistant to -
amylase or lipase. Inhibitory towards Staphylococcus 
aureus, Salmonella typhimurium, Bacillus cereus and 
E. coli. 
(Abd El-
Salam et 
al., 2004) 
B. longum 
BB-46 
Bifilong BB-
46 
Molecular weight of 25 to 127-kilodalton (kDa). No 
activity at pH 3, -20
oC, 121
oC. Considerable biological 
activity retained at pH 4 and 7 but reduced at pH 9. 
Sensitive to pepsin and trypsin, but resistant to -
amylase or lipase. Inhibitory towards Staphylococcus 
aureus, Salmonella typhimurium, Bacillus cereus and 
E. coli. 
(Abd El-
Salam et 
al., 2004) 
L. sake 
MI401, L. 
plantarum 
ST31, L. 
reuteri 
LTH2584 
Bavarin A, 
Plantaricn 
ST31, 
Reutericyclin 
Optimum pH range 4-6. Resistant to heat and acidity, 
and inactivated by proteolytic enzymes, except for 
reutericyclin. Inhibit Bacillus, Staphylococcus and 
Listeria strains.  
(Messens 
and De, 
2002) 
Lactobacillus 
gasseri SBT
2055 
Gassericin T  Inhibits most Gram-positive food pathogens  (Kawai et 
al., 2000)   44 
Table 1.3. A list of probiotics and the specific peptide (with antimicrobial properties) they produce 
(continued) 
 
Probiotic  Peptide/ 
Protein 
Properties  Reference
   
L. plantarum  Plantaricin 423  Resistant to treatment at 80
oC, but loses 50% 
of its activity after 60 min at 100
oC and 75% 
of its activity after 15 min at 121
oC. Stable at 
pH 1-10 but inactivated when treated with 
pepsin, papain, a-chymotrypsin, trypsin and 
Proteinase K. It inhibits Bacillus cereus, 
Clostridium sporogenes, Enterococcus 
faecalis, Listeria spp. and Staphylococcus 
spp. 
(van Reenen 
et al., 1998) 
L. plantarum  Plantaricin TF 
711 
Stable to heat and to treatment with 
surfactants and organic solvents. Optimum 
antimicrobial activity is between pH 1 and 9. 
It inhibits Bacillus cereus, Clostridium 
sporogenes and Staphylococcus aureus. 
(Hernandez 
et al., 2005) 
Lactobacillus 
gasseri KT7 
 
Gassericin KT7  Sensitive to proteolytic enzymes, resistant to 
heat, active over a wide range of pH. Active 
against food-borne pathogens including 
Listeria, Clostridium and Enterococcus. 
(Zhu et al., 
2000) 
Lactobacillus 
gasseri LF221A 
Acidocin 
LF221A/LF221
B 
Molecular weight of 3.5 to 5-kDa. 
Hydrophobic and heat stable. Have inhibitory 
activity against Lactococcus, Pediococcus, 
Staphylococcus, Enterococcus, Streptococcus, 
Listeria, Clostridium and Bacillus. 
(Majhenic et 
al., 2004) 
Lactobacillus 
acidophilus LAP
T1060 
Acidophilucin 
A 
Sensitive to proteolytic enzymes but stable at 
120
oC. 
(Toba et al., 
1991) 
Lactococcus 
lactis subsp.lactis
 strains 
Nisin  Molecular weight 3.5-kDa. Hydrophobic. Has 
inhibitory activity against a wide range of 
food-borne pathogens. 
(Jack et al., 
1995)   45 
1.3.4 Probiotic market value 
As  the  list  of  health  benefits  accredited  to  probiotics  continues  to  increase,  their 
industrial production and commercialization also continues to see a steep rise. It was 
estimated that the probiotic industry held about 10% share in the global functional food 
market, which represented €10 billion in 2008 (Champagne et al., 2011). The global 
probiotic  supplement  market  was  also  said  to  be  worth  about  $1.5  billion  in  2008 
(Champagne  et  al.,  2011).  The  market  is  set  to  witness  further  notable  growth  as 
consumers become more mindful about their health and use probiotics for preventative 
measures and as newer types of probiotic products (for example biscuit, cereals, chewing 
gums, chocolates, honey, ice cream, juices, pizzas, aftershave, anti-aging serum, face 
and  body  lotion,  toothpaste,  tampons,  shampoo,  douche  gel)  find  themselves  on  the 
shelves in supermarkets and pharmacies. Global probiotics market has been predicted to 
be worth $31.1 billion by 2015 and is forecasted to reach $48 billion in the next five 
years  (Global  Industry  Analysis  Report,  Transparency  Market  Research,  2013). 
According  to  the  report,  Europe  represents  the  largest  and  Japan  the  second  largest 
market. Within Europe, United Kingdom and Germany represent the largest market with 
trade accounting for almost half of the total market in Europe.  
With  the  increasing  industrialization  and  commercialization  of  probiotics,  more 
extensive research is needed to prove or support their health benefits; especially as new 
probiotic strains and new application of probiotics are being suggested. 
1.3.5 Testing methods for establishing potential health benefits of probiotics  
According to the WHO/FAO in its report on Expert Consultation on the Evaluation of 
Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live 
Lactic  Acid  Bacteria,  tests  for  establishing  health  benefits  of  probiotics  should  first 
involve the use of an appropriate in vitro study before undertaking in vivo investigations. 
In vitro tests such as antimicrobial production, gastrointestinal tolerance and adherence 
ability of probiotic organisms to human intestinal cells predict functionality of probiotics 
(FAO/WHO,  2001)  and  are  noted  to  be  important  for  anticipated  health  benefits 
(Gismondo  et  al.,  1999).  The  work  in  this  thesis  was  focused  on  the  antimicrobial 
production, gastric tolerance as well as the microbial stability of probiotics in mixed 
cultures.   46 
1.3.5.1 Antimicrobial production 
Traditionally, in vitro studies to determine the direct antagonistic activity of probiotics 
based on their antimicrobial substance production are done by two main methods even 
though  there  are  adaptations  to  these  methods.  The  first  method  is  based  on  the 
observation of the growths of probiotics (or bioproducts from probiotics) and potential 
pathogenic  organisms  in a  batch  of  medium  or  chemostats.  Thus  probiotics  or  their 
bioproducts are cultured together with pathogens of interest and changes in the microbial 
growth analyzed, usually by selective growth and colony counting (Apella et al., 1992, 
Drago et al., 1997, Annuk et al., 2003, Hutt et al., 2006), turbidity assay (Lee et al., 
2003), biochemical methods or by molecular biological methods (Folkers et al., 2010, 
Tejero-Sarinena et al., 2013).  
The second method, which is the most employed method for studying the antagonistic 
activity of probiotics is based on diffusion tests where potential probiotic is seeded on an 
agar plate together with a test bacterial organism (Annuk et al., 2003, Zhu et al., 2010) or 
agar  plates  spotted  with  probiotic  organisms  are  overlaid  with  agar  inoculated  with 
pathogenic organisms (Barbosa et al., 2005, Chapman et al., 2012, Tejero-Sarinena et 
al., 2012). Alternatively  bioproducts of  potential probiotics are applied into punched 
wells of agar plates or impregnated into disks, which are placed on agar plates seeded 
with test bacterial organism (Bhunia et al., 1988, Naaber et al., 2004, Trejo et al., 2006, 
Olivares et al., 2006, Jara et al., 2011, Schoster et al., 2013). Diffusion of bioproducts 
produced by the probiotic or from the wells/disks into the medium leads to inhibition of 
bacterial growth in the vicinity of the probiotic or the well/disk and to the formation of 
clear zones without any bacterial lawn. Measurement of the zone of clearing around the 
probiotic species, well or disk is used as an indicator of antagonism.  
1.3.5.2 Gastrointestinal tolerance  
Conventionally,  in  vitro  tests  for  studying  the  gastrointestinal  tolerance  of  potential 
probiotics are also performed by culturing the probiotics in simulated gastric fluids or 
intestinal fluids (usually buffer, saline solution or growth media acidified to low pH 
value or with added bile salts/pepsin) and sampling the culture at different times to 
determine  survival  by  plate  counting  (Cui  et  al.,  2000,  Sun  and  Griffiths,  2000,   47 
Chandramouli  et  al.,  2004,  Iyer  and  Kailasapathy,  2005,  Ding  and  Shah,  2009, 
Mokarram et al., 2009, Sahadeva et al., 2011, Cook et al., 2011).  
1.3.5.3 Advantages and limitations of the conventional methods 
As mentioned previously, these in vitro methods, which are also employed when testing 
other biological efficacy or assessing relative growth or potency in mixed cultures, are 
mostly based on culture techniques. Although these methods are well established and 
have several advantages including cost effectiveness, ease of use, and familiarity among 
users, their drawbacks are also well documented (Gracias and McKillip, 2004, Vine and 
Bishop, 2005, O'Mahony and Papkovsky, 2006, Sohier et al., 2014). These methods are 
widely  known  to  be  extremely  laborious  and  time  consuming  (O'Mahony  and 
Papkovsky, 2006, Schmidt et al., 2007, Sohier et al., 2014). For example, experiments 
based on mixed cultures (Apella et al., 1992, Drago et al., 1997, Annuk et al., 2003) 
demand selective or differential spread-plating to distinguish the different species in a 
culture and to determine their concentration. Such experiments comprise serial dilution 
followed by plating on agar with selective or differential media or agents, which permits 
the growth of only one of the species or differentiation of the bacterial species. This 
routine is labour involved and time consuming especially as the number of species or 
strains being assessed in mixed cultures increases (Spiegelman et al., 2005, Schmidt et 
al.,  2007).  In  some  instances,  differential  or  selective  plating  is  not  an  option  since 
selective media might not be available for each species (Schmidt et al., 2007). 
Also, measurements on agar using bioproducts produced by a species during growth, 
although easier alternatives to the broth culture assay, these assays are hinged on the 
diffusibility of the bioproducts (Linton, 1983, Rogers and Montville, 1991). Bioproducts 
that are large or interact with the agar may not readily diffuse (Hoover and Harlander, 
1993). Zones of inhibition could also be influenced by factors such as the nutritional 
status of the growth media (for example for fastidious bacteria) (Jorgensen and Ferraro, 
2009), the incubation temperature and duration and inoculum size (Linton, 1983). For 
example, too dense an inoculum may result in no zone of inhibition because the high 
initial cell numbers may mask any subsequent zone formation (Hoover and Harlander, 
1993).  Also,  large  zones  of  inhibition  could  be  formed  when  the  bacteria  are  slow 
growing; making this method not very suitable for the accurate testing of fastidious or 
slow glowing bacteria (Piddock, 1990, Jorgensen and Ferraro, 2009) although generally,   48 
for antimicrobial susceptibility testing, the diffusion method has been standardized by 
the Clinical and Laboratory Standards Institute (CLSI) for testing a number of species 
through the use of specialized media, inoculum size, incubation conditions, and specific 
zone size interpretive criteria (Clinical and Laboratory Standards Institute, 2009). 
Growth on plate or colony-forming ability is influenced by morphological alterations 
and also by the plating procedure hence there is the possibility that viable cells could be 
underestimated during cell enumeration (Davey, 2011, Sohier et al., 2014). To give an 
example, stress during the serial dilution and spread plating can cause underestimation of 
viable organisms. Organisms may also sometimes occur in chains and/or clumps or be 
unevenly  distributed  on  the  plate  and  this  could  underestimate  cell  numbers. 
Furthermore, some cells may exist in dormant, cryptobiotic, moribund or latent states 
after a particular treatment hence may not form colonies on plates even though they may 
have other measurable activity (Davey, 2011). Also, the plate technique allows one to 
determine viability in a retrospective manner, and there is really no evidence that no 
growth on plate during sampling is an indication that the cell was dead during the time 
of  sampling  (Postgate,  1976,  Davey,  2011).  The  use  of  turbidity  assay  for  cell 
enumeration although relatively rapid, non-labour intensive and amenable to automation, 
also  suffers  from  drawbacks  such  as  inability  to  analyse  heterogenous  or  complex 
samples and to distinguish viable cells from dead cells (Madigan et al., 1997, O'Mahony 
and Papkovsky, 2006).   
As  mentioned  previously,  there  are  a  number  of  molecular  and  other  rapid  and 
automated methods, which are being applied in these assays for detection or enumeration 
of organisms (Ben-Amor et al., 2001, Grattepanche et al., 2005, Moreno et al., 2006, 
Masco et al., 2007, Rueger et al., 2012, Tejero-Sarinena et al., 2013, Sohier et al., 2014). 
For  instance,  microscopic  techniques  such  as  fluorescence  microscopy  has  been 
employed by Moreno et al., (2006) for enumeration of viable lactic acid bacteria from 
commercial fermented milks. Flow cytometry has also been employed by Ben-Amor et 
al., (2001) to enumerate viable bifidobacteria after bile salt stress. However whilst some 
of these advanced techiques have enabled sensitive, more convenient and faster detection 
and enumeration, they may require special skills, reagents and the pretreatment of the 
culture before analysis, for example, fluorescently labeling of the organisms. Also in 
terms of enumeration of viable species in mixed cultures or determination of interspecies 
interactions, only few of the molecular techniques have been employed; most of them   49 
have been used for characterization of diversity of samples rather than the determination 
of absolute cell numbers or viable cell numbers (Spiegelman et al., 2005, Schmidt et al., 
2011, Rueger et al., 2012, Nagarajan and Loh, 2014). However, quantitative polymerase 
chain reaction (qPCR) has been employed by Grattepanche et al., (2005) for determining 
interaction between Lactococcus cremoris, Lactobacillus rhamnosus and Lactococcus 
diacetylactis during milk fermentation. Quantitative terminal restriction fragment length 
polymorphism analysis method (qT-RFLP) has been employed by Schmidt et al., (2007, 
2011) for enumeration of mixed cultures of Pseudomonas aeruginosa, Staphylococcus 
aureus and Burkholderia cepacia. Flow cytometry has also been employed by Rueger et 
al., (2012) for enumeration of viable cells in mixed cultures of S. aureus and B. cepacia. 
Fluorescent  in  situ  hybridization  (FISH)  has  also  been  employed  by  DuTeau  et  al., 
(1998) for differential enumeration of  Pseudomonas putida, Burkholderia sp. and B. 
subtilis. 
As  suggested  earlier,  a  possibility  to  avoid  some  of  the  disadvantages  of  the 
conventional methods is also offered by isothermal microcalorimetry. It is simple, fast, 
sensitive, and most importantly, can allow the continuous detection of biological activity 
without  sample  pretreatment  or  destruction.  It  could  also  overcome  the  tedium  of 
manually counting cells of a particular morphology, providing rapid acquisition of data 
in real-time and allowing analysis to be performed on heterogeneous systems although it 
has  its  own  limitations.  It  could  thus  complement  the  conventional  and  other  rapid 
methods for the routine evaluation of probiotics especially where mixed cultures are 
encountered. 
1.4 Isothermal microcalorimetry as a potential tool for characterizing potential 
health benefits of probiotics  
1.4.1 What is isothermal microcalorimetry? 
Microcalorimetry (from mikrós, Greek, meaning small, calor, Latin, meaning heat and 
metry, Greek, meaning measurement) is a technique that operates on the basic principle 
of measurement of heat, as a means of measurement of change in a material. It traces its 
origin to Lavoisier and Laplace who introduced its concept between 1782-1783. With an 
ice calorimeter (schematic diagram shown in Figure 1.3) and a guinea pig, these two   50 
realized  that  the  mass  of  liquid  water  produced  by  the  melting  ice  was  directly 
proportional to the heat produced by the activities of the guinea pig. Because they knew 
the quantity of water produced and the latent enthalpy of fusion of water, they were able 
to calculate the total heat output for the process. 
 
Figure 1.3.  A schematic diagram of the ice calorimeter designed by Lavoisier and Laplace.  
It is thought that when change (whether physical or chemical) occurs in a material, it 
invariably occurs with a change in heat content of the material, hence a calorimeter can 
detect  and  potentially  quantify  various  changes  in  a  wide  variety  of  materials  and 
processes including growth and metabolism of microorganisms (Gaisford and O’Neill, 
2006, Braissant et al., 2010a). For example, microcalorimetry is known for applications 
such as determination of the stability of a product (Runge and Heger, 2000, Simoncic et 
al.,  2007),  quantification  of  amorphous  content  (Gaisford,  2012),  determination  of 
critical micelle concentrations (Bouchemal et al., 2009), dissolution studies (Ashby et 
al.,  1989),  etc.  It  is  only  imperative  that  the  process  being  followed  in  a  material 
produces a detectable amount of heat and that the material  being studied fits in the 
calorimetric vessel. 
The term “isothermal” is generally used to imply the constant temperature at which 
samples are held during an experiment. It must be noted that broadly, calorimeters can 
be operated isothermally or non-isothermally (Gaisford and O’Neill, 2006). Thus, either 
there  is  temperature  change  over  time  (either  linear  or  modulated)  for  example  in 
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Differential Scanning Calorimetry (DSC) or the sample is held at a constant temperature 
throughout the experiment. The isothermal technique is more suited for study of growth 
of  bacteria.  Isothermal  microcalorimeters  are  instruments  designed  for  use  in  the 
microwatt range; those that make measurement in the nanowatt range are referred to as 
isothermal nanocalorimeters (Wadso and Goldberg, 2001). 
1.4.2 Isothermal microcalorimeters: principles and instrumentation 
Isothermal microcalorimeters measure heat by three main principles: 
  Adiabatic: where there is no heat exchange between the calorimetric vessel and 
its  surrounding.  An  adiabatic  shield  is  placed  between  the  vessel  and  its 
surrounding to obtain the adiabatic condition. In such arrangement, a change in 
heat  content  of  a  system  under  investigation  is  equated  to  the  change  in 
temperature (either endothermic or exothermic) that has occurred in the vessel 
multiplied  by  an  experimentally  determined  cell  constant.  In  practice,  true 
adiabatic  conditions  might  be  difficult  to  obtain  due  to  heat-leak  to  the 
surroundings. However, if the instrument balances these heat leaks, then semi-
adiabatic conditions are achieved and corrections are applied to the data (Wadso 
and Goldberg, 2001). 
 
  Power compensation: where the heat gained or removed during an endothermic 
or  exothermic  process  is  balanced  by  an  opposing  power,  supplied  by  an 
electrical element by using the Peltier principle (Wadso and Goldberg, 2001).  
 
  Heat conduction: where heat produced or absorbed during a course of reaction in 
the calorimetric vessel is allowed to flow to or from a surrounding heat sink. The 
heat sink is maintained at a constant temperature (Wadso and Goldberg, 2001). 
Most  isothermal  microcalorimeters  are  based  on  the  principle  of  heat  conduction. 
Isothermal condition is achieved by exchange of heat (q) produced or absorbed by the 
sample  with  the  surrounding  heat  sink  via  thermopiles  located  between  the  two 
compartments (Figure 1.4).  
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Figure 1.4. Schematic diagram of the heat-sink/thermopile arrangement in the Thermal Activity 
Monitor (TAM), courtesy of Thermometric 
 
Figure 1.5 A diagram of the TAM (left) and one of its unit (right), courtesy of Thermometric 
The thermopiles produce a voltage signal (U) proportional to the heat flowing across 
them anytime there is heat exchange between the vessel and the heat sink. This signal, 
when multiplied by a cell constant () obtained through electrical calibration, produces a 
raw power signal (PR) (Equation 1.1), which is plotted as a function of time (t) (Wadso 
and Goldberg, 2001, Gaisford and O’Neill, 2006). The total heat quantity (Q), released   53 
by a sample, is given by the product of the electrical potential time integral and the cell 
constant (Equation 1.2).   
PR = dq/dt = U                                                      Equation 1.1 
           Q =   Udt                                                      Equation 1.2 
It must be noted that the isothermal microcalorimeter used for all the work reported in 
this thesis was a Thermal Activity Monitor 2277 (TAM, TA Instruments Ltd., UK). It 
has four separate microcalorimetric channels and capable of taking measurements from 
four experiments simultaneously, Figure 1.5. All four channels are immersed in a closed 
thermostatted water bath (the heat sink) that can be finely set within the range of 5
oC and 
80
oC (Technical specifications, Thermometric). Each channel has both a sample and 
reference  chamber  connected  in  opposition.  These  chambers  accept  the  sample  and 
reference materials, which are often housed in 3-20 mL glass or stainless steel ampoules. 
The  reference  material  is  usually  an  inert  material,  which  must  be  of  similar  heat 
capacity  as  the  sample  and  is  used  in  the  same  quantity  as  the  sample.  During 
measurement, the sample and reference, both generate an electrical potential, which is 
reported as a differential. This ensures that any noise affecting the sample chamber or 
both chambers is minimized, allowing only the thermal output of the reaction to be 
recorded (Wadso, 2010). The instrument is equipped with an amplifier module, which 
can be set to different ranges for example,  3, 10, 30, 100, 300, 1000 and 3000 µW 
depending on the expected thermal output from a reaction or the sensitivity required 
(Technical  specifications,  Thermometric).  It  is  also  linked  with  a  computer,  which 
captures data every 10 s using the software package, Digitam™.  
Like most modern isothermal microcalorimeters, the TAM is very sensitive, has good 
reproducibility, precision and baseline stability. This is attributable to the efficiency with 
which isothermal conditions are achieved. To maintain such sensitivity and stability, 
they are often required to be housed in air-conditioned rooms that are maintained at a 
constant temperature of 20-30
 oC ± 0.1
oC (Technical specifications, Thermometric).    54 
1.4.2.1 Calibration 
Electrical calibrations are usually performed before an instrument is used for the first 
time and also any time there is loss of power supply, change in amplifier range or change 
in experimental conditions (Technical specifications, Thermometric). 
During  calibration,  the  TAM  is  loaded  with  two  reference  samples  (thus,  both  the 
reference  chamber  and  sample  chamber  are  loaded  with  the  reference  material  in 
quantities equal to the one to be used for subsequent experiments). It must be noted that 
during experiments, the ampoules are first lowered to the equilibrium position (above the 
thermopile)  for  a  period  of  30  min  in  order  for  the  ampoules  and  their  contents  to 
equilibrate with the temperature of the TAM. This reduces any thermal shock that would 
have otherwise been encountered. Once thermal equilibrium is attained, they are lowered 
into the measurement position carefully, with the aim of reducing frictional heat to the 
minimum. Since both the reference and sample chambers are loaded with the same inert 
material during calibration, it is expected that no power is produced and a baseline signal 
of zero should be attained. Practically, this may sometimes not occur because of noise. 
Therefore, when the baseline signal is stable for a period, it can be adjusted to zero via a 
potentiometer. Current is then passed through the calibration heater located at the base of 
the chamber for a given length of time, which should cause a deflection in the baseline 
signal to a constant set value. Usually during calibration, an amplitude range is set and 
the heater is expected to match this set limit. For example, if the amplifier is set to a 
range of 1000 µW, the heater is expected to produce a power of 997.2 µW (Technical 
specifications, Thermometric). Like the baseline signal, this value, can also be adjusted 
so that the output recorded by the instrument matches that delivered by the calibration 
heater. Current is then switched off and the signal should decay back to zero. During the 
calibration,  the  calibration  constant  or  coefficient  (),  which  is  the  proportionality 
constant between the measured signal (voltage) and the thermal power is obtained which 
is applied to the results (Wadso, 2010).  
1.4.2.2 Instrumental designs  
There  are  a  lot  of  designs  of  the  isothermal  microcalorimeter  due  to  its  diverse 
applications: for example, there are ampoule microcalorimeters, flow microcalorimeters, 
gas  perfusion  microcalorimeters,  isothermal  tritration  microcalorimeters,  solution   55 
microcalorimeters  and  so  on.  The  common  ones  that  have  been  explored  to  study 
microbial  systems  are  the  ampoule  microcalorimeter  and  the  flow  microcalorimeter 
(Monk and Wadso, 1975, Hartung, 1986, Zhao et al., 2000, Gaisford et al., 2009, Lago 
Rivero et al., 2013, Bonkat et al., 2012). They all have their advantages that can be 
explored and limitations. The ampoule was used for the work reported in this thesis.  
Ampoule microcalorimeters 
These  represent  the  closed  batch  culture  experiments.  They  use  removable  glass  or 
stainless steel ampoules, which are hermetically sealed. Samples (organism and reaction 
medium)  are  placed  in  these  ampoules,  sealed  and  placed  in  one  of  the  measuring 
channel of the isothermal microcalorimeter. Heat flow measurements are recorded and 
can be evaluated as they occur. A major limitation as with any batch culture experiment 
is that growth is only possible for a finite period of time as energy sources are depleted 
with  time.  Again,  because  the  ampoules  are  sealed,  it  is  difficult  to  control  the 
atmosphere inside of the ampoule (Winkelmann et al., 2004). Typically, the atmosphere 
within the ampoule is of limited oxygen supply (oxygen available is that dissolved in the 
medium and in the headspace), hence the study of aerobic microorganisms is difficult 
since aerobic respiration rapidly renders the medium anoxic (Braissant et al., 2010a). 
However, when it is ensured that the microorganisms have a  direct air interface for 
example through use of solid media (Wadso et al., 2004), oxygen depletion could be 
avoided and the study of aerobic microorganisms in sealed ampoules is possible.  
Another major limitation with the ampoule is that it does not allow the sampling of the 
system  during  investigation  or  the  addition  of  substances  during  experimentation. 
Attempts to do that will upset the thermal equilibrium of the calorimeter. The ampoule 
technique  does  not  also  allow  the  stirring  of  samples  during  experiments.  There  is 
therefore the risk of sedimentation of cells, which could cause concentration gradients of 
pH, nutrients, etc (Beezer, 1980). 
They also have associated benefits of batch culture experiments. For instance, they are 
simple, easily sterilized and also allow the study of samples without contact with the 
environment,  supporting  the  study  of  high-risk  organisms.  The  glass  ampoules  are 
disposable and prevent the risk of cross contamination during experiments.    56 
In summary, isothermal microcalorimeters allow for monitoring of chemical, physical or 
biological processes of samples as they occur through the measurement of heat released 
or  absorbed  by  the  sample  via  a  sample-thermopile  arrangement.  After  the 
standardization of an instrument through calibration, heat flow measurement of a sample 
can be taken for as long as it is of interest. Most isothermal microcalorimeters like the 
TAM are designed as twin instruments, and it is thus a differential signal (between a 
sample and a “blank” reference) that is measured. 
1.4.3 Data analysis- microbiological  
Heat released or absorbed from the heat sink  during the course of an experiment is 
expressed as power-time curves. The power-time curves are characteristic for a species if 
the  inoculum  is  standardized  and  the  experimental  conditions  are  completely 
reproducible  (explained  in  the  later  sections).  Data  therefore  obtained  from 
microcalorimetric  experiments  can  be  analysed  in  two  ways:  either  qualitatively  or 
quantitatively. Qualitative analysis is based on the description of changes that occurs in 
the power-time curves by the presence of a metabolic modifier, for example, a reduction 
in the power output by an antibiotic (Prat, 1953, Sedlacze.L et al., 1966, Said et al., 
2014). Such descriptive analysis is more popular since the power-time curves obtained 
from  a  growing  culture  of  bacteria  are  rather  too  complex  to  give  quantitative 
information on the organisms and also vary with changes in the metabolic performance 
of inocula. Quantitative information can nonetheless be obtained when the bacteria are 
allowed only to respire and not to increase in biomass by the use of defined medium 
with limited energy source (Vine and Bishop, 2005). Such controlled processes could be 
described mathematically; for example, the kinetic profile of the respiring bacteria can 
be described by the Michaelis-Menten kinetics and hence quantitative information can 
be obtained (Vine and Bishop, 2005). Also, the power-time curve and its integral (heat 
curve) can be analysed to obtain information such as the growth rate (µ) and generation 
time (t1/2), which are major growth indicators. These growth parameters could change 
depending on the particular treatment given to a culture, for example, whether a bacterial 
culture is growing with or without the presence of a metabolic modifier (Braissant et al., 
2013).    57 
1.4.4 Advantages and limitations of isothermal microcalorimetry 
Isothermal microcalorimetry offers a lot of advantages compared to traditional batch 
culture or continuous culture experiments. The most important of all, are the real time 
information it provides, its simplicity, non-laborious and non-destructive/non-invasive 
nature  of  the  experiments.  For  instance,  Prat  (1953)  demonstrated  that  addition  of 
streptomycin  to  a  culture  of  Esherichia  coli  inhibited  the  species  by  decreasing  the 
microcalorimetric  output  to  one  tenth  of  its  original  value  but  also  noted  that  the 
inhibitory  activity  of  the  drug  was  greater  when  the  culture  was  stirred.  Thus  the 
efficiency of the drug was limited by its rate of diffusion through the medium (Prat, 
1953).  If  his  experiment  had  been  performed  by  conventional  plate count,  the  same 
qualitative data would have been produced but in less detail since in such an assay, only 
end point data are obtained. Thus, the sample would have been taken at random time 
intervals and plated. Microcalorimetry does not also require the sample to be modified, 
for example, adding fluoresecent or radioactive labels nor does it alter samples during 
measurement, hence samples can be subjected to further assays after microcalorimetric 
measurements (Braissant et al., 2010c).   
It is also a  very sensitive technique.  According to Braissant et al.,  (2010a), modern 
isothermal  microcalorimeters  can  detect  as  low  as  10
4  -10
5  per  mL  bacterial 
concentration when approximately 2 pW per cell is expected when the cell is active. 
However it is generally maintained that at least 10
6
 microorganisms per mL is sufficient 
to produce detectable signals in most commercially used microcalorimeters (Gaisford et 
al., 2009). Lower cell density adds a time lag to the growth data until the cells have 
grown to this detectable concentration. Still this detectable concentration limit cannot be 
detected  using  conventional  turbidity  measuring  techniques  such  as  the  McFarland 
standards  which  calibrate  turbidity  of  bacterial  concentrations  to  a  minimum 
concentration  of  approximately  0.75  x  10
8  CFU/mL  or  spectrophotometry  (when 
measuring optical density at 600 nm) (Vine and Bishop, 2005, Braissant et al., 2010a). 
The  heat  sensitivity  of  isothermal  microcalorimeters  also  allows  large  changes  in  a 
sample to be measured apart from subtle ones (Braissant et al., 2010a). They also have 
good reproducibility, high precision, and are very simple and convenient to use; data 
acquisition  is  automated.  They  can  also  be  operated  isothermally  at  different 
temperatures, and this can be suited to the requirements of different reactions.    58 
Like any technique, isothermal microcalorimetry is not without it problems. Some of the 
limitations have already been outlined based on the design of their use. But a major 
limitation of the use of isothermal microcalorimeters is the non-specificity of the data 
obtained. Heat flow signals obtained are a sum of all the biological, chemical or physical 
processes taking place in a sample (Beezer, 1980, Johansson and Wadso, 1999a). As a 
result of this, the total heat measured with this technique may be contributed by the 
process  under  investigation  and  other  unknown  or  even  unwanted  phenomena.  This 
makes  data  interpretation  a  real  challenge.  Careful  planning  of  experimentation  is 
therefore  a  necessity.  Nevertheless,  when  the  process  under  investigation  is  well 
described and conducted under controlled conditions, the process can be studied with a 
high accuracy (O'Neill and Gaisford, 2011).  
Again, the use of the ampoule require that the ampoule together with samples contained 
in  it  are  allowed  to  reach  thermal  equilibrium  before  any  significant  data  can  be 
obtained. As mentioned already, the ampoules are placed in an equilibration position for 
a set time, usually, 30 min before they are placed in the measuring position. The problem 
with this is some reactions can be initiated before measurements are captured hence it is 
often not possible to determine the calorimetric signal at time zero. 
1.4.5 Isothermal microcalorimetry and its microbiological applications 
Dubrunfaut, (1856) was the first person who reportedly used calorimetric measurement 
to study quantitatively, the heat production by a microbial fermentation system. Since 
his study, many scientists used the calorimeter to study the growth and metabolism of 
bacteria and other microorganisms. For example, Bouffard, (1985) measured the heat 
evolved by 1 litre of culture using Berthelot’s instrument. Rubner, (1903, 1904, 1906, 
1908)  using  a  primitive  calorimeter,  also  reported  numerous  studies  on  the  heat 
evolvement of bacteria and yeast. So did Tangl, (1903), Terroine and Wurmser, (1922), 
Meyerhof, (1924), Shearer, (1921), Bayne-Jones, (1929), Prat et al., (1946),  Battley, 
(1960), Forrest et al., (1961), Belaich, (1962 and 1963), Boivinet, (1964), Monk and 
Wadso, (1968) and many more. Although these pioneering microbiological studies were 
done in the early days of calorimetry, the use of calorimetry for microbiological studies 
waned in the 1970s (Gaisford and O'Neill, 2006). In the last few years, there has been 
the resurgence of calorimetry in microbiological studies and this has been attributed to   59 
the  development  of  more  sensitive  and  high-throughput  instruments  (Gaisford  and 
O’Neill, 2006, Braissant et al., 2010a, Wadso and Galindo, 2009) and the consideration 
by  the  pharmaceutical  industry  seeking  more  rapid  and  improve  methods  for 
investigating microorganisms (Vine and Bishop, 2005, Gaisford and O’Neill, 2006).  
Microcalorimetry  has  applications  in  soil  and  environmental  microbiology  (Wadso, 
2009, Braissant et al., 2010a, Maskow et al., 2010, Ning et al., 2013), pharmaceutical 
and  medical  microbiology  (Vine  and  Bishop,  2005,  Braissant  et  al.,  2010a),  food 
microbiology (Wadso and Galindo, 2009) including other biological applications in food 
science (Wadso and Galindo, 2009), biomedical science (Braissant et al., 2010c) and soil 
and environmental sciences (Rong et al., 2007, Russel et al., 2009). For instance, it has 
been used for monitoring and quantification of soil microbial activity and contamination 
(Bravo  et  al.,  2011,  Guo  et  al.,  2012);  detection  of  infection  and  contamination  of 
clinical products and samples (Trampuz et al., 2007, von Ah et al., 2008, Braissant et al., 
2010d); determination of effects of antimicrobial compounds (Li et al., 2000, O’Neill et 
al.,  2003,  Gaisford  et  al.,  2009)  including  the  mode  of  action  of  antimicrobial 
compounds-bacteriostatic  or  bacteriocidal  (von  Ah  et  al.,  2009),  viral  infections  and 
activities of antiviral compounds (Tan and Lu, 1999, Heng et al., 2005); spoilage of food 
(Alklint et al., 2005) etc. The detailed microbiological applications of microcalorimetry 
in the different scientific fields are reviewed in the references cited under the respective 
field. Most of the microbiological applications of microcalorimetry are in soil quality, 
food deterioration, infection detection and antibiotic testing. 
1.4.6 Characterization of microorganisms 
When placed in an appropriate medium, a bacterium will consume the nutrient provided 
for growth. In the isothermal microcalorimeter, the calorimetric output which is referred 
to as “power-time curve” is the net metabolic activity of the bacterium. A typical power-
time curve shows an initial exponential increase in heat output followed by a series of 
peaks and troughs representative of the sequential utilization and exhaustion of different 
components of a given medium (Vine and Bishop, 2005). 
Under strictly defined conditions, and reproducible experimental conditions, individual 
bacterial species are known to yield characteristic power-time curves. This principle was 
suggested as a premise to identify microorganisms since Boling et al., (1973) reported   60 
that all Enterobacteriaceae tested, which included 17 species from 10 genera could be 
distinguished. Also, at least 200 clinically significant organisms representing 24 genera 
and 47 species could be distinguished by Russel et al., (1975) by means of their specific 
thermal  pattern.  Fujita  et  al.,  (1978)  also  identified  9  strains  of  lactic  acid  bacteria. 
Identification had also been implicit in earlier studies by Rubner (1906) and Prat et al., 
(1946) and studies by Staples et al., (1973) and Ljungholm (1976). But such universal 
identification  received  criticism  on  the  notion  that  it  was  impossible  to  reproduce 
experimental conditions in reality and the fact that even small changes can affect data 
generated with isothermal calorimeters (Beezer et al., 1979, Newell, 1980). Also, there is 
variation  between  calorimetric  instruments  and  procedures,  which  introduce 
discrepancies  between  experiments  that  are  supposedly  identical  (Monk  and  Wadso, 
1975).  The  biggest  challenge  is  the  standardization  of  an  inoculum  and  its  history. 
Beezer et al., (1976) addressed to some extent the standardization of an inoculum using 
freezing and storage protocols by freezing down and storing large volumes of a batch of 
an inoculum that allow an inoculum to be used as a “standard reagent”. Hence when 
using the same medium, experimental condition and instrument, a batch of inoculum can 
be  characterized.  For  instance,  after  the establishment  of  the  power-time  curve  of  a 
standardized organism using a specific medium, if a metabolic modifier is added to the 
medium,  the  power-time  curve  will  change  according  to  the  modifier  added,  the 
concentration it was added and the time it was added. The change of the power-time 
curve due to the presence of metabolic modifiers has allowed the study of wide-ranging 
processes, for example, the effects of antibiotics and antimicrobial agents (Zhao et al., 
2000, Li et al., 2002, O'Neill et al., 2003, Gaisford et al., 2009, Howell et al., 2012). 
Microcalorimetry has also been applied in the differentiation of strains and species. For 
example,  methicillin-susceptible  Staphylococcus  aureus  has  been  differentiated  from 
methicillin-resistant S. aureus from clinical samples (von Ah et al., 2008, Baldoni et al., 
2009).  Baker’s,  brewer’s  and  distiller’s  yeast  have  been  differentiated  in  the 
microcalorimeter by Newell, (1975). Lago Rivero et al., (2013) have also differentiated 
between and characterised the growth of S. aureus and Staphylococcus epidermis. The 
growth of S. aureus and E. coli (Zaharia et al., 2013) and E. coli, Proteus mirabilis and 
Klebsiella  pneumoniae  (Lago  Rivero  et  al.,  2012)  have  also  been  characterised  and 
compared.  
However,  to  date  there  are  very  few  reports  of  microcalorimetric  measurements  for 
detecting  species  in  mixed  cultures  or  monitoring  interpecies  interaction.  One  such   61 
measurement was performed by Schaeffer et al., (2004) to determine the growth optima 
for a mixed culture of a probiotic species and an aroma-producing mesophilic microbe 
which the probiotics rely on to generate taste in a product. Their experiment showed that 
the two cultures did not impede each other in mixed cultures. With their observation, 
they were able to expound production procedures for probiotic butter cream and heat-
resistant sour cream using the two cultures in a mixed product (Schaffer et al., 2004, 
Schaffer and Lorinczy, 2005). In another study, Chen et al., (2008) evaluated the toxic 
effect of cadmium on the growth of Candida humicola and Bacillus subtilis singularly or 
in mixed culture. Their result showed different growth rate and endurance for the two 
species and mixed culture. The sensitivity of B. subtilis to cadmium was higher than C. 
humicola  but  the  mixed  microorganisms  had  a  higher  endurance  than  single 
microorganisms.  These  authors  however  could  not  ascertain  whether  or  not  the  two 
microorganisms have an interaction when put together. In a similar study, Wang et al., 
(2009) followed the toxic effect of a trivalent iron on single and mixed culture of B. 
subtilis and C. humicola. The results indicated that C. humicola had highest tolerance to 
iron overload while the mixed culture had moderate tolerance compared with the single 
species and B. subtilis followed. The authors speculated that the moderate tolerance of 
the mixed culture could be due to the interaction between the two species (Wang et al., 
2009). Kong et al., (2012) also studied the effect of berberine on the growth of pure and 
mixed cultures of E. coli and B. subtilis. The authors demonstrated that the endurance of 
E.  coli  to  berberine  was  lower  than  B.  subtilis  and  also  demonstrated  that  E.  coli 
dominated the mixed culture and could reduce the endurance of B. subtilis in mixed 
culture (Kong et al., 2012). Recently, and very relevant, Vazquez et al., (2014) studied 
the interaction between E. coli and P. mirabilis by mixing them together at different 
proportions. Their result showed that P. mirabilis dominated in mixed cultures even at 
low proportions in a culture. Another study by Vazquez et al (2013) also demonstrated 
interaction between Enterococcus faecalis and Klebsiela pneumoniae.  
Although  the  relevant  application  of  microcalorimetry  in  detecting  species  in  mixed 
cultures  or  studying  interspecies  interactions  have  only  been  recently  explored,  no 
documentation in literature has been made for its exploration in studying the antagonistic 
effect of probiotics against potential pathogens.  
   62 
1.5 Aims and Objectives 
The main aims and objectives of the research in this thesis were 
  To  explore  the  potential  of  isothermal  microcalorimetry  to  detect  bacteria  in 
mixed cultures. This was to be applied:  
  To  investigate  the  behaviour  of  Pseudomonas  aeruginosa, 
Staphylococcus aureus and Esherichia coli in mixed cultures 
  To  investigate  whether  commercial  probiotics  can  inhibit  in  vitro 
potential  pathogenic  microorganisms  particularly,  the  clinically 
important gut pathogen, Clostridium difficile in the microcalorimeter 
  To investigate whether commercial probiotics, which are packaged and 
sold as multistrain, are stable as a product 
  To investigate whether a potential prebiotic substrate would increase the 
growth of pure probiotic species or specific members of colonic bacteria 
in the microcalorimeter 
Gastric tolerance assay of potential and commercial probiotics are routinely conducted in 
acidified saline solutions, buffers and growth media (Cui et al., 2000, Sun and Griffiths, 
2000, Chandramouli et al., 2004, Iyer and Kailasapathy, 2005, Ding and Shah, 2009, 
Mokarram et al., 2009, Sahadeva et al., 2011, Cook et al., 2011); without consideration 
to  other  physiological  factors  such  as  transit  time,  gastric  volume  and  presence  of 
enzymatic and digestive materials. Also, the plate technique is conventionally used to 
determine survival. This research also aimed to: 
  To develop a more realistic test for determining gastric tolerance of commercial 
probiotics  
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Chapter 2 Defined mixed culture of Pseudomonas aeruginosa, 
Staphylococcus aureus and Escherichia coli 
2.1 Introduction 
2.1.1 Defined mixed culture in the isothermal microcalorimeter 
As  reviewed  in  the  previous  chapter,  microcalorimetry  has  had  vast  microbiological 
applications in various fields (section 1.4.5 and 1.4.6). Despite all the applications, only 
few studies have been conducted on defined mixed culture with the aim of investigating 
the relationship between two or more bacteria (Schaffer et al., 2004, Kong et al., 2012, 
Vazquez et al., 2014).  
In this chapter, the growth and behaviour of Pseudomonas aeruginosa, Staphyloccocus 
aureus  and  Escherichia  coli  were  studied  as  mixed  culture  to  determine  if  the 
microcalorimeter  could  detect  their  relative  growth.  These  3  non-fastiduous  species, 
previously characterised in the microcalorimeter (O'Neill et al., 2003, Gaisford et al., 
2009, Said et al., 2014) were to be used in subsequent susceptibility test with some 
commercial probiotic strains.  
P. aeruginosa is an opportunistic human pathogen that can cause various infections, for 
example infections of the ear, eyes, skin, urethra and respiratory tract in cystic fibrosis 
and patients with severe burns, as well as other immunocompromised and chronically 
debilitated individuals (Garrity et al., 2005). It is a very adaptable bacterium, known to 
colonize  several  environmental  niches;  one  of  the  most  common  species  in  nature 
(Garrity et al., 2005, Khan et al., 2010). Its numbers are very low in the faeces but 
numbers can increase significantly after antibiotic treatment (Levison, 1977).  
S. aureus forms part of the normal human microbiome, and colonizes the skin, skin 
glands, mucous membranes, especially anterior nares (Schleifer and Bell, 2009). It is an 
important cause  of  nosocomial  infections  and  has  caused  considerable  mobidity  and 
mortality in hospitalised patients (Wisplinghoff et al., 2004, de Kraker et al., 2011). It is 
associated  with  surgical  infections,  lung  infections,  urogenital  tract  infections,  skin 
infections, abscesses of the muscle and bacteremias. Its enterotoxin is involved in food 
poisoning (Schleifer and Bell, 2009).   64 
E. coli is an essential part of the gut microbiota. Most strains are non-pathogenic but 
certain serotypes can cause diseases of the intestine and other parts of the body. They 
possess  a  variety  of  virulence  factors  responsible  for  their  pathogenicity  in  healthy 
patients.  For  example, enteropathogenic  and  enterotoxigenic  E.  coli cause  diarrhoea. 
Uropathogenic E. coli, neonetal meningitis E. coli and other types are described (Scheutz 
and Strockbine, 2005). 
2.1.2 Standardization of inocula: cryopreservation  
As a prerequisite for using bacteria as “standard reagents”, ensuring that any difference 
between experiments is solely due to deliberate changes made, an objective was set to 
develop a cryopreservation protocol for the microorganisms, which, while maintaining 
uniformity of inocula, would give viable cell recoveries of at least 95%.  
It must be noted that microbiological assays could be subject to inconsistencies between 
experiments because of variations in the metabolic performance of inocula used (Beezer 
et  al.,  1976).  While  this  variation  is  tolerated  in  some  assays  because  of  other 
standardization protocol in place by a particular method, for quantitative characterization 
or identification by microcalorimetry (for example, antibiotic susceptibility testing) this 
may not be the case (Beezer et al., 1976). The source of variation of an inoculum can be 
credited to the volume or size, the phase of growth and particularly the history of the 
inoculum  being  used  (Beezer  et  al.,  1976).  To  avoid  batch-to-batch  variability,  it  is 
important that inocula are  rigorously standardized. Standardization of inocula can be 
achieved through the development of standardized freezing and storage protocols for 
large volumes of inocula (Beezer et al., 1976, Gaisford et al., 2009). This will ensure that 
a consistent inoculum is used for each assay since the microorganisms would be sourced 
from the same batch per assay or would have gone through a similar cultivation process.   
In  the  frozen  state,  the  microorganisms  are  expected  to  remain  viable,  without  any 
alterations in genotypic or phenotypic characteristics (Tedeschi and De Paoli, 2011). 
They should also be easily restored to the same condition they were before freezing or 
cryopreservation  (Beezer  et  al.,  1976).  Conventionally,  microbiological  stocks  are 
preserved by storing at -4
oC to -80
oC. Storage at these temperatures has however been 
shown  to  be  less  effective  than  at  -160
oC  in  liquid  nitrogen  vapour  (McDaniel  and 
Bailey, 1968) or liquid nitrogen storage at -196
oC (Stapert et al., 1964, Sokolski et al.,   65 
1964, Hwang, 1966, Cowman and Speck, 1965, Beezer et al., 1976, Gaisford et al., 
2009). Freezing in liquid nitrogen at -196
oC can store living microorganisms for several 
years while maintaining viability and reproducibility (Beezer et al., 1976, Gaisford et al., 
2009, Tedeschi and De Paoli, 2011). For instance, some bacteria have been shown to 
store for up to 30 years without loss in viability (Gherna, 1981, Reimer and Carroll, 
2004). 
A  number  of  factors  are  known  to  affect  the  effectiveness  of  cryopreservation  of 
microorganisms,  for  example,  the  composition  of  the  freezing  medium,  the  storage 
temperature, the cooling rate and warming rate (Meryman, 1971, Beezer et al., 1976, 
Hubalek, 2003, Morgan et al., 2006, Tedeschi and De Paoli, 2011). The cooling rate 
during the freezing process is a critical factor for cell viability and recovery (Beezer et 
al., 1976). The optimal cooling rate for most bacteria has been suggested to be 1
oC per 
min  (Mazur  et  al.,  1972)  even  though  some  bacteria  will  withstand  less  than  ideal 
cooling rates (Tedeschi and De Paoli, 2011). Very slow cooling rate results in death of 
cells caused by changes in osmotic pressure whereas very fast freezing rate can cause 
cell death from mechanical damage of cell membranes caused by recrystallization of 
intracellular ice (Meryman, 1971). Another critical aspect in freezing is the efficiency of 
a cryoprotective agent in protecting cells from injury and death (Meryman, 1971). As 
already pointed out, during freezing and defrosting processes, cells could suffer severe 
osmotic stress and ice crystal damage.  A way of circumventing these possible lethal 
effects is to include a cryoprotectant prior to freezing. Addition of cryoprotectants has 
been  shown  to  improve  survivability  of  cells  (Harrison,  1956,  Postgate  and  Hunter, 
1961, Nash et al., 1963, Baumann and Reinbold, 1966, Gibson et al., 1966, Green and 
Woodford, 1992, Vekeman et al., 2013).  
There are different types of cryoprotectants and classifications: extensively reviewed by 
Meryman, (1971) and Hubalek, (2003). Briefly, there are those that penetrate the cells: 
methanol,  ethanol,  ethylene  glycol,  propylene  glycol,  dimethylformamide,  dimethyl 
sulfoxide (DMSO), methylacetamide and glycerol. There are others that do not penetrate 
the cells: mannitol, sorbitol, dextran, methyl cellulose, albumin, gelatin, other proteins, 
polyvinylpyrrolidone (PVP) etc., (Meryman, 1971). The non-penetrating ones provide 
only  extracellular  protection  whilst  the  penetrating  ones  can  also  delay  intracellular 
freezing and  provide  both  intracellular  and extracellular  protection  (Meryman,  1971, 
Hubalek, 2003).   66 
For the cryopreservation of the organisms, the effectiveness of different cryoprotective 
agents was tested in order to select the best cryoprotectant for the organisms to give 
recoveries of 95% or more. Storage of the stock was to be in liquid nitrogen because of 
the highlighted advantages from previous experiences (Beezer et al., 1976, Gaisford et 
al., 2009). 
2.2 Objectives 
The objectives of this chapter were: 
  To develop a cryopreservation protocol for the microorganisms with a suitable 
cryoprotectant which will ensure the standardization of the inocula, hence, the 
uniformity in the metabolic performance of all inocula 
  To  study  the  growth  of  the  microorganisms  as  pure  culture  in  the 
microcalorimeter 
  To  study  the  growth  of  mixed  cultures  of  the  microorganisms  in  the 
microcalorimeter 
2.3 Materials and Methods 
2.3.1 Microorganisms 
The strains used were Staphylococcus aureus NCIMB 9518, Pseudomonas aeruginosa 
NCIMB 8626 and Escherichia coli ATCC 25922.  
Staphylococcus aureus NCIMB 9518 and Pseudomonas aeruginosa NCIMB 8626 were 
obtained  from  ConvaTec  LTD.,  Escherichia  coli  ATCC  25922  was  obtained  from 
laboratory 208 (Department of Pharmaceutical and Biological Chemistry,  UCLSOP), 
originally purchased from American Type Culture Collection, USA.   67 
2.3.2 Microbiological media 
Nutrient broth (NB), agar powder, iso-sensitest agar (ISA), tryptone soya broth (TSB), 
cooked meat medium (CMM), macconkey agar (MCA), cetrimide agar, mannitol salt 
agar (MSA) and all other microbiological media were from Oxoid Ltd, Basingstoke, UK 
and purchased from Fisher Scientific, UK. 
2.3.3 Chemicals and reagents 
Ringer’s solution tablets and phosphate buffered saline (PBS) tablets were purchased 
from  Sigma-Aldrich,  UK.  Absolute  ethanol  (99%),  dimethyl  sulfoxide  and  glycerol 
(analytical  grade)  were  purchased  from  Fisher  Scientific,  UK.  Polyvinylpyrrolidone 
(PVP)  was  purchased  from  Sigma-Aldrich,  UK.  All  other  reagents  used  were  of 
analytical grade. Distilled water was used throughout. 
2.3.4 Sterilization of culture media, chemicals and solutions 
All culture media used were sterilized by autoclaving (21001 Classic Prestige Medical, 
England)  for  15  min  at  121
oC  prior  to  inoculation.  Chemicals  and  solutions  were 
sterilized by filtration using a membrane filter of 0.22 µm pore size (Sartorius AG, 
Germany) and a syringe. All procedures were carried out aseptically. 
2.3.5 Stock culture maintenance and purity 
To maintain a collection of all bacterial stock cultures: 
Staphylococcus  aureus  NCIMB  9518,  Pseudomonas  aeruginosa  NCIMB  8626  and 
Escherichia coli ATCC 25922 were obtained on agar slopes. Colonies were picked off 
the agar slopes using a sterile loop and streaked onto iso-sensitest agar (ISA) plate. This 
was incubated at 37
oC (1
oC) for 24 h. Cultures were checked for purity by observing 
colony types and absence of contaminants. Colonies of the respective bacterial strains 
were picked off with a sterile cotton swab and used to make a lawn on a fresh agar plate. 
After  incubation  of  the  respective  bacterial  lawns  at  37
oC  for  24  h,  the  respective   68 
colonies were picked off with a sterile cotton swab and inoculated into 15% v/v glycerol 
in  tryptone  soya  broth  (TSB)  to  make  a  thick  suspension  of  the  culture  which  was 
divided into multiple aliquots and stored at -80
oC until further use. 
2.3.6 Growth curves   
In  order  to  determine  the  correct  harvesting  points  for  the  bacterial  cells  during 
cryopreservation, growth curves of the bacteria were determined. Turbidity or optical 
density measurements, where an instrument measures the amount of light scattered by a 
suspension of cells was employed. Bacteria are known to scatter light in proportion to 
their numbers hence the turbidity or optical density (OD) of a cell suspension is directly 
related to the cell mass. Turbidity measurement does not however distinguish between 
viable  and  non-viable  cells.  Cell  numbers  or  colony  forming  units  (CFU)  can  be 
obtained by plate count.  
The CFU for a given range of OD values were determined to establish the number of 
viable cells in a cell suspension. Once this was established, the OD was used as an 
approximate measure of the CFU in a given sample. 
P. aeruginosa, S. aureus and E. coli were streaked on ISA plates and incubated (37
oC for 
24  h).  Starter  cultures  of  the  bacteria  were  prepared  by  picking  off  a  few  bacterial 
colonies with a sterile loop from the respective plates and inoculating into 7 mL bijous 
containing  5  mL  of  NB.  The  bijous  together  with  their  sterile  controls  were  then 
incubated respectively as described above.  
100 mL of sterile NB prepared previously was pre-warmed to 37
oC and inoculated with 
organism from the starter culture in a 1:100 dilution. The culture was placed in a shaking 
incubator (Innova 4080, New Brunswick Scientific, UK) at a speed of 274 rpm at 37
oC. 
Changes in cell density were monitored with a spectrophotometer (Heiosα, Thermo 
Scientific) at 600 nm. The OD reading was taken before the sample was placed in the 
shaking incubator representing the “0” time reading and every 30 min after, until the 
exponential growth phase ended. An uninoculated control was incubated under the same 
conditions. The OD readings were plotted with Origin Pro 8.6 (Microcal Software Inc.) 
to give the growth curve. Plate counts were done by taking 50 µL of the test culture at 
each time point and inoculating into 450 µL of PBS. Serial dilutions (1:10) were carried   69 
out until 1:10
7 dilutions. Thus, 450 µL of PBS was placed into bijous labelled 1 to 7. At 
each time point, 50 µL of the test culture was inoculated into a labelled bijou 1 (for a 1 
in a 10 dilution). Bijou 1 was vortexed for 30 s and 50 µL of it was transferred into bijou 
2 and repeated for all the bijous. 50 µL of the test bacterial suspension from the bijous 
were plated out using sterile glass spreader onto ISA agar. The plates were incubated and 
colonies counted after incubation at 37
oC over 24 h. 
2.3.7 Cryopreservation 
Cryopreservation and recovery of the bacterial stocks used was based on Beezer et al., 
(1976) method of cryopreservation of Saccharomyces cerevisiae. Freezing was carried 
out in a modified bath containing liquid nitrogen (Figure 2.1). 
 
 
Figure 2.1. Schematic representation of the modified bath used for cryopreservation of bacteria in 
liquid nitrogen at -196
oC. Cryovials were held in terry clips of racks, which were held above the 
surface of the liquid nitrogen 
Starter cultures of relevant bacteria were made by picking off a few colonies of bacteria 
from plates, inoculating into broth and incubating at 37
oC appropriately. The starter was 
inoculated into a freshly made relevant broth (200 mL) in a 1:100 dilution. The culture 
was then incubated in a shaking incubator (Innova 4080, New Brunswick Scientific, 
UK) until it reached a population density ca. 1x10
8 CFU/mL (from corresponding optical 
density reading). The cultures were then harvested by centrifuging at 2500 g for 10 min 
at 4
oC using the Heraues Stratosbiofuge (Thermo Scientific, UK). The supernatant was 
carefully  discarded  and  the  cells  washed  twice  in  PBS  by  centrifuging  at  the  same 
conditions.  The  washed  cells  were  resuspended  in  ¼  strength  Ringer’s  solution 
supplemented with a cryoprotectant in a reservoir. 1.8 mL of the cell suspension were 
dispensed  rapidly  while  shaking  the  reservoir  continuously  using  a  stirrer  to  ensure 
uniform dispensing of the suspension into 2 mL labelled sterile cryovials and sealed.  
Liquid nitrogen 
Cryovial 
Removable rack with terry clips   70 
A modified bath (the schematic diagram of the bath is shown above) was filled with 
liquid nitrogen to an appropriate level. The sealed cryovials were clipped onto terry clips 
of racks that gripped the caps of the vials. The loaded racks were then placed into the 
relevant  fixture  of  the  modified  bath  containing  liquid  nitrogen.  The  level  of  liquid 
nitrogen was measured and topped up to 7 cm below the level of the racks that the 
cryovials were attached to making sure the vials were not touching any liquid nitrogen. 
An alcohol thermometer was placed in an empty cryovial to monitor the temperature of 
freezing.  The  cryovials  were  cooled  gradually  in  the  nitrogen  vapour.  The  cooling 
temperature was monitored and recorded every minute. Once the temperature reached -
90
oC, the vials were released from the terry clips and dropped into liquid nitrogen. The 
vials were removed from the bath using pre-cooled forceps and placed into a storage 
container of liquid nitrogen until needed. 
2.3.7.1 Selection of a cryoprotectant for liquid nitrogen storage of the bacterial 
cells 
Glycerol, DMSO and PVP were tested in order to  select the best cryoprotectant for 
freezing  of  the  microorganisms.  E.  coli  was  used  as  the  test  organism.  The 
cryoprotectants were added to ¼ strength Ringer’s solution at a concentration of 10% 
v/v for DMSO and PVP and 15% v/v for glycerol. Previous experience indicated that ¼ 
strength  Ringer’s  solution  was  a  good  freezing  and  storage  medium  for  the 
microorganisms due to its isotonicity. A control, without cryoprotectant, was also tested. 
Plate count of the organism was done pre and post freezing by serial dilution described 
in section 2.3.6. Cell recovery after 1 day, 1 month and 6 months was monitored to 
assess the effect of storage time (in liquid nitrogen) on the viability of the culture.  
2.3.8 Defrosting of frozen bacteria 
Vials of the  frozen bacteria were removed from storage container of liquid nitrogen 
when needed. They were held in a floater (which kept their screwed caps above the 
surface of water) and placed in a water bath with temperature set at 40°C for 3 min. 
They were vortexed for 1 min before use.    71 
2.3.9 Microcalorimetric experiments 
A Thermometric Thermal Activity Monitor 2277 (TAM 2277) (TA Instruments Ltd., 
UK) was used for all the microcalorimetric experimentations reported in this thesis. The 
temperature  of  the  instrument  was  set  at  37
oC  (±  0.1
oC).  All  loaded  samples  were 
allowed  to  equilibrate  thermally  at  the  intermediate  position  for  30  min  before 
measurement. Data were collected every 10 s, with an amplifier range of 1000 μW using 
the software package, Digitam 4.1 and analysed using Origin Pro 8.6 (Microcal Software 
Inc.). The reference ampoule was loaded with 3 mL of sterile media respective of the 
experiment being carried out. The instrument was calibrated at regular intervals.  
Experiments  were  repeated  at  least  in  triplicate.  Plate  counts  and  pH  measurements 
(pHenomenal
®, UK) were done post calorimetric experiments.  
2.3.9.1 Pure culture experiments 
A vial was removed from the storage liquid nitrogen container, thawed at 40°C for 3 min 
and vortexed for 1 min. All stocks were frozen down to a population density of ca. 1x10
8 
CFU/mL. 30 µL of the thawed culture was inoculated into 2970 µL of pre-warmed broth 
(NB or CMM) in a sterile 3 mL calorimetric glass ampoule giving a population density 
of 10
6 CFU/mL. The ampoules were sealed with crimped caps and vortexed for 10 s. 
They were placed in the TAM and data recorded.  
All thawed aliquots were subcultured and checked for purity and uniformity of the stock. 
2.3.9.2 Mixed culture experiments 
One species was inoculated at a constant density of cell numbers (10
6 CFU/mL) and 
mixed with different densities of the other (10
3 - 10
6 CFU/mL) in a 3 mL calorimetric 
ampoule.  For  example,  30  µL  (representing  10
6 CFU/mL)  of  thawed  culture  of  one 
species and 30 µL (10
6 CFU/mL); 3 µL (10
5 CFU/mL); 0.3 µL (10
4 CFU/mL) etc. of the 
other organism were added to pre-warmed culture media to make a volume of 3 mL in a 
sterile calorimetric ampoule. The ampoule was treated as above. 
Two or three species were also inoculated at the same population density: 10
6 CFU/mL,   72 
10
5 CFU/mL and 10
4 CFU/mL. 
2.3.10 Statistical Analysis 
Results were expressed as mean and standard deviation throughout this thesis. Statistical 
analysis was performed in Origin Pro 8.6 (Microcal Software Inc.). T-test or Analysis of 
Variance  (ANOVA)  with  Turkey  post-hoc  analysis  for  means  comparison  was  used 
where  appropriate.  P  values  less  than  0.05  were  regarded  as  significant  difference 
between means. 
2.4 Results and Discussion 
2.4.1 Growth curves 
Given  an  appropriate  medium,  a  bacterium  will  grow  until  all  the  nutrients  in  the 
medium are used up or the medium condition is no longer conducive to growth due to 
for example, toxic waste accumulation. Bacteria grow characteristically through self-
replication.  This  implies  that  a  bacterium  is  able  to  produce  completely  identical 
daughter cells, which also have the potential to divide again. Hence cell numbers will 
increase  exponentially  as  a  function  of  time  in  an  appropriate  medium.  With  time 
however, the nutrient is exhausted and growth is considerably slower or ceases when the 
rate of consumption of nutrients exceeds the rate of supply. 
All the species studied, showed a typical bacterial growth pattern as shown in Figure 2.2. 
There was a lag period (A), during which the bacteria adapted their physiology to that 
required for growth on the available nutrients. This was followed by an active growth 
where the  increase in  bacterial  numbers  was  exponential  (B).  As  growth proceeded, 
nutrients  were  consumed  and  waste  materials  accumulated.  This  reduced the  rate  of 
growth  as  numbers  of  new  cells  formed  was  equal  to  those  that  were  dying;  the 
stationary phase (C). 
The reason for studying the growth curves of these organisms was to determine their 
point for harvesting.  Morgan et al.,  (2006), has proposed that the optimal phase for   73 
harvesting of cells depends on the organism in question. However, other authors have 
suggested that for all microorganisms, cells grown and harvested at the late logarithmic 
phase or early stationary phase are most stable and viable (Mary et al., 1986, Corcoran et 
al., 2004). Others also claim that cells need to be grown to an optimal population density 
for harvest. Historically a population of 1 x 10
8 cells mL
-1 or more has been proposed as 
ideal (Morgan et al., 2006, Prakash et al., 2013) on the basis that the higher the initial 
cell concentration, the  greater the  recovery  of  viable cells  within  a  sample  (Heckly, 
1978,  Alexander  et  al.,  1980,  Simione  and  Brown,  1991).  For  this  study,  the  time 
required for the organisms to reach a population density of 10
8 CFU/mL was determined 
by OD measurement and plate count. For S. aureus NCIMB 9518 the time required for 
this population was at ca. 4 h; 6 h and 40 min for P. aeruginosa NCIMB 8626 and 3 h 
and  30  min  for  E.  coli  ATCC  25922  with  OD  readings  at  ca.  0.31,  0.32  and  0.44 
respectively. The absorbance reading was used as a reference point for harvesting the 
cells in subsequent experiments. 
 
Figure 2.2. Growth curves of P. aeruginosa, S. aureus and E. coli in Nutrient broth 
2.4.2 Selection of a cryoprotectant for liquid nitrogen storage of the bacterial 
cells 
The  percentage  viable  cells  (if  the  total  number of  cells  before  freezing  is  taken  as 
100%)  of  freshly  harvested  and  frozen  samples  of  E.  coli  suspended  in  different 
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cryoprotective agents and a control without cryoprotectant (only ¼ Ringer’s solution) is 
shown  in  Figure  2.3.  The  result  showed  that  cell  recoveries  were  better  when  the 
cryoprotectants were added to the freezing medium.  
 
Figure 2.3. Comparison of the percentage viability of E. coli after freezing and storage using different 
cryoprotective agents. Bars indicate standard deviations from the mean of triplicate experiments 
As noted earlier, during freezing of bacterial cells for long-term storage, certain variables 
need to be considered. Among the variables, the composition of the freezing medium, 
the storage temperature and the cooling rate are critical and these were considered in this 
research  work.  For  the  work  conducted,  the  cooling  rate  recorded  during 
cryopreservation was between -4
oC and -7
oC per min. The cells were stored in liquid 
nitrogen;  it  was  observed  that  overall,  cell  numbers  were  not  significantly  affected 
(P>0.05) by the time of storage in liquid nitrogen for PVP, DMSO and glycerol but was 
significantly affected (P<0.05) for unsupplemented ¼ Ringer’s solution. 
The  addition  of  a  cryoprotectant  to  the  freezing  medium,  certainly  improved  the 
recovery of the cells over the time period tested. For the cryoprotectants tested, DMSO 
and glycerol showed the better protection of the cells. This does not come as a surprise 
because DMSO and glycerol are both penetrating agents (although DMSO has better 
penetrating  ability  than  glycerol;  Hubalek,  2003,  Prakash  et  al.,  2013)  capable  of 
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protecting  the  cells  from  both  intracellular  and  extracellular  damage.  PVP  is 
nonpenetrating (Hubalek, 2003) and mainly protects against extracellular ice formation 
by increasing the viscosity of the medium and keeping the structure of ice amorphous at 
the surface of the cell. But DMSO and glycerol can also reduce the amount of frozen 
water,  by  decreasing  the  freezing-point  of  water  and  by  so  doing,  lessening  the 
concentration  of  salt  dissolved  in  solution  which  effectively  inhibit  osmotic  shock 
(Lovelock,  1953,  Lovelock  and  Bishop,  1959).  For  example,  addition  of  glycerol  to 
water can decrease the freezing point of water to a minimum of -46
oC whilst addition of 
DMSO can decrease it to -73
oC (Hubalek, 2003). They also prevent the formation of 
large  ice  crystals  within  the  cells  but  stimulate  the  formation  of  fine  ice  crystals 
(quasiamorphous) within the cells (Hubalek, 2003).  
The selection of the cryoprotectants tested was based on their simplicity, universality 
and  availability.  The  selected  cryoprotectants,  particularly  DMSO  and  glycerol  are 
widely  used  for  cryopreservation  of  microbial  cells.  They  are  often  used  at  median 
concentrations of 10-15% v/v and have been shown to be safe for cells (Hubalek, 2003). 
At higher concentrations, they have been reported to be toxic to some cells. For example, 
growth  inhibitory  activity  of  DMSO  has  been  observed  and  reported  when  used  at 
concentrations  of  10%  v/v  for  Staphylococcus,  Micrococcus,  Pseudomonas, 
Streptococcus,  Lactococcus,  Corynebacterium,  and  E.  coli  (Fomin  et  al.,  1973)  and 
toxicity has been shown for some cells at 40% v/v (Tsutsaeva and Vysekantsev, 1983) 
although many bacteria have also been shown to tolerate very high concentration of 
DMSO without toxic effects (Fedorka-Cray et al., 1998). Toxicity to DMSO is generally 
higher  when  the  cells  are  kept  at  higher  temperatures  (Hubalek,  2003)  due  to  the 
association of temperature to the permeability into the cells. Glycerol has also shown 
toxicity to a number of bacterial species: Chlamydia spp., Staphylococcus, Micrococcus, 
Lactococcus,  Streptococcus,  Pseudomonas,  Corynebacterium  diphtheriae  and  E.  coli 
(Fomin et al., 1973) but PVP has the advantage of very low toxicity in  majority of 
microorganisms even at higher temperatures for which glycerol and DMSO were shown 
to be toxic (Osborne and Lee, 1975, Eidtmann and Schauz, 1992). In our selection of 
cryoprotectants, complex cryoprotectants such as yeast extract, malt extract and culture 
media,  peptides  and  proteins  and  sugars  were  not  considered  because  they  could 
introduce  complications  into  the  microcalorimetric  experiments,  being  possibly 
metabolised  by  the  cells  from  the  moment  they  were  thawed  which  could  cause 
deviations from heat output.    76 
In the present study and other studies using different organisms, (results not shown), 
glycerol consistently gave better recovery than DMSO and PVP with recoveries ≥ 95%. 
Glycerol was used for cryopreservation of all the organisms studied.  
2.4.3 Microcalorimetric experiments  
2.4.3.1 Pure culture experiments  
As stated in Chapter 1, when a culture of bacteria in an appropriate growth medium is 
placed into a microcalorimeter, a power-time curve is generated (Figure 2.4 black curve) 
which shows the heat produced by the growing bacteria. This power-time curve shows 
periods  of  rises  and  decline.  When  integrated  (Figure  2.4  red  curve),  it  shows 
characteristics comparable to the conventional turbidimetric growth curve of bacteria: an 
initial lag phase, followed by an exponential phase, and a plateau (stationary phase).  
And has been shown to be directly proportional to biomass measured by optical density, 
plate counts or protein concentration (Braissant et al., 2010a).  
 
Figure 2.4. The relationship between microcalorimetric measurement and microbial activity. The 
typical power-time curve of P. aeruginosa (black curve) is integrated (red curve) to give a curve 
which resembles a classical growth curve obtained from optical density measurements 
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The power-time curves for each of the species studied are shown below. The power-time 
curves are complex and characteristic of organisms growing in  complex media with 
restricted oxygen (the ampoule is sealed and the oxygen level is limited to that dissolved 
in the medium and present in the headspace). 
2.4.3.1.1 P. aeruginosa  
Figure 2.5 shows the power-time curves of 4 repeats of P. aeruginosa inoculated to a 
population density of 10
6 CFU/mL  and studied over 20 h duration. The power-time 
curves are reproducible. There is an initial exponential increase in heat output with peak 
at ca. 2 h, which is followed by a second peak at ca. 5 h. The decline in heat flow 
between the first and second peaks does not necessarily mean a major decline in cell 
numbers.  It  could  represent  the  diauxic  growth  of  the  organism  in  the  environment 
created  (complex  media  and  aerobic/anaerobic  atmosphere)  (Schaarschmidt  and 
Lamprecht, 1978, Von Stockar and Birou, 1989).  
 
Figure 2.5. Power-time curves of four repeats of P. aeruginosa inoculated to a cell density of 10
6 
CFU/mL in NB. Pa represents P. aeruginosa 
When bacteria are presented with multiple energy substrates, they would consume these 
substrates sequentially resulting in diauxic growth (Monod, 1949). They would utilize 
first the substrate that is easier to metabolize which leads to rapid growth, followed by a 
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lag phase (heat flow decrease), where the bacteria have to synthesize new enzymes to 
metabolize the second substrate. Thus, the change from one energy substrate to another 
often  requires  the  synthesis  of  new  enzymes  that  can  be  subjected  to  catabolite 
repression.  This  diauxic  growth  has  been  demonstrated  by  Schaarschmidt  and 
Lamprecht, (1978) when studying the anaerobic growth of Saccharomyces cerevisiae on 
defined  multiple  carbohydrate  sources  in  the  microcalorimeter.  These  authors 
demonstrated that on sole glucose or mannose, Saccharomyces cerevisiae had a single 
exponential  peak  in  an  anaerobic  environment  but  could  also  potentially  produce  a 
second growth phase from accumulated ethanol (from metabolism) when the culture had 
sufficient supply of oxygen. They  also demonstrated that  glucose-galactose, glucose-
sucrose,  fructose-maltose  and  sucrose-maltose combination all  showed  diauxy  in  the 
microcalorimeter. They illuminated that the two pairs of carbohydrates are taken up and 
degraded  by  different  enzyme  systems.  For  example,  galactose  metabolism  involves 
inducible transport in addition to inducible enzyme for degradation, requiring time for 
the  induction;  maltose  also  requires  an  induction  time  for  transport  and  hydrolysis 
whereas  glucose,  fructose  and  mannose  use  the  same  constitutive  transport  system 
(Schaarschmidt and Lamprecht, 1978). The biphasic or diauxic growth has also been 
reported to be observed when bacteria and yeast are switching from aerobic metabolism 
to anaerobic metabolism in the microcalorimeter (Beezer, 1980, Von Stockar and Birou, 
1989, Braissant et al., 2013). Some authors have suggested that for P. aeruginosa, the 
decline in heat flow between the first peak and second peak is the transition from aerobic 
growth to anaerobic growth (O'Neill et al., 2003, Gaisford et al., 2009). To test this, the 
experiment  was  conducted  in  an  anaerobic  environment  by  filling  and  sealing  the 
ampoule in a Don Whitley DG250 Scientific Anaerobic workstation, UK. The organism 
was also inoculated to the same density (10
6 CFU/mL) in 1 mL of broth in the same 3 
mL capacity ampoule, creating a larger headspace. Monophasic growth was observed 
(Figure  2.6)  with  a  larger  heat  intensity  and  longer  duration  for  a  1  mL  normal 
atmospheric fill. When the ampoule was filled and closed in an anaerobic environment, 
for a 1 mL fill, only one peak again was observed, with a peak maximum occurring at 
approximately the same time as the second peak for the 3 mL fill done under normal 
atmospheric condition suggesting that possibly the diauxic growth observed in a normal 
fill was due to the transition from aerobic to anaerobic metabolism. The integrated plot 
(Figure  2.6  [B])  of  these  power-time  data  suggested  that  the  preferred  or  primary 
metabolic pathway for P. aeruginosa was aerobic as the anaerobically filled samples 
returned infinitesimal cumulative heat.   79 
For the standard P. aeruginosa growth curves (Figure 2.5), after the second peak, there 
was a final exothermic activity (peak 3), which could be attributed to the  anaerobic 
utilization  of  an  unconsumed  energy  substrate  typical  with  complex  growth  media 
(Gaisford et al., 2009) before the return to baseline; shown to represent stationary phase 
(Fan et al., 2008, Kabanova et al., 2009, Braissant et al., 2013). The total area under the 
curve (AUC) for a P. aeruginosa culture over 20 h, representing the total heat output 
was 1.82 ± 0.12 J. 
 
Figure 2.6. Power and heat curves of P. aeruginosa filled and sealed under aerobic and anaerobic 
environments. [B] is the integrated plots of [A] 
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2.4.3.1.2 S. aureus 
Figure  2.7  shows  the  power-time  curves  of  4  repeats  of  S.  aureus  with  good 
reproducibility. The area under the curves, representing the total heat output was 3.91 ± 
0.83 J. The power-time curves show two peaks within the first 5 h. There is then a 
transition period (between ca. 5 and 11 h) and this is followed (at ca. 12.5 h) by a third 
peak, before the growth curve returned to the baseline. The first peak, which has been 
previously assumed to represent aerobic metabolism of the organism in the medium 
(O'Neill et al., 2003), is still present, though in lower intensity when the ampoule was 
filled and sealed under anaerobic condition (Figure 2.8). The second and third peaks, 
also previously assumed to be associated with sequential anaerobic metabolism of major 
carbohydrates  (O’Neill  et  al.,  2003)  are  also  present  when  the  oxygen  headspace  is 
increased.  The  third  peak  was  however  lost  when  the  ampoule  was  sealed  under 
anaerobic condition.  
 
Figure 2.7. Power-time curves of S. aureus inoculated to a cell density of 10
6 CFU/mL in NB. Sa 
represents S. aureus 
For an atmospheric fill, increasing the headspace meant a longer aerobic phase; hence it 
could be reasonably assumed that the peak that was amplified when the headspace was 
increased was the aerobic phase of metabolism. This peak (peak 3) was also absent in 
the anaerobic cultures. It is plausible that the third peak could be associated with aerobic 
growth. The initial exponential peaks could be associated with micro-aerophilic growth.  
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Figure 2.8. Power-time curves of S. aureus filled and sealed under aerobic and anaerobic 
environments  
2.4.3.1.3 E. coli 
The power-time curves of 4 repeats of E. coli in NB are shown in Figure 2.9 and they 
show exponential phases (occurring within 7.5 h) and a decline phase (after ca. 9 h). The 
area under the curve, representing the total heat output was 3.07 ± 0.44 J.  
 
Figure 2.9. Power-time curves of E. coli inoculated to a cell density of 10
6 CFU/mL in NB 
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Overall, the three species studied had very characteristic power-time curves in NB. The 
curves were very reproducible and could be used for identifying them. Between the three 
species, E. coli showed more peaks and troughs in the growth curve probably because it 
can utilize more substrates in the environment created than the other species (Scheutz 
and  Strockbine,  2005).  As  mentioned  and  shown  with  the  experiments,  the  gaseous 
environment within the ampoules was of limited oxygen supply and it was expected that 
the organisms would switch from aerobic metabolism to anaerobic. Both the aerobic and 
anaerobic growths are demonstrated by exponential increase in heat output followed by a 
decline. Also, a switch from one energy substrate to another will result in the decline of 
an  exponential  growth  and  a  rise  of  another  (Schaarschmidt  and  Lamprecht,  1978, 
Beezer, 1980). Therefore the complexity of the power-time data can be attributed to the 
gaseous environment in the ampoule as well as the complexity of the medium used and 
an organism’s ability to utilize the multiple energy substrates (including its metabolites 
(Schaarschmidt and Lamprecht, 1978) in the complex medium. For example, E. coli an 
Enterobacteriaceae, is known to ferment glucose and other carbohydrates to pyruvate, 
which is further converted to lactic acid, acetic and formic acids with part of the formic 
acids  degraded  into  CO2  and  H2  (Scheutz  and  Strockbine,  2005).  A  sequential 
degradation and uptake of the carbohydrates present in the medium (given the medium 
condition)  and  its  metabolites  (Narang  et  al.,  1997)  could  have  contributed  to  its 
complex curve.  
It can be expected that if an anaerobic environment is generated within the ampoule, the 
peaks and troughs of the power-time curves will be reduced, unless the species being 
studied utilizes a number of different fermentation pathways given a complex medium. 
This was observed when the ampoule was filled and sealed anaerobically and also when 
a reduced medium was used in Chapter 3. 
Among the three species, S. aureus showed metabolism for the longest time, producing 
metabolic heat for periods in excess 15 h. The heat curves and total heat output of the 
three species studied are compared in Figure 2.10 [A] and [B] respectively. The heat 
curve shows that the growth profile of the species within the first 2 h were similar but S. 
aureus and E. coli kept similar growth profile for a further 5 h whilst P. aeruginosa 
showed a biphasic log (diauxie) in the heat curve during that period. Also, P. aeruginosa 
recorded the least heat output whilst S. aureus recorded the highest inferring that  S.   83 
aureus metabolized the medium more energetically in the environment created than the 
others, the reason for this is not yet known.  
 
 
 
Figure 2.10. Comparison of [A] cumulative heat curves and [B] mean heat output of P. aeruginosa, S. 
aureus and E. coli inoculated to 10
6 CFU/mL in NB. The heat outputs were calculated from the AUC 
of four repeats.  
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2.4.3.2 Mixed culture experiments 
These  experiments  were  undertaken  to  study  how  a  species  of  bacteria  behaved 
metabolically in the presence of other species in the microcalorimeter. They were also 
done  to  establish  whether  heat  outputs  were  proportional  to  cell  numbers  of 
microorganisms in mixed cultures and whether the microcalorimeter could show the 
growth of the species concurrently.  
2.4.3.2.1 Mixed culture of P. aeruginosa and S. aureus 
The power-time curves and heat outputs of P. aeruginosa and S. aureus and a 1:1 mixed 
culture of them are compared in Figures 2.11 and 2.12 respectively.  
When P. aeruginosa and S. aureus were mixed in the same ratio in NB and placed in the 
TAM,  the  resulting  power-time  curve  that  was  generated  showed  similarities  to  the 
power-time curve of  P. aeruginosa alone in NB (Figure  2.11) even though the first 
exponential peak could also represent both species since they both had similar growth 
pattern over the first few hours. However the characteristic transitional phase between 
the second and third exponential phase of S. aureus was lost in the mixed culture power-
time curve. The heat output generated by the mixed culture was 2.10 ± 0.41 J. This heat 
output was significantly different (P<0.05) from heat output generated by a pure culture 
of S. aureus but did not significantly differ (P>0.05) from the heat output generated by a 
pure culture of P. aeruginosa (Figure 2.12). The results suggest that a mixed culture of 
P. aeruginosa and S. aureus behaves metabolically like P. aeruginosa alone, inferring 
that either P. aeruginosa suppressed the growth of S. aureus because the medium was 
nutritionally more favourable to the growth and metabolism of P. aeruginosa than S. 
aureus or that P. aeruginosa could adapt and use the medium faster in a mixed culture 
situation.  Another  explanation  that  can  be  given  to  the  observed  occurrence  is  the 
possibility that P. aeruginosa produced inhibitory factors that suppressed or inhibited the 
growth  of  S.  aureus.  These  inhibitory  factors  however  could  not  be  acidic;  this  is 
because when the two species were inoculated into NB with an initial pH of 7.15 ± 0.1, 
the final pH of the ampoule after the calorimetric experiment revealed a significantly 
lower pH for S. aureus (P<0.05), 6.31 ± 0.2, whilst the pH after growth of P. aeruginosa 
(6.77 ± 0.2) was not significantly different (P>0.05) from the uninoculated medium.    85 
 
Figure 2.11. Comparison of the power-time curves of P. aeruginosa (blue), S. aureus (red) and a 
mixed culture of them (black) in NB. Sa represents pure culture of S. aureus. Pa represents pure 
culture of P. aeruginosa. Sa-Pa represents co-culture of S. aureus and P. aeruginosa. The species 
were each inoculated to 10
6 CFU/mL. The final density in the mixed culture was 2 x10
6 CFU/mL 
 
Figure 2.12. A bar chart comparing the mean heat outputs (n=4) of P. aeruginosa, S. aureus and a 
mixed culture of them in NB. All species were inoculated to a final density of 10
6 CFU/mL. In a 
mixed culture, the individual species were each inoculated to 10
6 CFU/mL, therefore, the final density 
in the mixed culture was 2 x10
6 CFU/mL 
P. aeruginosa, a Gram-negative organism like E. coli is known to produce allelopathic 
substances  (Riley  and  Gordon,  1992,  Michel-Briand  and  Baysse,  2002,  Zhou  et  al., 
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2011) that target and kill other organisms. It is known to produce antistaphylococcal 
substances:  4-hydroxy-2-heptylquinoline-N-oxide  (HQNO),  hydrogen  cyanide  and 
pyocyanin that suppress the growth of S. aureus and many other Gram-positive bacteria 
(Machan et al., 1992, Biswas et al., 2009). This suppression has been observed by a 
number of authors. For instance, Kluge et al., (2012), during a batch cultivation of mixed 
culture  consisting  of  Burkholderia  cepacia,  Pseudomonas  aeruginosa,  and 
Staphylococcus  aureus  with  and  without  a  cephalosporin  antibiotic,  ceftazidime, 
observed the dominancy of P. aeruginosa in the mixed culture whilst S. aureus was 
inhibited in growth (Kluge et al., 2012). Inhibition of S. aureus by P. aeruginosa has 
also been reported by Perestelo et al., (1985), Hoffman et al., (2006), Biwas et al., (2009) 
and Baldan et al., (2014). 
This inhibition or suppression has been associated with the fact that in co-infections with 
S. aureus and P. aeruginosa, S. aureus is frequently less cultured although both could 
also be coisolated in infected cultures (Hoffman et al., 2006). For instance, for chronic 
lung infection of patients with cystic fibrosis, S. aureus is the pathogen most commonly 
cultured  from  the  respiratory  cultures  of  young  children  with  the  disease but  as  the 
patients  age,  the  infection  is  known  to  be  predominated  by  P.  aeruginosa  (Cystic 
Fibrosis Foundation 2008, Baldan et al., 2014). This predominance has been associated 
with this arsenal of compounds produced by P. aeruginosa in mixed cultures, which 
inhibits S. aureus (Biswas et al., 2009, Baldan et al., 2014).  
It is possible that the microcalorimeter was able to detect this inhibition or suppression. 
However, the inhibition was not absolute; a post microcalorimetric plate count of the 
mixed  culture  (Table  2.1)  still  showed  the  presence  of  viable  S.  aureus,  although 
decreased. Also, the power-time curve of the mixed culture was not an exact replica of 
that  of  the  pure  culture  of  P.  aeruginosa.  To  confirm  this  inhibition  in  the 
microcalorimeter, a study was carried out where the population density of S. aureus was 
kept constant (at 10
6 CFU/mL) and that of P. aeruginosa decreased from 10
6 to 10
3 
CFU/mL. The resulting power-time curves are compared in Figure  2.13. This figure 
shows that the power-time curve of a mixed culture of P. aeruginosa and S. aureus 
reverts gradually from the dominating characteristic curve of P. aeruginosa to curves 
that show recuperation of S. aureus as the population of P. aeruginosa was decreased in 
the mixed culture.    87 
 
Figure 2.13. Comparison of power-time curves of mixed culture of P. aeruginosa and S. aureus when 
the density of S. aureus was kept constant at 10
6 CFU/mL and that of P. aeruginosa was decreased 
from 10
6 to 10
3 CFU/mL. Sa-Pa 10
6-10
6 represents co-culture of S. aureus at a density of 10
6 CFU/mL 
and P. aeruginosa at 10
6 CFU/mL. The first value is representative of the preceding organism and the 
later for the later organism. Sa-Pa 10
610
5 represents co-culture of S. aureus at a concentration of 10
6 
CFU/mL and P. aeruginosa at 10
5 CFU/mL. The same trend applies for all cases of co-culture 
 
Figure 2.14. Comparison of power-time curves of mixed culture of P. aeruginosa and S. aureus when 
the density of P. aeruginosa was kept constant at 10
6 and that of S. aureus was decreased from 10
6 to 
10
3 CFU/mL 
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When plate counts of the different mixed culture of P. aeruginosa and S. aureus were 
done after the microcalorimetric experiment, it further confirmed inhibition (Table 2.1), 
showing  that  anytime  the  population  of  P.  aeruginosa  was  decreased  relative  to  S. 
aureus in a mixed culture, the growth of S. aureus was enhanced. When the population 
density  of  P.  aeruginosa  was  kept  constant  (at  10
6 CFU/mL)  and  that  of  S.  aureus 
decreased from 10
6 to 10
3 CFU/mL, the power-time curves suggested dominance of P. 
aeruginosa in all cases (see Figure 2.14). However, a time lag was added to the power-
time curve as the density decreased exponentially. To verify that the time lag was as a 
result of the decreasing volume of the inocula, both P. aeruginosa and S. aureus were 
inoculated in the same ratio but decreasing inoculum densities (10
6:10
6; 10
5:10
5; 10
4:10
4 
CFU/mL)  the  power-time  curves  generated  (Figure  2.15)  were  reproducible  at  these 
concentrations (and more identifiable with P. aeruginosa) and showed a clear time lag 
seen upon decreasing inoculum density (Figure 2.16) of a culture. 
 
Figure 2.15. Comparison of the power-time curves of mixed cultures of P. aeruginosa and S. aureus 
in NB when inoculated in the same ratio (1:1) but different CFU (10
6, 10
5, 10
4) 
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Figure 2.16. Power-time curves of decreasing inoculum density of P. aeruginosa showing linear time 
lags as the densities are decreased exponentially from 10
7 CFU/mL 
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Table 2.1. A table comparing the pH and bacterial plate counts of the species in NB post TAM 
experimentation. – no growth observed  
 
Post incubation analysis of cultures 
Pure Culture  pH  Plate count (log CFU/mL) 
 
P. aeruginosa  6.8 ± 0.2  7.8 ± 0.1
 
S. aureus  6.3 ± 0.2  8.1 ± 0.1
 
E. coli  5.2 ± 0.3  8.2 ± 0.2
 
Mixed Culture (CFU/mL)    P. aeruginosa  S. aureus 
P. aeruginosa : S. aureus: 10
610
6  6.3 ± 0.3  7.4 ± 0.2  5.7 ± 0.3 
P. aeruginosa : S. aureus: 10
610
5  6.4 ± 0.1  7.4 ± 0.3  6.5 ± 0.1 
P. aeruginosa : S. aureus: 10
610
4  6.4 ± 0.2  7.2 ± 0.4  6.0 ± 0.5 
P. aeruginosa : S. aureus: 10
610
3  6.5 ± 0.2  7.6 ± 0.2  3.1 ± 0.2 
P. aeruginosa : S. aureus: 10
310
6  6.3 ± 0.1  7.1 ± 0.2  7.2 ± 0.4 
P. aeruginosa : S. aureus: 10
410
6  6.4 ± 0.2  7.4 ± 0.3  7.4 ± 0.2 
P. aeruginosa : S. aureus: 10
510
6  6.4 ± 0.1  7.4 ± 0.2
  7.1 ± 0.2
 
 
 
P. aeruginosa  E. coli 
P. aeruginosa : E. coli: 10
610
6  5.4 ± 0.1  6.9 ± 0.5
  8.1 ± 0.1
 
P. aeruginosa : E. coli: 10
610
5  5.5 ± 0.2  6.8 ± 0.7
  8.2 ± 0.2
 
P. aeruginosa : E. coli: 10
610
4  5.8 ± 0.3  6.7 ± 0.1
  8.2 ± 0.2
 
P. aeruginosa : E. coli: 10
610
3  5.9 ± 0.2  7.4 ± 0.2
  8.2 ± 0.1
 
P. aeruginosa : E. coli: 10
310
6  5.6 ± 0.2  4.5 ± 0.3  8.2 ± 0.1
 
P. aeruginosa : E. coli: 10
410
6  5.5 ± 0.2  4.7 ± 0.1  8.2 ± 0.2
 
P. aeruginosa : E. coli: 10
510
6  5.4 ± 0.1  5.0 ± 0.3  8.3 ± 0.2 
    S. aureus  E. coli 
S. aureus : E. coli : 10
610
6  5.6 ± 0.1  5.4 ± 0.5
  7.9 ± 0.2
 
S. aureus : E. coli : 10
610
5  5.9 ± 0.1  6.1 ± 0.3
  7.7 ± 0.2
 
S. aureus : E. coli : 10
610
4  5.9 ± 0.3  6.6 ± 0.1
  7.3 ± 0.6
 
S. aureus : E. coli : 10
610
3  5.9 ± 0.1  6.8 ± 0.1
  6.4 ± 0.4 
S. aureus : E. coli : 10
310
6  5.4 ± 0.2  -
  7.9 ± 0.2
 
S. aureus : E. coli : 10
410
6  5.3 ± 0.1  -
  8.1 ± 0.1
 
S. aureus : E. coli : 10
510
6  5.3 ± 0.2  5.8 ± 0.2  8.1 ± 0.1   91 
2.4.3.2.2 Mixed culture of P. aeruginosa and E. coli  
When P. aeruginosa and E. coli were mixed in the same ratio in NB and placed in the 
TAM, the power-time curve that was generated could represent a power-time curve with 
the two species dominating equally (Figure 2.17). The power-time curve had some of the 
characteristic peaks of E. coli within the first two and half hours but the subsequent peak 
after that was identifiable with P. aeruginosa. The heat output generated by the mixed 
culture was  2.74 ± 0.52 J. This heat output was  not significantly different (P>0.05) 
(Figure  2.18)  from  the  heat  output  generated  by  a  pure  culture  of  E. coli  (although 
decreased) suggesting that heat output was not necessarily proportional to cell numbers 
in mixed cultures but probably related to the interspecies effect.  
 
 
Figure 2.17. Comparison of the power-time curves of P. aeruginosa (blue), E. coli (red) and a mixed 
culture of them (black) in NB. Pa-Ecoli represents co-culture of P. aeruginosa and E. coli. The 
species were each inoculated to a density of 10
6 CFU/mL 
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Figure 2.18. A bar chart comparing the mean heat outputs (n=4) of P. aeruginosa, E. coli and a mixed 
culture of them in NB. Each species was inoculated to a cell density of 10
6 CFU/mL 
Both P. aeruginosa and E. coli produce allelopathic substances. More than 90% of both 
environmental and clinical isolates of P. aeruginosa are known to produce bacteriocins 
(Michel-Briand and Baysse, 2002) and 10 to 80% of E. coli strains (Gordon and O'Brien, 
2006) produce bacteriocins: microcin and colicin (Gillor et al., 2008). In a mixed culture 
of  them  in  a  complex  medium,  E.  coli,  an  extensive  fermenter  of  carbohydrates, 
producing organic acids as products of fermentation, significantly decreased (P<0.05) 
the pH of the medium (from a starting pH of 7.15 ± 0.1 to 5.4 ± 0.1), which could have 
also inhibited  P. aeruginosa. It is likely they may have  both  dominated in a mixed 
culture. 
To  further  understand  what  was  happening,  experimentation  was  carried  out  like  P. 
aeruginosa – S. aureus where the population density of P. aeruginosa was kept constant 
(at 10
6 CFU/mL) and that of E. coli decreased from 10
6 to 10
3 CFU/mL. Again, the 
resulting power-time curves are compared in Figure 2.19. This figure shows that the 
power-time curve of mixed culture of P. aeruginosa and E. coli reverts gradually to P. 
aeruginosa as the population density of E. coli is decreased in the co-culture. When the 
population  density  of  E.  coli  was  kept  constant  (at  10
6  CFU/mL)  and  that  of  P. 
aeruginosa decreased from 10
6 to 10
3 CFU/mL, the power-time curve also reverted to 
that of E. coli (Figure 2.20).  
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Figure 2.19. Comparison of the power-time curves of mixed culture of P. aeruginosa and E. coli when 
the density of P. aeruginosa was kept constant at 10
6 CFU/mL and that of E. coli was varied between 
10
6 and 10
3 CFU/mL 
 
Figure 2.20. Comparison of the power-time curves of mixed culture of P. aeruginosa and E. coli when 
the density of E. coli was kept constant at 10
6 CFU/mL and that of P. aeruginosa was varied between 
10
6 and 10
3 CFU/mL 
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2.4.3.2.3 Mixed culture of S. aureus and E. coli 
The same trend of observation in mixed culture of P. aeruginosa and S. aureus was seen 
in mixed culture of S. aureus and E. coli (Figures 2.21, 2.22, 2.23 and 2.24). E. coli 
clearly dominated in its co-culture with S. aureus. Again, there is the possibility that E. 
coli inhibited the growth of S. aureus through the release of specific growth inhibitory 
substances. E. coli dominated irrespective of the population of S. aureus. S. aureus only 
began to persist when the population of E. coli began to decrease. Plate count done post 
microcalorimetry showed decreased presence of S. aureus in co-culture combinations 
especially when its inoculum density was less than 10
6 CFU/mL. 
 
Figure 2.21. Comparison of the power-time curves of S. aureus (blue), E. coli (red) and a mixed 
culture of them (black) in NB. Each species was inoculated to a cell density of 10
6 CFU/mL 
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Figure 2.22. A bar chart comparing the mean heat outputs (n=4) of S. aureus, E. coli and a mixed 
culture of them in NB. Each species was inoculated to a cell density of 10
6 CFU/mL. The error bars 
are SD from the mean 
 
Figure 2.23. Comparison of the power-time curves of mixed culture of S. aureus and E. coli when the 
density of E. coli was kept constant at 10
6 CFU/mL and that of S. aureus was varied between 10
6 and 
10
3 CFU/mL 
S. aureus  E. coli S. aureus-E. coli
0
1
2
3
4
5
H
e
a
t
 
o
u
t
p
u
t
 
(
J
)
Organisms in Nutrient Broth
0 5 10 15 20
0
50
100
150
200
250
300
350
P
 
(
µ
W
)
TIME (h)
 Ecoli-Sa 10
6-10
6 CFU/mL
 Ecoli-Sa 10
6-10
5 CFU/mL
 Ecoli-Sa 10
6-10
4 CFU/mL
 Ecoli-Sa 10
6-10
3 CFU/mL  96 
 
Figure 2.24. Comparison of the power-time curves of mixed culture of S. aureus and E. coli when the 
density of S. aureus was kept constant at 10
6 CFU/mL and that of E. coli was varied between 10
6 and 
10
3 CFU/mL 
2.4.3.2.4 Mixed culture of P. aeruginosa, S. aureus and E. coli 
The power-time curves and heat outputs of P. aeruginosa, S. aureus, E. coli and a mixed 
culture of all three species NB are compared in Figures 2.25 and 2.26. The power-time 
curve and heat output (2.66 ± 0.1 J) suggest that a mixed culture of the three species 
behaves like a co-culture of E. coli and P. aeruginosa. One could thus argue that both E. 
coli and P. aeruginosa dominated in the mixed culture. S. aureus could be said to be the 
weakest species of the three. Even though S. aureus is also a virulent species capable of 
producing exotoxins (Belay and Rasooly, 2002), both Peterson et al., (1962) and Noleto 
et al., (1987) have also shown it to be a poor competitor which grows slowly in the 
presence of other microorganisms. Using conventional plating approach, they were able 
to demonstrate that  S. aureus was outgrown in the mixed cultures and produced no 
enterotoxins in the mixed cultures unless the inoculum density of S. aureus was greater 
or  outnumbered  the  other  species  (Noleto  et  al.,  1987).  It  is  interesting  that 
microcalorimetry  also  detects  these  important  interactions  occurring  in  these 
staphylococci mixed cultures. 
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Figure 2.25. Comparison of the power-time curves of P. aeruginosa (black), S. aureus (red), E. coli 
(blue) and a mixed culture of them (magenta) in NB. Each species was inoculated to a cell density of 
10
6 CFU/mL. In a mixed culture, the individual species were each inoculated to 10
6 CFU/mL 
 
Figure 2.26. A bar chart comparing the heat outputs of P. aeruginosa, S. aureus, E. coli and a mixed 
culture of them in NB. All species were inoculated to a final density of 10
6 CFU/mL. In a mixed 
culture, the individual species were each inoculated to 10
6 CFU/mL, therefore, the final density in the 
three species mixed culture was 3x10
6 CFU/mL 
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2.4.3.2.5 Changing the medium 
As  already  indicated,  a  central  part  of  the  work  in  this  thesis  was  the  study  of  the 
antipathogenic activity of probiotics. The probiotics were therefore to be  co-cultured 
with  these  non-fastidious  species.  Probiotics  are  fastidious  organisms  that  grow  in 
anaerobic (for example Bifidobacterium) or microaerophilic (Lactobacillus) conditions 
with complex nutritional requirement. It was important that a medium was chosen that 
supported the growth of all these species in the microcalorimeter. CMM, an excellent 
medium  for  the  primary  growth  and  maintenance  of  aerobic,  microaerophilic  and 
anaerobic organisms supporting aerobic, microaerophilic and anaerobic organisms was 
chosen for the culture. The use of CMM for the growth of a variety of fastidious species 
has been demonstrated by Scythes et al., (1996) who found out that CMM was one of the 
three best media, that was able to support growth of the most variety of organisms at the 
lowest  inoculum  when  they  compared  the  nutritive  capacities  of  10  broths  which 
included brain heart infusion (BHI), BHI supplemented with BIO-X, a supplement for 
fastidious organisms, BHI supplemented with 5% sheep blood, thioglycolate medium, 
enriched  thioglycolate  broth,  fastidious  anaerobe  broth,  Wilkins-Chalgren  anaerobe 
broth, cooked meat enriched broth and Schaedler broth. CMM is composed of minced 
meat,  which  naturally  contains  reducing  substances,  which  produce  and  maintain 
anaerobic  conditions  in  the  medium  (Harrigan,  1998)  when  freshly  prepared  and 
cultured in sealed containers.  
Figures 2.27, 2.28 and 2.29 compares the power-time curves of the three species in NB 
and CMM.  
Except for E. coli, which some differences can be observed in the power-time curves in 
both media, the power-time curves for P. aeruginosa, and S. aureus in CMM showed 
similarities to the power-time curves in NB. It was easily recognizable which species 
was  metabolizing  by  observing  the  power-time  curves  in  both  media.  The  aerobic 
metabolic peaks of the curves were however decreased and this is due to the fact that the 
medium condition was quite anaerobic. The heat output generated in CMM was also 
identifiable  with  the  species  (Figure  2.30)  except  for  S.  aureus,  which  produced 
significantly less heat (P<0.05) in CMM than in NB.    99 
 
Figure 2.27. Comparison of the power-time curve of P. aeruginosa, in different culture media: NB 
and CMM. The density of both cultures was 10
6 CFU/mL 
 
Figure 2.28. Comparison of the power-time curve of S. aureus in different culture media: NB and 
CMM. The density of both cultures was 10
6 CFU/mL 
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Figure 2.29. Comparison of the power-time curve of E. coli in different culture media: NB and CMM. 
The density of both cultures was 10
6 CFU/mL 
 
 
Figure 2.30. A bar chart comparing the mean heat outputs (n=4) of P. aeruginosa, S. aureus and E. 
coli in the different culture media: NB and CMM. All species were inoculated to a final density of 10
6 
CFU/mL 
It has already been demonstrated that the power-time curve for a particular organism 
changes  respective  of  the  medium  and  medium  condition  (Beezer,  1980).  For  this 
experiment, the power-time curves of the species in the different media still showed 
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some similarities because these two media share some similarities in composition.  
The  power-time  curves  of  the  three  species  and  their  mixed  culture  in  CMM  are 
compared in Figure 2.31. The initial exponential phases (ca. between 0-5 h) of the curve 
of the mixed culture is quite identifiable with E. coli and the later exponential phase (ca. 
between 5-10 h), identifiable with P. aeruginosa (Figure 2.31). Again, it is likely that 
both E. coli and P. aeruginosa dominated the mixed culture.  
 
Figure 2.31. Comparison of the power-time curves of mixed cultures of P. aeruginosa, S. aureus and 
E. coli in CMM and that of pure culture of the species in CMM. Each species was inoculated to a 
density of 10
6 CFU/mL, hence a mixed culture of all three species had a final density of 3 x10
6 
CFU/mL 
2.5 Chapter summary 
The work in this chapter was a first step towards understanding of the behaviour of 
microorganisms in mixed cultures in the microcalorimeter. In this chapter, it was shown 
that P. aeruginosa, S. aureus and E. coli exhibit characteristic growth curves in a given 
medium; this was used for subsequent identification/detection of the species in mixed 
culture. In mixed cultures, it was shown that the growth profile of P. aeruginosa and E. 
coli  dominated  S.  aureus.  Plate  counts  done  after  microcalorimetric  measurements 
correlated with the observation in the microcalorimeter. It is likely the dominance of P. 
aeruginosa and E. coli could have been due to inhibitory substances produced by these 
species to which S. aureus may have been susceptible. As intimated, this dominancy has 
been  noted  to  occur  in  some  infected  environments.  For  instance,  in  cystic  fibrosis 
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infections, it was previously observed that the presence of P. aeruginosa in the sputum 
of infected patients significantly correlated with the absence of S. aureus (Machan et al., 
1992) but in the recent past, it has also been recognized that P. aeruginosa, through its 
inhibition could cause the selection for a different variant of S. aureus hence both could 
be co-isolated from an infection (Hoffman et al., 2006, Biswas et al., 2009). It has also 
been  previously  demonstrated  that  the  production  of  pyocyanin  (which  targets  the 
electron  transport  chain  of  S.  aureus)  coincides  exactly  with  the  time  S.  aureus 
concentration decreases in co-cultures with P. aeruginosa when both were previously 
growing  parallel  together  for  approximately  8  h  (Biwas  et  al.,  2009).  Thus  the 
experiments and results presented in this chapter concurs with previous studies and show 
that microcalorimetry could be a valuable tool for studying behaviour of mixed cultures 
and could potentially be used for studying clinically relevant interaction as it opens up a 
lot of possibilities.  
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Chapter 3 Antagonistic activity of probiotics against P. aeruginosa, 
S. aureus and E. coli  
3.1 Introduction 
Even  though  probiotics  have  been  associated  with  a  number  of  health  benefits,  as 
discussed in Chapter 1, the mechanism of probiosis has not been fully elucidated. It is 
however  believed  that  this  is  achieved  by  modulation  of  the  immune  system, 
enhancement of the epithelial barrier, competition for available nutrients or attachment 
sites on intestinal epithelial cells or the direct antagonism of pathogens (O'Toole and 
Cooney,  2008,  Bermudez-Brito  et  al.,  2012).  Direct  antagonism  through  specific 
inhibitory susbstance production (discussed in Chapter 1) is one of the most important 
functional properties which is often assessed in vitro for a strain if a potential probiotic 
effect is expected (Gismondo et al., 1999, FAO/WHO 2001, Jensen et al., 2012). This is 
often routinely tested using conventional techniques by culturing the probiotics or their 
bioproducts  together  with  targeted  pathogens  and  observing  relative  growth  of  the 
species or by the use of agar diffusion tests (Apella et al., 1992, Drago et al., 1997, 
Annuk et al., 2003, Naaber et al., 2004, Hutt et al., 2006, Trejo et al., 2006, Olivares et 
al., 2006, Jara et al., 2011, Chapman et al., 2012, Tejero-Sarinena et al., 2012, Schoster 
et al., 2013).  
In the work reported in this chapter, the microcalorimeter was explored to study the 
antimicrobial or antagonistic activity  of some  commercial probiotic strains using the 
probiotics in mixed culture with P. aeruginosa, S. aureus and E. coli.  
3.2 Objectives 
The objective of this chapter was: 
  To  study  the  growth  of  commercial  probiotic  strains  with  P.  aeruginosa,  S. 
aureus and E. coli in the microcalorimeter   104 
3.3 Materials and Methods 
3.3.1 Microorganisms 
Bifidobacterium  bifidum  ATCC  11863  was  purchased  from  American  Type  Culture 
Collection, USA. Pure cultures of Lactobacillus acidophilus LA-5
® and Bifidobacterium 
lactis BB-12
® were obtained from Chr. Hansen’s Culture Collection (Reading, UK). 
Staphylococcus  aureus  NCIMB  9518,  Pseudomonas  aeruginosa  NCIMB  8626  and 
Escherichia coli ATCC 25922 were obtained as previously reported in section 2.3.1 of 
Chapter 2. 
3.3.2 Microbiological media and chemicals 
Cooked meat medium (CMM), macconkey agar (MCA), cetrimide agar, mannitol salt 
agar (MSA), de man rogosa sharpe (MRS) broth and agar, brain heart infusion (BHI) 
broth and agar, agar powder, reinforced clostridial medium (RCM), nutrient broth (NB), 
iso-sensitest  agar  (ISA)  and  all  other  microbiological  media  were  from  Oxoid  Ltd, 
Basingstoke, UK and purchased from Fisher Scientific, UK. L- cysteine hydrochloride 
was purchased from Fisher Scientific, UK. D-(+)-glucose was purchased from Sigma-
Adrich, UK. 
3.3.3 Stock culture maintenance and purity 
B. bifidum ATCC 11863, L. acidophilus LA-5
® and B. lactis BB-12
® were obtained as 
freeze-dried cultures. These were stored at  -20
oC (±2
oC) before use.  B. bifidum was 
rehydrated with 5 mL RCM. To test for viability and purity, the suspension was sub-
cultured  onto  RCM  agar  and  BHI  agar  and  incubated  aerobically  (for  aerobic 
contamination check) and anaerobically in an anaerobic jar using AnaeroGen (Oxoid) to 
generate  the  anaerobic  environment  at  37
oC  for  48  h.  The  plates  were  checked  for 
contaminants. Single colonies from the RCM plate incubated anaerobically were picked 
using a sterile cotton swab and used to make a lawn of growth on a fresh agar plate. The 
plate was incubated anaerobically for 48 h at 37
oC after which the colonies were picked 
from the plate and inoculated into RCM supplemented with 15% v/v glycerol to make a   105 
thick suspension of the cells and stored at -80
oC until further use. 
L. acidophilus, LA-5
® and B. lactis, BB-12
® were rehydrated with MRS broth and MRS 
broth supplemented with 0.05% w/v L-cysteine hydrochloride “MRSc” respectively. The 
broth suspensions were sub-cultured onto MRSc agar to obtain single colonies, which 
were used to make respective lawns of the strains. Thick suspensions of the cells  in 
MRSc supplemented with 15% v/v glycerol  were made from the lawn and  this was 
stored at -80
oC until further use. To test for the absence of aerial contaminants, they 
were streaked onto BHI agar and incubated aerobically at 37°C for 48 h and observed for 
colony type. 
3.3.4 Cryopreservation and defrosting of bacteria 
Cryopreservation of the organisms was done according to section 2.3.7. Parent stocks of 
B. bifidum, BB-12
® and LA-5
® were streaked onto respective agar plates, RCM (for B. 
bifidum) and MRSc (for BB-12
® and LA-5
®). Pure colonies obtained were inoculated 
into 7 mL RCM or MRSc broth and incubated anaerobically at 37
oC for 24 h to make 
starter cultures of the organisms. A 1 in 100 dilution of the starter cultures were made in 
fresh media and these were incubated anaerobically and harvested by centrifugation at 
3500 g for 10 min at 4
oC when the cells reached their stationary phase of growth. The 
cells were washed twice with PBS, resuspended with ¼ Ringer’s solution supplemented 
with 15% v/v glycerol to a concentration of 10
8 CFU/mL and dispensed into multiple 
aliquots  in  cryovials.  Cryopreservation  procedure,  recovery  determination,  and 
defrosting procedures were carried out as previously described for the other species.  
3.3.5 Pure and mixed culture of probiotic strains and P. aeruginosa, S. aureus 
and E. coli in the isothermal microcalorimeter 
This  was  done  according  to  the  method  in  section  2.3.9  of  the  previous  chapter.  A 
dilution of a thawed culture of the species was made in CMM or CMM supplemented 
with 2% w/v glucose (“CMMg”) to give a pure culture density of 10
6 CFU/mL in a 
sterile 3 mL calorimetric glass ampoule. The ampoules were sealed with crimped caps 
and vortexed for 10 s. They were placed in the intermediate position of a TAM 2277 for 
thermal equilibration. The loaded ampoules were allowed to equilibrate at 37
oC at the   106 
intermediate position for 30 min before being lowered into the measurement position. 
Probiotic  species:  B.  bifidum,  LA-5
®  and  BB-12
®  were  mixed  with  S.  aureus  or  P. 
aeruginosa or E. coli, to produce a 10
6 CFU/mL of each species in 3 mL CMMg in the 
calorimetric ampoules. The ampoules were treated as above.  
3.3.6 Preparation of cell-free culture supernatants from probiotic cultures 
The culture supernatants of the probiotics were prepared by cultivating the respective 
probiotic species in CMMg over 48 h anaerobically. The cells and debris were removed 
by centrifuging at 3500 g for 10 min at 4
oC. The supernatant was collected and filter-
sterilized  to  remove  cells  using  a  0.22  µm  membrane  syringe  filter  (Sartorius  AG, 
Germany). The pHs of the supernatants were examined and equal aliquots modified by: 
adjusting the pH to neutral (pH 7.0) with 1M NaOH and heat treatment (heating the 
supernatant at 100
oC for 60 min).  
3.3.7 Agar well diffusion assay 
Cell-free culture supernatants (CFS) of B. bifidum, LA-5
® and BB-12
® were examined 
for their antimicrobial activity by the agar well diffusion assay as described by Jara et 
al., (2011) with some modifications. After the treatment, the supernatants were filter 
sterilized through a 0.22 µm membrane syringe filter. 10
6 CFU/mL of S. aureus, P. 
aeruginosa and E. coli were spread onto ISA agar plates with a sterile cotton swab to 
give a lawn of confluent growth of cells. Wells of 9 mm diameter were made with a 
sterile borer and filled with 100 µL of unmodified, neutralised and heat-treated CFS. The 
plates were kept on the bench for 2 h for diffusion of the CFS from the wells into the 
agar and incubated after at 37
oC. The zones of inhibition were measured after 24 h of 
incubation.  
3.3.8 Co-incubation of P. aeruginosa, S. aureus and E. coli with probiotic culture 
supernatants in the microcalorimeter  
1.5 mL of unmodified CFS, (repeated for neutralised and heat treated CFS), as obtained 
in section 3.3.6 for B. bifidum, LA-5
® and BB-12
® was added to 1.5 mL double strength   107 
CMMg  “dsCMMg”.  The  mixture  was  vortexed  for  10  s.  The  species:  S.  aureus,  P. 
aeruginosa  and  E.  coli  were  individually  inoculated  into  the  respective  CFS-broth 
mixture to a population density of 10
6 CFU/mL and placed in the TAM. Power-time 
measurements were taken for as long as the sample was generating a signal in the TAM. 
A control experiment was done by replacing the CFS with sterile distilled water. Plate 
counts of the species were done after the TAM experiments.  
3.3.9 Statistical Analysis 
Statistical analysis was performed in Origin Pro 8.6 (Microcal Software Inc.). T-test or 
Analysis of Variance (ANOVA) with Turkey post-hoc analysis for means comparison 
was  used  where  appropriate.  P  values  less  than  0.05  were  regarded  as  significant 
difference between means. 
3.4 Results and Discussion 
3.4.1 Pure culture of the different species in CMMg 
The probiotic species: B. bifidum, BB-12
® and LA-5
® showed poor growth in CMM but 
very good growth in CMMg. Figure 3.1 shows the power-time curves of 3 repeats of 
LA-5
® inoculated to a density of 10
6 CFU/mL in CMM unsupplemented. The power-
time curves of 10
6 CFU/mL repeats of pure cultures of the probiotic species and the 
other species inoculated into CMMg are shown in Figures 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7. 
The  power-time  curves  of  the  different  species  were  characteristic  in  CMMg  even 
though  the  curves  lacked  the  complexity/structure  demonstrated  in  CMM  or  NB  in 
Chapter 2. The cumulative heat outputs associated with the growth of LA-5
® and most of 
the species were significantly greater (P<0.05) in CMMg than in unsupplemented CMM.   108 
 
Figure 3.1. Power-time curves of 3 repeats of L. acidophilus, LA-5
® in CMM inoculated to 10
6 
CFU/mL 
 
 
Figure 3.2. Power-time curves of 3 repeats of L. acidophilus LA-5
® in CMMg inoculated to 10
6 
CFU/mL 
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Figure 3.3. Power-time curves of 3 repeats of B. lactis BB-12
® in CMMg inoculated to 10
6 CFU/mL 
 
Figure 3.4. Power-time curves of 3 repeats of B. bifidum in CMMg inoculated to density of 10
6 
CFU/mL 
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Figure 3.5. Power-time curves of 3 repeats of P. aeruginosa in CMMg inoculated to density of 10
6 
CFU/mL 
 
Figure 3.6. Power-time curves of 3 repeats of S. aureus in CMMg inoculated to density of 10
6 
CFU/mL 
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Figure 3.7. Power-time curves of 3 repeats of E. coli in CMMg inoculated to density of 10
6 CFU/mL 
It should be noted that most of the members of the Lactobacillus genus are facultative 
anaerobic  organisms  (Schleifer,  2009).  Optimal  growth  is  however  achieved  in 
microaerophilic or anaerobic conditions for some members (Schleifer, 2009). Members 
of the Bifidobacterium genus are however obligate anaerobes. S. aureus and E. coli on 
the  other  hand  are  facultative  anaerobes  (Schleifer  and  Bell,  2009,  Scheutz  and 
Strockbine, 2005) and P. aeruginosa, an aerobe, but sometimes considered a facultative 
anaerobe  because  it  is  known  to  survive  in  anaerobic  environments  using  nitrate  or 
nitrite if available as terminal electron carriers or arginine in the absence of nitrate or 
nitrite  (Eschbach  et  al.,  2004,  Garrity  et  al.,  2005).  Growth  is  however  generally 
favoured  in  aerobic  environment  for  P.  aeruginosa  (Garrity  et  al.,  2005)  also 
demonstrated by the results in Chapter 2. Thus the probiotic species, in particular, the 
bifidobacteria species can only be grown in oxygen-free environments which is achieved 
by the utilisation of natural medium containing reducing substances or by the addition of 
reducing substances for example glucose, sodium thioglycollate, ascorbic acid, cysteine 
hydrochloride etc. to some media (Charteris et al., 1997, Champagne et al., 2011). They 
are easily killed when exposed to oxygen because of their lack or limited activity of 
superoxide dismutase and or catalase (Brioukhanov et al., 2002). On the other hand, the 
other species in particular P. aeruginosa, require oxygen for growth and has limited 
growth in anaerobic environment, hence the ampoule oxygenation or deoxygenation was 
very  important  in  the  study  of  the  growth  of  the  species  in  mixed  cultures.  Also, 
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compared to the other species, the probiotic species are fastidious and metabolise by 
fermentation.  For  instance,  LA-5
®,  which  grew  optimally  in  microaerophilic  or 
anaerobic  environment  is  extremely  fastidious  and  is  adapted  to  complex  organic 
substrates.  Apart  from  requiring  carbohydrates  as  energy  and  carbon  sources,  these 
species also require nucleotides, amino acids, and vitamins (Schleifer, 2009) for growth. 
The various requirements for essential nutrients of these species are however normally 
met when the media contains fermentable carbohydrate, peptone, meat and yeast extracts 
(Harrigan, 1998).  
CMM consists of minced meat in  nutrient broth (Harrigan, 1998). The minced meat 
naturally  contains  reducing  substances,  which  produce  and  maintain  anaerobic 
conditions in the medium (Harrigan, 1998). As has been stated  in Chapter 2 of this 
thesis, CMM is a useful media for the culture of both aerobic and anaerobic organisms. 
By heating the medium, dissolved oxygen is removed and anaerobic environment can be 
maintained  by  incubation  in  an  oxygen-free  environment.  Similarly,  aerobic 
environment can be achieved when the medium is incubated uncapped or with loosed 
cap. Aerobic organisms grow at the top of the medium whilst anaerobic grow deeper in 
the medium. The addition of 2% w/v glucose to CMM to reduce the medium further for 
optimum growth of the probiotic species notably changed the power-time curves of the 
other species as well. Its addition in a naturally reduced medium kept the concentration 
of oxygen extremely low in the sealed ampoules. Hence, the characteristic aerobic peaks 
of all the facultative species were completely lost. Presumably, only anaerobic or also 
possibly microaerophilic growth occurred in the CMMg filled calorimetric ampoules. 
The species also metabolised more energetically and for longer time likely because of 
the substrate potential of the additional glucose. This is well illustrated by LA-5
®, S. 
aureus  and  E.  coli,  which  produced  mean  heat  outputs  of  34.52  ±  1.2  J  in  CMMg 
compared to 0.70 ± 0.03 J in unsupplemented CMM; 13.63 ± 0.66 J compared to 2.23 ± 
0.32 J and 14.34 ± 1.08 J compared to 3.63 ± 0.30 J respectively. 
Comparing all of the species in CMMg (Figure 3.8), the power-time and heat curves 
suggest that BB-12
® and B. bifidum are slower growing species relative to the other 
species. The peak of the growth curves occurred at ca. 10 h for BB-12
® and 11 h for B. 
bifidum; whilst it occurred at 7 h for LA-5
®; 4.5 h for P. aeruginosa; 6.5 h for S. aureus 
and  5  h  for  E.  coli.  Amongst  the  species,  LA-5
®  showed  maximum  growth  in  the   113 
medium generating the greatest heat outputs and reducing the pH of the medium the 
most (from 7.20 ± 0.2 to 4.0 ± 0.13).  
 
 
 
Figure 3.8. Comparison of the power-time curves [A] and heat curves [B] of pure cultures of LA-5
®, 
BB-12
®, B. bifidum, P. aeruginosa, S. aureus and E. coli in CMMg at densities of 10
6 CFU/mL of 
each. The curves show differences in the growth peaks and lag time duration respectively for the 
different species 
P. aeruginosa on the contrary showed the least growth, with heat output of 2.17 ± 0.31 J 
and changing the pH of the medium only slightly. The superior growth of LA-5
® in the 
medium  relative  to  the  other  species  could  be  probably  because  the  environment 
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generated in the ampoule suited its growth the most. P. aeruginosa on the other hand 
showed least growth in this reduced medium probably due to its inability to ferment 
available substrates in the medium for growth like the others. To illuminate further, it 
has been previously shown by Eschbach et al., (2004) that apart from denitrification and 
arginine fermentation, P. aeruginosa is also capable of fermenting pyruvate; but while 
this  fermentation  has  been  shown  to  afford  it  a  capacity  for  long-term  survival  in 
anaerobic environment, it has been shown not to sustain significant anaerobic growth 
(Eschbach et al., 2004). 
3.4.2 Mixed culture of the species in CMMg 
The power-time curves for the mixed cultures of the probiotic species: LA-5
®, BB-12
® 
and B. bifidum with P. aeruginosa, S. aureus and E. coli are shown in Figures 3.9, 3.10 
and 3.11. The power-time curves suggest the likely growth of both the probiotic and the 
other species in mixed culture.  
 
 
Figure 3.9. Comparison of the power-time curves of LA-5
® (black) and as mixed culture with P. 
aeruginosa (red), S. aureus (blue) and E. coli (green) in CMMg. All species were inoculated to 10
6 
CFU/mL 
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Figure 3.10. Comparison of the power-time curves of BB-12
® (black) and as mixed culture with P. 
aeruginosa (red), S. aureus (blue) and E. coli (green) in CMMg. Each species was inoculated to a 
density of 10
6 CFU/mL 
 
Figure 3.11. Comparison of the power-time curves of B. bifidum (black) and as mixed culture with P. 
aeruginosa (red), S. aureus (blue) and E. coli (green) in CMMg. Each species was inoculated to a 
density of 10
6 CFU/mL 
It should be noted that lactic acid bacteria are known to produce two main varieties of 
antimicrobial compounds which may affect both the lactic acid bacteria themselves as 
well  as  undesirable  or  pathogenic  strains  (Piard  and  Desmazeaud,  1991,  Piard  and 
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Desmazeaud, 1992). They produce low molecular weight compounds such as organic 
acids (acetic, formic and lactic), metabolites of oxygen (H2O2 and free radicals), which 
may have bacteriocidal or bacteriostatic effects on themselves or other microorganism. 
They  also  produce  proteinaceous  compounds  called  bacteriocins,  which  may  have  a 
narrow  spectrum  of  activity  (Barefoot  and  Klaenhammer  1983,  Anand  et  al.,  1984, 
Anand et al., 1985, Kang et al., 1989).  
In these experiments, it was expected that the probiotic species would inhibit the other 
species through release of these antimicrobial compounds. However the other species 
likely  contributed to growth curves/heat outputs when co-cultured with the  probiotic 
species. In co-culture with LA-5
®, P. aeruginosa may have contributed a peak at 4.5 h 
(Figure 3.9). The total area under the control curve (total heat output) of LA-5
® which 
was reproducible to 3.5% (n=3) was increased by almost 10% by the presence of P. 
aeruginosa. It was quite inconclusive whether S. aureus and E. coli also contributed to 
the growth curve in their co-culture with LA-5
® although an increase in heat output of 
ca. 10%  was also observed. Co-cultures of the  species with BB-12
® and B. bifidum 
clearly showed the presence of the pathogenic species in all the co-cultures, Figures 3.10 
and 3.11 respectively. This synchronous or preceding growth of the other species with 
the  probiotic  species  may  have  occurred  because  the  probiotic  species  were  slower 
growing species as evident by the late occurrence of the peak of the curves or the longer 
lag phase (Figure 3.8) compared to the other species hence it is likely that P. aeruginosa, 
S.  aureus  and  E.  coli  could  have  attained  exponential  phase  of  growth  before  the 
probiotics could begin exponential growth. For instance, comparing a co-culture of BB-
12
® with P. aeruginosa (Figure 3.12a), it is very likely that P. aeruginosa contributed 
the first peak and the second growth peak contributed by BB-12
®. The curve for BB-12
® 
however commenced just before P. aeruginosa attained stationary growth phase. The 
peaks  also  occurred  later  for  P.  aeruginosa  (ca.  6  h)  and  earlier  for  BB-12
®  in 
comparison to their control curves. It could therefore be reasoned that perchance BB-12
® 
to some extent inhibited P. aeruginosa since a change in inoculum density results in a 
linear change in heat output (ie. a time lag is added to the curve). To that effect even 
though both species were inoculated at 10
6 CFU/mL, the presence of BB-12
® possibly 
influenced P. aeruginosa (by competing for nutrients) such that it was detected when its 
population had increased from 10
6 CFU/mL.   117 
 
Figure 3.12a. Comparison of the power-time curves of BB-12
® (black) P. aeruginosa (red) and their 
mixed culture (blue) in CMMg 
 
Figure 3.12b. Comparison of the power-time curves of BB-12
® with P. aeruginosa: both 
unconditioned (black), conditioned for 4 h (red) and conditioned for 9 h (blue) in CMMg 
It had been a concern that, when inoculated into medium immediately after being thawed 
from  liquid  nitrogen  storage,  organisms  will  adapt  differently  in  the  medium  (some 
recovering earlier than others). BB-12
® and P. aeruginosa were therefore inoculated into 
media and left to adapt (“conditioned”) for 4 h and 9 h before being co-cultured into 
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fresh medium and placed in the TAM. The resulting curves are compared in Figure 
3.12b.  Conditioning  of  the  organisms  for  4  h  added  a  time  lag  to  the  curve  of  P. 
aeruginosa with peak occurring at ca. 7 h. When the culture was conditioned for 9 h, the 
peak  occurred  earlier,  ca.  3  h  45  min.  Conditioning  the  culture  for  9  h  meant  P. 
aeruginosa was well into its exponential phase of growth hence the volume of culture 
inoculated  into  fresh  medium  contained  more  organisms  per  mL  than  the  culture 
conditioned for only 4 h (which could have been a mere dilution of the initial inocula of 
P. aeruginosa). On the other hand, conditioning of BB-12
® for any of the time used was 
simply a dilution of the initial population. 
For all mixed cultures of probiotics with the other species, inhibition was only detected 
by plating out at the end of incubation (after TAM measurement). Plating out of all co-
cultures showed total inhibition of P. aeruginosa, S. aureus and E. coli (see Table 3.2 for 
plate count post TAM). Plating out during the first 5 h of co-cultures of the probiotics 
with E. coli (Table 3.1) showed growth of both the probiotics and E. coli.  
Table 3.1. Plate count of BB-12
®- E. coli co-culture and LA-5
®- E. coli co-culture within first 5.5 h of 
microcalorimetric incubation 
 
Time    
(h)  
Plate  count  of  mixed  culture  of  BB-12
® 
and E. coli in CMMg (CFU/mL) 
Plate count of mixed culture of LA-5
® and 
E. coli in CMMg (CFU/mL) 
BB-12
®  E. coli  LA-5
®  E. coli 
0.5  9.5 x 10
5   1.2 x 10
6   2.4 x 10
6   9.5 x 10
5  
1  8.8 x 10
5  1.1 x 10
6   2.1 x 10
6   9.5 x 10
5  
1.5  1.1 x 10
6   1.2 x 10
6   2.4 x 10
6   9.3 x 10
5  
2  9.5 x 10
5   1.4 x 10
6   2.4 x 10
6   1.2 x 10
6  
2.5  2.3 x 10
6   4.0 x 10
6   2.1 x 10
6   1.9 x 10
6  
3  4.8 x 10
6   1.6 x 10
7   1.0 x 10
7   1.0 x 10
7  
3.5  1.9 x 10
7   2.8 x 10
7   6.7 x 10
7   4.2 x 10
7 
4.5  9.7 x 10
7   2.0 x 10
8   1.9 x 10
7   3.0 x 10
8  
5.5  1.2 x 10
8  6.4 x 10
8  1.1 x 10
8   8.1 x 10
8    119 
Table 3.2. A table comparing the post TAM profile of the pure culture and mixed culture of probiotics 
and P. aeruginosa, S. aureus and E. coli 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organism in CMMg  pH post TAM  Plate count (CFU/mL) post TAM 
Pure Culture     
L. acidophilus LA-5
®  4.00 ± 0.13  3.6 x 10
8 
B. lactis BB-12
®  4.55 ± 0.01  8.0 x 10
8 
B. bifidum  4.79 ± 0.01  4.6 x 10
7 
P. aeruginosa  6.78 ± 0.09  2.8 x 10
7 
S. aureus  5.05 ± 0.05  1.8 x 10
8 
E. coli  5.39 ± 0.01  3.9 x 10
8 
Mixed Culture    Probiotic (LA-5
® or 
BB-12
® or B. 
bifidum 
 P. aeruginosa or S. 
aureus or E. coli 
LA-5
® and P. aeruginosa  4.30 ± 0.01  2.5 x 10
8  0 
LA-5
® and S. aureus  4.12 ± 0.02  4.5 x 10
8  0 
LA-5
® and E. coli  4.20 ± 0.05  2.0 x 10
8  0
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Table 3.2. A table comparing the post TAM profile of the pure culture and mixed culture of probiotics 
and P. aeruginosa, S. aureus and E. coli (continued) 
 
 
This implied that the probiotic species could have only inhibited the other species after 
an active or exponential growth. Thus they produced extracellular inhibitory susbstances 
after consumption of the nutrient substrates and accumulation of inhibitory substances; 
prior to that phase, they could only coexist with the other species. This observation 
agrees with a previous study by Apella et al., (1992) who showed that Shigella sonnei 
could grow together with Lactobacillus casei or L. acidophilus in mixed culture for the 
first  few  hours  but  noted  that  inhibition  began  at  6  h  and  death  phase  at  9  h  of 
incubation.  A  study  by  Bendali  et  al.,  (2011)  also  demonstrated  that  co-cultures  of 
Lactobacillus paracasei with either E. coli or Salmonella typhimurium showed inhibition 
at approximately 2 h and 6 h respectively when the growth kinetics of the mono-cultures 
of  the  pathogens  were  compared  with  the  co-cultures.  Another  study  by  Kos  et  al., 
(2008)  showed  that  S.  typhimurium  was  immediately  inhibited  in  growth  when  the 
species was added to a selection of previously growing probiotics but inhibition occurred 
Organism in CMMg  pH post TAM  Plate count (CFU/mL) post TAM 
Mixed culture    Probiotic (LA-5
® or 
BB-12
® or B. 
bifidum 
 P. aeruginosa or S. 
aureus or E. coli 
BB-12
® and P. aeruginosa  4.35 ± 0.02  6.1 x 10
8  0 
BB-12
® and S. aureus  4.30 ± 0.06  9.2 x 10
8  0 
BB-12
® and E. coli  4.45 ± 0.02  1.8 x 10
8  0 
B. bifidum and P. 
aeruginosa 
4.48 ± 0.01  8.6 x 10
8  0 
B. bifidum and S. aureus  4.49 ± 0.08  2.7 x 10
8  0 
B. bifidum and E. coli  4.48 ± 0.01  4.6 x 10
8  0
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much later and also for Listeria monocytogenes when the probiotics were co-cultured 
together with the pathogenic species at the same time. 
3.4.3 Co-incubation of probiotic supernatant with P. aeruginosa, S. aureus and 
E. coli 
It was observed that there was significant acidification of the medium after incubation of 
the probiotic species (Table 3.2) from pH of 7.2 ± 0.2 of the medium to 4.0 ± 0.13 for 
LA-5
® (P<0.05),  4.55  ±  0.01  (P<0.05)  for  BB-12
®  and  4.79  ±  0.01(P<0.05)  for  B. 
bifidum in CMMg. This low pH (depicting the presence of organic acids) could have 
most likely produced the inhibitory effects of the probiotics towards the other species. 
To determine if there were other extracellular substances contributing to the antibacterial 
effects of the probiotic strains, the cell free culture supernatants (CFS) of the probiotics 
were evaluated after neutralisation of the pH and heat inactivation. Figure 3.13 compares 
the  power-time  curves  of  P.  aeruginosa  inoculated  into  a  double  strength  CMMg 
“dsCMMg”  diluted  (1  in  2  times)  with  water  and  diluted  with  CFS  (unmodified, 
neutralised and heat treated) of LA-5
®. It also shows the power-time curves of S. aureus 
and E. coli inoculated into diluted CFS of LA-5
®. The power-time curves demonstrate 
the inhibition of the species with the CFS of LA-5
®. The inhibitory activity of LA-5
® 
was however lost when neutralised.  
The same inhibitory effect was demonstrated with the CFSs of BB-12
® (Figure 3.14) and 
B.  bifidum  (Figure  3.15).  Again,  inhibitory  activities  were  lost  upon  neutralisation 
(evident by the reappearance of the growth curve of P. aeruginosa) but retained after 
heat treatment. It was however observed that even though the power-time curve for P. 
aeruginosa reappeared after neutralisation of the CFS of BB-12
® and B. bifidum, these 
growth curves peaked at a much later time and in lesser intensity compared with the 
control,  suggesting  that  inhibitory  activities  of  the  CFSs  of  these  species  were  not 
completely lost upon neutralisation. Plate count of the co-culture of the supernatants of 
the probiotics with the species only showed survival of the species when the CFSs were 
neutralised (Table 3.3). The plate count did not however suggest that the cells were 
inhibited in growth by the neutralised CFSs.    122 
 
Figure 3.13. Comparison of the power-time curves of P. aeruginosa control (black) and P. aeruginosa 
with cell free supernatant (CFS) of LA-5
® unmodified (red), neutralised (blue) and heat treated 
(magenta); S. aureus (green) and E. coli (violet) with CFS of LA-5
® 
 
Figure 3.14. Comparison of the power-time curves of P. aeruginosa control (black) and P. aeruginosa 
with cell free supernatant (CFS) of BB-12
® unmodified (red), neutralised (blue) and heat treated 
(magenta); S. aureus (green) and E. coli (violet) with CFS of BB-12
® 
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Figure 3.15. Comparison of the power-time curves of P. aeruginosa control (black) and P. aeruginosa 
with cell free supernatant (CFS) of B. bifidum unmodified (red), neutralised (blue) and heat treated 
(magenta) and S. aureus (green) and E. coli (violet) with CFS of B. bifidum 
Table 3.3. Plate count demonstrating antagonistic activity of unmodified and modified cell free 
supernatant (CFS) of LA-5
®, BB-12
® and B. bifidum against P. aeruginosa, S. aureus and E. coli after 
microcalorimetric co-incubation. 
 
Supernatant    CFU of target bacteria (CFU/mL) 
P. aeruginosa  S. aureus  E. coli 
LA-5
® CFS  0  0  0 
LA-5
® CFS neutralised  3.0 x 10
7  2.2 x 10
8  4.0 x 10
8 
LA-5
® CFS heat treated  0  0  0 
BB-12
® CFS  0  0  0 
BB-12
® CFS neutralised  2.3 x 10
7  8.9 x 10
7  1.7 x 10
8 
BB-12
® CFS heat treated  0  0  0 
B. bifidum CFS  0  0  0 
B. bifidum CFS neutralised  4.2 x 10
7  4.0 x 10
8  2.9 x 10
8 
B. bifidum CFS heat treated  0  0  0 
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3.4.4 Agar well diffusion assay 
The diameters of growth inhibition zones of P. aeruginosa, S. aureus and E. coli are 
shown  in  Table  3.4  and  images  of  zones  of  inhibition  of  P.  aeruginosa  with  the 
unmodified and modified CFS of LA-5
® are shown in Figure 3.16. In the experiment, P. 
aeruginosa was most sensitive towards the CFS of the probiotics and E. coli, the least 
sensitive. Again, by this test, it was confirmed that inhibitory activities of the CFSs were 
lost after neutralisation but retained when heat-treated implying that these extracellular 
substances were heat stable and could probably be acids.  
Table 3.4. Zones of inhibition of unmodified and modified cell free supernatant (CFS) of LA-5
®, BB-
12
® and B. bifidum against P. aeruginosa, S. aureus and E. coli. The values are arithmetic means 
(n=4) ± SD of inhibition zones (mm)  
 
Supernatant  Zone of inhibition of target bacteria (mm) 
  P. aeruginosa  S. aureus  E. coli 
LA-5
® CFS  9.0 ± 0.8  5.5 ± 1.2  2.5 ± 0.6 
LA-5
® CFS neutralised  0.0 ± 0.0  0.0 ± 0.0  0.0 ± 0.0 
LA-5
® CFS heat treated  12.0 ± 0.8  13.5 ± 0.6  3.5 ± 2.1 
BB-12
® CFS  5.8 ± 1.5  4.8 ± 0.5  2.0 ± 0.0 
BB-12
® CFS neutralised  0.0 ± 0.0  0.0 ± 0.0  0.0 ± 0.0 
BB-12
® CFS heat treated  7.5 ± 1.0   6.0 ± 0.0  2.3 ± 0.5 
B. bifidum CFS  6.3 ± 1.0  5.8 ± 0.5  3.0 ± 1.4 
B. bifidum CFS neutralised  0.0 ± 0.0  0.0 ± 0.0  0.0 ± 0.0 
B. bifidum CFS heat treated  9.3 ± 0.5  6.3 ± 1.0  3.8 ± 2.2 
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Figure 3.16. Images of zone of inhibition of P. aeruginosa by unmodified [A], heat treated [B] and 
neutralised [C] CFS of LA-5
® 
The zones of inhibition values were plotted against the change in pH of the different 
probiotic culture supernatants compared to the pH of the broth prior inoculation for each 
of the respective species to find out if there was a correlation between the amount of acid 
production by the probiotic species and their inhibitory effect. The plots are shown in 
Figure 3.17. A good correlation (R
2 value of 0.8135) was obtained for P. aeruginosa but 
very weak correlations (respective R
2 values of 0.0054 and 0.0878) were obtained for S. 
aureus  and  E.  coli.  The  result  suggests  that  the  amount  of  acid  production  by  the 
probiotics could have been a critical factor for the inhibition of P. aeruginosa but not S. 
aureus  and  E.  coli.  Between  the  three  species,  both  S.  aureus  and  E.  coli  could 
themselves produce acids; they both also significantly lowered (P<0.05) the pH of the 
broth  (Table  3.2).  It  is  likely  these  two  species  could  have  the  ability  to  protect 
themselves from the self-produced acids and thereby may have developed the necessary 
factors for surviving acid stress (Cotter and Hill, 2003, Chung et al., 2006) relative to P. 
aeruginosa. These two species may have also been mainly inhibited by other non-acidic 
metabolites  or  may  have  been  synergistically  hindered  by  the  acidic  and  non-acidic 
antimicrobial metabolites of the probiotic species. This is however not in total agreement 
with the other results, for instance, the co-incubation enumeration assay with the CFSs 
of the probiotics, which suggests that inhibition was acid dependent for all the species 
(Table  3.3).  Inhibition  zones  were  also  not  observed  for  the  neutralised  CFSs.  This 
disparity in the results may be due to firstly, the possibility that the other non-acidic 
antimicrobial metabolites were produced in smaller quantities than the acids and were 
further diluted during the CFS co-culture assay or their activities depended on the acidity 
of the supernatant and were therefore hindered when neutralized. Oliveira et al., (2008) 
have shown the possibility of the latter situation. Messens and De, (2002) have also 
reported that most lactic acid bacteria and bacteriocins show maximum activity at lower 
pH. 
               [A]                           [B]                           [C]           126 
 
 
 
Figure 3.17. Zones of inhibition of the different species plotted against change in pH of the culture 
supernatant of the different probiotic species. (Black series, LA-5
® CFS; red, BB-12
® CFS and blue, 
B. bifidum CFS) 
The results obtained show some consistency and constrast with results from previous 
studies. For instance, a study by Tirloni et al., (2014) reported that among food spoilage 
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or potential pathogenic species tested against Lactobacillus animalis and L. paracasei, 
P.  aeruginosa  was  one of  the  least  susceptible  species  although  other  Pseudomonas 
species were the most susceptible. The Enterobacteriaceae showed variable susceptibility 
but a strain of E. coli also showed least susceptibility and S. aureus showed moderate 
susceptibility.  The  authors  also  reported  a  lack  of  activity  by  the  neutralized  CFS. 
Sepova et al., (2011) also reported that among potential pathogens tested against a lactic 
acid bacterium E isolated from a lamb, when the species tested in the present study are 
considered, the inhibition potential of their lactic acid bacterium E against the potential 
pathogens decreased from S. aureus, P. aeruginosa to E. coli. Other authors have also 
reported different degrees of inhibition by different potential probiotic species and have 
shown either loss or retention of activity after neutralisation (attributable to presence or 
absence of other extracellular substances apart from acids) using either broth culture or 
agar  diffusion  assay  (Vaughan  et  al.,  1994,  Drago  et  al.,  1997,  Annuk  et  al.,  2003, 
Ammor et al., 2006). However in the present study, the data from the microcalorimeter 
indicates that there could be other extracellular susbstances in the CFS, which could 
have had an influence on the metabolic activity or growth of the species (especially CFS 
produced from BB-12
® and B. bifidum); although data from the plate count and the agar 
diffusion assay do not give this indication. 
In the present study, it was observed that heat-treated CFS of the various probiotics 
demonstrated significantly greater (P<0.05) inhibition zones against the species. During 
the heat treatment, 100
oC for 60 min, it was likely that some water evaporated from the 
CFS resulting in the concentration of the CFS. This provides some evidence that the CFS 
contained other non-acidic inhibitory substances, which could have been produced in 
smaller quantities but concentrated during heat treatment. Smaller zones of inhibition 
were also noted for the CFSs when they were stored at 4
oC for one week even though the 
pHs of the CFSs were not significantly affected during storage. These stored CFSs also 
did not demonstrate bactericidal activity against the species as cell counts of 10
6-10
5 
CFU/mL were obtained for the species when co-cultured in the unmodified CFSs. This 
suggests  that  the  inhibitory  substances  were  unstable  in  the  supernatant  which  is  in 
agreement with findings by Najim et al., (2012) who reported significant reduction in 
activity of CFS obtained from a L. acidophilus isolate containing a bacteriocin during 
storage  at  4
oC  or  room  temperature  for  21  days.  They  explained  that  the  decreased 
activity  during  storage  could  be  due  to  the  action  of  proteolytic  enzymes  in  the 
supernatant. Their CFS was also reported to be heat stable (80 and 60
oC).    128 
3.5 Chapter summary 
In the work reported in this chapter, the potential of the isothermal microcalorimeter was 
explored to assess the antagonism of some commercial probiotics using the probiotic 
strains in mixed culture with P. aeruginosa, S. aureus and E. coli. It was shown that the 
microcalorimeter  could  differentiate  between  the  species.  However  detailed  structure 
(peaks and troughs) of the curves was lost in contrast to that obtained in Chapter 2. This, 
as explained in Chapter 2 could be due to the anaerobic environment generated in the 
ampoule  as  well  as  the  saturation  of  the  medium  with  one  energy/carbon  source 
(glucose).  
The  results  demonstrated  that  the  probiotic  species  could  have  co-existed  with  the 
pathogenic species in the microcalorimeter when co-cultured together but inhibited them 
after  a particular duration. This  implied that antagonism of the probiotics  may have 
depended  on  their  production  and  accumulation of  extracellular  inhibitory  metabolic 
products, which could have occurred after they had fermented the nutrient sources but 
during which the other species may have grown because of their faster growth rate. This 
was in agreement with previous studies which have demonstrated inhibitory activity of 
potential probiotics occurring after active growth of the probiotics (Apella et al., 1992, 
Kos et al., 2008) or inhibition occurring after a particular duration when the kinetics of 
the  growth  of  monoculture  of  potential  pathogenic  species  were  compared  with  co-
cultures with potential probiotic species (Apella et al., 1992, Kos et al., 2008, Bendali et 
al., 2011). However, the antagonistic activity of the probiotics could not be observed 
with the live cells in the microcalorimeter due to exhaustion of nutrient sources as a 
result of the static batch culture model that was simulated in the microcalorimeter by the 
use of the ampoule. The exhaustion of nutrient sources in the ampoule made it difficult 
to  distinguish  between  the  dead  or  inactive  pathogenic  species  and  live  stationary 
probiotics cells (determined during plate count and also when CFS produced by the 
probiotics were used instead of the live cells). This limitation could be circumvented 
with a flow microcalorimeter where growth media can be constantly pumped into the 
reaction vessel (Beezer et al., 1979, Morgan et al., 2001) or by titrating fresh media into 
the reaction vessel at determined intervals using a titration unit (Johansson and Wadso, 
1999b). These are also not without their own limitations. For example, attaining thermal 
equilibrium of the continuously added medium could take a very long time if it is added 
in large volumes.       129 
Inhibition of the pathogenic species by the probiotics was shown to be pH-dependent 
using the CFS produced by the probiotics. But the results from the microcalorimeter also 
indicated that other non-acidic metabolites could have contributed to the inhibition of the 
species. These non-acidic metabolites, likely bacteriocins (Barefoot and Klaenhammer 
1983,  Anand  et  al.,  1984,  Anand  et  al.,  1985,  Kang  et  al.,  1989)  could  have  been 
produced in small quantities relative to the acids. The inhibitory substances produced by 
the probiotics were also shown to be heat stable but unstable during  storage, which 
correlated with a previous study by Najim et al., (2012).  
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Chapter 4 Probiotics for treatment/prevention of Clostridium 
difficile infection: Antagonistic activity of probiotics against C. 
difficile 
4.1 Introduction 
4.1.1 Pathogenesis of Clostridium difficile infection 
As discussed in Chapter 1, the normal human gut microbiota suppresses the growth of 
opportunistic pathogens and prevents the invasion of potential pathogens (Gordon and 
Pesti,  1971,  Stecher  and  Hardt,  2008,  Walker  and  Lawley,  2013).  This  was  in  fact 
recognised in the 1950s when Bohnhoff et al., (1955) showed that when mice were 
treated with antibiotics, the dose of Salmonella enterica serovar Typhimurium needed to 
infect them decreased by 100000 fold relative to untreated group (Bohnhoff et al., 1955). 
So far, none of the elements of the mammalian immune system has been shown to 
provide such a degree of protection (Walker and Lawley, 2013). The protective effect of 
the  resident  microbiota,  proposed  to  be  brought  about  by  competition,  immune 
modulation, direct antagonism towards potential pathogens (O'Toole and Cooney, 2008, 
Bermudez-Brito et al., 2012) coupled with the hostile acidic environment of the stomach, 
peristalsis and intestinal washout are factors which prevent invading microorganisms 
from colonizing or suppresses the growth of pathogenic members of the gut (Stecher and 
Hardt, 2008, Walker and Lawley, 2013).  
The protective function of the microbiota is however reduced or compromised when 
there  is  dysbiosis  through  host  lifestyle  (diet,  stress),  medical  practices  (the  use  or 
overuse  of  antibiotics,  chemotherapy,  vaccination,  toxic  compounds,  hygiene),  host 
genetics (Stecher and Hardt, 2008, Round and Mazmanian, 2009, Dore and Corthier, 
2010). Following the disturbance of the resident microbiota through these practices or 
compounds, there is a consequential overgrowth of the opportunistic pathogens of the 
microbiota or colonization by invading ones (Figure 4.1).  
Clostridium  difficile  is  the  pathogen  most  often  associated  with  opportunistic 
proliferation after disruption of the normal microbiota through use of broad-spectrum 
antibiotics (Tedesco, 1981, Parkes et al., 2009, Rupnik et al., 2009).    131 
 
 
Figure 4.1. Pathogenesis of C. difficile infection.  
It  is  a  fastidious,  Gram-positive,  anaerobic,  spore-forming  bacillus.  During  its 
overgrowth/infection,  which  occurs  as  a  result  of  antibiotic  usage  and  or  through 
ingestion of spores of the organism, spread via the faecal-oral route (which germinate in 
the intestine), it produces two toxins, Toxins A (Tcd A) and Toxin B (Tcd B) which are 
responsible for its pathogenicity (Warny et al., 2005, Kelly and LaMont, 2008). When 
these  toxins  are  produced  in  sufficient  amounts,  they  bind  and  structurally  damage 
epithelial cells and/or the tight junctions, and compromise the gut barrier, consequently 
leading to an inflammatory cascade also involving the nervous system (Hell et al., 2013). 
Specifically,  Toxin  A  is  proposed  to  increase  intestinal  permeability,  inhibit  protein 
synthesis, disrupt colonic mucosal cell adherence to colonic basement membrane and 
also damage villous tips (Poxton et al., 2001, Tonna and Welsby, 2005). Toxin B enters 
the cell by endocytosis and induces apoptosis; it is thought to induce its effect once the 
gut wall has been damaged (Poxton et al., 2001). Toxin B has been reported to be 1000 
times more potent with 100-fold higher enzymatic activity than toxin A, this accounting 
for the difference in cytotoxic activity between the two (Poxton et al., 2001, Tonna and 
Welsby, 2005). Both toxins however stimulate monocytes and macrophages, which in 
turn release interleukin 8, resulting in tissue infiltration with neutrophils (Tonna and 
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Welsby, 2005). The consequent manifestation of their activities are diarrhoea, colitis, 
pseudomembranous  colitis,  toxic  megacolon  and  in  worst  case,  death  (Mitty  and 
LaMont, 1994, Hurley and Nguyen, 2002, Rupnik et al., 2009). However, the infection 
could also be asymptomatic in some people infected with toxigenic strains, which has 
implied that there could be other factors, including the environment within the gut which 
are important for disease pathogenesis (Haslam et al., 1986, Karlsson et al., 2003, Tonna 
and Welsby, 2005, Kuijper et al., 2006). Collectively, the manifestations of C. difficile 
infection are known as Clostridium difficile associated disease (CDAD). 
As hinted, C. difficile is not uncommon in a healthy intestine. It can be cultured in the 
stools of 1-3% of healthy adults and up to 80% of healthy newborns and infants (Viscidi 
et al., 1981, Bartlett, 2002). Generally, contamination of hospital environments with C. 
difficile  spores  is  a  major  factor  associated  with  infection  spread  (Cloud  and  Kelly, 
2007). When indigenous gut microbiota is disrupted with antibiotics, C difficile spores 
germinate,  resulting  in  vegetative  growth,  and  toxin  production,  which  consequently 
leads to the clinical manifestations of the disease. It should be noted that there are some 
strains of C. difficile which are non-toxigenic i.e., they do not produce either toxin A or 
B hence do not cause C. difficile infection (Rupnik et al., 2009, Best et al., 2012), while 
there are also strains which produce toxin B but not A but these strains are also capable 
of causing C. difficile infection (Lyras et al., 2009, Hell et al., 2013). Strains which 
produce toxin A but not B may not necessarily be virulent (Drudy et al., 2007, Lyras et 
al., 2009). A third, so called C. difficile toxin (CDT) associated with epidemic strains has 
also been identified (Schwan et al., 2009, Kuehne et al., 2014).  
4.1.2 History of C. difficile infection 
C. difficile was first described by Hall and O’Toole in 1935 as a commensal organism, in 
the faecal flora of healthy newborn infants. They referred to it as Bacillus difficilis; its 
unusual name, difficilis because unlike other bacteria, they noticed it grew slowly and 
was difficult to isolate (Lamont, 2002). They also noticed and reported that B. difficilis, 
secreted toxins that were lethal to animals. But because it had been isolated from normal 
infants,  and  there  was  no  indication  that  its  presence  had  any  adverse  effects  on 
newborns, so for the next forty years, B. difficilis or C. difficile was considered a part of 
the normal microbiota of infants and remained unimportant clinically until 1978 (Lyerly   133 
et al., 1988).  
In the 1960s and 1970s, pseudomembranous colitis (Figure 4.2), which had also been 
described  as  early  as  1893,  characterized  by  inflammation  of  the  colon  with  the 
formation  of  plaques,  or  pseudomembranes  (composed  of  fibrin,  mucous,  necrotic 
epithelial cells and leukocytes) (Lyerly et al., 1988), had become prevalent following the 
introduction  into  clinical  practice,  broad-spectrum  antibiotics  for  the  treatment  of 
infections (Tedesco, 1981, Lyerly et al., 1988, Parkes et al., 2009). The incidence of 
pseudomembranous  colitis  was  reported  to  be  as  high  as  10%  in  some  hospitals 
following use of the broadspectrum antibiotics, which in some patients presented as a 
sheath  over  the  entire  colonic  mucosa  at  autopsy  (Lyerly  et  al.,  1988). 
Pseudomembranous  colitis  was  therefore  thought  to  be  caused  by  broad-spectrum 
antibiotics that were commonly prescribed: clindamycin and lincomycin (Tedesco, 1981, 
Lyerly et al., 1988). The condition was then referred to as “clindamycin colitis” (Cohen 
et al., 1974) and was thought to have a high mortality rate but was later associated with 
other antibiotics (Lyerly et al., 1988). Although many aspects of research were ongoing 
during this era, it was the intensive research that was conducted during the late 1970s 
utilizing animal models that brought to light the association of clostridial species and 
later, the toxins reported by Hall and O’Toole to be implicated in the disease (Tedesco, 
1981, Lyerly et al., 1988). Indeed it was the study of Bartlett and colleagues (1977) that 
demonstrated an overgrowth of a clostridial species to be associated with enterocolitis in 
clindamycin-treated hamsters (Bartlett et al., 1977). Larson et al., (1977) also discovered 
that cell free filtrates of stools of patients with pseudomembranous colitis had cytopathic 
activities on cell cultures and proposed that pseudomembranous colitis may be caused by 
a bacterial toxin (Larson et al., 1977). Studies conducted after these important findings 
showed  that  the  cell  free  filtrate  toxins  found  in  the  stool  of  patients  with 
pseudomembranous  colitis  were  produced  by  clostridial  species  (Rifkin  et  al.,  1977, 
Bartlett et al., 1978, Tedesco, 1981). At first, the species was thought to be Clostridium 
sordellii since the cytopathic effects of the toxin could be neutralised with C. sordellii 
antitoxin,  but  later,  the  organism  was  confirmed  as  C.  difficile  (Rifkin  et  al.,  1977, 
Bartlett et al., 1978, Tedesco, 1981).   134 
 
 
Figure 4.2. Pseudomembranous colitis: pseudomembranes appear during colonoscopy of patients with 
C. difficile infection. Pseudomembranes are visible as raised yellow plaques scattered over the 
colorectal mucosa. (Figure obtained from Medscape. March 2014. Clostridium difficile colitis. 
[online]. Available from:  http://emedicine.medscape.com/article/186458-overview#aw2aab6b2b4 
[Accessed on 7 May 2014] ) 
4.1.3 Epidemiology, risk factors and burden of C. difficile infection 
Rates of C. difficile infection kept increasing from its discovery through to the 1990s, 
but it saw a dramatic increase in the incidence, severity and relapse in the 2000s due to 
the emergence of hypervirulent strains such as C. difficile ribotype 027 (Kuijper et al., 
2008, Islam et al., 2012) which were resistant to fluoroquinolone antibiotics. The regions 
most affected were in North America (especially Quebec, Canada) and Europe (Kuijper 
et al., 2008). Within the United Kingdom, the rate of the infection was highest in 2007 
with more than 50,000 cases reported and with 80% of affected patients aged over 65 
years (Islam et al., 2012, Public Health England, 2014). Ribotype 027 of C. difficile was 
associated with epidemics and accounted for more than 40% of C. difficile isolates from 
English hospitals by 2007 (Islam et al., 2012). There has been a huge effort by the NHS 
which was also supported by the Department  of  Health to decrease the rates of the 
infection (Duerden, 2011, Islam et al., 2012). Interventions used include rapid diagnosis, 
root cause analysis, patient isolation, improved infection control practice, and antibiotic 
stewardship  policies,  which  focuses  on  decreasing  the  use  of  “high  risk 
antibiotics”(Gerding et al., 2008a, Owens and Ambrose, 2007). From 2007, the rate of 
C. difficile infection has fallen, with a decreasing prevalence of ribotype 027 strains 
being  reported  (Islam  et  al.,  2012).  However,  between  April  2013  and  March  2014 
alone, a total of 13,361 cases of C. difficile infection were reported across the NHS. This 
number represents a 9.1% reduction on the cases reported between 2012 and 2013 and   135 
75.9% reduction on numbers reported between 2007 and 2008 (Public Health England, 
2014). Whilst this indicates a significant reduction of cases reported across England, and 
a decreasing prevalence of ribotype 027 strains in the UK, other virulent strains have 
also been described (CDRN report for England and Northern Ireland, 2011-2013). C. 
difficile  still  remains  a  significant  (up  to  20-30%)  cause  of  antibiotic-associated 
diarrhoea and is responsible for almost all cases of pseudomembranous colitis (Bartlett, 
2002, Rea et al., 2013). 
C.  difficile  infection  predominantly  occurs  in  older  patients  mainly  because  of  their 
healthcare contact (McFarland et al., 1990, Bauer et al., 2011) and the reduced diversity 
of their microbiota, (predominantly, a reduction of the anaerobes and bifidobacteria) 
(Hebuterne, 2003) which reduces their colonization resistance. This occurs as a result of 
repeated courses of antibiotics and a background of an ageing immune system (Islam et 
al.,  2012,  Burke  and  Lamont,  2014).  Other  patients  who  are  at  risk  include 
immunocompromised patients, patients on proton pump inhibitors (Dial et al., 2004) and 
patients who have undergone organ transplant (Munoz et al., 2007, Bouza, 2012). 
C. difficile infection imposes a lot of burden on both patients and the healthcare systems. 
First of all, patients experience significant morbidity and in the worst case, mortality 
from  the  debilitating  manifestations  of  the  disease,  which  include  profuse  diarrhea, 
pseudomembranous  colitis,  abdominal  pain,  nausea,  fever,  intestinal  perforations, 
peritonitis, megacolon and fulminant colitis (Hurley and Nguyen, 2002, Kuijper et al., 
2006, Bouza, 2012, Burke and Lamont, 2014). C. difficile infection is more a frequent 
cause of nosocomial than community-acquired infections (Kuijper et al., 2006, Na and 
Kelly, 2011, Bouza, 2012). Patients in the hospital who develop the disease are often 
isolated and given specific antibiotics to treat the infection apart from the therapy they 
were already receiving for their underlying disease. Such measures are usually costly for 
the healthcare facility especially when the patients develop serious form of the disease or 
complications or have a recurring infection (Kuijper et al., 2006, Vonberg et al., 2008). 
Besides  the  cost  associated  with  new  antibiotics  needed  for  the  treatment  of  the 
infection, the rigorous hygiene in patient care, environmental decontamination, and in 
instances when an outbreak arises, the burden of closure of a ward (Kuijper et al., 2006) 
adds to the financial burden of healthcare facilities. The cost of longer hospital stays is 
also a burden both to the patient and the healthcare facility (Dubberke and Wertheimer, 
2009). On average, patients with C. difficile infection could spend an extra one to three   136 
weeks in hospital compared with patients who have not contracted the infection (Kuijper 
et al., 2006). This increase in hospital stay is the most significant factor on the cost of C. 
difficile infection (Dubberke and Wertheimer, 2009) to a healthcare facility. The total 
average cost of treating patients with C. difficile infection compared to a cohort with the 
same underlying condition was 78% more expensive (Vonberg et al., 2008). A study by 
Mc Farland et al., (1999) in the USA also reported a mean lifetime cost of $10,970 per 
patient for treatment of C. difficile infection and its complications and recurrences. In 
Europe, the management of C. difficile infection was estimated by Kuijper et al., (2006) 
to be around 3000 million euros per year and this they predicted to rise in line with the 
ageing population of Europe (Kuijper et al., 2006).  
4.1.4 Management of C. difficile infection 
Despite the discovery that C. difficile was the causative agent of pseudomembranous 
colitis  in  1978,  due  to  usage  of  broad-spectrum  antibiotics  (which  included 
cephalosporins from the 1980s and fluoroquinolones, especially in the 2000s together 
with  the  lincosamides  and  penicillins  which  were  implicated  earlier;  Hookman  and 
Barkin, 2009, Bartlett, 2010, Britton and Young, 2012), antimicrobial treatments for the 
disease  did  not  changed  much  in  the  intervening  period.  First  line  treatments  for 
Clostridium difficile associated disease (CDAD) still remain limited to vancomycin and 
metronidazole; metronidazole more widely prescribed because of its lower cost and the 
need to prevent resistance to vancomycin (Gerding et al., 2008b, Best et al., 2012). More 
recently (2011) fidaxomicin was approved in the United States for the treatment of mild 
to moderate C. difficile and was approved for treatment of the infection in Europe in 
2012 (Johnson and Wilcox, 2012) but its use has not been popular because of its cost and 
lack of trial data (Bartsch et al., 2013,  Burke and Lamont, 2014). Faecal microbiota 
transplantation, by which donor faeces is infused into a patient’s gastrointestinal lumen, 
has been one effective way of treating recurrent CDAD but its aesthetic acceptability and 
safety has been its major drawback (Burke and Lamont, 2013). 
4.1.5. Probiotics for management of C. difficile infection 
Although antibiotics are generally effective in achieving symptomatic recovery from C. 
difficile infection, the disease frequently relapses, partly because antibiotics do not only   137 
kill C. difficile, but also disrupt the already compromised colonisation resistance of the 
gut microbiota (Blossom and McDonald, 2007, Britton and Young, 2012, Rea et al., 
2013). For example, it was shown that, metronidazole reduces the depth of the mucus 
layer which consequently reduces its barrier function and causes a secondary infection 
(Wlodarska  et al., 2011). It was also demonstrated  by Brandl et al., (2008) that the 
combinations  of  neomycin,  vancomycin  and  metronidazole  in  mice  could  induce 
infection by vancomycin-resistant enterococci (Brandl et al., 2008). 
Usually about 15-35% of patients who have had a first episode of C. difficile infection 
develop another episode of the disease within 2 months (Pepin et al., 2005, Maroo and 
Lamont, 2006, Gerdings et al., 2008b, Bauer et al., 2011). After a cycle of antibiotic 
treatment of a recurrent infection, the risk of another relapse  also increases again to 
about  33-65%  (Gerding  et  al.,  2008b).  The  high  rate  of  recurrence  of  C.  difficile 
infection in patients has been attributed to the decreased susceptibility of C. difficile to 
these antibiotics (Baines et al., 2008, Brazier et al., 2008, Huang et al., 2009) and the 
inability of antibiotics to restore the ecology of the gut to the normal state, but rather 
disturb it further (Blossom and McDonald, 2007, Giel et al., 2010, Rea et al., 2013, 
Britton  and  Young,  2014)  and  consequently,  the  deficiency  of  these  antibiotics  to 
efficiently manage the disease. There is therefore the need of finding other alternatives 
for  the  management  of  C.  difficile  infection.  A  good  management  for  C.  difficile 
infection  would  therefore  aim  at  eliminating  the  organism  and  restoring  the  gut 
microbiota.  
There have been clinical interests in using probiotics to manage C. difficile infection but 
this  has  received  mixed  reviews  (Pattani  et  al.,  2013,  Rainkie  and  Kolber,  2013, 
Goldenberg et al., 2013, Allen et al., 2013, Hickson, 2011, Pillai and Nelson, 2008, Na 
and Kelly, 2011). To give an example, a review published by Pillai and Nelson in 2008 
in the Cochrane library, which initially investigated the effect of probiotics either used 
alone or in conjunction with antibiotics for the treatment of C. difficile infection reported 
that only one study out of the four that met the inclusion criteria showed significant 
benefit of the probiotics. The authors concluded that there was insufficient evidence for 
the  use  of  probiotics  in  the  treatment  of  C.  difficile  infection  as  an  adjunct  in 
conventional therapy and that there was no evidence of its use for sole treatment. For 
most authors that have criticised the use of probiotics for management of C. difficile 
infection, the main issue that they raised, besides the limitations of the clinical studies   138 
themselves  (sample  size,  methodological  problems,  influence  of  funding),  was  the 
specificity  of  the  strains.  A  large  number  of  clinical  studies  done  on  probiotics  are 
conducted without any reliable evidence from laboratory studies to show that they can 
address  a  specific  condition  (Allen  et  al.,  2013,  Smith,  2013).  For  instance,  for  the 
prevention or treatment of C. difficile infection, it will be useful to show from laboratory 
studies that a strain or product has anti-clostridial effect. Assuming that all products 
claimed  to  be  probiotics  can  eliminate  C.  difficile  or  prevent  the  occurrence  of  the 
infection in patients is anecdotal and  is preventing beneficial probiotics which could 
potentially be used in the management of the disease to be dismissed. Currently, the UK 
Health Protection Agency and the Society for Healthcare Epidemiology of America and 
the Infectious Diseases Society of America have not endorsed the use of probiotics for 
the management  of  C.  difficile infection  (Hickson,  2011,  Rainkie and  Kolber,  2013, 
Public Health England, 2013) even though these countries are among those that have 
been  historically  hardest  hit  with  epidemics  (McMaster-Baxter  and  Musher,  2007). 
Because of the very large number of commercially available products claiming to be 
probiotics and probiotic combinations that are now available, it would be useful if in 
vitro studies could be done to streamline those with anti-clostridial effect before further 
laboratory or clinical studies. This will save the clinical and economic cost of inapt 
studies. 
Only few studies have reported on the anti-clostridial activity of potential or commercial 
probiotic strains in vitro (Schoster et al., 2013). Lee et al., (2003) demonstrated that out 
of 109 strains of lactic acid bacteria isolated from 32 healthy Korean infants, only 12 
showed activity against a toxigenic C. difficile strain. Naaber et al., (2004) showed that 
only 5 out of 50 intestinal lactobacilli strains were inhibitory towards all 23 pathogenic 
strains of C. difficile tested on agar plates; 27 strains did not show antagonistic activity 
(Naaber et al., 2004). Trejo et al., (2006) also showed that all strains of bifidobacteria 
isolated from a healthy infant inhibited two strains of C. difficile but they also detected 
that the degree of inhibition was strain specific (Trejo et al., 2006). Tejero-Sarinena et 
al., (2013) using pH-controlled anaerobic batch cultures containing mixed faecal bacteria 
and  analysing  bacterial  population  by  fluorescent  in  situ  hybridation  (FISH)  also 
demonstrated that inhibition of C. difficile by probiotic strains and mixtures was strain 
specific. Schoster et al., (2013) have also studied and showed that some commercial 
strains of probiotics were capable of inhibiting C. difficile whilst others could not. Ten 
commercial probiotic strains out of seventeen strains they analysed using broth culture   139 
and  agar  well  diffusion  assays  inhibited  a  reference  strain  of  C.  difficile.  They  also 
commented  on  the  lack  of  scientific  studies  scrutinizing  potential  and  commercial 
probiotics  for  anticlostrial  activity  since  they  also  believed  this  activity  was  strain 
specific (Schoster et al., 2013).   
The work in this chapter aimed to investigate the in vitro anti-clostridial activity of the 
commercial  probiotic  strains  and  commercially  available  probiotic  products  either 
packed as a single strain or multi-strain using the isothermal microcalorimeter.  
As introduced in Chapter 1, probiotics are usually members of the lactic acid bacteria, 
mainly members of the genera Lactobacillus and Bifidobacterium (but not exclusively) 
because they are known as members of the microbiota, which significantly contribute to 
the health effect and also because of their long history of safe use (Salminen et al., 1998, 
FAO/WHO 2001, Iannitti and Palmieri, 2010). Some researchers believed that it was 
unlikely a single strain could colonize the gut and achieve all therapeutic benefit and 
therefore suggested that probiotics should consist of multiple strains and also because 
probiotics could be used for targeting a number of diseases but each targeted disease will 
require a specific probiotic property, which cannot be found in a single strain (Dunne et 
al., 1999, Famularo et al., 1999, Sanders and Huis in't Veld, 1999, Timmerman et al., 
2004).  Probiotics  packaged  and  used  as  multistrain  or  multispecies  is  now  common 
practice and although some have not shown superior benefits (Tejero-Sarinena et al., 
2013, Chapman et al., 2013), some evidence exist on their greater efficacy compared to 
single strain (Apella et al., 1992, Drago et al., 1997, Chapman et al., 2011, Chapman et 
al., 2012,  Hell et al., 2013). To give examples, Chapman et al., (2013) and Tejero-
Sarinena et al., (2013), determining the relative efficacy of  multi-species and single-
species  probiotics  against  urinary  pathogens  (E.  coli  and  E.  faecium)  and  enteric 
pathogens (C. difficile, and Salmonella typhimurium) respectively reported insignificant 
difference between the two (Chapman et al., 2013) or better potency of inhibition by 
some  single  species  than  by  probiotic  mixtures  (Tejero-Sarinena  et  al.,  2013).  Yet 
Chapman et  al’s  previous  study  in  2012  demonstrated  that  5 multi-species  probiotic 
preparations had significantly (P < 0.05) greater inhibitions in 12 out of 24 cases towards 
C. difficile, E. coli and S. typhimurium, than 15 single-species probiotics (Chapman et 
al.,  2012).  Studies  conducted by  Apella  et al.,  (1992)  and  Drago  et  al.,  (1997)  also 
showed the superior potency of mixtures than single strains.    140 
However, less is known about the stability of probiotic mixtures, i.e. whether there is 
possibility  of  inhibition  of  probiotic  strains  in  a  mixture  (Chapman  et  al.,  2011, 
Chapman et al., 2012). In this chapter, the potential of isothermal microcalorimetry to 
distinguish  between  a  commercial  multi-strain  probiotic  product  and  its  component 
strains and their mixed culture was explored. This was to find out if all strains were 
present in the product at the point of consumption.  
4.2 Objectives 
The objectives of this chapter were: 
  To  use  the  isothermal  microcalorimeter  to  test  for  anti-clostridial  effect  of 
commercial probiotic strains and products 
  To  investigate  the  microbial  stability  of  a  commercial  probiotic  product 
consisting of multiple strains 
4.3 Materials and Methods 
4.3.1 Microorganisms 
Clostridium difficile NCTC 13565 was purchased from the National Collection of Type 
Cultures  (NCTC),  Public  Health  England.  It  is  a  toxigenic  strain  which  had  been 
previously  isolated  from  the  faeces  of  a  patient  with  pseudomembranous  colitis. 
Lactobacillus acidophilus LA-5
® and Bifidobacterium lactis BB-12
® were obtained as 
previously reported in section 3.3.1 of Chapter 3. Constituent species of a commercial 
probiotic  product,  Symprove
TM:  Lactobacillus  acidophilus,  Lactobacillus  plantarum, 
Lactobacillus  rhamnosus  and  Enterococcus  faecium  referred  to  in  this  thesis  as  L. 
plantarum SYM A, L. rhamnosus SYM B, L. acidophilus SYM C and E. faecium SYM 
D were all obtained from Symprove Ltd., UK.   141 
4.3.2 Commercial probiotics 
The commercial products used included: Actimel
® (Groupe Danone, France), Align
® 
(Procter and Gamble, USA), Bio-kult
® (Protexin Lopen Head, UK), Biobalance Support 
(Boots  Company,  UK),  Symprove
TM  (Symprove  Ltd,  UK),  VSL#3
®  (Ferring 
Pharmaceuticals Ltd), Yakult
® (Yakult Ltd, UK) and Probio 7
® (manufactured in France 
and distributed in the UK by Forever Young International, UK). Details of the products 
can be found in section 5.3.1 of Chapter 5. 
4.3.3 Microbiological media and chemicals 
Brain  heart  infusion  (BHI)  broth  and  agar,  reinforced  clostridial  medium  (RCM), 
Clostridium difficile agar base, were all from Oxoid Ltd, Basingstoke, UK and purchased 
from  Fisher  Scientific,  UK.  Defribinated  horse  blood  (Oxoid,  Basingstoke,  UK)  and 
Clostridium  difficile  selective  supplement  (Oxoid,  Basingstoke,  UK)  were  also 
purchased  from  Fisher  Scientific.  Sodium  taurocholate  was  purchased  from  Sigma-
Aldrich, UK. 
4.3.4 Stock culture maintenance and purity 
C. difficile NCTC 13565, received as a freeze dried culture was rehydrated with 0.5 mL 
RCM. A loopful of the rehydrated culture was streaked onto RCM agar and incubated 
anaerobically at 37
oC for 48 h. A few colonies were picked from the plate and used to 
make  a  lawn  on  a  fresh  plate  using  a  sterile  cotton  swap.  This  was  incubated 
anaerobically  for  48  h  after  which  the  lawn  of  cells  was  inoculated  into  RCM 
supplemented with 15% v/v glycerol and frozen at -80
oC. Stocks of L. acidophilus LA-
5
® and B. lactis BB-12
® were obtained as previously reported in section 3.3.3 of Chapter 
3. The constituent strains of Symprove
TM: L. plantarum SYM A, L. rhamnosus SYM B, 
L. acidophilus SYM C and E. faecium SYM D, obtained as freeze dried powders were 
also each rehydrated with MRSc and sub cultured onto MRSc. Single colonies obtained 
were picked off and spread onto a fresh MRSc agar plate. Colonies obtained on the 
incubated  plates  were  used  to  make  a  thick  suspension  of  the  cells  in  MRSc  broth 
supplemented with 15% v/v glycerol, which were stored at -80
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4.3.5 Cryopreservation and defrosting of bacteria 
Cryopreservation of the organisms was done according to section 2.3.7. Parent stocks of 
C.  difficile  and  the  constituent  strains  of  Symprove
TM  (L.  plantarum  SYM  A,  L. 
rhamnosus SYM B, L. acidophilus SYM C and E. faecium SYM D), were streaked onto 
RCM  agar  and  MRSc  agar  respectively  and  incubated  anaerobically  for  48  h.  Pure 
colonies obtained were inoculated into 7 mL RCM or MRSc and incubated anaerobically 
at 37
oC to make starter cultures of the organisms. A 1 in 100 dilution of the starter 
cultures  were  made  in  fresh  RCM  or  MRSc  and  was  incubated  anaerobically  and 
harvested by centrifugation at 3500 g for 10 min at 4
oC when the organisms reached 
their  stationary  phase  of  growth.  The  organisms  were  washed  twice  with  PBS, 
resuspended  with  ¼  Ringer’s  solution  supplemented  with  15%  v/v  glycerol  and 
dispensed  into  multiple  aliquots  in  cryovials.  Cryopreservation  procedure,  recovery 
determination, and defrosting procedures were carried out as previously described for 
the other species.  
4.3.6 Determination of spore of C. difficile culture 
10 μL of the thawed culture of C. difficile was used to make smears on glass slides, 
which had been cleaned with 70% v/v ethanol. The smeared glass slides were air dried 
for approximately 2 min and heat fixed. They were then stained with malachite green 
and safranin according to the Schaeffer–Fulton method (Schaeffer and Fulton, 1933). 
The cells on the fixed slides were firstly stained with malachite green by flooding the 
glass slides with the stain and heating over steam generated from a pan of boiling water 
for 5 min. The slides were washed under running tap water to remove excess stain. The 
cells on the slides were then counterstained with safranin for 30 s. The slides were rinsed 
with water and dried after which they were observed under oil immersion with a light 
microscope. 
4.3.7 Determination of optimum condition for vegetative growth of C. difficile in 
the isothermal microcalorimeter 
C. difficile is a spore-forming organism (Modaber, 1975, Wiegel, 2009). Unlike other 
species, it forms spores when there is a change in its environment that is unfavourable   143 
for its growth. In order to cause diseases, C. difficile must be vegetative to produce the 
toxins. The influence of different medium and compounds on the germinantion of C. 
difficile was assessed. As per the supplier’s instructions, C. difficile was inoculated into 
RCM. C. difficile was also inoculated into BHI and BHI supplemented with 0.1% w/v 
cysteine  hydrochloride  “BHIc”,  BHI  supplemented  with  0.1%  w/v  cysteine 
hydrochloride and 0.1% w/v sodium taurocholate “BHIct” and BHI supplemented with 
0.1% w/v cysteine hydrochloride, 0.1% w/v sodium taurocholate and 5 mg/mL of yeast 
extract  “BHIcty”.  Inoculations  were  done  in  3  mL  calorimetric  glass  ampoules 
containing  the  media.  Samples  were  placed  in  the  TAM  and  studied  as  previously 
described.  Optical  density  measurements  at  600  nm  (OD600)  of  samples  incubated 
under  the  same  conditions  were  taken  at  24  h  and  48  h  with  a  spectrophotometer 
(Heλiosα, Thermo Scientific). 
4.3.8  Pure  and  mixed  culture  of  C.  difficile  and  probiotic  strains  and 
commercial probiotic products in the isothermal microcalorimeter 
For pure culture experiments, the species were inoculated into BHIct to a population 
density of 10
6 CFU/mL in 3 mL calorimetric glass ampoules. 30 µL of commercial 
liquid probiotic products and hydrated lyophilised products (in 10 mL of PBS) was also 
inoculated into 2970 µL of BHIct in 3 mL calorimetric ampoules. For mixed culture 
experiments,  10
6  CFU/mL  of  the  probiotic  strains  or  30  µL  of  hydrated  or  liquid 
commercial probiotic products were mixed with C. difficile. The sealed ampoules were 
vortexed for 10 s, and placed into the intermediate position in the TAM 2277 for 30 min 
after which calorimetric study was conducted as previously described in section 2.3.9.  
4.3.9 Preparation of cell-free culture supernatants from probiotic cultures 
The  culture  supernatants  of  the  probiotic  strains  were  prepared  by  cultivating  the 
respective probiotic species in BHIct or MRSc over 48 h anaerobically. The cells were 
removed by centrifuging at 3500 g for 10 min at 4
oC. The supernatant was collected and 
filter-sterilized using a 0.22 µm membrane syringe filter. The pHs of the supernatants 
were examined and equal aliquots modified by adjusting the pH to 5, 6, 7 and 8 with 5 
M NaOH. Neutralised supernatants were also concentrated by freeze-drying (Modulyo 
D-230, Thermo Scientific, UK) and reconstituted with sterile distilled water to achieve   144 
2.5-fold, 5-fold, 10-fold and 20-fold concentration. Modified supernatants were filter-
sterilized before use. 
4.3.10 Co-incubation of C. difficile with probiotic culture supernatants in the 
isothermal microcalorimeter  
1.5  mL  of  unmodified  or  modified  CFS  of  LA-5
®,  BB-12
®  and  the  strains  of 
Symprove
TM  was  added  to  1.5  mL  double  strength  BHIct  “dsBHIct”  in  3  mL 
calorimetric  glass  ampoule.  The  mixture  was  vortexed  for  10  s.  C.  difficile  was 
inoculated into this mixture and vortexed. The ampoule was placed in the TAM and 
power-time measurements were taken for as long as the sample was generating a signal 
in the TAM. A control experiment was done by replacing the CFS with sterile distilled 
water or MRSc.  
4.3.11 Agar well diffusion assay 
CFS of LA-5
® and BB-12
® were examined for their antibacterial activity against C. 
difficile by the agar well diffusion assay as described by Trejo et al., (2006) with some 
modifications. A C. difficile lawn was made by seeding a culture of the organism in 
molten BHIct agar (45
oC). The agar was left to solidify. Wells of 9 mm diameter were 
made with a sterile borer and filled with 100 µL of unmodified and pH modified CFSs. 
The plates were kept in anaerobic jars and retained on the bench for 2 h after which they 
were incubated at 37
oC for 48 h in the Don Whitley DG250 Anaerobic workstation. The 
zones of inhibition were measured after 48 h of incubation.  
4.3.12 Microbial stability of multi-strain probiotics: pure and mixed cultures of 
the strains of Symprove
TM in the isothermal microcalorimeter 
The strains of Symprove
TM: L. plantarum SYM A, L. rhamnosus SYM B, L. acidophilus 
SYM C and E. faecium SYM D were each inoculated into BHIc or MRSc in 3 mL 
calorimetric ampoules to give individual population densities of 10
6 CFU/mL and loaded 
into the intermediate position of the TAM for 30 min. Measurements were taken as 
described  in  section  2.3.9.  30  µL  each  of  10  batches  of  the  commercial  product,   145 
Symprove
TM obtained from the manufacturer was also inoculated into BHIc or MRSc 
and individual microcalorimetric measurements taken. 
4.3.13 Statistical Analysis 
Statistical analysis was performed in Origin Pro 8.6 (Microcal Software Inc.). T-test or 
Analysis of Variance (ANOVA) with Turkey post-hoc analysis for means comparison 
was  used  where  appropriate.  P  values  less  than  0.05  were  regarded  as  significant 
difference between means. 
4.4 Results and Discussion 
4.4.1 Determination of optimum condition for vegetative growth of C. difficile in 
the isothermal microcalorimeter 
As  previously  mentioned,  C.  difficile  is  a  spore-forming  bacterium  (Modaber,  1975, 
Wiegel, 2009). It is an obligate anaerobe when in its vegetative state but its spores can 
persist in dry, aerobic environment and even on inanimate surfaces for several years 
(Cloud and Kelly, 2007, Gerding et al., 2008a, Wiegel, 2009, Paredes-Sabja et al., 2014). 
The spores play a very important role in the transmission of the disease (section 4.1.1) 
but to cause disease, the spores must return to the vegetative state and produce the two 
major toxins, toxins A and B (Gerding et al., 2008a,  Kelly and LaMont, 2008, Burns et 
al., 2010, Burke and Lamont, 2014).  
After the cryopreservation of C. difficile, there was no viable cell recovery on RCM agar 
plates. It was therefore suspected that C. difficile may have been killed or had formed 
spores during the procedure. A Schaeffer-Fulton spore stain indeed revealed spores of C. 
difficile. The spores may have formed as a means of the cells surviving the limiting 
nutrient in the medium and the metabolic waste products that had accumulated during 
the  culture.  Also,  the  cells  were  exposed  to  oxygen  during  the  harvesting  and 
cryopreservation procedure hence their ability to sustain vegetative growth may have 
been compromised due to these stressing factors. Efforts were therefore made to keep C. 
difficile in its vegetative state through the selection of a medium and conditions that   146 
support vegetative C. difficile growth. As per the suppliers guide, RCM was used in 
maintaining  C.  difficile  but  this  showed  delayed  growth  of  the  organism  in  the 
microcalorimeter (Figure 4.3, peaking at ca. 40 h) and no recoveries on plates indicating 
that  the medium condition was not adequate for supporting vegetative growth of  C. 
difficile. BHI broth, which contains in g/L, brain infusion solids 12.5; beef heart infusion 
solids 5.0; proteose peptone 10.0; glucose 2.0 and disodium phosphate, 2.5, has been 
suggested to be a nutrient rich medium for germination of C. difficile (Paredes-Sabja et 
al., 2008). The use of this medium however did not boost the growth or germination of 
C. difficile; it even slowed the onset time of  growth of the organism (lag time was 
increased, Figure 4.3) relative to RCM. 
 
Figure 4.3. Power-time curves of C. difficile in different media and in the presence of germinants. 
RCM is Reinforced Clostridial Medium, BHI is Brain Heart Infusion Medium, BHIc is BHI 
supplemented with 0.1% w/v cysteine hydrochloride, BHIct is BHIc further supplemented with 0.1% 
w/v sodium taurocholate and BHIcty is BHIct supplemented with 5 mg/mL yeast extract. Growth was 
enhanced in the presence of the germinants 
Addition  of  0.1%  w/v  cysteine  hydrochloride  to  BHI,  which  reduced  the  medium, 
increased growth. Further growth was observed when 0.1% w/v of sodium taurocholate, 
a  primary  bile  salt  was  added  to  BHI  together  with  cysteine  hydrochloride.  Further 
addition of yeast extract to BHI supplemented with 0.1% w/v cysteine hydrochloride and 
0.1% w/v sodium taurocholate changed growth only slightly. The OD600 for 24 h and 
48  h  cultures  of  C.  difficile  in  the  respective  media  are  shown  in  Table  4.1.  The 
differences in the media in supporting vegetative growth of C. difficile can be observed 
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in the table; only BHIct and BHIcty  showed OD values consistent with exponential 
growth during 24 h of incubation.  
Table 4.1. Optical density of C. difficile culture in different medium after 24 and 48 h of incubation  
 
Media  Optical Density at 600 nm 
24 h incubation  48 h incubation 
RCM  0.058  0.882 
BHI  0.012  0.088 
BHIc  0.039  0.716 
BHIct  1.213  1.169 
BHIcty  1.323  1.444 
 
Germination  of  spores  is  understood  to  be  initiated  when  the  spores  sense  specific 
effectors known as germinants (Burns et al., 2010). For Bacillus subtilis, a well studied 
spore  forming  organism,  germination  is  known  to  occur  by  the  binding  of  nutrient 
germinants, L-alanine or a mixture of asparagine, glucose, fructose and potassium ions, 
to  specific  receptors:  GerA,  GerB  and  GerK  which  are  located  in  the  spore  inner 
membranes (Paidhungat and Setlow, 2000). After binding, the spore is known to go 
through  stages  of  events  requiring  the  spore  to  encode  specific  proteins  which 
subsequently results in the hydrolysis of the spore peptidoglycan cortex during which the 
spore  is  hydrated  and  is  returned  to  the  vegetative  state  for  enzymatic  activity, 
metabolism and growth (Paidhungat and Setlow, 2000). The mechanism of germination 
or the specific condition required for germination of C. difficile spore is however not 
well defined (Paredes-Sabja et al., 2008, Burns et al., 2010, Paredes-Sabja et al., 2011, 
Paredes-Sabja et al., 2014). So far, in vitro studies have pointed to the role of bile salts 
(cholate  and  its  derivatives  (taurocholate,  glycocholate,  cholate,  and  deoxycholate) 
(Wilson, 1983, Giel et al., 2010, Burns et al., 2010, Heeg et al., 2012) or glycine as co-
germinant (Sorg and Sonenshein, 2008) or the use of nutrient media, mainly BHI with or 
without yeast extract for the germination of  C. difficile spores (Paredes-Sabja et al., 
2008,  Heeg  et  al.,  2012).  The  germination  property  of  BHI  was  initially  argued  by 
Paredes-Sabja et al., (2008) to be due to the inorganic phosphate ions and potassium ions 
content  of  BHI  because  they  were  able  to  demonstrate  that  sodium  phosphate  and   148 
potassium chloride could on their own germinate C. difficile (Paredes-Sabja et al., 2008). 
However their later study in 2009 (Paredes-Sabja et al., 2009) explained that spores of C. 
difficile used in their previous study (Paredes-Sabja et al., 2008) was contaminated with 
Clostridium  perfringens  spores  and  that  C.  difficile  spores  germinated  poorly  with 
potassium chloride or sodium phosphate (Paredes-Sabja et al., 2009). 
In this work, the result suggests that germination occurred significantly in the presence 
of  sodium  taurocholate.  The  presence  of  the  reducing  agent,  cysteine  hydrochloride 
which made the medium anaerobic  was required for growth. It should be noted that 
whilst the germination potential of sodium taurocholate has been demonstrated in vitro 
and ex vivo by other authors (Wheeldon et al., 2008, Giel et al., 2010, Heeg et al., 2012), 
germination of C. difficile has also been associated to be non-dependent on aerobic or 
anaerobic environment (Plowman and Peck, 2002, Wheeldon et al., 2008, Paredes-Sabja 
et al., 2008). Thus in the present study, the results suggest that the anaerobic condition 
was required for vegetative growth of C. difficile. The germination of C. difficile with 
sodium taurocholate in vitro, from results of present study and previous studies (Sorg 
and Sonenshein, 2008, Paredes-Sabja et al., 2009, Giel et al., 2010, Heeg et al., 2012) 
could be related to the germination of the spore of the organism in the human gut. As 
noted earlier, it is the spore form of C. difficile, which is usually ingested and normally 
survive transit through the stomach to the intestine (Mitty and LaMont, 1994, Gerding et 
al., 2008a). The vegetative cell can hardly survive in the inanimate environment nor can 
it survive gastric acid (Jump et al., 2007, Nerandzic et al., 2009). In the gut, proposed 
segments where germination and overgrowth could occur include the proximal small 
intestine which has significant amount of bile salt (Kalantzi et al., 2006) and the colon; a 
suitable environment for anaerobic growth (Roediger, 1980). However, the symptoms of 
C. difficile infection are largely derived from the colon and less so within the small 
intestine (Hurley and Nguyen, 2002). This may be probably because while the spores 
can start germinating in the small intestine due to the presence of the bile salt (Wilson et 
al., 1985) and the non-dependency of germination on aerobic or anaerobic environment 
(Plowman and Peck, 2002, Wheeldon et al., 2008, Paredes-Sabja et al., 2008) they might 
not outgrow there to cause disease but  only outgrow in the colon, which presents a 
favorable condition for anaerobic growth (Roediger, 1980).  
Previous studies have pointed to the germination of C. difficile within the small intestine 
or colon. Wilson et al., (1985) showed that 78% of spores inoculated intragastrically into   149 
a hamster and studied with a 
51Cr tracer germinated within the small intestine (Wilson et 
al., 1985). Paredes-Sabja et al., (2008) also demonstrated germination of C. difficile by 
potassium salts and inorganic phosphate with an optimum pH of 6, while bile salt had 
little effect on the germination of their collection of C. difficile strains in vitro including 
clinical isolates. These authors previously concluded that C. difficile spore could either 
germinate in the early segments of the duodenum when  the spores sensed inorganic 
phosphate or the colon, where the authors reasoned had high levels of potassium ions 
(Paredes-Sabja et al., 2008). However their work was unreproducible and later, they 
explained  that  their  previous  study  was  contaminated  with  spores  of  C.  perfringens. 
Their final conclusion was that spores of C. difficile are able to germinate with sodium 
taurocholate  and  also  with  glycine  (Paredes-Sabja  et  al.,  2008,  Paredes-Sabja  et  al., 
2009).  Findings  from  Nerandzic  et  al.,  (2009)  also  support  that  germination  of  C. 
difficile could occur in either the small intestine or colon. These authors showed that 
germination of C. difficile in mice occurred to the same degree in the small intestinal and 
caecal contents and demonstrated that germination could not occur in the stomach even 
when the pH of the stomach was modified to 5.4 with a Proton Pump Inhibitor (PPI) 
(Nerandzic et al., 2009). 
Since germination of C. difficile spore is necessary for the pathogenesis of the disease, it 
is important that compounds that cause germination of the organism are researched and 
the  mechanism  surrounding  the  germination  elucidated.  The  identification  of  these 
compounds  and  the  mechanism  of  germination  will  help  in  the  potential  design  of 
therapeutics which can inhibit  or manipulate  germination hence prevent  CDAD.  For 
instance, it is known that spores of C. difficile are resistant to all sorts of chemical and 
physical agents (Setlow, 2007, Gerding et al., 2008a) and this has been the mechanism of 
its persistence on inanimate surface which leads to infection when accidentally ingested 
(Gerding et al., 2008a). Identification of compounds that can cause germination could 
have positive implications in routine cleaning or decontamination and management of 
outbreak of the infection.  
Subsequent experiments were focussed on the influence of probiotics on the germination 
and consequent growth of C. difficile in the microcalorimeter. Experiments as indicated 
in the methods were conducted in BHIct since this medium supported vegetative growth 
of  C.  difficile.  Enumerations  of  CFU/mL  were  done  by  serial  dilution  in  PBS   150 
supplemented with 0.1% w/v sodium taurocholate and plating on BHIct. Viable counts 
were not affected by the presence or absence of yeast extract.  
4.4.2  Pure  and  mixed  culture  of  C.  difficile  and  probiotic  strains  in  the 
isothermal microcalorimeter 
The power-time curves of pure cultures of C. difficile, LA-5
® and BB-12
® in BHIct are 
shown  in  Figures  4.4,  4.5  and  4.6  respectively.  The  power  time  curves  were 
characteristic  for the  different species. Both LA-5
® and BB-12
® showed exponential 
growth in this medium without significant time lag unlike C. difficile which metabolised 
energetically prior ca. 7 h of dormancy in the microcalorimeter. The long lag phase that 
occurred for C. difficile could be associated with its slow rate of growth (Carroll, 2013). 
It could as well be associated with the period required for the spores to adapt, sense the 
suitable  environment  for  germination  and  subsequently  germinated  and  commenced 
vegetative growth (Stringer et al., 2011). The former events may have been associated 
with metabolic activity (Stringer et al., 2011) but possibly with related heat outputs, 
which was below the detection limit of the microcalorimeter.  
 
Figure 4.4. Power-time curves of 3 repeats of C. difficile in BHIct 
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Figure 4.5. Power-time curves of 3 repeats of L. acidophilus, LA-5
® in BHIct 
 
Figure 4.6. Power-time curves of 3 repeats of B. lactis, BB-12
® in BHIct 
The total heat outputs associated with the metabolism of C. difficile was 9.93 ± 0.38 J 
and was significantly higher (P< 0.05) than that of LA-5
® and BB-12
® in BHIct which 
were 6.05 ± 0.40 and 6.93 ± 0.36 J, respectively. The higher heat output associated with 
the  metabolism  of  C.  difficile  relative  to  the  probiotic  species  could  be  due  to  the 
cumulative effect of germination and metabolism leading to vegetative growth, which 
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together might have been a higher energy yielding process relative to sole vegetative 
growth. A previous study by Kalakoutskiai and Pozharitska, (1968) has shown that the 
emergence of germ tubes of spores of Actinomyces streptomycini in the microcalorimeter 
was associated with great heat output which was noted to be in the upper limit of heat 
generated by growing cultures of E. coli. The authors also demonstrated that the swelling 
prior  to  exponential  growth  was  not  associated  with  significant  heat  production 
(Kalakoutskiai  and  Pozharitska,  1968).  Also,  it  is  likely  the  medium  might  have 
favoured the growth C. difficile relative to the probiotic species, which could have been 
inhibited by the bile salt content of the medium (Begley et al., 2005). Exclusion of bile 
salt from the medium however did not change the power-time curves of the probiotic 
species.  
A post TAM analysis of the culture showed a significantly less turbid culture of LA-5
® 
relative to the other species and previous cultures of it in CMMg. It was also noted that 
the probiotic species did not produce as many acidic metabolites in BHIct as they had 
previously done in CMMg (Chapter 3). Nonetheless, they significantly reduced (P<0.05) 
the pH of the medium to 5.13 ± 0.04 and 4.92 ± 0.01 respectively for LA-5
® and BB-12
® 
whilst C. difficile also reduced the pH of the medium to 5.88 ± 0.05 (P<0.05) from an 
initial value of 6.77 ± 0.01.  
The power-time curves of mixed cultures of C. difficile with LA-5
® and C. difficile with 
BB-12
® are shown in Figures 4.7 and 4.8. The power-time curves of the mixed cultures 
lacked  the  characteristic  curve  of  C.  difficile  and  showed  only  the  growths  of  the 
probiotics.  
In the previous section, it was demonstrated that C. difficile could germinate and grow in 
the environment created, BHIct, pH 6.8. This medium could simulate the environment of 
the small intestine (due to the bile salt) (Kalantzi et al., 2006) or the colon (Paredes-
Sabja et al., 2008) due to the potassium and phosphate content of BHI (Paredes-Sabja et 
al., 2008). Also, the culture of C. difficile that was inoculated into BHIct consisted of 
mainly spores of C. difficile, which could simulate the oral transmission of the infection 
(Gerding et al., 2008a, Burns et al., 2010, Burke and Lamont, 2014). The results suggest 
that  the  consequent  vegetative  growth  and  production  of  toxins  associated  after 
germination  may  be  prevented  in  the  intestine  by  the  probiotics  since  C.  difficile 
germination may not have occurred in the presence of the probiotics.   153 
 
Figure 4.7. Comparison of the power-time curves of pure culture of L. acidophilus, LA-5
® and C. 
difficile, Cdiff and their mixed culture (LA-5+Cdiff) in BHIct 
 
Figure 4.8. Comparison of the power-time curves of pure culture of B. lactis, BB-12
® and C. difficile, 
Cdiff and their mixed culture (BB-12+Cdiff) in BHIct 
As indicated earlier, spores of the organism are pivotal for transmission of the infection; 
but they need to return to the vegetative state through germination for consequent toxin 
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production and clinical manifestations of the infection. In the previous section, bile salt 
was demonstrated to play an important role in the germination of the organism but in the 
presence of the probiotic species, germination may not have progressed. These probiotic 
species could potentially play a major role in the prevention or treatment of the infection 
in  susceptible  individuals  since  no  toxins  would  be  consequently  produced  to  cause 
CDAD. 
The mechanism of inhibition of C. difficile by the probiotic species was likely due to the 
probiotic  species  competitively  utilizing  the  nutrient  sources  in  the  media  before  C. 
difficile could be adequately capable of metabolic activity. Furthermore, the probiotics 
produced acids, or likely other non-acidic metabolites during their growth, which might 
have caused C. difficile to remain in spore form. The pH of the medium after growth of 
the  mixed  cultures  of  LA-5
®  and  C.  difficile  and  BB-12
®  and  C.  difficile  were 
significantly reduced (P<0.05) to 5.24 ± 0.19 and 4.92 ± 0.03 respectively showing that 
they  indeed  still  produced  acidic  metabolites  in  mixed  culture  which  could  have 
inhibited the growth of C. difficile.  
In the previous experiments of mixed culture of the probiotic species with P. aeruginosa, 
S. aureus and E. coli in Chapter 3, it was observed that growth of the probiotics occurred 
after or concurrently with the growth of the other faster growing species. To determine 
whether  C.  difficile  could  germinate  and  grow  in  the  presence  of  other  species,  C. 
difficile was also co-cultured with P. aeruginosa. The power-time curve showed the 
presence of both species (Figure 4.9), which implied that the inhibition of C. difficile by 
the probiotics might have been specific. 
Enumerations  of  vegetative  cells  of  C.  difficile  post  TAM  experiments  on  selective 
medium,  Clostridium  difficile  selective  agar  supplemented  with  Clostridium  difficile 
selective  supplement  (cycloserine  250  mg/L,  cefoxitin  8  mg/L)  and  0.7%  v/v 
defibrinated horse blood “CDSAsb” gave no recoveries of C. difficile on plates for the 
mixed cultures with probiotics (Table 4.2).    155 
 
Figure 4.9. Power-time curve of mixed culture of P. aeruginosa (first peak) and C. difficile in BHIct 
Table 4.2. A table comparing the mean heat output and post TAM profile of the pure culture and 
mixed culture of probiotics and C. difficile. n=3 for numerical values 
 
Culture in BHIct  Heat output (J)  pH post TAM  Cell count post TAM 
(log CFU/mL) 
C. difficile  9.93 ± 0.38  5.88 ± 0.05  6.00
 ± 0.60 
B. lactis BB-12
®  6.93 ± 0.36  4.92 ± 0.01  6.47
 ± 0.07 
L. acidophilus LA-5
®  6.05 ± 0.40  5.13 ± 0.04  5.19 ± 0.19 
C. difficile and B. lactis BB-12
®   6.63 ± 0.35  4.92 ± 0.03  Cdiff  BB-12
® 
0  6.50 ± 
0.03 
2.1x10
5 
C. difficile and L. acidophilus LA-5
®  5.79 ± 0.52  5.24 ± 0.19  Cdiff  LA-5
® 
0  5.04 ± 
0.09
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4.4.3 Co-incubation of probiotic supernatant with C. difficile 
It  had  already  been  established  in  Chapter  3  that  the  probiotics  produced  acidic 
extracellular products, which were inhibitory towards P. aeruginosa, S. aureus and E. 
coli. To find out if inhibition of germination and growth of C. difficile was solely due to 
the acidic metabolites or was also due to the presence of other non-acidic or secondary 
metabolites produced by the probiotic species in BHIct, C. difficile was co-incubated 
with  1  in  2  dilutions  (in  double  strength  BHIct  “dsBHIct”)  of  unmodified  and  pH 
modified  CFS  of  the  probiotics.  The  results  are  shown  in  Figures  4.10  and  4.11 
respectively for CFS of LA-5
® and BB-12
®. 
 
 
 
Figure 4.10. Power-time curves of C. difficile in LA-5
® CFS produced in BHIct. Growth in 1 in 2 
dilutions of the unmodified CFS (red) or neutralised CFS (blue) in dsBHIct is compared with a control 
of the organism (black) 
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Figure 4.11. Power-time curves of C. difficile in BB-12
® CFS produced in BHIct. Growth in 1 in 2 
dilutions of the unmodified CFS (red) or neutralised CFS (blue) in dsBHIct is compared with a control 
of the organism (black) 
The results indicate inhibition of C. difficile by the CFS of the probiotics. For the CFS 
produced by LA-5
®, a 1 in 2 dilution of the CFS in dsBHIct did not completely inhibit C. 
difficile in the microcalorimeter but delayed growth. The growth of C. difficile in the 
CFS of LA-5
® may be due in part to the role played by the live cells in inhibition which 
were not present in the CFS. Also, as noted earlier, the pH of BHIct after growth of LA-
5
® was 5.13 ± 0.04. After a 1 in 2 dilution with dsBHIct, the final pH of the medium pre-
inoculation was 6.12 ± 0.02. BB-12
® on the other hand had a pH of 4.92 ± 0.01 after 
incubation.  After  dilution  with  dsBHIct,  the  final  pH  of  the  CFS  of  BB-12
®  with 
dsBHIct was 5.97 ± 0.01 pre-inoculation. It was therefore most likely that inhibition was 
due to acidic metabolites produced, due to the pH-dependency of inhibition. Similarly, 
the pH of a 1 in 2 dilution of neutralised CFS of LA-5
® and BB-12
® in dsBHIct were 
6.73 ± 0.03 and 6.72 ± 0.01 respectively. C. difficile growth was augmented (lag period 
was  decreased)  in  the  neutralised  CFS  of  LA-5
®.  The  CFS  of  BB-12
®  which  had 
previously showed complete inhibition of C. difficile growth in the microcalorimeter for 
the duration tested also showed growth of C. difficile when neutralised.  
It should be highlighted that, previous studies have also indicated the pH-dependency of 
inhibition of C. difficile by some probiotics. For instance, inhibition of the C. difficile 
strain used by Schoster et al., (2013) was reported to be only observed when the pH of 
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the supernatants obtained from the probiotic species was not neutralised. In a study by 
Trejo et al., (2006) the inhibition of the bifidobacteria strains against C. difficile were 
determined to be dependent on their production of lactic acid and acetic acid with the 
exception  of  one  strain.  A  study  by  Naaber  et  al.,  (2006)  also  demonstrated  the 
correlation of H2O2 and lactic acid production with inhibition of C. difficile by intestinal 
lactobacilli while Tejero-Sarinena et al., (2012) confirmed these substances to be lactic 
acid and acetic acid. As discussed in Chapter 1 and 3, lactic acid bacteria are capable of 
releasing  specific  antimicrobial  metabolites  (Anand  et  al.,  1984,  Anand  et  al.,  1985, 
Kang et al., 1989) and low molecular weight compounds; organic acids (acetic, formic 
and  lactic  acids)  and  hydrogen  peroxides  (Piard  and  Desmazeaud,  1991,  Piard  and 
Desmazeaud, 1992) which directly target pathogenic bacteria including themselves or 
purportedly decreases the luminal pH of the intestine to prevent overgrowth of potential 
pathogens (Ng et al., 2009, Gerritsen et al., 2011). Some studies in humans have shown 
likely  differential  changes  in  the  luminal  pH  of  patients  on  probiotics  relative  to  a 
control group based on breath test and changes in faecal SCFA (Butler et al., 2001). 
Some  studies  on  animals  have  also  directly  assessed  changes  in  luminal  pH  in  the 
digestive tract. For instance, Fonseca et al., (2010) showed that the pH of the crop of 
chickens  whose  feed  were  supplemented  with  probiotics  were  significantly  lower  in 
comparison to a control group. Despite this, in ewes (Kumagai et al., 2004) no localised 
luminal pH reduction in the rumen was observed when the feed was supplemented with 
probiotics even though differences were observed in the microbial population between 
control groups and treatment groups of both studies (Fonseca et al., 2010, Kumagai et 
al., 2004). When considering the results from other related studies, and these animal 
studies, it would seem that localised reductions of the luminal pH of the intestine may or 
may  not  occur  after  ingestion  of  probiotics  and  there  needs  to  be  further  studies  to 
determine if indeed it could occur with these probiotics in vivo. 
In the present study, it was anticipated that the probiotics could modify the primary bile 
salt, sodium taurocholate that was supplemented into the medium to secondary bile salts, 
such as deoxycholate through dehydroxylation, which would have inhibited C. difficile. 
Intestinal bacteria have been demonstrated by Giel et al., (2010), to be capable of such 
modification with inhibitory activity against C. difficile. In their experiment, Giel et al., 
incubated washed caecal contents of mice (either treated with antibiotics or not) with 
0.1% w/v taucholate and observed that the bile salt in the caecal contents of untreated 
mice had been modified to the secondary form whilst the antibiotic treated mice had not   159 
been converted to the secondary form (Giel et al., 2010). The authors were also able to 
demonstrate a decrease in colony formation of C. difficile spores using the secondary 
bile salt. It was therefore expected that neutralised CFS of the probiotics should still 
inhibit the germination and subsequent growth of C. difficile due to the presence of bile 
salt in the medium. The probiotic species were probably not capable of metabolizing the 
primary bile salt to secondary bile salts or otherwise, C. difficile was not inhibited by the 
secondary bile salts if it had been produced.  
During the study, it was also noted that growth yields in BHIct for the probiotic species, 
especially LA-5
® were poor relative to C. difficile and previous cultures of it in MRSc or 
CMMg.  Both  probiotic  species  were  therefore  also  grown  in  MRSc  and  the  CFS 
obtained. It is worth noting that MRS was developed by de Man, Rogosa and Sharpe (De 
Man et al., 1960) to provide a medium which would generally support good growth of 
lactobacilli, including related strains which showed poor growth in existing media. It is 
indeed known to produce more profuse growth of all strains of lactobacilli and related 
strains, especially difficult and slow growing ones which could be overgrown in general 
purpose media (De Man et al., 1960). It was believed that the probiotic species evaluated 
could potentially produce important metabolites in MRSc because they had previously 
shown better growth yields/more profuse growth in MRSc compared to BHIct.  
CFSs were therefore obtained after 48 h of anaerobic incubation in MRSc. The final pHs 
of the dilutions of the CFS with dsBHIct are given in Table 4.3.  
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Table 4.3. Mean pH (n=3) of media and CFS - media mixtures used. 
 
Uninoculated media  pH 
BHIct  6.77 ± 0.01 
dsBHIct  6.63 ± 0.02 
dsBHIct + LA5
® CFS (BHIct) unmodified 1in 2 dilution  6.12 ± 0.02 
dsBHIct + LA5
® CFS (BHIct) pH 7  6.73 ± 0.03 
dsBHIct + BB-12
® CFS (BHIct) unmodified 1 in 2 dilution  5.97 ± 0.01 
dsBHIct + BB-12
® CFS (BHIct) pH 7  6.72 ± 0.01 
dsBHIct + MRSc  6.30 ± 0.04 
dsBHIct + LA-5 CFS (MRSc) unmodified  4.73 ± 0.04 
dsBHIct+ LA-5 CFS (MRSc) 1 in 4 dilution  5.60 ± 0.04  
dsBHIct+ LA-5 CFS (MRSc) 1 in 6 dilution  6.00 ± 0.01  
dsBHIct + LA-5 CFS (MRSc) pH 5  5.86 ± 0.06 
dsBHIct + LA-5 CFS (MRSc) pH 6  6.45 ± 0.07 
dsBHIct + LA-5 CFS (MRSc) pH 7  6.71 ± 0.01 
dsBHIct + LA-5 CFS (MRSc) pH 8  6.90 ± 0.04 
dsBHIct + BB-12 CFS (MRSc) unmodified  5.20 ± 0.03 
dsBHIct + BB-12 CFS (MRSc) 1 in 4 dilution  5.93 ± 0.05 
dsBHIct + BB-12 CFS (MRSc) 1 in 6 dilution  6.19 ± 0.03 
dsBHIct + BB-12 CFS (MRSc) pH 5  5.84 ± 0.09 
dsBHIct + BB-12 CFS (MRSc) pH 6  6.48 ± 0.02 
dsBHIct + BB-12 CFS (MRSc) pH 7  6.76 ± 0.01 
dsBHIct + BB-12 CFS (MRSc) pH 8  6.89 ± 0.03 
 
The power-time curves of C. difficile inoculated into the MRSc produced CFS-dsBHIct 
mixtures are shown in Figures 4.12, 4.13, 4.14 and 4.15. The probiotic species indeed 
produced more acidic metabolites in MRSc. The pH of the CFSs produced were 4.12 ± 
0.01 (P<0.05) and 4.62 ± 0.01 (P<0.05) respectively for LA-5
® and BB-12
®. For LA-5
®   161 
CFS, complete inhibition of C. difficile in the microcalorimeter was observed at 1 in 2 
dilutions of the CFS. But partial inhibition was observed at 1 in 4 and 1 in 6 dilutions. 
Upon pH modification of the CFS of LA-5
®, inhibitory activities were lost at pH 6, 7 
and 8 (Figure 4.13) of the modified CFS. 
 
Figure 4.12. Power-time curves of C. difficile in LA-5
® CFS: 1 in 2 dilution (red), 1 in 4 dilution 
(blue) and 1 in 6 dilution (magenta) compared to a control of the organism in dsBHIct-MRSc (black) 
 
Figure 4.13. Power-time curves of C. difficile in LA-5
® CFS unmodified (red), pH modified to 5 (light 
blue) 6 (magenta), 7 (green), 8 (dark blue) compared to a control of the organism in dsBHIct-MRSc 
(black) 
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Figure 4.14. Power-time curves of C. difficile in BB-12
® CFS:1 in 2 dilution (red), 1 in 4 dilution 
(blue) and 1 in 6 dilution (magenta) compared to a control of the organism in dsBHIct-MRSc (black) 
 
Figure 4.15. Power-time curves of C. difficile in BB-12
® CFS unmodified (red), pH modified to 5 
(blue) 6 (magenta), 7 (green), 8 (dark blue) compared to a control of the organism in dsBHIct and 
MRSc (black) 
LA-5
® CFS adjusted to pH 7 and 8 surprisingly enhanced the growth of C. difficile as the 
onset  time  of  growth  was  decreased.  This  indicated  that  not  only  was  inhibition 
dependent on pH but also germination and growth of C. difficile was pH-dependent and 
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also further that possibly there was an optimum pH required for germination and growth 
of C. difficile. Table 4.3 tabulates the final pH of the medium and mixtures of CFS with 
dsBHIct.  
LA-5
® CFS modified to pH 7 and 8 when mixed with equal volumes of dsBHIct had 
final  pH  of  6.71  ±  0.01  and  6.90  ±  0.04  respectively.  The  controls  for  the  MRSc 
produced CFS were conducted in dsBHIct diluted with MRSc and had pH of 6.30 ± 
0.04. It is likely the optimum pH for germination and growth of C. difficile is ca. pH 6.7 
as pH above this value did not significantly increase growth. This concurs with previous 
findings by Wheeldon et al., (2008) who reported an optimum pH between 6.5 and 7.5 
for germination of C. difficile with decreased rate and extent of germination occurring at 
pH  5.5  and  8.5  (Wheeldon  et  al.,  2008).  It  further  supports  that  germination  of  C. 
difficile could occur anywhere between the proximal small intestine and the descending 
colon but likely in the small intestine. The pH of the proximal small intestine is between 
6.15-7.35.  That  of  the  distal  small  intestine  is  6.80-7.88.  The  ascending  colon  has 
variable pH range between 5.26-6.72 and the descending colon 5.20-7.07 (Press et al., 
1998, Cook et al., 2012). 
An interesting observation was also made with the CFS of BB-12
®. A 1 in 4 dilution of 
BB-12
®  CFS  showed  complete  inhibition  of  C.  difficile  (Figure  4.15)  in  the 
microcalorimeter unlike the CFS of LA-5
® even though it had a significantly higher pH 
of 5.93 ± 0.05 compared to 5.60 ± 0.04 (P<0.05) of the 1 in 4 dilution of LA-5
® CFS. 
Also, CFS of BB-12
® modified to pH 5 showed no growth of C. difficile for the time 
period studied unlike that for LA-5
®. At neutral pH of the CFSs, the anticlostridial effect 
of BB-12
® CFS was also not completely lost. This confirmed with results obtained in 
Chapter 3 and corroborates with other findings (Messens and De, 2002, Ruiz et al., 2009, 
Sourabh  et  al.,  2011,  Cruz-Guerrero  et  al.,  2014)  that  there  could  be  non-acidic 
antimicrobial metabolites  (bacteriocins or bacteriocin-like compounds) (Anand et al., 
1984, Anand et al., 1985, Kang et al., 1989, Cheikhyoussef et al., 2008) produced by the 
probiotic species.  
One major concern of the experiments was the dilution of the CFS that occurred when 
modifying the pH and when obtaining the CFS-media mixture for inoculation of  C. 
difficile (which also occurred in Chapter 3). Since nutrient source was necessary for the 
detection of the growth of the species in the microcalorimeter, the CFS had to be always   164 
diluted with growth media because of the exhausted nutrient sources in the CFS.  To 
compensate for the effect of dilution, the neutralised CFSs were concentrated by freeze-
drying and evaluated as described by Lee et al., (2003). The freeze-drying was done with 
a Modulyo D-230 (Thermo Scientific, UK). At the end of the freeze-drying, the dried 
powder was diluted with 2.5, 5, 10 or 20-fold less water and filter sterilized. Figures 4.16 
and 4.17 compare the power-time curves of C. difficile inoculated into dsBHIct with 
neutralised CFS unconcentrated, 2.5-fold, 5-fold, 10-fold and 20-fold concentrated of 
LA-5
® and BB-12
® CFS, respectively. The power-time curves demonstrate the presence 
of other non-acidic antimicrobial metabolites in LA-5
® and BB-12
® CFS whose activity 
had been obscured because of dilution caused during pH modification and during the 
growth experiments. The non-acidic antimicrobial metabolites were likely produced in 
larger quantities in BB-12
® than LA-5
® demonstrated by the higher concentration of the 
neutralised CFS of LA-5
® needed for complete inhibition in the microcalorimeter. Also, 
dilutions and pH modifications of the CFS of BB-12
® consistently inhibited C. difficile. 
 
Figure 4.16. Power-time curves of C. difficile in LA-5
® CFS unmodified (red), neutralised (blue), 
neutralised but concentrated by 2.5 folds (magenta), neutralised and concentrated by 5 folds (green), 
neutralised and concentrated by 10 fold (violet) and neutralized and concentrated by 20 fold (light 
blue) compared to a control of the organism in dsBHIct and MRSc (black) 
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Figure 4.17. Power-time curves of C. difficile in BB-12
® CFS unmodified (red), neutralised (blue), 
neutralised but concentrated by 2.5 folds (magenta), neutralised and concentrated by 5 folds (green) 
compared to a control of the organism in dsBHIct and MRSc (black) 
As discussed previously, some probiotics species have been shown to produce specific 
proteinaceous antimicrobial compounds (bacteriocins and bacteriocin-like compounds), 
which can inhibit undesirable pathogens (Anand et al., 1984, Anand et al., 1985, Kang et 
al., 1989, Cheikhyoussef et al., 2008). It has been demonstrated in these experiments that 
the commercial strains that were tested had such potential and that microcalorimetry 
could detect it. This supports previous findings by Lee et al., (2003) and Kos et al., 
(2008) who also showed the likely presence of these compounds in some screened lactic 
acid  bacteria  and  selected  probiotics  using  optical  density  measurements  and  agar 
diffusion assay respectively. In Lee et al’s study, they also noticed about 41% increased 
inhibition of growth of C. difficile by a 20-fold concentrated CFS of one of the selected 
strains they evaluated (Lee et al., 2003).  
It must be mentioned that these compounds have a history dating back to the early 1920s 
(Nes,  2011).  Anand  et  al.,  (1984,  1985),  Kang  et  al.,  (1989)  and  Barefoot  and 
Klaenhammer (1983) isolated them from B. bifidum (bifidin) and B. longum (biflong) 
and  L.  acidophilus  (lactacin  B).  Indeed  Bifilact  BB-12  and  lactacin  B  have  been 
respectively reported to be produced by B. lactis BB-12
® and L. acidophilus LA-5
® by 
Abd El-Salam et al., (2004) and Tabasco et al., (2009). Lactacin B produced from L. 
acidophilus LA-5
® was found to display inhibitory activity against taxonomically related 
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bacteria with sensitive strains limited to members of the genus Lactobacillus (Tabasco et 
al., 2009). Bifilact BB-12 was however shown to be inhibitory towards S. aureus, S. 
typhimurium, Bacillus cereus and E. coli (Abd El-Salam et al., 2004). The present study 
suggests that these compounds inhibit C. difficile and could have a prospective role in 
the management of C. difficile infection. However the specificity of their action needs 
further  studies.  Generally  the  mechanism  of  action  of  these  compounds  has  been 
proposed to include direct killing of pathogens, allowance of probiotics to compete with 
the resident microbiota and acting as a signalling factor to recruit other bacteria in the 
gut or immune system to fight and eliminate pathogenic bacteria (Rea et al., 2013). 
Thuricin CD isolated from a strain of Bacillus thuringiensis was shown by Rea et al., 
(2010) to be capable of specifically targeting C. difficile and not significantly upsetting 
the  wider  microbiota  of  the  gut  unlike  vancomycin  and  metronidazole  which  were 
shown to lead to abundance of Enterobacteriaceae at the expense of other beneficial 
microbiota (Rea et al., 2010, Rea et al., 2011). However some have been shown to be 
non-specific.  For  instance,  nisin,  produced  by  Lactococcus  lactis  although  showed 
strongest  bactericidal  activity  against  C.  difficile  compared  to  metronidazole  or 
vancomycin, was also shown to have broad-spectrum inhibitory acitivity against some 
Gram-positive bacteria (Bartoloni et al., 2004, Field et al., 2010).  
4.4.4 Agar well diffusion assay 
Microcalorimetric  experiments  were  correlated  with  conventional  methods.  The 
diameters  of  growth  inhibition  zones  of  C.  difficile  (with  the  CFSs  of  the  probiotic 
strains produced in MRSc) are shown in Table 4.4. By this test, it was established that 
the CFSs were inhibitory towards C. difficile but inhibitory activities of the CFSs were 
lost upon neutralisation. CFS obtained from BB-12
® demonstrated superior inhibition 
(P<0.05) and this could be as the result of the greater quantities of the other non-acidic 
inhibitory metabolites produced by BB-12
® relative to LA-5
® which was demonstrated 
in the previous section.  
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Table 4.4. Zones of inhibition of unmodified and modified cell free supernatant (CFS) of LA-5
® and 
BB-12
® against C. difficile. The values are mean ± SD. n=4 for zone of inhibition values 
 
Cell Free Supernatants (CFS)  pH  Zone of inhibition of C. 
difficile (mm) 
L. acidophilus CFS unmodified  4.12 ± 0.01  7 ± 0.0 
L. acidophilus CFS neutralised   7.0  0.0 ± 0.0 
B. lactis CFS unmodified  4.62 ± 0.01  7.5 ± 0.72 
B. lactis CFS neutralised  7.0  0.0 ± 0.0 
 
It should be pointed out that although the results from the agar well diffusion assay 
correlates well with the microcalorimetric data and previous findings  (Naaber et al., 
2004, Trejo et al., 2006, Schoster et al., 2013), if this was the only assay employed in the 
study, the other findings may have been missed. To illuminate this point, the agar well 
diffusion assay suggests that inhibitory activities were totally lost for both species when 
the CFS was neutralised whilst the microcalorimetric data indicates that this is not the 
case. A study by Schoster et al., (2013), which also determined inhibitory activity by 
both agar well diffusion and broth culture assays showed that while the CFS of some 
strains showed no inhibitory activity by agar well diffusion assay, the CFS of those same 
strains demonstrated inhibitory activity against C. difficile or Clostridium perfringens in 
broth. As discussed previously, this may be due to the capacities of agents within CFS to 
diffuse through agar.  
4.4.5 Screening of commercially available probiotic products for anticlostridial 
activity 
Commercial  probiotic  products:  Actimel
®,  Align
®,  Biobalance-support,  Bio-kult
®, 
Probio 7
®, Symprove
TM, VSL#3
® and Yakult
®, were screened to determine if they could 
also inhibit germination and growth of C. difficile in the microcalorimeter. The results 
are presented in Figures 4.18a to 4.18h. Each commercial product showed individual 
characteristics that could be used for identification; each showed a different time of   168 
onset of growth, which could be related to their differences in viable cell concentration 
and  strain(s)  characteristics.  With  the  exception  of  Probio  7
®  (Figure  4.18e),  all 
commercial  probiotics  tested  showed  power-time  curves  that  suggested  inhibition  of 
germination and growth of C. difficile. Correspondingly, with the exception of Probio 
7
®, all products did not give colonies on “CDSAsb”. The phase contrast image of one of 
the  mixed  cultures  of  the  commercial  products  (Symprove
TM)  with  C.  difficile  after 
microcalorimeteric experiment is shown in Figure 4.19. The image shows some spores 
of C. difficile supporting that spores of C. difficile could not complete germination in the 
presence of the probiotic product. 
 
Figure 4.18a. Power-time curves of pure Actimel
® (black) and C. difficile (Cdiff) and their mixed 
culture (Actimel+Cdiff, red) in BHIct 
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Figure 4.18b. Power-time curves of pure Align
® (black) and C. difficile (blue) and their mixed culture 
(Align+Cdiff, red) in BHIct 
 
Figure 4.18c. Power-time curves of pure Bio-kult
® (black) and C. difficile (blue) and their mixed 
culture (Bio-kult+Cdiff, red) in BHIct 
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Figure 4.18d. Power-time curves of pure Biobalance support (black) and C. difficile (blue) and their 
mixed culture (Biobalance support+Cdiff, red) in BHIct 
 
Figure 4.18e. Power-time curves of pure Probio 7
® (black) and C. difficile (blue) and their mixed 
culture (Probio7+Cdiff, red) in BHIct 
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Figure 4.18f. Power-time curves of pure Symprove
TM (black) and C. difficile (blue) and their mixed 
culture (Symprove+Cdiff, red) in BHIct 
 
Figure 4.18g. Power-time curves of pure VSL#3
® (black) and C. difficile (blue) and their mixed 
culture (VSL3+Cdiff, red) in BHIct 
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Figure 4.18h. Power-time curves of pure Yakult
® (black) and C. difficile (blue) and their mixed 
culture (Yakult+Cdiff, red) in BHIct 
 
Figure 4.19. Phase contrast image of a mixed culture of C. difficile with Symprove
TM post TAM 
experiment showing some endospores of C. difficile 
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The results from this work therefore suggest that these commercial products with the 
exception of Probio 7
® could have a potential role in the management of C. difficile 
infection in susceptible individuals.  As discussed in the introduction of this chapter, 
although antibiotics are the main treatment option of C. difficile infection (Gerding et al., 
2008b),  the  infection  is  known  to  be  often  recurrent  in  patients  due  to  decreased 
susceptibility of the pathogen to the antibiotics (Baines et al., 2008, Brazier et al., 2008, 
Huang et al., 2009) and reinfection; associated with the inability of the antibiotics to 
restore  the  compromised  colonization  resistance  of  the  gut,  a  property  directly  (eg. 
through  antimicrobial  production)  or  immunologically  related  to  its  microbial 
composition and diversity (Britton and Young, 2012, Lawley and Walker, 2013, Walker 
and Lawley, 2013, Briton and Young, 2014). From the results of the present study it 
seems  that  these  probiotics  could  potentially  prevent  germination  and  growth  of  C. 
difficile in vivo. If indeed they are able to, and also able to potentially restore the gut 
microbiota then, consequently  the  colonization resistance  of the microbiota could be 
restored and this could prevent occurrence or recurrence of the infection when they are 
used. As already indicated in the introduction of this chapter, the UK Department of 
Health has not endorsed the use of probiotics for management of C. difficile infection 
even  though  faecal  transplant  (due  to  its  treatment  success)  has  been  strongly 
recommended for recurring C. difficile infection (Public Health England, 2013, Debast et 
al., 2014). It would therefore be useful if further laboratory studies (also with different 
strains  of  C.  difficile)  or  clinical  test  could  be  done  to  determine  if  indeed  these 
probiotics could play evidential role in prophylaxis or treatment of the infection. 
4.4.6 Microbial stability of multi-strain probiotics: pure and mixed cultures of 
the strains of Symprove
TM 
The power-time curves of 10 batches of the commercial multi-strain probiotic product, 
Symprove
TM in BHIc are shown in Figure 4.20. The power-time curves are reproducible 
but show different lag period among some batches suggesting reproducibility of content 
but differences in the concentration of viable bacteria in the batches. The power-time 
curves of 10
6 CFU/mL of the component strains of the product: L. plantarum SYM A, L. 
rhamnosus SYM B, L. acidophilus SYM C and E. faecium SYM D in the same medium 
are shown in Figures 4.21, 4.22, 4.23 and 4.24, respectively. The power-time curves 
were characteristic for each strain. E. faecium SYM D metabolised the medium most   174 
energetically and L. acidophilus SYM C the least. It is likely that the medium was more 
favourable for the growth of E. faecium than the lactobacilli strains. The reason for this 
is not yet known. 
 
Figure 4.20. Power-time curves of 10 batches of Symprove
® inoculated into BHIc at 1 in 100 dilution 
 
Figure 4.21. Power-time curves of 3 repeats of L. plantarum SYM A inoculated into BHIc at a cell 
density of 10
6 CFU/mL 
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Figure 4.22. Power-time curves of 3 repeats of L. rhamnosus SYM B inoculated into BHIc at a cell 
density of 10
6 CFU/mL 
 
Figure 4.23. Power-time curves of 3 repeats of L. acidophilus SYM C inoculated into BHIc at a cell 
density of 10
6 CFU/mL 
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Figure 4.24. Power-time curves of 3 repeats of E. faecium SYM D inoculated into BHIc at a cell 
density of 10
6 CFU/mL 
Figure 4.25 compares the power-time curves of 10
6 CFU/mL of the component strains of 
Symprove
TM, a 1 in 100 inoculation of a batch of the commercial product and a mixed 
culture of the four strains at equal cell density in BHIc. The mixed culture of all strains 
suggested that E. faecium SYM D might have dominated the mixed culture in BHIc. 
However, the power-time curves of the batches of Symprove
TM showed similarities to 
the power-time curve of sole culture of L. plantarum SYM A. It is likely L. plantarum 
SYM A could have inhibited the other strains and dominated the commercial product or 
was present in higher concentration in the product. When the medium was changed to 
MRSc, the same trend of observation was noted; the power-time curves of batches of the 
product had similarities to the sole curve of  L. plantarum SYM A (Figure 4.26). In 
contrast to BHIc, a defined mixed culture of all the strains in MRSc under the same 
conditions was not likely dominated by E. faecium SYM D however.  
Relative to the other strains, E. faecium SYM D and L. acidophilus SYM C did not have 
a significant period of lag before exponential growth proceeded in BHIc, which was very 
energetic in the former species. It was therefore likely that the dominance of E. faecium 
SYM D in the mixed culture in BHIc could have been more of an “adaptive effect” or 
“competitive nutrition” in BHIc than of superior antimicrobial effect against the other 
species. Also as discussed in section 4.4.3 of this chapter, it is likely that the general-
purpose medium, BHI was more favourable towards the growth of E. faecium SYM D 
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than the other lactobacilli strains (De Man et al., 1960) as repitition of the experiment in 
MRSc did not show superior growth of E. faecium SYM D.  
 
Figure 4.25. Comparison of the power-time curves of the individual strains of Symprove
TM inoculated 
to respective cell densities of 10
6 CFU/mL, their mixed culture at equal cell density and a 1 in 100 
dilution of a batch of the commercial product in BHIc 
 
Figure 4.26. Comparison of the power-time curves of the individual strains of Symprove
TM, 
inoculated to respective cell densities of 10
6 CFU/mL, their mixed culture at equal cell density and a 1 
in 100 dilution of a batch of the commercial product in MRSc 
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Figure 4.27. Power-time curves of Symprove
TM strains in the CFS of each other; the strains in the CFS 
of [A], L. plantarum, [B], L. rhamnosus, [C], L. acidophilus, [D], E. faecium 
Table 4.5. Cell count of the respective species of Symprove
TM after incubation in the CFSs of each 
other 
 
CFS of strains  Cell count (CFU/mL) of species post CFS incubation 
L. plantarum 
SYM A 
L. rhamnosus 
SYM B 
L. acidophilus 
SYM C 
E. faecium SYM 
D 
L. plantarum 
SYM A CFS 
1.9 x 10
7  1.2 x 10
7  2.0 x 10
5  3.5 x 10
4 
L. rhamnosus 
SYM B CFS 
1.6 x10
7  1.8 x10
7  3.4 x 10
5  2.3 x 10
5 
L. acidophilus 
SYM C CFS 
1.9 x 10
7  2.4 x 10
7  3.1 x 10
6  1.2 x 10
7 
E. faecium SYM 
D CFS 
9.9 x 10
7  3.8 x 10
7  3.5 x 10
7  2.2 x 10
7 
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CFS obtained from the other lactobacilli strains of Symprove
TM inoculated into cultures 
of  the  species  in  double  strength  BHIc,  dsBHIc  actually  inhibited  the  growth  of  E. 
faecium SYM D (Figure 4.27, Table 4.5). Its CFS did not on the other hand inhibit the 
lactobacilli strains. 
The pure  strains  of  Symprove
TM  and  the  product  were  also  assessed  on MRSc  agar 
supplemented  with  0.002%  w/v  of  bromophenol  blue  “MRSc-BPB”  (Lee  and  Lee, 
2008). Bromophenol blue is an acid-base indicator with a useful indicator range of pH 
3.0  and  4.6.  At  pH  3.0,  it  appears  yellow  and  appears  blue  at  pH  4.6  (Product 
specification,  Sigma-Aldrich).  The  dye  was  used  to  detect  the  different  strains  in 
Symprove
TM product due to the different pH values they develop during culture. It was 
noted that cultures of L. plantarum SYM A, L. rhamnosus SYM B, L. acidophilus SYM 
C and E. faecium SYM D produced acidic metabolites and decreased the pH of MRSc to 
mean values of 3.76, 3.83, 3.99 and 4.37 respectively (measured with a pH probe).  
The respective colonies of the pure strains of Symprove
TM: L. plantarum SYM A, L. 
rhamnosus SYM B, L. acidophilus SYM C and E. faecium SYM D on MRSc-BPB are 
shown  in  Figure  4.28.  Though  each  strain  had  individual  colony  morphology 
characteristics on MRSc-BPB agar plate, only two types of colonies were isolated in a 
commercial product, the numerically dominant  organism isolated in the product was 
consistent with the colony morphology of L. plantarum SYM A (also identified as L. 
plantarum with an API 50 CHL biochemical identification test). The other organism, 
which was present in lower numbers, had been identified by the API 50 CHL test as L. 
rhamnosus. It therefore seems plausible that the other strains in the commercial product 
were inhibited by L. plantarum SYM A and L. rhamnosus SYM B since they were not 
isolated from the commercial product. Amongst the strains of Symprove
TM, L. plantarum 
SYM  A  produced  the  greatest  quantity  of  antimicrobial  substance,  evident  with  the 
lowest  pH  of  the  medium  after  growth  comparative  to  the  other  strains.  Also  the 
antimicrobial substances produced by L. plantarum SYM A and L. rhamnosus SYM B 
had the greatest inhibitory activity towards the other strains (Figure 4.27, Table 5.5). It is 
therefore likely that at the point of consumption, the commercial product, Symprove
TM 
contained  the  dominant  species  L.  plantarum  SYM  A,  with  L.  rhamnosus  SYM  B 
present in lower quantities.   180 
 
 
 
 
 
 
Species specificity of probiotics for inhibition of pathogens is a valid argument. While it 
has encouraged the use of different probiotics for targeting different pathogens based on 
evidence (Chapman et al., 2011, Chapman et al., 2012, Hell et al., 2013), it has also 
encouraged the use of cocktail of strains in commercial products by manufacturers who 
may have misinterpreted it as “the more the strains, the better the product” without a 
proper understanding of interspecies interaction. As demonstrated with Symprove
TM, and 
throughout this thesis, interactions of species do occur with consequent inhibition (or 
possible variant selection; Biswas et al., 2009). A study by Chapman et al., (2012) which 
also  tested 14 single species of probiotics by cross-streak and agar spot assays also 
demonstrated  inhibition  of  all  probiotic  combinations  (Chapman  et  al.,  2012).  Their 
findings and findings from the present study are consistent with that from Be'er et al., 
(2009) who also observed inhibition between sibling strains, thus closely-related strains 
Figure 4. 28. Colonies of strains 
of Symprove
TM on MRSc agar 
supplemented with 
Bromophenol blue (MRSc-
BPB). Following anaerobic 
incubation of the plates for 48 
h, each strain produced 
individual colony 
characteristics on MRSc-BPB 
agar. Photographic images were 
taken: [A], L. plantarum SYM 
A; [B], L. rhamnosus SYM B; 
[C], L. acidophilus SYM C; 
[D], E. faecium SYM D. 
Colonies of L. plantarum SYM 
A were yellowish and circular 
with bluish green centered 
spots. L. rhamnosus SYM B 
appeared creamy white and had 
the tendency to merge even on 
low density when multiple 
colonies were present. Colonies 
of L. acidophilus SYM C and E. 
faecium SYM D were smaller, 
circular and light blue. The 
commercial product, 
Symprove
TM had one dominant 
type of colony [E] isolated. The 
colony characteristics were 
similar to L. plantarum SYM A. 
The other colony isolated from 
the commercial product was 
consistent with the colony 
morphology of L. rhamnosus 
SYM B. Its numerical number 
was lower relative to the other 
colony.  
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of Paenibacillus dendritiformis (Be'er et al., 2009). The results from the present study 
and that of Chapman et al., (2012) show the importance and the need that manufacturers 
research into the interspecies interaction of potential strains before putting them together 
as a product.  
The  multistrain  product,  Symprove
TM  demonstrated  inhibitory  activity  against  C. 
difficile. Its component strains were also screened for activity against C. difficile in the 
microcalorimeter and they all showed anticlostridial activity (results not shown). The 
results from the microcalorimeter did not however demonstrate whether the mixture or 
the  individual  single  species  had  greater  activity  against  C.  difficile.  But  whilst  it 
indicates  that  each  strain  in  the  commercial  Symprove
TM  product  had  probiotic 
characteristics and specifically, anticlostridial activity, the same cannot be said for all 
multistrain commercial products. For instance, it was shown by Lema et al., (2001) who 
wanted to demonstrate the efficacy of different probiotics in reducing E. coli  O157:H7 
shedding by sheep, that whilst one of the monostrain probiotic; S. faecium was observed 
to lower the count of E. coli, another, L. acidophilus did not relative to a control. But as 
a combined preparation, both probiotic species, L. acidophilus and S. faecium did not 
reduce E. coli shedding in sheep as much as sole S. faecium supplementation (over the 
entire experimental period of 7 weeks) although a 5-probiotic mixture of L. acidophilus, 
S. faecium, L. casei, L. fermentum and L. plantarum reduced shedding the most (Lema et 
al., 2001). The point being made is that, if competitive inhibition of strains occurs in 
some multistrain products, a consumer would derive no benefit if the strain(s) inhibited 
are those with specific activity. From other related studies, what is also possible is that 
the strains in a multistrain or multispecies product could affect each others potency, 
inhibit each other or adversely react hence defeating the purpose, issues also echoed by 
Myllyluoma  et  al.,  (2008)  when  studying  the  effects  of  multispecies  probiotic 
combinations on Helicobacter pylori infection in vitro and Grandy et al., (2010) when 
studying two different probiotic preparations for treatment of acute rotavirus diarrhoea. 
4.5 Chapter summary 
In this chapter, the anticlostridial activity of some commercial probiotics was assessed. 
The results demonstrate that two commercial probiotic strains and seven out of the eight 
commercial products that were assessed inhibited germination and growth of C. difficile 
as  assessed  by  microcalorimetry.  These  strains  and  products  inhibited  C.  difficile   182 
germination  and  growth  in  a  pH-dependent  manner,  which  suggested  the  likely 
production of organic acids. This correlates with previous studies: Naaber et al., (2004), 
Trejo et al., (2006) and Schoster et al., (2013). The results also suggested that the strains, 
which were further tested, may have produced other antimicrobial substances apart from 
the acids, which could have inhibited the germination and growth of C. difficile. The 
other antimicrobial substance, likely bacteriocins,  may have been produced in larger 
quantities by bifidobacteria than the lactobacilli strain since inhibitory effect of the CFS 
of  the  former  organism  was  always  greater  and  needed  less  concentration  for  total 
inhibition of C. difficile in the microcalorimeter when it was neutralised. The work also 
demonstrated that the germination and growth of C. difficile was greatly influenced by 
pH. The work suggests that the optimum pH for germination and growth of C. difficile 
could  be  ca.  pH  6.7;  correlating  with  and  lending  weight  to  results  obtained  by 
Wheeldon et al., (2008). 
Multi-strain probiotics are very common due to their advocacy (Sanders and Huis in't 
Veld, 1999, Dunne et al., 1999, Timmerman et al., 2004, Chapman et al., 2011). There 
has been however few studies on the inter/intra-species compatibility and stability in 
multistrain probiotic products (Timmerman et al., 2004, Chapman et al., 2012). In this 
chapter, it was also demonstrated that some strains could be inhibitory to others in a 
mixture using the component strains of a commercially available product. The results 
obtained in the study was consistent with previous findings of Be'er et al., (2009) and 
Chapman  et  al.,  (2012)  who  reported  the  inhibition  of  closely  related  strains  and 
species/genera respectively. 
The studies in this chapter had several limitations. Firstly, the C. difficile work, although 
showed the potential of the evaluated probiotic strains or products in inhibition of C. 
difficile, cannot be directly extrapolated to the  in vivo situation. For treatment of  C. 
difficile infection, there should be an established infection to which the probiotics could 
be  targeted  to  treat  but  this  could  not  be  simulated  in  the  closed  system  of  the 
calorimetric ampoule which was also a very simple in vitro medium compared to the 
complexity in vivo. When a biorelevant intestinal juice obtained from an animal was 
used as the medium to simulate the in vivo environment, loss of the structure of the 
power-time curve occurred hence different species gave the same thermal curve in the 
medium.   183 
Also, for the stability study, the concentration of each strain dosed in the commercial 
multi-strain product could not be exactly replicated in the experiments.  
Notwithstanding  these  limitations,  the  study  suggests  that,  component  strains  of 
commercial multi-strain probiotics could compete for nutrient sources and could also 
mutually inhibit each other. Despite the fact that they could inhibit each other, in this 
instance, one strain may have dominated the product under study and was still effective 
in inhibiting C. difficile. Also, the study suggests that the probiotics that were tested, 
except one, could have relevance for the management of C. difficile infection. However, 
further laboratory studies need to be conducted to determine whether they can achieve a 
therapeutic benefit.  
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Chapter 5 Microbiological and microcalorimetric evaluation of 
commercial probiotic products: in vitro gastric tolerance 
5.1 Introduction 
As discussed in Chapter 1, probiotics have become a huge commercial success due to 
their  claimed  health  benefits,  which  stems  from  their  relationship  with  the  gut 
microbiota. Although the work in this thesis has addressed the potential use of some 
commercial  probiotics  for  gastrointestinal  disease;  particularly  antibiotic  associated 
diarrhoea as the microcalorimetric studies have shown, their real therapeutic benefit will 
also principally depend on their ability to withstand gastrointestinal barriers and be able 
to colonise the intestinal tract (FAO/WHO 2001,  Gismondo et al., 1999).  The main 
barriers of the gastrointestinal tract, which they need to withstand include the gastric 
secretion, intestinal motility, pancreatic enzymes, lysozyme, and intestinal secretion and 
microbiota (Sarker and Gyr, 1992).  
The stomach and its secretion: gastric juice is a crucial barrier to most bacteria. The juice 
consists of HCl, salts, water, pepsinogens, intrinsic factors (Pocock et al., 2006) and can 
kill bacteria within 15 min when the pH is less than 3.0 (Giannell et al., 1972). The 
stomach  displays  large  variability  in  characteristics  under  different  conditions,  for 
example during the fed and fasted states (Fordtran and Walsh, 1973, Kalantzi et al., 
2006). Under fasted conditions the pH in a healthy human stomach is acidic, generally 
ranging between 1 and 3 (Dressman et al., 1990, Kalantzi et al., 2006). After food, the 
stomach environment varies considerably over the course of gastric residence of the 
meal (Kalantzi et al., 2006) and the pH climbs briefly to a median peak value of 6.7 and 
then declines back to the fasted state value within two hours or less (Dressman et al., 
1990). The stomach also displays large variability in emptying times both between fed 
and fasted states and within these states there are also large inter-individual variations 
(Coupe et al., 1991, Kalantzi et al., 2006, Mudie et al., 2010). In the fasted state, gastric 
emptying is largely controlled by the migrating myoelectric complex (MMC), which 
cycles every 90 to 120 min (McConnell et al., 2008b), while in the fed state, gastric 
emptying is controlled by low-amplitude contractions, duodenal feedback mechanism 
and pyloric resistance (Mudie et al., 2010). Generally, emptying time in both the fasted 
and fed state is also influenced by the size, amount and nature of liquid or solid ingested 
and the phase of contraction during which it was ingested (Mudie et al., 2010). Emptying   185 
times in the fasted state are known to be considerably quicker than those in the fed state. 
Mean  time  for  half  gastric  emptying  of  12  min  and  15.8  min  have  been  reported 
respectively after the ingestion of saline solution and 300 mL of water in the fasted state 
(Granger et al., 1985, Steingoetter et al., 2006) while mean half gastric emptying time of 
32±7, 46±9, 67±9 and 76±6 min have been reported for liquids (Marciani et al., 2001) 
and 105±21 min for solids respectively in the fed state (Coleman et al., 2003, Mudie et 
al., 2010).  
There is also variability in the complexity of the chemical constituents of the gastric 
juice and in the volume of the gastric contents (Pocock et al., 2006); the capacity of the 
stomach has been noted to be 1.5 L (Aulton, 2013) but can contain up to 63 mL of free 
fluid in the fasted state (McConnell et al., 2008b).  
Gastric tolerance assays for potential new probiotic formulations (Chandramouli et al., 
2004, Iyer and Kailasapathy, 2005, Ding and Shah, 2009, Mokarram et al., 2009, Cook 
et al., 2011) and commercial probiotic products (Sahadeva et al., 2011) or organisms 
(Jensen et al., 2012) routinely use either buffer or saline solutions adjusted to pH 1.2 to 
4, or growth media, adjusted to these same pH’s to simulate the gastric juice. These 
simulated fluids often lack the complexity of the real fluids and often, gastric volumes 
are not accounted for or ignored. In addition, gastric tolerance assays as discussed in 
Chapter 1 frequently use the plate count technique to assess the survival of bacteria after 
exposure and this has inherent problems discussed previously.  
The study in this chapter was designed to investigate the in vitro gastric tolerance of 
commercially available probiotics to a bio-relevant fluid and simulated fluids with the 
specific aims of developing a more realistic test and understanding the factors that must 
be controlled in delivering viable species to the gut. The study investigated selected 
commercial probiotics representative of those available to consumers and of the different 
classes of product available. As previously mentioned, due to their extrapolated clinical 
significance  (without  substantial  evidence  in  all  cases),  probiotics  have  had  a  huge 
commercial success in the last decades. New probiotic products are hence introduced 
onto the market at a fast pace, inevitably competing for the consumers’ income. In this 
study, it was also set out to firstly identify and enumerate the viable organisms present in 
the products to determine if the label claim was representative of the actual contents of 
the products before gastric tolerance was assessed. Previous studies have indicated that   186 
the product quality of commercial probiotics is poor; with most products not accurately 
meeting their label claim (Temmerman et al., 2001, Weese, 2002, Elliot and Teversham, 
2004, Drago et al., 2004, Drago et al., 2010, Aureli et al., 2010, Weese and Martin, 
2011). For example, Weese and Martin, (2011), assessing 25 commercial probiotics used 
in animal health reported that only 4 out of 15 products that stated the concentration of 
viable content on the label, met their label claim. Similarly, a previous study by Weese 
in 2002 on both human and verterinary probiotics reported that only 15% of products 
accurately described and contained their claim content (Weese, 2002). Also, Drago et al., 
(2010) evaluating commercial probiotic products available on the USA market in 2009 
reported that only 4 out of the 13 products fulfilled their label claim. These authors 
recommended the need for adequate control of probiotic production and the periodical 
screening of probiotic products for effect of storage on product quality (Drago et al., 
2010).  
It was believed that due to the competitive market, the quality of probiotics might have 
possibly improved. The study therefore aimed to investigate this.  
The  study,  as  the main  focus  of  this thesis  explored  the  use  of  microcalorimetry  to 
measure gastric tolerance of the probiotics in or after exposure to simulated gastric fluid. 
The  stability  of  lyophilised  Lactobacillus  acidophilus,  LA-5
®  was  studied  at  two 
different storage conditions to investigate the effect of storage on viability.  
5.2 Objectives 
The objectives of this chapter were: 
  To  identify  and  enumerate  viable  organisms  present  in  commercial  probiotic 
products 
  To determine gastric survival of commercial probiotics using a biorelevant and 
simulated gastric fluid 
  To  explore  the  potential  of  isothermal  microcalorimetry  to  measure  gastric 
survival of probiotics  
  To study the effect of storage on the viability of a lyophilised probiotic    187 
5.3 Materials and Methods 
5.3.1 Commercial probiotic products 
Eleven commercial products, in total were used in the study (Table  5.1). They were 
either  purchased  from  local  supermarkets  or  pharmacies  or  obtained  from  the 
manufacturers or marketers. After purchase, the products were stored appropriately in 
cool, dry places, away from light or in the fridge at 4
oC as per the information on their 
labels. They were all used before the expiry dates printed on the labels. 
5.3.2 Probiotic control strains 
Probiotic strains, Lactobacillus acidophilus LA-5
®, Bifidobacterium lactis BB-12
® and 
Bifidobacterium bifidum ATCC 11863 were used as control strains or as live free cells 
for  the  gastric  tolerance  assay.  10
8  CFU/mL  cell  suspensions  of  these  strains  were 
obtained as described in section 3.3.4.   188 
Table 5.1. Commercial probiotic products evaluated in this study 
 
Product 
 
Manufacturer 
/Marketer 
Form  Probiotic strains  Volume or 
weight 
measured 
per content 
or dose 
Claimed 
Culture 
concentration 
Other Ingredients  Dosage/adminstration 
instructions 
Actimel
®  Groupe Danone, 
France 
Liquid 
(milk) 
Lactobacillus casei DN 114 001 
(main strain), Lactobacillus 
bulgaricus and Streptococcus 
thermophilus 
100 mL  10 billion per 
100 mL 
Yogurt (skimmed milk, 
skimmed milk 
concentrate/powder, 
cream, yogurt cultures), 
skimmed milk, 
sugar/liquid sugar (sucrose 
7.3%), dextrose, milk 
mineral concentrate, 
vitamins (B6, D) 
One bottle per day as 
part of breakfast 
Align
®  Procter and 
Gamble, USA. 
Solid 
(Capsule) 
B. infantis 35624  0.174 g  1 billion per 
capsule 
Microcrystalline cellulose, 
hypromellose, sucrose, 
magnesium stearate, 
sodium caseinate, titanium 
dioxide, trisodium citrate 
dihydrate, propyl gallate 
One capsule should be 
taken per day 
Biobalance 
support 
Boots Ltd.  Solid 
(Capsule) 
B. bifidum, L. acidophilus, and B. 
lactis 
0.300 g  12.5 billion per 
capsule 
Fructooligosaccharides, 
microcrystalline cellulose, 
hydroxypropyl 
methylcelluose, silicon 
dioxide, magnesium 
stearate 
 
Capsules are to be taken 
once daily with liquid   189 
Product 
 
Manufacturer 
/Marketer 
Form  Probiotic strains  Volume or 
weight 
measured 
per content 
or dose 
Claimed 
Culture 
concentration 
Other Ingredients  Dosage/adminstration 
instructions 
Biobalance 
Travel 
Boots Ltd.  Solid 
(Capsule) 
B. bifidum, L. acidophilus, and B. 
lactis 
  10 billion per 
capsule 
Ginger powder, capsule 
shell (hydroxypropyl 
methylcellulose), silicon 
dioxide, magnesium 
stearate 
One capsule a day with 
liquid 
Bio-kult
®  Protexin Lopen 
Head, UK. 
Solid 
(Capsule) 
Bacillus subtilis PXN 21, 
Bifidobacterium spp. (B. bifidum 
PXN 23, B. breve PXN 25, B. 
infantis PXN 27, B. longum PXN 
30), Lactobacillus spp. (L. 
acidophilus PXN 35, L. 
delbrueckii spp. bulgaricus PXN 
39, L. casei PXN 37, L. 
plantarum PXN 47, L. 
rhamnosus PXN 54, L. helveticus 
PXN 45, L. salivarius PXN 57), 
Lactococcus lactis ssp. lactis 
PXN 63, Streptococcus 
thermophilus PXN 66  
0.171 g  2 billion per 
capsule 
Cellulose (bulking agent), 
vegetable capsule 
(hydroxypropyl methyl 
cellulose), traces of soya, 
milk products at level that 
would not affect lactose 
intolerance sufferers 
One or two capsules, 
once or twice daily. 
Capsule can be opened 
and the contents can be 
sprinkled on food, taken 
in a drink or swallowed 
whole 
Digestive 
Health 
Boots Ltd  Solid 
(Capsule) 
L. acidophilus, B. bifidum, B. 
lactis 
0.298 g 
 
12.5 billion per 
capsule 
Fructo-oligosaccharides, 
cellulose, hydroxypropyl 
methylcellulose, anti-
caking agents (silicon 
dioxide, magnesium 
stearate). Contains milk 
Take one or two 
capsules with food or 
drink   190 
Product 
 
Manufacturer 
/Marketer 
Form  Probiotic strains  Volume or 
weight 
measured 
per content 
or dose 
Claimed 
Culture 
concentration 
Other Ingredients  Dosage/adminstration 
instructions 
OptiBac  Wren 
Laboratories 
Ltd. 
Solid 
(powdered 
sachet) 
L. acidophilius Rosell-52, L. 
casaei Rosell-215, Lactococcus 
lactis Rosell-1058, and B. 
bifidum Rosell-71. 
-  5 billion per 
sachet 
Fructooligosaccharides 
(FOS), stabilizer 
(maltodextrin) 
One sachet daily with 
breakfast. Pour sachet 
into an inch of water in 
a tall glass, leave to 
dissolve and swirl 
vigorously 
Probio 7
®  Forever Young 
International, 
UK. 
Soid 
(Capsule) 
L. casei, L. rhamnosus, L. 
plantarum, L. acidophilus, 
Streptococcus thermophilus, B. 
bifidum, B. breve and B. longum. 
0.439 g  10 billion 
probiotic 
organisms plus 1 
billion 
Saccharomyces 
boulardii per 
capsule 
Chicory inulin fibre 
(Fructo-oligosaccharide), 
vegetable cellulose 
(capsule shell), 
maltodextrin, soy fibre, 
magnesium stearate, 
asocobic acid 
One capsule per day. 
Capsule should be 
swallowed whole 
Symprove
TM  Symprove Ltd.  Liquid 
(non-
milk) 
L. rhamnosus, L. planatarum, L. 
acidophilus, and Enterococcus 
faecium 
60 mL  10 billion per 50 
mL 
Barley, Vitamin C, 
potassium sorbate, 
trisodium citrate 
1 mL per kilogram of 
bodyweight as a liquid 
drink to be taken prior 
to food in the morning 
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Product 
 
Manufacturer 
/Marketer 
Form  Probiotic strains  Volume or 
weight 
measured 
per content 
or dose 
Claimed 
Culture 
concentration 
Other Ingredients  Dosage/adminstration 
instructions 
VSL#3
®  Ferring 
Pharmaceuticals 
Ltd. 
Solid 
(powdered 
sachet) 
Streptococcus thermophilus 
DSM 24731, B. breve DSM 
24732, B. longum DSM 24736, 
B. infantis DSM 24737, L. 
acidophilus DSM 24735, L. 
plantarum DSM 24730, L. 
paracasei DSM 24733 and L.  
delbrueckii subsp. bulgaricus 
DSM 24734. 
4.447 g  450 billion per 
sachet 
Maltose, silicone dioxide 
(anti-caking agent) 
One sachet once or 
twice daily. Sachets can 
either be spinkled on 
food or reconstituted 
with cold water or any 
non-fizzy drink and 
consumed 
Yakult
®  Yakult, UK  Liquid 
(milk) 
L. casei Shirota  65 mL  6.5 billion per 65 
mL 
Skimmed milk solids  One or two bottles per 
day 
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5.3.3 Chemicals  
HCl  (37%),  Skim  milk  powder  and  D-(+)-Trehalose  dihydrate  were  purchased  from 
Sigma-Aldrich,  UK.  NaCl  (AnalaR  BDH  58.44g/mol)  was  obtained  from  VWR 
International, UK. 
5.3.4 Isolation and identification of probiotic species in commercial products 
Seven of the commercial products: Actimel
®, Biobalance Support, Biobalance Travel, 
Digestive Health, OptiBac, Symprove
TM and Yakult
® were used for this test. They were 
obtained  from  a  visit  to  a  local  pharmacy  and  supermarket  at  Brunswick  Centre 
(London, UK) or from the manufacturer. The solid (lyophilised) commercial products 
(Biobalance Support, Biobalance Travel, Digestive Health and OptiBac) were hydrated 
in  3  mL  MRSc  broth.  A  loopful  of  the  hydrated  lyophilised  products  or  the  liquid 
products was streaked onto MRSc agar plates and incubated at 37
oC anaerobically. After 
48 h of incubation, the colonies obtained, which could be differentiated by size and 
appearance were sub-cultured to obtain pure cultures of the selected colonies. Gram 
staining was performed on the pure cultures isolated. Gram staining was also performed 
on  pure  colonies  of  Lactobacillus  acidophilus  LA-5
®  and  Bifidobacterium  bifidum 
ATCC  11863  which  were  used  for  reference  or  controls  for  identification  by 
microscopic imaging. Biochemical tests for identification of the bacteria were carried out 
using the commercial kits API 50 CHL for Lactobacillus and related genera and API 
Rapid ID 32A for anaerobes. The tests were conducted according to the manufacturers 
instructions.  
5.3.5 Enumeration of viable organisms in commercial probiotic products 
Only  one  product  per  manufacturer  was  employed  for  this  experiment  and  the 
subsequent  experiments.  Eight  products  were  used  and  included:  Actimel
®,  Align
®, 
Biobalance  Support,  Bio-kult
®,  Probio  7
®,  Symprove
TM,  VSL#3
®  and  Yakult
®.  The 
content of a capsule or sachet of the lyophilised products (Align
®, Biobalance Support, 
Bio-kult
®, Probio 7
® and VSL#3
®) was dispersed in 10 mL sterile PBS. The mixture was 
left to hydrate for 10 min, was vortexed to homogeneity, serially diluted in PBS and   193 
spread-plated  on  MRSc  agar.  Liquid  products  (Actimel
®,  Symprove
TM  and  Yakult
®) 
were  also  serially  diluted  and  spread-plated  on  MRSc  agar.  All  plates  were  then 
incubated at 37
oC anaerobically. Colonies were counted after incubation for 48 h. The 
actual contents of a dose of these products were calculated using the formula: 
Actual content (CFU/dose) = (CFU/mL)*dose                                                Equation 5.1 
for the different form of the product, lyophilised or liquid, content of viable cells per 
dose was calculated using Equations 5.1.1 and 5.1.2 respectively 
content per capsule or sachet = (CFU/mL)*10 mL                                      Equation 5.1.1 
content per dose =(CFU/mL)* recommended volume                                  Equation 5.1.2 
Experiments were performed in triplicate and the number of colony forming units was 
expressed as log values.  
5.3.6 Obtainment of porcine gastric fluid and preparation of simulated gastric 
fluids 
Three  types  of  gastric  fluid  were  used  for  the  study;  porcine  gastric  fluid  (PGF), 
simulated gastric fluid (SGF*) and fasted state simulated gastric fluid (FaSSGF). PGF 
was obtained from the stomach of an adult animal, fed ad libitum; obtained from an 
abattoir. Juices were dispensed into multiple aliquots and frozen at -80
oC. Prior to use, 
they were thawed at room temperature, centrifuged at 10000 rpm (Mini spin, Eppendorf, 
Germany) for 10 min at 25
oC. The supernatant obtained was sterilized by filtration using 
a membrane filter of 0.22 µm pore size.  
SGF*  was  prepared  by  adding  HCl  to  a  2  g/L  solution  of  NaCl  and  adjusting  pH 
(pHenomenal
®, UK) to 1.2 ± 0.1 and 3.4 ± 0.1.  
FaSSGF  was  prepared  according  to  the  composition  presented  by  Vertzoni  and  co-
workers (Vertzoni et al., 2005) with SIF
® powder (Biorelevant Ltd.). Briefly, NaCl (2 g) 
was  dissolved  in  purified  water  (1  L)  and  the  pH  adjusted  to  either  1.6  or  3.4  as 
appropriate  with  HCl.  0.06  g  of  SIF
®  powder  was  added  to the prepared  HCl/NaCl   194 
solution to a volume of 1 L to give a final composition of sodium taurocholate 80 µM; 
lecithin 20 µM; pepsin 0.1 mg/mL; sodium chloride 34.2 mM.  
The artificial fluids were used within 48 h of preparation. 
5.3.7 Measurement of surface tension, osmolality, buffer capacity and pH of the 
porcine and simulated gastric fluids 
The tensiometer, Delta-8, Kibron Inc, Finland was employed for measurement of the 
surface  tension  of  the  fluids  using  the  Delta-8  manager  software  (version  3.8).  The 
temperature of the instrument was between 27.7-27.9
oC. Measurements were taken on 
50 µL/well of 8 samples of each fluid in 96-well plates. Calibration was done with 
deionized water prior to the experiments.  
The  osmolality  of  the  fluids  were  measured  using  the  freezing  point  depression 
technique with a digital micro-osmometer, Hermann Reobling Messtechnik, Germany on 
100 µL samples. Calibration was done with deionized water and measurements made in 
triplicates.  
The buffer  capacities of the fluids were measured by adding 0.1 M NaOH standard 
solution (Sigma-Aldrich, Germany) to 3 mL of the fluids and noting the volume of 
NaOH needed to change the pH by 0.5 unit. The buffer capacity was determined using 
the equation,  
β (mmol ⁄ L ⁄ ∆pH) =∆AB/∆pH                                         Equation 5.2 
where ∆AB is the small increment in mol/L of the amount of acid or base added to 
produce a pH change of ∆pH in the buffer. This equation can be rewritten as:  
β (mmol ⁄ L ⁄ ∆pH) = ((Ma*Va) / ∆pH) * (1000 /Vb )                                        Equation 5.3 
where Ma is the molarity of the acid or base, Va is the volume of acid or base in mL, Vb is 
the volume of buffer in mL, ∆pH is the change in pH unit. The equation is multiplied by 
1000 to express the volume in litre.    195 
5.3.8 In vitro gastric tolerance of probiotics mimicking the fasted state 
For these tests, it was assumed that the stomach has a fluid volume of 60 mL in the 
fasted state (McConnell et al., 2008b). Doses of the commercial products were mixed 
with 60 mL of the artificial fluids (SGF* and FaSSGF) to simulate in vivo condition 
upon ingestion of a dose of the commercial product in the fasted state. Thus 60 mL of 
Symprove
TM, entire contents of bottles of Actimel
® and Yakult
®, the entire content of 
capsule/sachet of Align
®, Bio-kult
®, Biobalance Support, Probio 7
® and VSL#3
® were 
added to 60 mL of the artificial fluids. The entire contents of the lyophilised products 
were also hydrated with 10 mL of sterile distilled water for 10 min and mixed with the 
simulated gastric fluids at pH 3.4. This was to mimic situations where the manufacturer 
instructs the consumer to reconstitute with liquid before consumption. 
For the porcine gastric fluid, representative dose of the commercial products was mixed 
with the fluid in a ratio representative of the artificial fluids to the commercial products 
(4.4  mg  of  Align
®,  7.5  mg  of  Biobalance  support,  4.4  mg  of  Bio-kult
®,  11  mg  of 
Probio7
®, 111.7 mg of VSL#3
®, 2.5 mL of Actimel
®, 1.5 mL of Symprove
TM and 1.63 
mL of Yakult
® was mixed with 1.5 mL of porcine gastric fluid).  
The  samples  were  vortexed  at  maximum  settings  for  10  s  and  incubated  at  37
oC. 
Aliquots of 50 µL were withdrawn at 5, 10, 20, 30 and 120 min, serially diluted in PBS 
and plated on MRSc agar plates for the determination of viable count.  
To determine gastric tolerance of live free cells of probiotic strains in gastric fluid, 17 
µL  of  a  10
8  CFU/mL  cell  suspensions  of  LA-5
®  and  BB-12
®  were  added  to  1  mL 
porcine gastric fluid and tolerance assay performed as above. 
5.3.9 In vitro gastric tolerance of probiotics mimicking the fed state in PGF 
Gastric tolerance in the fed state was done on the assumption that the fed stomach had a 
fluid capacity of 1.5 L (Aulton, 2013). A representative dose of the commercial products 
was  mixed  with  porcine  gastric  fluid  in  a  ratio  depictive  of  in  vivo  situation  upon 
ingestion.  The  total  volume  of  porcine  fluid  used  was  1.5  mL.  Thus,  100  µL  of 
Actimel
®, 60 µL of Symprove
TM, 65 µL of Yakult
®, 0.174 mg of Align
®, 0.300 mg of 
Biobalance Support, 0.171 mg of Bio-kult
®, 0.439 mg of Probio 7
® and 4.45 mg of   196 
VSL#3
® were added to 1.5 mL PGF. The entire contents of the lyophilised products 
were also hydrated with 10 mL of sterile water for 10 min, vortexed to homogeneity and 
10 µL mixed with 1.5 mL of PGF. The mixture was vortexed at maximum settings for 
10 s and incubated at 37
oC. Aliquots of 50 µL were withdrawn at 5, 10, 20, 30, 90, 120 
and  180  min,  serially  diluted  in  PBS  and  plated  on  MRSc  agar  plates  for  the 
determination of viable count. 
5.3.10 Microcalorimetric gastric tolerance assay mimicking the fasted state  
The  fasted  state  gastric  tolerance  of  the  products  in  PGF  was  simulated  in  the 
microcalorimeter,  by  mixing  the  respective  ratio of  PGF  to  product  in  3  mL  sterile 
calorimetric glass ampoule and recording the heat output. The volumes of PGF and 
quantities of products used were as follows: 
Product  Volume of PGF (mL)  Volume /Weight of Product  
Actimel
®  1.125  1.875 mL 
Symprove
TM  1.500  1.500 mL 
Yakult
®  1.440  1.560 mL 
VSL#3
®  3.000  0.220 g 
 
Alternatively,  the products were exposed to  the  porcine  and  simulated gastric  fluids 
(PGF, SGF* and FaSSGF, at pH 3.4, 1.2 or 1.6) mimicking the fasted state for 30 min as 
described in section 5.3.6 after which 30 µL of the mixtures were inoculated into 2970 
µL  of  pre-warmed  MRSc  broth  in  a  sterile  3  mL  calorimetric  glass  ampoule.  T he 
ampoules were sealed with crimped caps and vortexed for 10 s. They were placed in the 
thermal equilibration position of the  TAM and allowed to equilibrate to temperature. 
Data were captured after 30 min with Digitam 4.1 every 10 s over an amplifier range of 
1000 µW or 3000 µW until the power-time data returned to baseline.    197 
5.3.11 Pharmaceutical consideration: Freeze-drying and storage of lyophilised 
probiotic, LA-5
® 
LA-5
® was grown anaerobically in MRSc broth at 37
oC. At the end of incubation, the 
culture was divided into equal aliquots and centrifuged at 3500 g for 10 min at 4
oC. The 
pellet  obtained  in  each  aliquot  was  washed  twice  with  PBS.  The  pellets  were 
resuspended and mixed in different protectants:  
  15% v/v glycerol,  
  10% w/v trehalose,  
  10% w/v reconstituted skim milk  
1  mL  of  each  suspension  was  dispensed  into  vials  and  freezed  over  liquid  nitrogen 
vapour as described in section 2.3.7 to a temperature of -50
oC. At the end of the freezing 
process, vials from each protectant were thawed at 40
oC for 3  min and viable cells 
enumerated as described previously. Viable count was compared with the count before 
freezing.  The  rest  of  the  vials  were  transferred  to  a  freeze  dryer,  Modulyo  D-230 
(Thermo Scientific, UK) whose sample shelf was equilibrated at -50
oC. The vials were 
kept at this temperature and under 0.5 mbar vacuum for 22 h for the primary drying 
stage after which a secondary drying stage began for a further 6 h at 10
oC. At the end of 
the freeze drying process, the samples were separated into two; one set was stored at 4
oC 
in the fridge and the other stored at room temperature (RT) to  replicate the storage 
condition  instructed  by  manufacturers  of  the  lyophilised  products  evaluated.  The 
viability of the freeze dried probiotic strain in the different protectants was determined 
immediately after freeze-drying and after 3 days, 7 days, 10 days, 14 days, 28 days, 2 
months, 3 months and 6 months of storage either in the fridge at 4
oC or at RT.  
5.3.12 Statistical Analysis 
Statistical analysis was performed in Origin Pro 8.6 (Microcal Software Inc.). T-test or 
Analysis of Variance (ANOVA) with Turkey post-hoc analysis for means comparison 
was  used  where  appropriate.  P  values  less  than  0.05  were  regarded  as  significant 
difference between means.   198 
5.4 Results and Discussion 
5.4.1 Isolation and identification of probiotic species in commercial products 
Colonies were formed on all the incubated MRSc plates streaked with liquid or hydrated 
lyophilised product. The colonies isolated were similar in appearance i.e. creamy white, 
smooth  and  circular.  They  were  further  sub-cultured  on  the  basis  of  the 
size/characteristics of the colonies to obtain pure strains. The Gram stain appearance of 
the  control  strains  and  the  classification  of  the  colonies  isolated  from  each  product 
according  to  the  API  identification  software,  based  on  their  biochemical  profile  are 
summarized in Tables 5.2 and 5.3 respectively.  
Almost all the products contained at least one probiotic bacteria indicated on their label. 
According to the label, Biobalance Support, Biobalance Travel and Digestive Health 
contained three probiotic bacteria mixture: Lactobacillus acidophilus, Bifidobacterium 
bifidum  and  Bifidobacterium  lactis.  In  this  study  only  two  types  of  colonies  were 
isolated  from  these  products.  A  Gram  stain  of  the  colonies  revealed  Gram-positive, 
straight,  rounded  end  rods  in  chains  or  presented  singularly  which  were  similar  to 
colonies  of  LA-5
®.  The  API  50  CHL  test  confirmed  that  both  colonies  were  L. 
acidophilus.  The  API  rapid  ID  32A  test  however  suggested  that  they  could  be 
bifidobacteria except one of the isolates of Digestive Health. 
OptiBac,  which  was  labelled  to  contain  L.  acidophilus,  Lactobacillus  casaei, 
Lactococcus lactis and B. bifidum, also gave two isolates. The API rapid ID 32A test 
suggested that the isolates could either be L. acidophilus or Bifidobacterium spp.  The 
API 50 CHL however suggested that both isolates were Lactobacillus species.  
Symprove
TM, as indicated in the previous chapter, was labeled to contain four strains: 
Lactobacillus  rhamnosus,  Lactobacillus  plantarum,  Lactobacillus  acidophilus  and 
Enterococcus faecium but only two of the strains indicated on the label were isolated. 
The API 50 CHL identified the strains as L. plantarum and L. rhamnosus. 
Actimel
® also indicated it contained Lactobacillus casei DN 114 001 as the main strain. 
Only one type of colony was isolated from it. The colony was identified as L. paracasei   199 
with the API 50 CHL test kit. The other yoghurt cultures, Lactobacillus bulgaricus and 
Streptococcus thermophilus were not isolated. 
A single isolate was obtained from Yakult
® which was also labeled to contain L. casei 
Shirota. The strain was identified as L. paracasei with the API 50 CHL test kit. 
It is worth mentioning that L. casei and L. paracasei form a closely related taxonomic 
group within the heterofermentative lactobacilli (Ward and Timmins, 1999). These two 
species  even  though  well  distinguishable  from  other  lactobacilli  species  (except  L. 
rhamnosus),  are  known  to  be  difficult  to  differentiate  using  traditional  fermentation 
profiles (Ward and Timmins, 1999) which most often, identify L. casei was L. paracasei 
(Yeung et al., 2002).  
Table 5.2. Gram stain of control strains, L. acidophilus LA-5
® and B. bifidum ATCC 11863 
 
Control Strain  Gram stain 
morphology 
Gram stain image 
Lactobacillus 
acidophilus, LA-5
® 
Gram-positive, straight, 
solid, single or in 
chains, rounded end 
rods 
 
Bifidobacterium 
bifidum ATCC 11863 
Gram-positive, thin, 
short, curved, single or 
in chains, rods 
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Table 5.3. Gram stain appearance and biochemical identification of colonies isolated from commercial probiotic products 
 
Product  Isolates  Gram Stain Appearance  API 50 CHL Identification  API Rapid ID 32A 
Identification 
Actimel
®  1  Gram-positive, straight, solid rounded end 
rods in chains or singles 
Lactobacillus paracasei  - 
Biobalance Support  2  Gram-positive, straight, solid rounded end 
rods single or in chains 
Gram-positive, straight, solid rounded end 
rods single or in chains  
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Bifidobacterium spp. 
Bifidobacterium spp. 
Biobalance Travel  2  Gram-positive, straight, solid rounded end 
rods single or in chains  
Gram-positive, straight, solid rounded end 
rods single or in chains 
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Bifidobacterium spp. 
Bifidobacterium spp. 
Digestive Health  2  Gram-positive, straight, solid rounded end 
rods single or in chains 
Gram-positive, straight, solid rounded end 
rods single or in chains  
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Bifidobacterium spp. 
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Table 5.3. Gram stain appearance and biochemical identification of colonies isolated from commercial probiotic products (continued) 
 
Product  Isolates  Gram Stain Appearance  API 50 CHL Identification  API Rapid ID 32A 
Identification 
OptiBac
  2  Gram-positive, straight, solid rounded end 
rods single or in chains 
Gram-positive, straight, solid rounded end 
rods single or in chains 
Lactobacillus paracasei 
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Bifidobacterium spp. 
Symprove
TM  2  Gram-positive, straight, solid rounded end 
rods single or in chains 
Gram-positive, straight, solid rounded end 
rods single or in chains  
Lactobacillus plantarum 
Lactobacillus rhamnosus 
- 
- 
Yakult
®  1  Gram-positive, straight, solid rods single or 
in chains  
Lactobacillus paracasei  - 
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The results of this study suggest that bifidobacteria cannot be identified using the API 50 
CHL tests, which has also been recognized by Carmen Collado and Hernandez, (2007). 
Strains  that  the  API  50  CHL  identified  as  lactobacilli  were  also  identified  as 
bifidobacteria by the API rapid ID 32A. This may indicate the selectively of the API 50 
CHL for identification of lactobacilli and the API rapid ID 32A for identification of 
bifidobacteria  than  lactobacilli  and  the  likely  limitation  of  both  tests;  mainly 
misidentification.  However,  the  Gram  stain  showed  that  the  morphology  of  all  the 
isolates matched the lactobacillus control strain than the bifidobacterium strain. Also, the 
API 50 CHL test depended on the metabolism of carbohydrates by the strains and relied 
on colour changes caused by pH modifications during fermentation of the substrates in 
the kits by the growing strains (Moll et al., 1996, Herbel et al., 2013) whilst the API 
rapid ID 32A test depended on colour changes caused by preformed enzymes (Moll et 
al.,  1996).  These  colour  changes  were  noted  visually  after  either  48  h  or  4  h  of 
incubation for the respective tests. For the API 50 CHL, the pH indicator in all the tests 
were originally purple and were meant to change to yellow to indicate a positive result 
after 48 h of incubation except for one tube where a colour change from purple to black 
indicated a positive result. These changes were easier to note than the API rapid ID 32A, 
where  colour  changes  were  subtle;  for  example,  colour  change  from  red  to  yellow-
orange after shorter incubation time (4 h). Hence it was more likely that the API rapid ID 
32A could result in erroneous result; that from the API 50 CHL could therefore be more 
accurate. Generally, the specificity of these identification tests has been challenged by a 
number of authors. For instance, Boyd et al., (2005) found out that 33 out of 97 strains of 
lactobacilli  were  misidentified  by  the  API  50  CHL  test  as  L.  acidophilus  or  L. 
fermentum. Other authors such as Nagy et al., (1991), Alvarez-Olmos et al., (2004) and 
Collado et al., (2005) have also reported such likely misidentification. It is possible these 
misidentifications  occurred  because  the  same  strain  could  have  had  different 
carbohydrate fermentation pattern for the different protocol or assay condition used for 
the different test or different strains could have had the same enzymatic profile therefore 
may have showed the same fermentation pattern. Or the test could have been influenced 
by the wholesomeness of the cultures used. Moll et al., (1996) analysing fresh, frozen 
and lyophilised isolates have reported that the API rapid ID 32A test worked better with 
fresh  cultures  than  lyophilised  cultures  and  remarked  that  the  use  of  this  system  to 
identify organisms from freeze-dried products, which needed multiple sub culturing to 
recover  could  lead  to inaccuracy  (Moll  et  al,  1996).  They  further  criticized  that the 
incubation period for the kit was not sufficient for identification of some species.    203 
The results of the present study also suggest that bifidobacteria could be more difficult to 
isolate and appropriately identify using MRSc medium and the API tests respectively or 
may not have been contained in products claiming their content. It must be noted that the 
detection and enumeration of probiotic microorganisms in a product can be performed in 
a number of ways. In some instances, the respective species or genera in a product can 
be selectively isolated and enumerated using selective media or one plating medium can 
be used which supports the growth of the different species or genera (Charteris et al., 
1997). Differentiation between the species or genera is then carried out on the basis of 
the morphological characteristics of the colonies (Charteris et al., 1997). A number of 
media have been suggested for selectively isolating and growing species of lactobacilli 
and bifidobacteria and yoghurt starter cultures which are too numerous to list (Charteris 
et al., 1997, Nebra and Blanch, 1999, Shah, 2000, Tharmaraj and Shah, 2003, Tabasco et 
al., 2007, Ashraf and Shah, 2011, Saccaro et al., 2011). But generally, MRS agar is used 
for the specific isolation and growth of lactobacilli with added antibiotics, bile, maltose 
or  trehalose  (Charteris  et  al.,  1997)  and  incubated  under  aerobic  condition  for  sole 
proliferation  of  lactobacilli  (Charteris  et  al.,  1997).  Media  used  for  isolation  of 
bifidobacteria apart from the main fermentable substrates which also generally includes 
MRS (routinely), Reinforced clostridial medium (Champagne et al., 2011), Trypticase 
phytone yeast extract (Barrett et al., 2012), Columbia blood agar (Nebra and Blanch, 
1999,  Weese  and  Martin,  2011),  may  require  fortification  with  substances  such  as 
cysteine,  ascorbic  acid  and  sodium  sulphite  to  lower  redox  potential  and  keep  the 
medium anaerobic with antibiotics such as kanamycin and mupirocin and supplements 
such  as  horse  or  sheep  blood,  raffinose,  added  for  the  selective  growth.  Also, 
Transgalactosylated  oligosaccharides  (TOS)  agar  and  TOS  agar  supplemented  with 
neomycin sulphate, paromycin sulphate, nalidixic acid and lithium chloride (NPNL) and 
BLOG agar, which is based on blood-glucose-liver medium with additional selective 
ingredients  (oxgall  and  gentamicin)  have  been  used  for  selective  enumeration  of 
bifidobacteria  (Sonoike  et  al.,  1986,  Wijsman  et  al.,  1989,  Lim  et  al.,  1995). 
Bifidobacterium medium (BFM) (Nebra and Blanch, 1999) has also been used. They are 
generally incubated anaerobically (Champagne et al., 2011, Charteris et al, 1997). But 
MRS  (supplemented  with  0.05%  L-cysteine  hydrochloride)  and  Homofermentative-
heterofermentative  differential  (HHD)  medium  (based  on  bromocresol  green  pH 
indicator)  has  also  been  used  for  isolation  of  mixed  cultures  of  lactobacilli, 
bifidobacteria and yoghurt starter cultures (Charteris et al., 1997, Camaschella et al.,   204 
1998, Lin et al., 2006, Aureli et al., 2010, Champagne et al., 2011, Sahadeva et al., 
2011).  
Previous studies reported in the other chapters of this thesis had shown growth of L. 
acidophilus, L. plantarum, L. rhamnosus, B. lactis, B. bifidum and E. faecium on MRSc, 
which were the main species contained in the products evaluated besides L. casei and 
Lactococcus lactis, which were contained in a few other products. In this study, it is 
likely L. lactis was not isolated. It is also likely the bifidobacteria strains in the products 
could not grow well or were outgrown by the lactobacilli species on MRSc agar or were 
not isolated in the products claiming their content since as indicated previously, the 
Gram stain results corroborated well with the API 50 CHL results which was also a more 
detailed  and  rigourous  tests,  consisting  of  fermentation  tests  with  longer  growth 
incubation duration compared with the API rapid ID 32A, which depended on preformed 
enzymes by mostly previously lyophilised species, hence whose results may have only 
confirmed the species isolated were anaerobic. Moreover, Moll et al., (1996) have also 
reported in their study that some lactobacilli species were identified as bifidobacteria by 
the API rapid ID 32A.  
Also, it has been reported by other authors (Aureli et al., 2010, Drago et al., 2010) that 
bifidobacteria were not usually found in products claiming their content. For instance, 
Drago et al’s evaluation of 13 commercial probiotics on the USA market highlighted that 
products containing mixed species with bifidobacteria did not contain them, which they 
attributed,  could  be  due  to  the  higher  sensitivity  of  bifidobacteria  to  inadequate 
processing, packaging and storage than other bacteria (Drago et al., 2010). Aureli et al., 
(2010) also reported that B. bifidum was usually sporadically detected (4 out of 25) in 
products claiming its contents and when detected, were mostly dead (Aureli et al., 2010). 
In  Aureli  et al’s assay,  they  used  both  phenotypic  and  genotypic  (polymerase  chain 
reaction, PCR) methods for species identification, which was more confirmatory than the 
Gram  staining,  morphological  characteristics  and  biochemical  profiling  used  in  the 
present  study  and  in  Drago  et  al’s  study.  PCR  and  PCR-denaturing  gradient  gel 
electrophoresis (PCR-DGGE) (Charteris et al, 1997, Tannock 1999), quantitative real 
time  PCR  (qPCR),  pulsed  field  gel  electrophoresis  (PFGE),  randomly  amplified 
polymorphic DNA (RAPD) are among the genotypic methods that have been used or 
recommended (FAO/WHO, 2001) for identification of species in probiotic products. The 
sole use of the biochemical test kits for identification was one of the main limitations of   205 
this study. These biochemical tests could be unreliable and should therefore be always 
accompanied by other phenotypic or genotypic tests or physico-chemical identification 
method for the accurate determination of specific species within a product.  
In  summary,  the  evaluation  showed  that  all  the  probiotic  products  contained  viable 
probiotic organisms. Both Actimel
® and Yakult
® contained one species identified by the 
API test as L. paracasei. Symprove
TM contained two species identified as L. plantarum 
and  L.  rhamnosus.  Biobalance  Support,  Biobalance  Travel  and  Digestive  Health 
contained L. acidophilus and a Bifidobacterium spp. OptiBac contained L. paracasei, L. 
acidophilus or a Bifidobacterium spp. The API test kits could not accurately discern the 
phenotypic variability within members of the different genus. But it is also likely that 
bifidobacteria were not isolated from the products: those that were supposedly identified 
with API rapid ID 32 A could not be differentiated at the species level. But overall, the 
identification test gave some information about the quality of the products, which agrees 
with  previous  studies  about  the  microbial  composition  of  commercial  probiotics 
(Temmerman et al., 2001, Weese, 2002, Elliot and Teversham, 2004, Drago et al., 2004, 
Drago et al., 2010, Aureli et al., 2010, Weese and Martin, 2011).  
5.4.2 Enumeration of viable organisms in commercial products 
The purpose of this test was to compare the viable organisms present per dose in each 
probiotic product to the viability stated on their respective packaging. The products used 
for this test and the subsequent tests included: Actimel
®, Align
®, Biobalance Support, 
Bio-kult
®,  Probio  7
®,  Symprove
TM,  VSL#3
®  and  Yakult
®.  The  products  could  be 
classified into two categories: lyophilised products (i.e. lyophilised powders packed into 
capsules or sachet which included Align
®, Biobalance Support, Bio-kult
®, Probio 7
® and 
VSL#3
®) and liquid products (i.e. milk based: Actimel
® and Yakult
® and water based, 
Symprove
TM).  
Full  cell  recovery  was  observed  for  the  liquid  products:  Actimel
®,  Symprove
TM  and 
Yakult
® (Figure 5.1). Recovery in excess of 1-log unit was obtained for Actimel
® and 
0.5-log  for  Yakult
®  respectively.  The  lyophilised  products  had  lower  viable  content 
compared to their stated claim. Align
®, Bio-kult
® and Biobalance support had 0.4 to 1.5-
log less in viability and Probio 7
® showed almost a major 4-log reduction in viability.   206 
 
Figure 5.1. Claimed content and actual content of 8 commercial probiotic product evaluated. BS is 
Biobalance support. Values are expressed as log 10. Bars are SD of means of three determinations. 
Actual content was the same as or more than the claimed content for Actimel
®, Yakult
®, and 
Symprove
TM 
Even though there is no global agreement on the number of bacteria a probiotic product 
should  contain,  it  is  generally  agreed  that  a  probiotic  product  should  contain  ≥  10
6 
CFU/g or mL of product and that for any therapeutic benefit, a total of 10
9 probiotic 
microorganisms should be consumed per serving or daily (Minelli and Benini, 2008, 
Champagne et al., 2011, Health Canada, 2009, Italian Ministry of Health, 2013). While 
most of the lyophilised products contained <10
9 CFU/dose, the entire products tested 
contained >10
6 CFU/dose, which implies they could have a potential clinical efficacy. 
However, it is only reasonable to assume that a product with a high number of viable 
organisms is much more likely to have a potential clinical efficacy than a product with a 
low number. Thus, the higher the initial cell concentration, the higher the chances of 
intestinal  colonization  and  health  benefit  due  to  the  barriers  they  need  to  withstand 
before establishing in the lower intestinal tract.  
Previous studies (Temmerman et al., 2003, Lin et al., 2006) have also reported higher 
recovery  of  cells  in  liquid  products  compared  to  lyophilised  or  solid  products.  For 
instance, Lin et al., (2006) evaluating 8 brands of commercial lactic acid products, in the 
form of milk and yoghurt products, granule powders, and tablet formulations reported 
higher recovery  for the liquid products than the solid products. Also,  2 of the solid 
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products they evaluated did not contain any viable count of lactic acid bacteria although 
these products were labelled to contain them. Temmerman et al., (2003) also tested 10 
commercially available probiotic products, 5 of which were lyophilised products, 4 dairy 
products,  and  one  fruit  drink.  They  utilised  both  culture-dependent  and  independent 
analysis to determine cell counts. Their results also indicated that cell counts were much 
lower  in  the  lyophilised  products,  yielding  values  between  10
5  and  10
7  CFU/g  of 
product, while the count in dairy products were between 10
7 and 10
9 CFU/mL.  
While it is acknowledged that discrepancies could occur between different media used 
for the determination of viable content or the techniques employed, for instance culture-
dependent versus culture-independent methods (Temmerman et al., 2003), there seems 
to  be  a  significant  difference  in  recoverable  viable  content  between  liquid  and 
lyophilised products irrespective of the methods employed which is strengthened in the 
present study. It is likely the lower viable content may be contributed by injured cells, 
suboptimal  reconstitution  of  the  products  or  possible  instability  of  the  lyophilised 
products amongst other factors (Ray et al., 1971, De Valdez et al., 1985a, Champagne et 
al., 1991, Zhao and Zhang, 2005, Champagne et al., 2011). 
A lot of research has been carried out on the reconstitution of lyophilised bacteria due to 
their susceptibility to injury during lyophilisation (Ray et al., 1971, De Valdez et al., 
1985a, Champagne et al., 1991, Zhao and Zhang, 2005, Santivarangkna et al., 2007, 
Muller et al., 2010, Champagne et al., 2011). While some authors have demonstrated or 
argued that the reconstitution medium was important to the recovery of bacteria (De 
Valdez et al., 1985a, Charteris et al., 1997, Zhao and Zhang, 2005) and recommended 
careful recovery of lyophilised products to levels comparable to those of wet cultures not 
previously dried (Charteris et al., 1997), others have  shown otherwise. For instance, 
Teixeira et al.,  (1995) found out that the recovery of  Lactobacillus bulgaricus spray 
dried  in  milk  matrix  was  not  significantly  affected  when  rehydrated  in  skim  milk, 
phosphate buffer, MRS broth or water. Ray et al., (1971) in their work on effect of 
rehydration on recovery, repair and growth of injured freeze-dried Salmonella anatum 
also demonstrated that added milk during lyophilisation provided the needed nutrients 
for  the  cells  during  reconstitution  and  masked  the  effect  of  any  additional  nutrients 
added  to  reconstitution  media  (Ray  et  al.,  1971).  Other  authors  have  otherwise 
demonstrated or reviewed that not only is the reconstitution medium important but also 
all other substances carried over from the drying process, for example the milk used as   208 
the matrix or other cryoprotective agents used during the formulation, the medium used 
for harvesting the bacteria and time of harvesting of the bacteria all played significant 
role  in  the  recovery  of  dried  products  and  even  further  advised  that  reconstitution 
medium was strain specific. They also argued that lyophilised bacteria could contain 
dead cells, unharmed cells and sub-lethally injured cells, which could repair and regain 
normal  function  if  rehydrated  under  adequate  conditions  which  includes  besides  an 
optimal rehydration medium, the temperature of hydration, the volume of rehydration 
medium and the rate of hydration (De Valdez et al., 1985a, De Valdez et al., 1985b, 
Zhao and Zhang, 2005, Morgan et al., 2006, Muller et al., 2010, Zhang et al., 2012).  
In the present work, a buffered saline solution was used for reconstitution as most of the 
dried products already contained milk or other protectants or stabilizers (Table  5.1). 
Rehydration was carried out for 10 min at room temperature. Other comparative studies 
on commercial products have also used buffered saline solution (Coeuret et al., 2004, 
Lin et al., 2006) or peptone physiological solution (PPS) (0.1% w/v peptone, 0.85% w/v 
NaCl) (Temmerman et al., 2003) or Ringers (Maukonen et al., 2006). Other studies that 
have mostly assessed dried probiotic products have also routinely used normal saline or 
media (but some did not comment on the duration or temperature of hydration) and have 
generally  reported  lower  viable  content  in  relation  to  claimed  content  (Elliot  and 
Teversham, 2004, Drago et al., 2004, Drago et al., 2010). The observed lower viable 
content with the dried products could therefore be reasoned to be as a result of the stress 
the organisms are subjected to during freeze-drying or the method employed for their 
recovery  (reconstitution  medium,  duration  of  reconstitution,  temperature  of 
reconstitution  etc.)  or  perhaps  their  instability  during  storage.  Aureli  et  al.,  (2010) 
assessed probiotic products produced and distributed on the Italian market between 2005 
and  2006  which  they  collected  from  the  processing  plants  or  from  retailers  after  3 
months, 8 months and 13 months and reported instability of the products. Only 7 out of 
the 24 collected after 3 months were of the same composition as those obtained from the 
manufacturer. By the 13 months, only 1 product had the same composition (Aureli et al., 
2010).  
More research is therefore needed for full recovery of viable content of these products or 
ensuring stability of their viable content. It is likely manufacturers also perform their 
own viability checks of microbial composition and populations in their products hence 
they should also advise on the optimum means of reconstitution prior ingestion for their   209 
specific product or means of ensuring the stability of their products. For the lyophilised 
products  evaluated,  manufacturers  who  advised  on  reconstituiton  instructed  the 
consumer to reconstitute in water or a drink (which may be detrimental to the cells if a 
consumer  chooses  a  fruit  juice  or  a  drink  which  may  be  acidic).  Storage  was  only 
advised to be in cool and dry places, with some stating positively that refrigeration was 
not needed.  
5.4.3 Measurement of surface tension, osmolality, buffer capacity and pH of the 
porcine and simulated gastric fluids 
The measurements of surface tension, osmolality, pH and buffer capacity of the porcine 
and simulated gastric fluids are tabulated in Table  5.4. Among the fluids, only  PGF 
closely mimicked all the characteristics of the human gastric fluid. The other simulated 
fluids, SGF* and FaSSGF showed some differences to the human gastric fluid. 
A lot is known about the fluid in the human stomach; it is known to have an ionic 
strength of 0.1 ± 0.025 mM and concentrations of potassium, sodium, chloride, calcium, 
at 13.4 ± 3.0 mM, 68 ± 29 mM, 102 ± 28 mM, and 0.6 ± 0.2 mM respectively (Lindahl 
et al., 1997). Its bile salt concentration has been reported to be approximately 0.06 mM 
in the fed (Rhodes et al., 1969) and 0.2 ± 0.2 mM in the fasted state (Lindahl et al., 
1997) but Kalantzi et al., (2006) have reported insignificant levels in both the fasted and 
fed  states  (below  their  quantification  limit  of  500  M).  Pepsin  level  has  also  been 
reported to be in the range from 0.11 to 0.22 mg/mL by Kalantzi et al., (2006) while 
others have reported it to be in the range of 0.1 and 1.3 mg/mL in the fasted state 
(Schmidt et al., 1970, Lambert et al., 1968). In the fed state, pepsin level has been 
reported to be in the range from 0.26 to 1.72 mg/mL (Lambert et al., 1968, Kalantzi et 
al., 2006). Lipase activity has also been shown to be in the range from 11.4 to 43.9 
U/mL in the fed stomach (Armand et al., 1996) while in the fasted state, Vertzoni and 
coworkers state that its activity may not be important because it is known to be active in 
the pH range of 3–6 and thought to be present at concentrations of 0.1 mg/mL (Vertzoni 
et al., 2005). Other characteristics of the human gastric fluid are given in Table 5.4. 
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Table 5.4. Buffer capacity, osmolality, pH and surface tension of the porcine and simulated gastric 
fluids 
 
a Evans et al., 1988; 
b Fortran et al., 1973; 
c Kalantzi, et al., 2006; 
d Efentakis & Dressman, 1998.  
**PGF was taken from a freely fed animal; volume was the only variable for the fed versus fasted test 
system. 
+FaSSGF is made to pH 1.6 to represent the fasted state 
To  date,  various  media  have  been  developed  to  simulate  the  fasted  gastric  content 
(British Pharmacopoeia, 2013, FDA, 2000, United States Pharmacopoeia, 2008). Often, 
these media try to mimic the salt concentration of the gastric fluid through the addition 
of 0.5% w/v of sodium chloride to HCl (Charteris et al. 1998). Surface tension and bile 
content is also simulated through the addition of bile salt, pepsin and/or surfactants to 
HCl (Vertzoni et al., 2005, Aburub et al., 2008). These characteristics and compositions 
Simulated 
fluid 
pH  Buffer capacity (mmol.L
-
1.∆pH
-1) 
Osmolality 
(mOsm.Kg
-1) 
Surface tension 
(mN.m
-1) 
PGF**  3.38 ± 
0.03 
12.85 ± 0.68  255.33 ± 0.58  46.08 ± 2.55 
SGF* 1.2  1.21 ± 
0.02 
43.33 ± 0.71  255.67 ± 0.58  74.18 ± 3.56 
FaSSGF 1.6
+  1.60 ± 
0.01 
41.70 ± 0.40  138.00 ± 1.00  52.04 ± 2.20 
SGF* 3.4  3.36 ± 
0.02 
1.70 ± 0.42  82.25 ± 1.89  73.18 ± 0.25 
FaSSGF 3.4  3.37 ± 
0.04 
1.23 ± 0.24  83.50 ± 1.92  65.38 ± 1.86 
Human gastric 
fluid 
1-
 2.5
 a  
up to 5 
(fed)
b 
7-18 (fasted)
c 
14-28 (fed)
c 
559-217
c  30-31
c 
35-45
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have been shown to be very important, and have a major influence on substrates (eg. 
drugs) or processes in the stomach (Nicolaides et al., 1999, Jantratid et al., 2008, Mudie 
et al., 2010). For example, the pH and buffer capacity affects the dissolution of ionizable 
drugs.  Pepsin  is  also  known  to  interfere  with  the  stability  of  proteins  and  peptides 
(Mudie et al., 2010). Lipase activity affects drug release from lipid-based dosage forms 
(Dressman et al., 1998) whilst bile salt concentration decrease the surface tension and 
enhance wetting of drugs as well as increase the solubility of some drugs (Dahan and 
Amidon,  2008).  These  compositions  and  characterisitics  could  also  have  a  major 
influence on the survival capacity of probiotics. For instance Zhu et al., (2006) have 
shown that the rate of killing of E. coli and Helicobacter pylori at pH 2.5, 3 and 3.5 in 
solutions  was  increased  significantly  upon  the  addition  of  pepsin  (effect  of  pepsin-
mediated proteolysis). 
SGF* (Simulated Gastric Fluid, USP), which has traditionally been used to simulate the 
gastric conditions showed measured differences to the human gastric fluid in this study. 
The FaSSGF fluid, representing Fasted-State Simulated Gastric Fluid, was proposed by 
Vertzoni et al., in 2005 to simulate the human basal gastric juice with a glass of water, 
which is often taken with a dosage form. This fluid has constituted a good simulation of 
fasting  gastric  contents  and  has  gained  decent  acceptance  for  use  for  in  vitro 
dissolution/solubility  studies  (Vertzoni  et  al.,  2005,  Vertzoni  et  al.,  2007).  Our 
evaluation of this fluid however showed that it differed at different pH from reported 
characteristics of the human gastric fluid characterized in this study in terms of buffer 
capacity, osmolality and surface tension.  
The results obtained concurs with a recent study by Pedersen et al., (2013) who also 
evaluated  and  highlighted  differences  between  FaSSGF,  HCl  (pH  1.2)  and  their 
measured characteristics of aspirates of human gastric fluid obtained from volunteers 
between 20-79 years during gastroscopic examinations (Pedersen et al., 2013). Apart 
from the differences in the pH, buffer capacity, osmolality and surface tension between 
the simulated fluids and the human gastric fluid they reported, which is in agreement 
with the results obtained in the present study, these authors also demonstrated lower 
viscosity  of  FaSSGF  and  HCl  compared  to  the  human  gastric  aspirates  which  they 
attributed could be due to the presence of mucus components present in the aspirate but 
absent in the simulated fluids.    212 
As mentioned previously, these non-acidic characteristics or constituents of the human 
gastric fluid may majorly influence the survival of probiotics and may have been the 
deficiency of previous studies that have assessed survival of probiotics (Chandramouli et 
al., 2004, Ding and Shah, 2009, Mokarram et al., 2009, Sahadeva et al., 2011, Jensen et 
al., 2012).  
5.4.4 In vitro gastric tolerance of commercial probiotic products and strain in 
porcine and simulated gastric fluid, fed and fasted states; plate technique 
The gastric tolerance of the commercial products in porcine gastric fluid simulating the 
fed state is presented in Figure 5.2. Four of the lyophilised products (Align
®, Biobalance 
support, Bio-kult
® and Probio 7
®) and one liquid product (Yakult
®) exhibited complete 
loss of viability within 90 min of simulated gastric transit. Symprove
TM, VSL#3
® and 
hydrated Bio-kult
® showed retained viability for the duration tested. Actimel
® showed 
retained viability for 90 min but significant reduction (P<0.05) in viability after 90 min. 
Symprove
TM exhibited the best tolerance relative to the other products in the fed state 
with no significant reductions throughout the test duration.  
The  fasted  state  gastric  tolerances  of  the  commercial  products  in  the  porcine  and 
simulated  gastric  fluids  at  similar  pH  are  also  compared  in  Figure  5.3a  to  5.3c.  In 
general, the viabilities of the products within the first 30 min were improved relative to 
the fed state. For all test systems at this pH (3.4), the results also highlighted important 
differences  between  the  more  bio-relevant  fluid,  PGF  (Figure  5.3a),  and  the  other 
simulated fluids: SGF* (Figure 5.3b) and FaSSGF (Figure 5.3c), particularly evident for 
some products.    213 
 
Figure 5.2. Gastric tolerance of commercial probiotic products in porcine gastric fluid mimicking the 
fed state. Viable count (log CFU/mL) of each product at 5, 10, 20, 30, 90, 120 and 180 min were 
compared with log CFU/mL in the product at 0 min. The results are expressed as mean ± SD (n=3). 
*means hydrated  
 
Figure 5.3a. Gastric tolerance of commercial probiotic products in PGF pH 3.4 mimicking the fasted 
state. Viable count (log CFU/mL) of each product at 5, 10, 20, 30, and 120 min were compared with 
log CFU/mL in the product at 0 min. The results are expressed as mean ± SD (n=3). *means hydrated. 
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Figure 5.3b. Gastric tolerance of commercial probiotic products in SGF* pH 3.4 mimicking the fasted 
state. Viable count (log CFU/mL) of each product at 5, 10, 20, 30, and 120 min were compared with 
log CFU/mL in the product at 0 min. The results are expressed as mean ± SD (n=3) *means hydrated.  
 
Figure 5.3c. Gastric tolerance of commercial probiotic products in FaSSGF pH 3.4 mimicking the 
fasted state. Viable count (log CFU/mL) of each product at 5, 10, 20, 30, and 120 min were compared 
with log CFU/mL in the product at 0 min. The results are expressed as mean ± SD (n=3). *means 
hydrated.  
0 5 10 15 20 25 30 120
0
2
4
6
8
10
12
V
i
a
b
l
e
 
c
e
l
l
s
 
(
l
o
g
 
c
f
u
/
m
l
)
Time (min)
 Actimel
 Align
 Align*
 BS
 BS*
 Bio-kult 
 Bio-kult*
 Probio7
 Probio7*
 Symprove
 VSL3
 VSL3*
 Yakult
0 5 10 15 20 25 30 120
0
2
4
6
8
10
12
V
i
a
b
l
e
 
c
e
l
l
s
 
(
l
o
g
 
c
f
u
/
m
l
)
Time (min)
 Actimel
 Align
 Align*
 BS
 BS*
 Bio-kult 
 Bio-kult*
 Probio7
 Probio7*
 Symprove
 VSL3
 VSL3*
 Yakult  215 
In PGF, Align
®, and unhydrated Probio 7
® showed complete loss of viability within 10 
min whilst unhydrated Biokult
®, Biobalance support and hydrated Probio 7
® showed 
loss of viability within 2 h. The other products retained viability for the duration of the 
assay  in  PGF  (Figure  5.3a).  In  SGF*  and  FaSSGF  adjusted  to  pH  3.4,  the  product 
performances were significantly improved with only Probio 7
® showing complete loss of 
viability within 2 h of product tolerance (Figure 5.3b and 5.3c).  
The results from gastric tolerance testing at the lower pH for SGF* (1.2) and FaSSGF 
(1.6) are also shown in Figure 5.4a and 5.4b. The artificial fluids at this pH, especially 
FaSSGF (1.6) were more in congruent with PGF than at pH 3.4.  
The fasted state gastric tolerance of the two commercial strains, L. acidophilus, LA-5
® 
and B. lactis, BB-12
® are shown in Figure 5.5. Both strains had poor resistance in PGF 
but they showed different degrees of tolerance. The lactobacilli strain showed complete 
loss of viability within 10 min of exposure but the bifidobacteria strain showed gradual 
exponential loss of viability in PGF.  
 
Figure 5.4a. Gastric tolerance of commercial probiotic products in SGF* 1.2. Viable count (log 
CFU/mL) of each product at 5, 10, 20, 30, and 120 min were compared with log CFU/mL in the 
product at 0 min. The results are expressed as mean ± SD (n=3).  
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Figure 5.4b. Gastric tolerance of commercial probiotic products in FaSSGF pH 1.6. Viable count (log 
CFU/mL) of each product at 5, 10, 20, 30, and 120 min were compared with log CFU/mL in the 
product at 0 min. The results are expressed as mean ± SD (n=3).  
 
Figure 5.5. Gastric tolerance of free cells of La-5
® and BB-12
® in simulated gastric fluid, PGF 
mimicking the fasted state. Viable count (log CFU/mL) of each strain at 5, 10, 20, 30, 90 and 120 min 
was compared with log CFU/mL at 0 min. The results are expressed as mean ± SD (n=2) 
0 5 10 15 20 25 30 120
0
2
4
6
8
10
12
V
i
a
b
l
e
 
c
e
l
l
s
 
(
l
o
g
 
c
f
u
/
m
l
)
Time (min)
 Actimel
 Align
 BS
 Bio-kult 
 Probio7 
 Symprove
 VSL3
 Yakult
0 10 20 30 40 50 60 70 80 90 100 110 120 130
0
2
4
6
8
V
i
a
b
l
e
 
c
e
l
l
s
 
(
l
o
g
 
c
f
u
/
m
l
)
Time (min)
 L. acidophilus
 B. lactis  217 
The  findings  from  this  work  suggest  a  number  of  things.  Firstly  that  the  probiotics 
evaluated survived better in the fasted state than the fed. As pointed out earlier, in the 
fed state, large volumes of gastric juice is secreted to digest the food ingested. Volumes 
as large as 800 mL have been reported to be secreted in response to 400 mL of ingested 
solid meal (Malagelada et al., 1976, Goetze et al., 2009). In the fasted state, however, 
volumes of gastric juice are much lower. At the same pH for the fed and fasted, the 
results show that the products reacted differently. For the liquid products, the volumes 
per dose were equivalent to the volume of gastric fluid in the fasted state or more. This 
meant some of these products may have diluted the gastric fluid and produced a final pH 
that was more tolerable to the probiotics contained in the product. For example, a dose of 
Actimel
®  was  100  mL;  more  than  60%  the  volume  of  simulated  gastric  fluid.  This 
volume was quite adequate to dilute the simulated fluid in the fasted state during the 
study compared to the other products or even the other liquid products given that the pH 
of  a  freshly  opened  Actimel
®  (4.26  ±  0.01)  was  significantly  higher  (P<0.05)  than 
Symprove
TM (3.83 ± 0.01) or Yakult
® (3.67 ± 0.01). For instance, upon addition of 
Actimel
® to SGF* pH 1.2, the pH of the final mixture was 3.30 compared to 1.68 for a 
final SGF*-Yakult
® mixture. This buffering effect however might not occur in in vivo 
situation, as the stomach may react to this and may reduce the pH further so negating 
any benefit. At higher volume of gastric fluid however, the effect of product volume was 
not  as  pronounced  even  though  the  liquid  products  still  fared  better.  This  increased 
volume also affected VSL#3
® whose strains may also have depended on other properties 
instead of their intrinsic resistance to the gastric fluid. This product, relative to the others 
except Actimel
®, contained higher initial load of organisms per dose of product with a 
dose weight more than ten times of any of the other lyophilised products. In a tolerance 
assay simulating the fasted state in PGF, the viability was equivalent or better than the 
liquid products, which could have been due to the buffering effects of its excipients in 
the  small  volume  of  gastric  fluid  (unlike  other  lyophilised  products,  VSL#3
® 
significantly altered the pH of gastric fluid in the fasted state) however in the fed state, 
when exposed to greater volume of gastric fluid, the overall loss was greater.  
The residence time is also a major important factor for viability in both the fasted and 
fed state. The residence time of ingested products is much longer in the fed state than in 
the fasted state. In the fed state, normal gastric transit times are 90-180 min even though 
they could also range between 70-130 min (Dressman, 1986) and are usually influenced 
by contractions, pyloric resistance and feedback mechanisms in the duodenum resulting   218 
in slower and linear emptying pattern (Mudie et al., 2010). In the fasted state however, 
gastric emptying is known to be mostly controlled by the migrating myoelectric complex 
(MMC), and therefore is known to be much shorter (mean half- time for emptying water 
is 15.8 min) and exponential but is also affected by the nature, size, or amount of liquid 
or  solid  ingested  (Mudie  et  al.,  2010).  For  example,  Dressman,  (1986)  was  able  to 
demonstrate that a 25% glucose solution influenced the MMC and consequently emptied 
in 75 min when ingested. This implies that in in vivo situation, the stomach may treat 
some of these products as food and may retain them for longer even in the fasted state. 
In that vein, consumers might still benefit from the liquid products as these showed 
sustained  tolerance  for  periods  of  120  min  in  the  fasted  state  unlike  the  lyophilised 
products  in  the  bio-relevant  fluid.  Even  among  the  liquid  products,  the  water-based 
probiotic (Symprove
TM) might fare better in vivo as it will be expected to transit faster 
due to the less amount of food ingredient it contains. 
The findings from this work secondly suggest that gastric survival of probiotics majorly 
depends  on  the  way  the  products  are  formulated.  The  investigation  looked  at 
representative  samples  of  the  different  formulations  available  to  consumers,  namely 
solid lyophilised preparations both capsules and powder and liquid formulations, both 
dairy and non-dairy based. Free-living unformulated commercial probiotic strains were 
also investigated. Even though it is a prerequisite that commercial probiotic organisms 
should  be  able  to  survive  in  simulated  gastric  juices  (FAO/WHO,  2001),  some 
commercial strains, as demonstrated by the results  and other studies (Collado et al., 
2005, Jensen et al., 2012) rarely possess this property. For instance, Jensen et al., (2012) 
investigating the gastric tolerance of eighteen commercial and potential probiotic lactic 
acid bacteria to simulated gastric fluid at pH 3, also demonstrated significant reductions 
within 90 min of gastric tolerance for half of the strains with four strains showing less 
than 1.2 log-CFU/mL of viable cells. 
From  results  obtained  in  this  study  and  previous  studies,  it  seems  that  survival  of 
probiotics in gastric fluids and survival during transit may consequently depend on the 
way  they  are  formulated.  In  other  words,  gastrointestinal  challenges  can  also  be 
overcome if a non-intrinsically gastric resistant probiotic is adequately provided with 
protection systems for the low pH. Symprove
TM for instance, may depend on the barley 
(Table 5.1), a prebiotic, not digested by pancreatic enzymes for enteric protection of the 
organisms against the harsh gastric environment, which may also provide the probiotic   219 
organisms with a source of nutrient. A study by Charalampopoulos et al., (2003) has 
revealed protective effects of barley on viability of L. plantarum, L. acidophilus and L. 
reuteri  under  acidic  conditions.  About  3-log  and  1.5-log  cycles  of  improvement  of 
viability  was  noted  for  L.  plantarum  and  L.  acidophilus  (which  are also component 
species  of  Symprove
TM)  in  the  presence  of  barley  (Charalampopoulos  et  al.,  2003). 
Actimel
® and Yakult
® on the other hand are fermented milk products which may depend 
on the milk proteins for protection and nourishment (Livney, 2010). In addition, the fat 
content  of  these  products  may  protect  the  organisms  in  passage  through  the 
gastrointestinal tract (Ranadheera et al., 2012); a small study has highlighted this by 
showing significant reductions of L. casei DN-114 001 within Actimel
® Fat Free (0.428 
±  0.059-log  CFU  mL
-1),  after  5  h  of  simulated  gastrointestinal  transit  (P<0.05), 
compared  with  insignificant  reductions  for  Actimel
®  Original  (Wills,  2012). 
Furthermore, as already pointed out, the pH of these liquid products were acidic, likely 
due to the metabolic activities of the probiotic strains themselves or other starter cultures 
hence, they may have developed the necessary factors for acid stress (Cotter and Hill, 
2003) and may have therefore coped better than the lyophilised products when placed 
into systems akin to their natural milieu. The results suggest that even among the liquid 
products,  there  may  have  been  less  acid  shock  for  products  with  lower  product  pH 
especially within the first few minutes in simulated gastric environment.  
The lyophilised products on the other hand may not have had robust systems for enteric 
protection  besides  their  possible  lack  of  intrinsic  or  relevant  acid  stress  adaptation 
mechanism  or  factors.  Besides,  their  dispersion  in  the  simulated  fluids  did  not 
significantly alter pH except VSL#3
®. However it was also observed that although most 
of these lyophilised products demonstrated poor tolerance in the porcine and simulated 
gastric  fluids  relative  to  the  liquid  products,  when  rehydrated  prior  tolerance,  these 
products  generally  showed  appreciable  viability.  This  may  be  due  to  the  improved 
integrity or repair (through hydration) of the cells (which were possibly damaged during 
lyophilisation), which made the cells perhaps more tolerant to the harsh treatment in the 
simulated gastric fluid.  
Generally, consumers often prefer solid-dose products as they are less bulky, convenient 
and require less specific storage conditions (Aulton, 2013). When compared to solid 
formulations,  liquid  dosage  forms  are  often  quite  unstable  once  opened  (Bansal and 
Garg, 2008, Aulton, 2013). Solid dosage forms of probiotic may therefore present an   220 
advantage of stability and long shelf life; the lyophilised products evaluated however did 
not  particularly  exhibit  this.  Means  of  ensuring  their  stability  and  gastrointestinal 
survival need to be explored.  
Thirdly, the findings suggest that the PGF provided a harsher environment than the other 
simulated  systems:  SGF*  and  FaSSGF  at  similar  pH.  Even  when  these  simulated 
systems were used at pH more consistent with the human stomach, results with some of 
the  products  were  sometimes  not  as  poor  as  in  PGF.  PGF  may  have  represented  a 
harsher environment as a result of the enzymatic and digestive substance composition of 
the fluid; these are important variables of the human gastric fluid that are often ignored 
in viability testing. The measurements of surface tension, osmolality and buffer capacity 
of the gastric fluids also corroborate the relevance of using a more bio-relevant fluid for 
gastric  tolerance  testing.  The  results  from  the  PGF  system  may  therefore  be  more 
representative of how the products evaluated will perform in vivo and are also important 
in terms of relevant results for decisions about which product consumers should use and 
how to use them. 
5.4.5 Microcalorimetric gastric tolerance assay mimicking the fasted state 
The  power-time  curves  of  Actimel
®,
  Symprove
TM,  VSL#3
®  and  Yakult
®  in  PGF 
simulating the ratio of fluid to product in the fasted stomach are shown in Figure 5.6. 
The power-time curves show the abrupt decay of the products in PGF after very brief 
period of growth. Amongst the products, VSL#3
® was associated with the most heat 
output during its metabolism in the simulated fluid.    221 
 
Figure 5.6. Power-time curves of Actimel
®, Symprove
TM, VSL#3
® and Yakult
® in PGF mimicking the 
ratio of fluid to product in the fasted stomach  
The  cumulative  heat  plots  of  the  different  products  in  MRSc  after  30  min  gastric 
tolerances in the different simulated fluids mimicking the fasted state are also shown in 
Figures 5.7a-5.7c and 5.8a-5.8b. The results show very good correlation with the plate 
count. The liquid products showed better tolerance to the simulated gastric fluids as they 
showed less lag period  compared to the lyophilised products. The differences in the 
simulated fluids were also highlighted with the microcalorimeter; showing again that the 
PGF was harsher and feasibly, a more realistic simulant of the human gastric fluid. The 
effect of hydration of the products was also demonstrated as some of the lyophilised 
products  (especially  Biokult
®  and  Biobalance  support)  showed  better  performances 
when hydrated prior in SGF*(3.4) and FaSSGF (3.4), which were comparable to the 
liquid  products  (Figure  5.7b  and  5.7c)  even  though  the  inocula  of  the  hydrated 
lyophilised  products  were  more  dilute  relative  to  their  unhydrated  counterparts. 
However,  the  measured  characteristics  of  the  simulated  fluids  suggested  SGF*  and 
FaSSGF at pH 3.4 do not adequately mimic the human gastric fluid, hence survival of 
the cells in these fluids were not biologically relevant for predicting in vivo tolerance.  
The simulated fluids at lower pH were also in agreement with PGF for some products 
than  at their  equivalent pH.  The  better  survival  of  the  products  in  SGF*  at  pH  3.4 
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relative to 1.2 for both the microcalorimetric assay and the plate method is in accordance 
with findings from  Sahadeva et al., (2011) who also reported tremendous reductions in 
viability at pH 1.5 for some probiotics but unchanged viability when the products were 
assessed in the simulated fluid at pH 3 relative to the viability at 0 h.  
 
Figure 5.7a. Heat curves of commercial products inoculated into MRSc broth after 30 min of gastric 
tolerance in PGF pH 3.4 representing fasted state tolerance 
0 10 20 30 40 50 60 70 80 90
0
10
20
30
40
C
u
m
u
l
a
t
i
v
e
 
H
e
a
t
 
(
J
)
Time (h)
 Actimel
 Align
 Align *
 BS
 BS *
 Bio-kult
 Biokult *
 Probio7
 Probio 7 *
 Symprove
 VSL3
 VSL3 *
 Yakult  223 
 
Figure 5.7b. Heat curves of commercial products inoculated into MRSc broth after 30 min of gastric 
tolerance in SGF* pH 3.4 representing fasted state tolerance 
 
Figure 5.7c. Heat curves of commercial products inoculated into MRSc broth after 30 min of gastric 
tolerance in FaSSGF pH 3.4 representing fasted state tolerance 
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Figure 5.8a. Heat curves of commercial products inoculated into MRSc broth after 30 min of gastric 
tolerance in SGF* pH 1.2 representing fasted state tolerance 
 
Figure 5.8b. Heat curves of commercial products inoculated into MRSc broth after 30 min of gastric 
tolerance in FaSSGF 1.6 representing fasted state tolerance 
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The results from the microcalorimeter are important in that they simulate the survival of 
the  probiotics  in  the  gastric  fluid  and  possible  growth  thereafter.  Hence,  for  solid 
products that may have delivery systems to prevent acid release, the microcalorimetric 
data could have provided evidence of release in non-acidic environment.  Also, even 
though the microcalorimetric data were collected over periods of 90 h, (which was for 
the sake of comparative analysis with the plate technique) data could have been gathered 
over a much shorter duration and inoculations could have also been made to higher 
concentrations. For some of the multistrain products, the microcalorimeter additionally 
was able to differentiate different cells that had survived hence in some instances, some 
multistrain products assumed the same power-time curve (differentiated data not shown) 
inferring  that  some  species  in  some  of  these  products  were  possibly  killed  in  the 
simulated fluids and the species remaining were similar to the species contained in other 
products. 
When  the  product-simulated  gastric  fluid  mixtures  were  directly  placed  in  the 
microcalorimeter and studied, the power-time curves generated showed decay unlike the 
classic growth curves possibly due to the harsh environment of the fluid. The curves 
suggested  mere  survival  of  the  cells  in  the  harsh  environment  of  the  gastric  fluid. 
However because the instrument was measuring heat output derived from respiring cells 
in the product-gastric fluid mixture, it is likely the simulated ratio of gastric fluid to 
product skewed the results to favour the highest volume of gastric fluid (due to extra 
nutrient available to the few cells) or the lowest volume of gastric fluid (due to the extra 
volume of nutrient available in the product itself). The ampoule microcalorimeter was 
therefore not useful for such study design. 
Overall, this gastric tolerance study is the first to provide comparative data on actual 
products in situations that most closely mimic the in vivo condition. Other studies only 
test tolerance of individual strains of bacteria rather than products and often look at these 
strains  or  product  in  isolation  (Sun  and  Griffiths,  2000,  Huang  and  Adams,  2004, 
Corcoran et al., 2004, Chandramouli et al., 2004, Iyer and Kailasapathy, 2005, Sabikhi et 
al., 2008, Ding and Shah, 2009, Mokarram et al., 2009). The few studies that have 
compared products (Lin et al., 2006, Sahadeva et al., 2011) like most other studies used 
test systems that may also have little relevance for the in vivo situation.   226 
5.4.6 Pharmaceutical consideration: Freeze-drying and storage of LA-5
® 
The survival of LA-5
® at each stage of the freeze-drying process is shown in Figure 5.9. 
The viability loss was greatest during the drying process than the controlled freezing 
with  significant  loss  (P<0.05)  occurring  when  cells  were  freeze  dried  in  15%  v/v 
glycerol.  
 
Figure 5.9. Viability of probiotic strain, LA-5
® after freezing and freezing-drying using different 
protectants: 10% w/v skim, 10% w/v trehalose and 15% v/v glycerol. n=3. There was significant loss 
of the cells when freeze-dried 
The viability of the cells freeze-dried in the different protectants during storage at room 
temperature  and  at  4
oC  is  also  shown  in  Figure  5.10a  and  5.10b.  Differences  were 
observed among the protectants and the two storage conditions. For 15% v/v glycerol, 
total loss of viability was observed within 3 days after freeze-drying. During storage at 
4
oC,  viability  was  generally  maintained  for  1  month  with  no  significant  reduction 
(P>0.05) in viability observed for cells freeze dried in skim milk or trehalose.  
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Figure 5.10a. Viability of freeze-dried L. acidophilus LA-5
® using the protective agents during storage 
at 4
oC for 6 months. Data are expressed as mean ± SD (n=3). d = days, m = months 
 
Figure 5.10b. Viability of freeze-dried L. acidophilus LA-5
® using the protective agents during storage 
in room temperature for 6 months. Data are expressed as mean ± SD (n=3). d = days, m = months 
For  the  room  temperature  storage,  the  viability  of  the  cells  in  both  skim  milk  and 
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trehalose decreased over time but the losses that occurred were not significantly different 
(P>0.05) from day 0 up to day 14 day for each protectant. Trehalose performed better in 
protecting the cells at this storage condition.  
Even  though  freeze-drying  is  the  favourite  method  of  producing  bacterial  cultures 
(Morgan et al., 2006), there are losses in cell viability during the process. One of the 
main causes of the loss of viability is the need of freezing the samples before dessication 
(Morgan et al., 2006). The freezing process and especially the cooling rate could damage 
the cells as discussed in Chapter 2. Our experience with freezing bacteria indicated that 
freezing  of  bacteria  over  liquid  nitrogen  vapour  produced  better  recoveries  than 
uncontrolled freezing in liquid nitrogen or in the freezer where larger ice crystals may 
form which can damage the cell membrane leading to death of the culture. In the study, 
when LA-5
® was frozen over liquid nitrogen vapour, the results showed insignificant 
losses of cell viability during the freezing process. The results showed that the major 
losses occurred during drying. As previously described, freeze-drying process involves 
two key drying stages: primary and secondary drying (Tang and Pikal, 2004, Morgan et 
al., 2006). During the primary drying, samples are held at low temperatures and the 
water in the frozen sample sublimed by the reduction of the chamber pressure below the 
ice pressure within the sample (Tang and Pikal, 2004). During the secondary drying, the 
bound water within a sample is sublimed by slowly increasing the chamber temperature. 
The removal of water can cause loss of the structure and function of these cells and this 
can be prevented when protective agents are added (Costa et al., 2000, Abadias et al., 
2001a, Carvalho et al., 2004a, Morgan et al., 2006). These protectants either increase the 
viscosity inside or outside the cells to reduce the molecular mobility to a minimum value 
(Morgan  et  al.,  2006)  or  form  hydrogen  bonds,  which  help  to  maintain  the  tertiary 
protein structure (Leslie et al., 1995). 
The  results  show  that  even  though  15%  v/v  glycerol  was a  good  cryoprotectant  for 
freezing of bacteria, it was not a good protectant for freeze-drying. During drying, the 
aqueous medium in which glycerol was dissolved may have been initially evaporated, 
leaving a concentrated glycerol solution which might have caused an osmotic shock in 
the cells. Between the other two protectants, trehalose performed better in protecting the 
cells  when  they  were  stored  at  room  temperature.  This  is  not  surprising  because 
trehalose has a high glass transition temperature, Tg, of 110
oC (Hernandez Garcia, 2011) 
in the anhydrous form hence will enable an amorphous trehalose obtained as a result of   229 
freeze-drying  to  remain stable  at  elevated  temperatures,  for  example,  at  25
oC  (room 
temperature). Apart from this, trehalose is also capable of forming crystalline hydrates 
and it has been suggested that formation of some crystalline hydrate results in keeping 
the remaining amorphous sugar dry, thereby maintaining a high Tg and stability of the 
freeze  dried matrix  (Crowe  et al.,  1998).  Skim milk,  on  the other  hand has  a  glass 
transition of 92
oC (Roos, 2002) and is also known to be stable above its glass transition 
with acknoweledged extra positive factors such as providing protective coating for the 
cells  through  its  proteins  and  also  creating  porous  structure  in  freeze-dried  samples 
hence  making  rehydration  easier  (Carvalho  et  al.,  2004b).  However,  presence  of 
moisture has been found to significantly alter its glass transition. For example a moisture 
content of 4.52 g/100 g of dry powder has been shown to lower the glass transition of 
skim milk to 46.7
oC (Ozmen and Langrish, 2002). Trehalose may therefore be better as a 
protectant for storage in humid environments. Both protectants were nevertheless better 
when stored at 4
oC than at room temperature even though there were still significant 
losses in viability over the duration of storage at 4
oC, which could be attributed to factors 
such  as  the  water  activity  in  the  freeze-dried  bacteria  and  also  the  absence  of 
antioxidants. These factors are evinced in Kurtmann et al., (2009) study in which they 
showed the combined effect of water activity, oxygen level and the concentration of 
ascorbate on the 12 weeks storage stability of LA-5
® freeze–dried using maltodextrin or 
sucrose as protectants with or without sodium ascorbate. These authors demonstrated 
that increasing water activities decreased the survival of LA-5
® during storage whilst 
reduced  oxygen  level  significantly  improved  the  storage  stability  of  the  cells.  The 
authors also showed that the detrimental effect of oxygen was eliminated by including 
ascorbate in the freeze-drying medium (Kurtmann et al., 2009). 
Almost all of the lyophilised commercial products stated the product did not require 
refrigeration. Most were instructed to be stored in cool and dry places. Only one of 
products stated it should be stored in the fridge. The results clearly demonstrate the 
advantage of storing these products in the fridge. Other studies (Abadias et al., 2001b, 
Costa et al., 2002, Savini et al., 2010) have also shown the advantage of storing freeze-
dried probiotics or bacteria at 4
oC than at room temperature storage. For instance, Costa 
et al., (2002) reported a 3-log reduction of viability of freeze-dried Pantoea agglomerans 
after storage in room temperature for 90 days compared to 0.5-log reductions at 4
oC.    230 
5.5 Chapter summary 
The use of probiotics has gained worldwide recognition and has a huge market. Proper 
product quality control needs to be conducted to ensure that the content claims of labels 
are actually present at the time the product reaches a consumer. There also needs to be 
stringent assays nonetheless simulating the human gut to determine if products could 
potentially survive and colonize the intestine for therapeutic benefit. The results from 
this study have shown that the probiotic products evaluated contained at least one of the 
labelled species, but generally, some did not meet their label claim, which agrees with 
previous studies (Temmerman et al., 2001, Weese, 2002, Elliot and Teversham, 2004, 
Drago et al., 2004, Drago et al., 2010, Aureli et al., 2010, Weese and Martin, 2011).  
For the gastric tolerance assays, the study differentiated between the fed and fasted state. 
It was assumed that in the fasted state the fluid volume of the stomach was 60 mL and in 
the fed state, 1500 mL. The ratios of simulated gastric fluid to product volume used to 
complete  the  tolerance  assays  were  determined  according  to  the  stated  dose  on  the 
product. The assays were conducted for 2 h to mimic the transit through the stomach in 
the fasted state and in excess to mimic the longer transit time in the fed state. The results 
suggest that the probiotic products survived better in the fasted state hence it would be 
appropriate if they are  taken on an empty  stomach as this will ensure that they are 
exposed to less fluid volume and transit faster to the intestine where the cells could be 
more stable. The results also highlighted important differences between the bio-relevant 
porcine gastric fluid and the other simulated gastric fluids showing that the other fluids 
at lower pH were in agreement with PGF at pH 3.4 than at equivalent pH with PGF. 
Although food-based probiotics account for majority of commercial products, probiotics 
are also frequently sold as supplements- dried form; freeze-dried powders packed into 
capsules  or  sachet  (Saxelin,  2008)  as this  offers  a  convenient  means  of  storage  and 
transport for both the manufacturer and the consumer and also reduces the overall cost to 
both.  Findings  from  this  study  were  that  most  of  the  lyophilised  probiotics  did  not 
survive well in the products. A small study investigated their survival at different storage 
conditions by  freeze-drying  LA-5
® and storing at room temperature and at  4
oC. The 
different stages of the freeze-drying and storage showed that significant losses occurred 
during the drying stage than the controlled freezing. Storage of the freeze-dried cells at 
4
oC was better than at room temperature.    231 
The  limitations  of  these  experiments  were  that  for  the  identification  of  the  species 
contained  in  the  commercial  products,  morphological  identification  of  the  colonies, 
Gram stain appearance and biochemical tests were used to identity the strains without 
any  genetic  method.  Misidentification  of  the  species  sometimes  occurred  and 
bifidobacteria could also be only identified at the genus level. The results may have also 
been influenced by the culturing condition used. Still, given this limitation, the results 
gave useful information about the quality of the products.  
The tolerance assays did not simulate the processes of digestion, gastric secretion and 
transit  however  the  test  systems  that  were  used  mimicked  the  gastric  composition, 
volume and emptying rate. Also, while PGF appeared to be the most bio-relevant fluid 
tested, the pH of this fluid was higher than that generally seen in the fasted human 
stomach since this was taken from a freely fed animal. In the PGF test systems, volume 
was  therefore  the  only  variable  factor  between  the  fed  and  fasted  state.  Also,  other 
crucial  factors  that  could  affect  viability  in  the  gut  such  as  intestinal  transit  or  the 
adhesive properties of the bacteria in the large intestine, which are important for survival 
and functionality of probiotics apart from gastric tolerance, were not tested.  
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6 Prebiotic effect 
6.1 Introduction 
The  in  vitro  assessment  of  efficacy  of  prebiotics  usually  involves  elaborate 
microbiological  techniques  or  a  combination  of  microbiological  techniques  and 
molecular methods (Sghir et al., 1998, Venema et al., 2003, Probert et al., 2004, Van de 
Wiele  et  al.,  2004,  Van  den  Abbeele  et  al.,  2013).  In  this  small  study,  the 
microcalorimeter was applied to investigate the effect of a potential prebiotic.  
Prebiotics are non-digestible food ingredients that stimulate the growth of beneficial 
microorganisms  of  the  microbiota.  Its  concept  was  first  introduced  by  Gibson  and 
Roberfroid,  (1995)  who  defined  them  as  “non-digestible  food  ingredients  that 
beneficially affects the host by selectively stimulating the growth and or activity of one 
or a limited number of bacteria in the colon and thus, improves health” (Gibson and 
Roberfroid, 1995). In 2004, the definition of a prebiotic was amended as “a selectively 
fermented  ingredient  that  allows  specific  changes,  both  in  the  composition  and/or 
activity in the gastrointestinal microflora that confers benefits upon host wellbeing and 
health”  (Gibson  et  al.,  2004).  At  the  6
th  Meeting  of  the  ISAPP  (London,  Ontario), 
prebiotics  were  redefined  as  “selectively  fermented  dietary  ingredients  that  result  in 
specific changes, in the composition and/or activity of the gastrointestinal microbiota, 
thus conferring benefit(s) upon host health”. The concept of prebiotics was based on the 
fact that establishment of exogenous bacteria (probiotics) could be limited with their 
manipulative  effect  on  the  endogenous  microbiota  only  short-lived  (Gibson  and 
Roberfroid, 1995). Hence prebiotics were introduced to selectively stimulate the growth 
and or activity of bacterial species already resident in the colon by providing a specific 
substrate  for  their  growth  and  metabolism  (Gibson  and  Roberfroid,  1995).  The 
microbiota  derives  substrates  for  growth  from  the  diet,  such  as  substrates  that  have 
escaped digestion in the upper gastrointestinal tract  and endogenous sources such as 
mucins (Rowland et al., 1985, Cummings et al., 1989). Most of the bacteria found in the 
colon (the most heavily colonized part of the gut) are strict anaerobes and these achieve 
nutrition basically by  fermentation. The major substrate of fermentation which these 
bacteria  use  for  growth  are  dietary  non-digestible  carbohydrates  which  comprise 
resistant starches, resistant dextrins, dietary fibres, non-digestible oligosaccharides (eg. 
raffinose,  stachyose,  inulin-type  fructans,  galactans  and  mannnans),  non-starch   233 
polysaccharides  (NSP  eg.  pectins,  arabinogalactans,  gum  Arabic,  guar  gum  and 
hemicellulose), undigested disaccharides (eg. lactose) and sugar alcohols (eg. lactitol and 
isomalt)  (Bingham et al.,  1990,  Cummings  and Macfarlane,  1991,  Roberfroid  et  al., 
2010). These are part of the diet, which are not digested in the upper part of the digestive 
system. It must be noted that while the microbiota is distributed throughout the gut, 
transit of food through the stomach and small intestine is usually rapid for the microbiota 
to exert a significant effect until the available food substrates get to the colon, where 
movement is markedly slow, hence the colonic microbiota have ample time to degrade 
(Flint et al., 2008, Roberfroid et al., 2010). It is known that although an extensive variety 
of colonic microbiota ferment resistant starch, NSP, most dietary fibres and some non-
digestible oligosaccharides, their respective degree of degradation may vary  (Englyst 
and Macfarlane, 1986). Some non-digestible oligosaccharides  (for example raffinose, 
inulin-type fructans and galactans) arriving at the colon are known to be rapidly and 
selectively fermented by only smaller number of bacteria for example, bifidobacteria and 
lactobacilli (Roberfroid et al., 2010). 
The main bacteria of the colonic microbiota that are saccharolytic and contribute to most 
of  the  fermentative  activity  in  the  gut  are  members  of  the  genera  Bacteroides, 
Bifidobacterium,  Ruminococcus,  Eubacterium,  Lactobacillus  and  Clostridium 
(Roberfroid  et al.,  2010).  Apart  from  the  dietary  non-digestible  carbohydrates,  other 
substrates used by the colonic microbiota for growth include proteins, peptides, amino 
acids,  lysed  bacteria  and  sloughed  epithelial  cells.  The  proteolytic  members  of  the 
colonic microbiota are members of the genera Bacteroides and Clostridium (Roberfroid 
et al., 2010). The degradation of proteins by the colonic microbiota may lead to toxic 
metabolites such as ammonia, phenolic compounds and amines and has been linked to 
diseases such as colon cancer and IBD when the protein fermentation occurs in excess in 
the distal colon (Macfarlane et al., 1986, Smith and Macfarlane, 1996, Roberfroid et al., 
2010). But saccharolytic fermentations leads to end products such as SCFA, lactate, 
pyruvate, ethanol, succinate and gases such as H2, CO2, CH4 and H2S (Cummings, 1981, 
Macfarlane  and  Macfarlane,  1997).  The  usefulness  of  the  products  of  carbohydrate 
fermentation of these bacteria has already been discussed in Chapter 1. Consequently, an 
important aspect of prebiotics is their selectivity for the growth of some saccharolytic 
members (mostly the Bifidobacterium and Lactobacillus) of the microbiota hence their 
ingestion would cause the population of  specific species or genera of bacteria to be 
increased in a system and therefore contribute to an enhanced beneficial effect of these   234 
bacteria  (Gibson  and  Roberfroid,  1995,  Roberfroid  et  al.,  2010).  Some  of  these 
beneficial  effects  include  the  change  of  the  gut  microbiota  towards  a  healthier 
composition; improvement of the intestinal functions such as prevention of constipation, 
and managing lactose intolerance; increasing of mineral absorption and improvement of 
bone  health;  modulation  of  the  immune  system;  prevention  of  intestinal  infection; 
reduction in risk of colon cancer, type 2 diabetes, intestinal inflammation, obesity and 
metabolic syndrome (Roberfroid et al., 2010). Clinical evidence of prebiotic effects of 
some substrates are reviewed by Macfarlane et al., (2006) and Roberfroid et al., (2010).  
Substrates used as prebiotics are expected to be neither hydrolysed nor absorbed in the 
upper part of the GI tract (Gibson and Roberfroid, 1995, Gibson et al., 2004, Roberfroid 
et al., 2010). They are also expected to be resistant to gastric acidity (Gibson et al., 2004, 
Roberfroid et al., 2010). They must be selectively fermented by potentially beneficial 
bacteria in the colon; a very high degree of selective fermentation by bifidobacteria and 
lactobacilli  is  usually  desirable  (Roberfroid  et  al.,  2010).  They  must  also  alter  the 
composition of the colonic microbiota towards a healthier composition and preferably 
induce effects, which are beneficial to the host health (Gibson and Roberfroid, 1995, 
Roberfroid et al., 2010).  
The  most  commonly  used  prebiotics  are  fructo-oligosaccharides  and  galacto-
oligosaccharides which are known to enhance the growth of bifidobacteria (Macfarlane 
et al., 2008). Also, other dietary carbohydrates such as soybean oligosaccharides (Lan et 
al.,  2007),  resistant  starch  (Lesmes  et  al.,  2008,  Giuberti  et  al.,  2013),  xylo-
oligosaccharides (Moura et al., 2007, Zhang et al., 2008), lactose, lactulose and lactitol 
(Saarela et al., 2003) etc. have shown in vitro prebiotic effects. 
Traditionally,  in  vitro  prebiotic  potential  of  substrates  is  investigated  by  incubating 
potential substrates with either pure culture of  selected bacteria or faecal samples in 
simple batch cultures (Rycroft et al., 2001, Ghoddusi et al., 2007) or single and multi-
stage chemostats to mimic the complexity of the human large intestine (Molly et al., 
1994, Probert et al., 2004, Van de Wiele et al., 2004, Van den Abbeele et al., 2013). 
Microbial changes are analysed using either traditional microbiological techniques or 
molecular techniques or both to show the selectivity of fermentation by the bacterial 
species (for example selective utilization of the substrate by bifidobacteria and not E. 
coli or Streptococcus faecalis or Lactobacillus acidophilus, Minami et al., 1983); to   235 
show  changes  in  faecal  microbiota  (for  example  increase  in  bifidobacteria  but  not 
clostridia, Rycroft et al., 2001) and comparison of the efficacy of different substrates 
(Rycroft et al., 2001, Probert and Gibson, 2002, Ghoddusi et al., 2007, Van den Abbeele 
et  al.,  2013).  Some  of  the  in  vitro  studies  also  aim  to  measure  and  compare  the 
production of SCFA and gases as a result of fermentation of different substrates (Rycroft 
et al., 2001, Cardelle-Cobas et al., 2012). 
A small study was designed by including a potential prebiotic in the growth media of 
pure cultures of the probiotic species or faecal slurry to observe growth in the presence 
of the substrate in the microcalorimeter.  
6.2 Objectives 
The objective of this study was: 
  To investigate whether a potential prebiotic substrate would increase the growth 
of  pure  probiotic  species  or  specific  members  of  colonic  bacteria  in  the 
microcalorimeter 
6.3 Materials and Methods 
6.3.1 Microbiological media and chemicals 
Peptone water and yeast extract were obtained from Oxoid Ltd, UK. KH2PO4, K2HPO4, 
NaHCO3, sodium taurocholate, haemin, vitamin K, resazurin, Tween 80 and inulin were 
purchased from Sigma-Aldrich, UK. NaCl, MgSO4.7H2O, CaCl2.6H2O were obtained 
from  VWR  International,  UK.  L-cysteine  hydrochloride  was  purchased  from  Fisher 
Scientific, UK. 
6.3.2 Preparation of faecal slurry 
Faecal slurry was prepared by obtaining freshly voided human faeces from three healthy 
volunteers who had not been on any medications or antibiotics for a period of at least 6   236 
months. The faecal material was transferred into an Anaerobic Workstation kept at 37
oC 
and was diluted with PBS solution (in per litre quantity: KH2PO4 1g; K2HPO4 2 g; NaCl 
7.5 g), to obtain a 40% w/w slurry (eg. 60 g of faecal material was diluted with 90 g of 
PBS). This mixture was homogenized using an Ultra Turrax (IKA T18 Basic) at a speed 
of 18000 rpm until no large solid agglomerates could be observed. This was sieved 
through an open mesh fabric (Sefar Nitex
TM) with pore size of 350 µm to remove any 
unhomogenised  fibrous  material.  A  sterile  basal  medium  prepared  with  composition 
described by Hughes et al., (2008) (in per litre quantity: peptone water 2 g; yeast extract 
2 g; NaCl 0.1 g; K2HPO4 0.04 g; MgSO4.7H2O 0.01 g; CaCl2.6H2O 0.01 g; NaHCO3 2 g; 
haemin  0.005  g;  L-cysteine  hydrochloride  0.5  g;  bile  salts  0.5  g;  Tween  80  2  mL; 
vitamin  K  10  µL;  resazurin  solution  0.025%  4  mL)  was  added  to  the  sieved 
homogenised faecal slurry to achieve a 1:1 dilution (Yadav et al., 2013). The faecal 
slurry obtained was added to a sterile 50% v/v glycerol in ¼ strength Ringer’s solution 
in a 3:1 dilution (eg. 35 mL of faecal slurry was diluted with 15 mL of 50% v/v glycerol 
in ¼ Ringer’s). The attained faecal slurry was dispensed into 3 mL aliquots, sealed and 
frozen at -80
oC.  
6.3.3 Defrosting of frozen faecal slurry 
Defrosting of frozen faecal slurry was done in the same way as defrosting of frozen 
bacterial stocks from liquid nitrogen described in section 2.3.8. 
6.3.4 Microcalorimetric fermentations  
3  mL  of  fresh  faecal  slurry  was  filled  into  a  sterile  3  mL  calorimetric  ampoule, 
aseptically sealed and placed in the TAM. Data were recorded as described previously. 
This was repeated for the frozen faecal samples after defrosting. Defrosted faecal slurry 
was  also  inoculated  in  a  3  mL  50%  v/v  BHI  in  CMM  (CMM-BHI)  in  a  sterile 
calorimetric ampoule to a 1 in 100 dilution and studied in the microcalorimeter. The 
fermentation of the faecal slurry in the presence of a potential prebiotic was studied by 
inoculating faecal slurry (1 in 100) into CMM-BHI supplemented with 1% w/v inulin in 
a calorimetric ampoule. Data were recorded as described previously.    237 
Pure cultures of LA-5
® and BB-12
® were also inoculated into CMM-BHI supplemented 
with 1or 3% w/v inulin and studied in the microcalorimeter. 
6.4 Results and Discussion 
Faecal samples are crude; hence their composition cannot be standardized in replicate 
experiments.  To  standardize  the  inoculum  and  control  reproducibility,  slurries  made 
from  the  faecal material were  frozen  down  so  that  instead  of  obtaining  fresh  faecal 
material to make fresh slurry for every experiment, which could introduce variability, 
the frozen samples from one batch of slurry was used. Frozen samples were comparable 
to the fresh sample as indicated by Figure 6.1. The power-time curves showed organisms 
possibly in a stationary phase; there was probably not enough energy source for growth 
as a steady decay of the growth curve was observed. When the slurry was inoculated into 
fresh medium (CMM-BHI), there was exponential growth of the organisms (Figure 6.2), 
with a reduction of pH of the culture from an initial 7.24 ± 0.01 to 6.39 ± 0.03 after 
microcalorimetric measurement. Greater growth was observed when 1% w/v inulin was 
added to the medium evident with the increase of the AUC or heat output (representing 
growth, Braissant et al., 2010a, Figure 6.3) and further decrease of the pH of the medium 
to 5.86 ± 0.02 from an initial value of 7.24 ± 0.01 (Table 6.1). When 1% w/v inulin was 
supplemented  into  the  growth  media  of  LA-5
® and  BB-12
®,  the  power-time  curves 
indicated that the growth of these species were not significantly enhanced (Figures 6.4 
and 6.5) but significant change of the pH of the medium occurred (Table 6.1). It must be 
noted that the pH of the medium with and without inulin supplementation preinoculation 
was  not  different.  Supplementation  with  3%  w/v  inulin  caused  a  slight  increase  in 
growth  of  the  species  especially  that  of  LA-5
®  at  ca.  6  h.  Also  whilst  the 
unsupplemented culture returned to baseline ca. 13 h and remained there after, inulin 
supplemented cultures of LA-5
® showed further metabolic activity after ca. 30 h which 
continued for the duration tested.    238 
 
Figure 6.1. Power-time curves of cryopreserved faecal slurry: fresh and frozen samples. 
 
Figure 6.2. Power-time curve of faecal slurry inoculated into fresh medium (CMM-BHI). 
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Figure 6.3. Comparison of power-time curve of faecal slurry in CMM-BHI and medium supplemented 
with 1% w/v inulin. 
 
Figure 6.4. Power-time curves of LA-5
® with and without inulin (1% and 3% w/v) 
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Figure 6.5. Power-time curves of BB-12
® with and without inulin (1% and 3% w/v) 
Table 6.1. Final pH after experiments with and without inulin supplementation of the culture 
 
Culture  Final pH 
Faecal slurry in CMM-BHI without inulin  6.39 ± 0.03 
Faecal slurry in CMM-BHI with 1% w/v inulin  5.86 ± 0.02 
LA-5
® in CMM-BHI without inulin  5.70 ± 0.10 
LA-5
® in CMM-BHI with 1% w/v inulin  5.40 ± 0.04 
LA-5
® in CMM-BHI with 3% w/v inulin  4.57 ± 0.15 
BB-12
® in CMM-BHI without inulin  5.51 ± 0.01 
BB-12
® in CMM-BHI with 1% w/v inulin  5.36 ± 0.04 
BB-12
® in CMM-BHI with 3% w/v inulin  5.12 ± 0.11 
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                                                             [A]            [B]   
Figure 6.6. Images of ampoules of cultures of LA-5
® without [A] and with 3% w/v inulin [B] 
supplementation 
Post TAM assessment of the ampoules also revealed a very cloudy culture of inulin 
supplemented LA-5
® compared to an unsupplemented culture (Figure 6.6). 
Inulin is a known prebiotic and its prebiotic potential has been investigated extensively. 
For  instance,  Van  den  Abbeele  et  al.,  (2013)  comparing  inulin  and  long-chain 
arabinoxylan (a wheat derived fiber) and also two elaborate chemostats, simulator of the 
human intestinal microbial ecosystem model (SHIME) and dynamic TNO in vitro model 
of the colon (TIM-2) combined with conventional plate count, DGGE (to monitor shifts 
within the SHIME microbiota) and the intestinal-chip (I-chip, a phylogenetic microarray, 
applied  standardly  to  monitor  microbial  shifts  in  the  TIM-2),  reported  increased 
abundance of bifidobacteria (including B. catenulatum, B. adolescentis, B. angulatum 
and B. bifidum) whilst members of the Bacteroidetes were decreased. Also a significant 
reduction of Ruminococcus bromii was reported with inulin. Another study by Wang and 
Gibson  (1993)  demonstrated  the  prebiotic  effects  of  inulin  and  oligofructose.  Their 
bacterial growth data showed that bifidobacteria were preferentially stimulated in growth 
whilst E. coli and Clostridium were maintained at low levels (Wang and Gibson, 1993). 
It is not surprising that microcalorimetry was able to detect  increased growth of the 
faecal culture with inulin supplementation. What is unusual is the similarity in shape of 
power-time curve produced with and without supplementation with inulin. Faecal slurry 
could contain different groups of bacteria: Bacteroides, Bifidobacterium, Lactobacillus, 
C. leptum, C. sporogenes, Enterobacteria etc (Van den Abbeele et al., 2013). While 
some groups (as exemplified by previous studies) may be able to effectively metabolise   242 
inulin, other groups may not. Even amongst groups, some species, and strains may not 
be  able  to  metabolise  inulin.  For  example,  Bifidobacterium  breve  Yakult  and  B. 
adolescentis  LMG  10734  were  shown  not  to  be  able  to  degrade  inulin  whereas  B. 
longum LMG 11047 and B. angulatum LMG 11039T could partially degrade inulin and 
also  degrade  oligofructose  when  grown  in  coculture  fermenations  with  Bacteroides 
thetaiotaomicron LMG 11262, a strain able to metabolize both inulin and oligofructose 
(Falony et al., 2009). So it is expected that, upon addition of inulin to the medium, 
certain groups or species of bacteria multiply preferentially than other groups and this 
should reflect in the power-time curve that is generated. The power-time curve would be 
expected  to  be  different  from  that  which  was  produced  from  the  unsupplemented 
medium.  
From our experiences from the other studies in the previous chapters, the power-time 
curve that was generated could mean that a group of bacteria dominated the ampoule 
(given  the  medium  and medium condition) and this  group  again  metabolised  inulin, 
dominating the others in the ampoule. When inulin was supplemented into the growth 
media of LA-5
® and BB-12
®, although the final pH and appearance of the cultures after 
microcalorimetric measurements implied inulin may have been fermented by the pure 
species especially when it was supplemented at 3% w/v for LA-5
®, the prebiotic effect 
of inulin for the pure species shown in the microcalorimeter was not as pronounced as 
the faecal culture. It is likely the pure species may have partially degraded inulin or 
possibly degraded it when the other nutrient sources in the medium were exhausting. For 
instance,  for  LA-5
®,  the  “inulin  effect”  was  more  noticeable  after  30  h  of 
microcalorimetric  incubation  (Figure  6.4).  The  reason  for  this  may  be  that  the  pure 
species may have adapted on the other sources of nutrients supplied in the medium and 
may  have  therefore  preferentially  metabolised  the  other  substrate  (with  possibly 
accumulated toxic waste) before inulin. Another observation was that BB-12
® may not 
have been favoured in growth in the medium and condition in the ampoule since the heat 
output was significantly less than the other cultures.  
In summary, the data shows that inulin was degraded by the faecal culture; possibly by a 
specific group, which dominated the culture. Inulin might have been degraded by the 
pure species: BB-12
® and LA-5
® but was more obvious at higher concentration. It is also 
likely degradation of inulin occurred after other carbohydrate sources in the medium 
were exhausting. Overall, the data show that the prebiotic potential of substrates could   243 
be studied in the microcalorimeter. As mentioned previously, the methods currently in 
use to determine microbial changes when studying the prebiotic potential of substrates 
are based on conventional microbiological techniques (colony counts on selective agars) 
and molecular techniques.  The  plate technique, apart  from  being  laborious  and  time 
consuming  is  also  unable  to  account  for  unculturable  organisms  (Liesack  and 
Stackebrandt, 1992) hence differences exists between microbiological approaches and 
molecular  tools.  For  example,  Sghir  et  al.,  (1998)  using  fructo-oligosaccharide 
discovered  that  analysing  the  microbiota  using  traditional  plate  technique  gives  a 
different population profile compared to the use of 16S ribosomal nucleic acid genus 
specific probes demonstrating that the probe method was more consistent with the SCFA 
profile of the population than the plate technique (Sghir et al., 1998). Van de Wiele et 
al., (2004) were also able to show that PCR was a more precise technique to detect 
differences in bifidobacterial populations than conventional culturing techniques (Van de 
Wiele et al., 2004) when they used the SHIME to study the prebiotic effect of chicory 
inulin.  The  results  obtained  from  this  study  suggest  that  microcalorimetry  offers  a 
potential to study the prebiotic potential of substrates and could complement the current 
methods. However, it has its own limitations for instance, the influence of interspecies 
effect  (thus  the  possibility  of  competition  between  species  even  pre-supplementation 
with a potential substrate since the microcalorimeter measures the overall activity of a 
culture embracing interspecies effect). But it could still be explored further for prebiotic 
studies. 
The current study had several limitations in its design. For instance, the medium used for 
the study contained other carbohydrates sources (eg. glucose), which could have been 
preferentially utilised by the pure species. A more effective design was to use inulin as 
the sole carbohydrate source so that the organisms would have been limited by the sole 
substrate for metabolism. Also, pure culture of selected bacteria could have also been 
used  to  have  control  over  the  microcalorimetric  data  and  to  enable  easier  post 
microcalorimetric analyses of the culture, for example plate counting.  
 
 
   244 
Chapter 7 Conclusions and future work 
It has been shown through the work presented in the different chapters of this thesis and 
also by many different authors (Beezer, 1980, Vine and Bishop, 2005, Wadso 2009, 
Braissant et al., 2010a, Braissant et al., 2010c, Ning et al., 2013) that microcalorimetry is 
a useful and versatile technique for the study of many aspects of bacteria. As stated by 
Vine and Bishop (2005), several features of bacteria also make them very suitable for 
study  by  microcalorimetry.  For  instance, they  have  high  metabolic  rates  hence  even 
small numbers are easy to detect in a heterogenous system. To date, it has been shown 
that heat output is a dependable and characteristic feature of bacterial cells. It is clear and 
established that with pure cultures of bacteria, one could possibly identify and determine 
the effects of substrates on an organism on the basis of heat production (Beezer, 1980, Li 
et al., 2000, O'Neill et al., 2003, Bonkat et al., 2012, Lago Rivero et al., 2012, Lago 
Rivero  et  al.,  2013),  but  the  possibility  of  achieving  the  same  with  mixed  cultures, 
acknowledging possible and relevant interspecies interaction and effect was the central 
subject of investigation of this thesis.  
The work in this thesis has shown that microcalorimetry is undoubtedly, very useful for 
the difficult task of detection of growth of bacteria in mixed cultures. The results from 
Chapter 2 demonstrated interspecies interaction: competition and coexistence between 
mixed cultures of P. aeruginosa, S. aureus and E. coli in the microcalorimeter. Chapters 
3,  4  and  5  also  demonstrated  that  microcalorimetry  could  be  used  to  study  some 
functional characteristics of probiotics, surmounting some of the issues associated with 
the conventional plate enumeration or plate diffusion assay. Chapter 6 also demonstrated 
that  the  prebiotic  potential  of  substrates  could  potentially  be  studied  in  the 
microcalorimeter. 
However,  it  is  also  apparent  from  the  experiments  conducted  and  the  results  that 
microcalorimetry also has some severe limitations when used for these applications. For 
instance,  growth  differentiation  in  mixed  cultures  were  purely  based  on 
microcalorimetric identification, hence differentiation was limited when identification 
was  reduced.  The  results  from  Chapter  2  and  3  showed  that  power-time  curves  of 
individual species that were distinct under a particular condition, were varied at ease 
with minor changes in medium composition and oxygen level in the ampoule and also 
depended  on  the  metabolic  properties  of  the  organism  being  studied.  Hence  as  the   245 
ampoule condition moved towards an anaerobic environment, loss of detailed structure 
of  the  power-time  curve  occurred  unless  perhaps  there  was  varied  energy  sources 
available  to  the  organism  which  could  utilize  different  metabolic  pathways. 
Consequently the utilization of the microcalorimeter to differentiate between species was 
restricted and became time dependent when loss of structure or thermal detail of the 
power-time curve occurred. In those instances, inocula concentration was very critical, 
as any shift in the power-time curve along the abscissa could have complicated the 
identification of a species. This finding is consistent with previous reports (Monk and 
Wadso, 1975, Newell, 1980 (and references therein)). For instance Monk and Wadso 
(1975) also demonstrated in their study that the characteristic profiles of bacterial growth 
were strongly related to the oxygen status of the growth medium. They demonstrated 
that in anaerobic conditions, Streptococcus faecalis showed the same simple bell shaped 
curve  as  Streptococcus  faecium  and  Streptococcus  agalactiae  (a  -haemolytic 
Streptococcus  sp.)  although  a  different  curve  (with  more  detail)  was  obtained  for 
Streptococcus faecalis under aerobic condition or partially aerobic conditions (Monk and 
Wadso,  1975).  Since  the  detail/structure  is  required  for  differentiating  between 
organisms,  a  biphasic  growth  with  respect  to  oxygen,  substrates  (Schaarschmidt and 
Lamprecht,  1978,  Newell,  1980)  or  the  metabolic  complexity  of  a  species  may  be 
needed to maximize identification or differentiation in mixed culture. Whilst this implies 
that strict control of oxygen in the calorimetric ampoule is not needed for differentiation 
and consequent applications, the desired condition may also not be necessarily optimal 
for  growth  and  hence  characterization  of  some  species  in  mixed  culture  in  the 
microcalorimeter. Also, for meaningful interpretation of metabolic data, it has often been 
suggested  that  strictly  defined  medium  and  condition  need  to  be  simulated  in  the 
calorimetric ampoule to allow mathematical expression of the data (Beezer, 1980). Both 
purposes:  growth  differentiation  and  quantitative  data  (eg.  metabolic  activity 
contributing  to  a  heat  peak  or  relevant  substrate/metabolite  concentration)  could  be 
difficult to satisfy at the same time unless perhaps “strictly defined complexity” is used 
eg.  limiting  3  or  more  defined  substrates  in  an  anaerobic  environment  or  defined 
partially aerobic environment. 
The  results  also  demonstrated  that  microcalorimetric  characterisation  is  a  growth 
dependent  process  and  therefore  is  subject  to  all  the  constraints  operating  upon  all 
growth processes for example nutrient depletion, pH shifts, accumulation of waste etc. 
when operated in a batch of medium. As discussed in Chapter 1, there are two main   246 
types  of  designs  of  the  microcalorimeter  applicable  to  microbiological  studies:  the 
ampoule,  representing  the  simple  batch and the  flow-system.  For  the  later  design,  a 
reaction  medium  is  held  in  a  reservoir  outside  the  microcalorimeter,  usually  in  a 
thermostatic  bath  and  is  pumped  through  a  calorimetric  cell.  Used  media  can  be 
collected as waste through channels or returned into the media reservoir. Although the 
ampoule is commonly used for characterization (O' Neill et al., 2003, Lago Rivero et al., 
2012, Bonkat et al., 2012, Lago Rivero et al., 2013) and was employed for all the studies 
in this thesis, the flow design has also been used for characterisation (Beezer et al., 1979, 
Beaubien et al., 1987) but to a limited extent due to its disadvantages: time-consuming 
sterilizations, possible contamination and safety concerns during experiments. As has 
been  argued  for  growth  experiments  in  batch  cultures,  extrapolation  or  transfer  of 
findings from these systems to describe growth in natural systems is not in accord as 
these systems are oversimplified (Monod, 1950, Novick and Szilard, 1950, Hoskisson 
and Hobbs, 2005). The chemostats may therefore be “the best laboratory idealization” of 
natural systems (Novick and Szilard, 1950, Veldkamp and Jannasch, 1972, Hoskisson 
and Hobbs, 2005, Schmidt et al., 2011) as they involve pH controlled single and multiple 
component continuous culture systems which could more represent natural environments 
and could control factors such as nutrient depletion (a major limitation of the study in 
Chapter 3) and accumulation of metabolic waste products (which although useful for 
studying interspecies interaction, may not be always necessary). As already stated in this 
thesis, the mechanism for probiosis, although not elucidated in detail, has been proposed 
to  involve  several  components:  bacteria-host  interaction  and  bacteria-bacteria 
interactions (O'Toole and Cooney, 2008, Bermudez-Brito et al., 2012). The antagonistic 
activities  of  probiotics  could  also  involve  several  mechanisms:  from  production  of 
antimicrobial  substances  (organic  acids,  peroxides,  antimicrobial  peptides  including 
bacteriocins,  deconjugated  bile  acids)  to  competitive  adhesiveness  and  interference 
(Servin, 2004, Bermudez-Brito et al., 2012, Hassan et al., 2012). If full appreciation of 
these  mechanisms  is  sought  after,  or  comprehensive  interpretation  of  the 
microcalorimetric  data  is  required,  nutrients  may  need  to  be  constantly  supplied  or 
accumulated  waste  or  acids  removed  from  the  environment  and  this  calls  for  other 
components and analytical sensors, for instance pH electrodes, sensors for measuring 
metabolites formed and consumed, sensors for measuring available energy source, entry 
ports  for  buffers,  etc.  incorporated  into  the  calorimetric  design.  Presently  its  design 
limits its relevant application. There have been attempts by some authors, for instance, 
Johansson  and  Wadso,  (1999b)  who  constructed  an  isothermal  microcalorimetric   247 
titration vessel equipped with pH and oxygen electrodes and a spectrophotometer as a 
means  of  controlling  growth  processes  and  to  reduce  the  unspecificity  of  the  data 
obtained  (Johansson  and  Wadso,  1999b).  Though  their  design  was  promising,  such 
designs are still not commercially available and needs further research.  
Also, the comparison of the power-time curves between pure species and mixed cultures 
for the assessment of interspecies interactions (antagonism) or effects necessitates more 
than  a  subjective  judgment.  An  objective  assessment  needs  to  employ  the  use  of 
mathematical analysis programmes or by deriving parameters such as growth rate, lag 
phase duration or maximum growth (Xie et al., 1988, Yang et al., 2008, Kong et al., 
2009). Such parameters are achieved by the use of growth models. The use of these 
growth models has been reviewed by Braissant et al., (2013) who has highlighted some 
advantages,  limitations  and  assumptions  when  they  are  compared  with  conventional 
methods such as plate methods or OD. There is still room for further research in that 
area. 
The use of microcalorimetry for growth detection in mixed cultures or polymicrobial 
systems with its associated applications may always require followed up analysis with 
other analytical methods or incorporated analytical support components or sensors to 
interpret microcalorimetric data, which could be nonspecific. But from the results, it is 
also apparent that a lot can be accomplished within the ampoule. Its clear advantage is 
that unlike the conventional plate technique, it does not record mere endpoint process 
but gives the kinetics of the process and also overcomes the tedium associated with the 
conventional  method.  There  are  now  multichannel  instruments,  which  offer  high 
throughput screening (eg. TAM III, TAM 48, TA Instruments; calScreener
TM, SymCel) 
but  these  instruments,  which  are  batch  microcalorimeters,  still  suffer  from  the 
fundamental shortcomings of the batch systems discussed. 
In summary, the work in this thesis has demonstrated clearly that microcalorimetry is a 
valuable tool for detection of bacteria growth in mixed cultures and assessing functional 
characteristics  of  probiotics  and  potential  prebiotics.  It  has  huge  potential  in 
microbiological assays, and could potentially address some microbiological problems. 
Other areas, which need further research, are the prebiotic effect of potential substrates 
in the microcalorimeter. Discussed in Chapter 6 is the asserted effect of prebiotics to 
selectively stimulate the growth of beneficial members of the microbiota (Roberfroid et   248 
al., 2010). To demonstrate the prebiotic potential of a substrate, a defined medium need 
to be constructed with the prebiotic as the sole energy and carbon source. In that way, a 
species, which had previously adapted to other carbohydrate sources, may need to solely 
degrade the prebiotic for growth.  
Also,  for  the  C.  difficile  work,  a  gut  model  of  Clostrium  difficile  infection  can  be 
constructed with the flow design or by simulating the in vivo complexity with multi-
stage  fermenters  alongside  other analytical  sensors  or  methods  incorporated  into  the 
microcalorimetric  design.  C.  difficile  spores  can  be  infected  into  the  system  and 
monitored  for  dominance  in  the  system.  Potential  probiotics  could  be  added  to  the 
system  to  investigate  if  there  is  any  shift  towards  dominance  of  the  probiotics  or 
reduction in C. difficile toxins using the combined effort of microcalorimetry and other 
conventional or non-coventional methods. However this model will still not simulate 
immunological events, which are proposed to occur in the human gut (Sekirov et al., 
2010, Bermudez-Brito et al., 2012). Adherence and interference could be simulated with 
added human cell lines (Chan et al., 1985, Reid et al., 1987, Bernet et al., 1994, Gopal et 
al.,  2001)  but  overly  complex  design  will  risk  the  relevant  interpretation  of  the 
microcalorimetric data. 
Additionally  for  the  C.  difficile  work,  other  C.  difficile  strains  should be tested and 
further animal studies need to be done to determine if the commercial probiotics that 
demonstrated  in  vitro  anticlostridial  activities  can  indeed  play  evidential  role  in 
prophylaxis or treatment of the infection in animal models. Also, the specificity of action 
of the antimicrobial compounds contained in the supernatant of the probiotic cultures 
needs further investigation.  
Also, during the studies conducted in Chapter 5, it was realized that compared to the 
solid probiotic products, which performed poorly in terms of survival in the product and 
during gastric tolerance assay, the liquid products showed better gastric tolerance and 
stability (within product shelf life) but they may involve higher cost for transport and 
storage and have a shorter shelf life. Means of ensuring the stability and gastrointestinal 
survival of solid probiotics need further research since they present an advantage of cost 
and convenience. There are delivery strategies such as microencapsulation, which has 
potential for improving survival of solid probiotics (Chandramouli et al., 2004, Ding and 
Shah, 2009, Islam et al., 2010, Cook et al., 2012). Probiotics are also marketed as tablets,   249 
granules, pellets etc. and there have been attempts to enteric coat some probiotic tablets 
and  pellets  (Brachkova  et  al.,  2009).  But  significant  losses  occur  from  tableting  or 
pelletization process alone (Brachkova et al., 2009). Capsules have the advantage of not 
requiring a compression step, hence the heat exposure which could be associated with 
significant  viability  loss  during  tableting  (Bansal  and  Garg,  2008).  Lyophilised 
probiotics filled into capsule could therefore be explored for enteric coating to control 
release of the capsule content. Also, other colonic or enteric delivery strategies could be 
explored as a future work. 
In  vitro  susceptibility  testings  are  usually  conducted  in  pure  culture,  which  is  not 
representative of many of the infections in human, which occur as consortia of two or 
more bacterial species. As discussed in Chapter 2, and shown by other authors (Hoffman 
et al., 2006, Biswas et al., 2009, Riedele and Reichl, 2011, Kluge et al., 2012), bacterial 
interactions might affect the pathogenicity of the co-infecting species and could have 
consequences on the therapeutic efficacy of a selected antibiotic. Co-pathogenicity of 
species in mixed infection could arise due to the possible protective effect of the species 
over each other or the likelihood that a species could adapt relevant virulence strategies 
to  resist  a  dominating  species  (Riedele  and  Reichl,  2011).  It  will  be  an  interesting 
investigation to find out how the population distribution could change when there is an 
antibiotic challenge with the mixed cultures in Chapter 2 or when an effective antibiotic 
of  one  of  the  species  in  pure  culture  is  used  against  it  in  mixed  cultures  in  the 
microcalorimeter.  
  
 
 
 
 
   250 
Presentations and Publications 
The work reported in this thesis has been presented at the following conferences: 
  A real-time study of defined mixed cultures of bacteria, XVIII International Society 
of Biological Calorimetry, Lund, Sweden, Podium Presentation, June, 2014 
  In  vitro inhibition  of  Clostridium  difficile  by  commercial  probiotics:  a real  time 
study, PhD Research Day, UCL School of Pharmacy, Podium Presentation, April, 
2014 
  A microcalorimetric assay of probiotic viability after exposure to gastric fluids, APS 
UKPharmSci, Hertfordshire, Hartfield, UK, Podium Presentation, September, 2014 
  In  vitro  demonstration  of  inhibition  of  Clostridium  difficile  by  commercial 
probiotics: a real time study, 24
th ECCMID Conference, Barcelona, Spain, Poster 
Presentation, May, 2014 
  A microcalorimetric study of mixed cultures of P. aeruginosa, S. aureus and E. coli, 
Poster  Presentation  AAPS  Annual  Meeting  and  Exposition,  San  Antonio,  USA, 
November, 2013; APS UKPharmSci, Edinburgh, UK, September, 2013 
  Continuous real time observation of inhibition of Clostridium difficile by probiotics 
Poster  Presentation,  AAPS  Annual  Meeting  and  Exposition,  San  Antonio,  USA, 
November, 2013; APS UKPharmSci, Edinburgh, UK, September 2013; UKICRS, 
Reading, UK, April, 2013 
  Assessment of commercial probiotic viability in pig and simulated gastric fluids 
Poster  Presentation,  AAPS  Annual  Meeting  and  Exposition,  San  Antonio,  USA, 
November, 2013 
  Probiotics:  are  they  effective?  Thermal  Methods  Group  Meeting,  Ware,  UK, 
November, 2012 
 
The  following  manuscripts  have  been  accepted  or  are  under  preparation  from  the  work 
reported in this thesis: 
  Comparative  survival  of  commercial  probiotic  formulations:  Tests  in  biorelevant 
gastric  fluids  and  real-time  measurements  using  microcalorimetry  (Beneficial 
Microbes). 
  A  microcalorimetric  study  of  mixed  cultures  of  Pseudomonas  aeruginosa, 
Staphylococcus aureus and Escherichia coli 
  A microcalorimetric study of mixed cultures of Clostridium difficile and commercial 
probiotics   251 
References 
AAS, J. A., PASTER, B. J., STOKES, L. N., OLSEN, I. & DEWHIRST, F. E. 2005. Defining the normal bacterial flora of the oral cavity. 
Journal of Clinical Microbiology, 43, 5721-5732. 
ABADIAS, M., BENABARRE, A., TEIXIDO, N., USALL, J. & VINAS, I. 2001a. Effect of freeze drying and protectants on viability of 
the biocontrol yeast Candida sake. International Journal of Food Microbiology, 65, 173-182. 
ABADIAS, M., TEIXIDO, N., USALL, J., BENABARRE, A. & VINAS, I. 2001b. Viability, efficacy, and storage stability of freeze-dried 
biocontrol agent Candida sake using different protective and rehydration media. Journal of Food Protection, 64, 856-861. 
ABD EL-SALAM, M. H., SALEH, F. A., KHOLIF, A. M., EL-SAYED, E. M., ABDOU, S. M. & EL-SHIBINY, S., 2004. Isolation and 
characterization of bacteriocins produced by Bifidobacterium lactis BB-12 and Bifidobacterium longum BB-46. 9th Egyptian 
Conference for Dairy Science and Technology, Cairo, Egypt. 9–11 October. 
ABRAHAMSSON,  T.  R.,  JAKOBSSON,  T.,  BOTTCHER,  M.  F.,  FREDRIKSON,  M.,  JENMALM,  M.  C.,  BJORKSTEN,  B.  & 
OLDAEUS, G. 2007. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. 
Journal of Allergy Clinical Immunology, 119, 1174-1180. 
ABURUB, A., RISLEY, D. S. & MISHRA, D. 2008. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains 
sodium lauryl sulfate and proposal of a modified recipe. International Journal of Pharmaceutics, 347, 16-22. 
ADLERBERTH, I., LINDBERG, E., ABERG, N., HESSELMAR, B., SAALMAN, R., STRANNEGARD, I. L. & WOLD, A. E. 2006. 
Reduced enterobacterial and increased staphylococcal colonization of the infantile bowel:  An effect of hygienic lifestyle? 
Pediatric Research, 59, 96-101. 
AGERHOLM-LARSEN, L., BELL, M. L., GRUNWALD, G. K. & ASTRUP, A. 2000. The effect of a probiotic milk product on plasma 
cholesterol: a meta-analysis of short-term intervention studies. European Journal of Clinical Nutrition, 54, 856-860. 
ALEXANDER, M., DAGGETT, P. M., GHERNA, R., JONG, J. & SIMIONE, F. 1980. American Type Collection Methods. Laboratory 
manual on preservation, freezing, and freeze-drying as applied to algae, bacteria, fungi and protozoa. American Type Culture 
Collection, Rockville, MD. 1–46. 
ALKLINT, C., WADSO, L. & SJOHOLM, I. 2005. Accelerated storage and isothermal microcalorimetry as methods of predicting carrot 
juice shelf-life. Journal of the Science of Food and Agriculture, 85, 281-285. 
ALLEN, S. J., WAREHAM, K., WANG, D. L., BRADLEY, C., HUTCHINGS, H., HARRIS, W., DHAR, A., BROWN, H., FODEN, A., 
GRAVENOR, M. B. & MACK, D. 2013. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea 
and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre 
trial. Lancet, 382, 1249-1257. 
ALVAREZ-OLMOS, M. I., BAROUSSE, M. M., RAJAN, L., VAN DER POL, B. J., FORTENBERRY, D., ORR, D. & FIDEL, P. L. 
2004. Vaginal lactobacilli in adolescents - Presence and relationship to local and systemic immunity, and to bacterial vaginosis. 
Sexually Transmitted Diseases, 31, 393-400. 
AMMOR, S., TAUVERON, G., DUFOUR, E. & CHEVALLIER, I. 2006. Antibacterial activity of lactic acid bacteria against spoilage and 
pathogenic bacteria isolated from the same meat small-scale facility - 1 - Screening and characterization of the antibacterial 
compounds. Food Control, 17, 454-461. 
ANAND, S. K., SRINIVASAN, R. A. & RAO, L. K. 1984. Antimicrobial activity associated with Bifidobacterium bifidum-I. Cultured 
Dairy Products Journal 2, 6–7. 
ANAND, S. K., SRINIVASAN, R. A. & RAO, L. K. 1985. Antimicrobial activity associated with Bifidobacterium bifidum-II. Cultured 
Dairy Products Journal 2, 21–23. 
ANNUK, H., SHCHEPETOVA, J., KULLISAAR, T., SONGISEPP, E., ZILMER, M. & MIKELSAAR, M. 2003. Characterization of 
intestinal lactobacilli as putative probiotic candidates. Journal of Applied Microbiology, 94, 403-412. 
APELLA, M. C., GONZALEZ, S. N., DEMACIAS, M. E. N., ROMERO, N. & OLIVER, G. 1992. In vitro studies on the inhibition of the 
growth of Shigella-sonnei by Lactobacillus-casei and Lact-acidophilus. Journal of Applied Bacteriology, 73, 480-483. 
ARMAND, M., BOREL, P., PASQUIER, B., DUBOIS, C., SENFT, M., ANDRE, M., PEYROT, J., SALDUCCI, J. & LAIRON, D. 1996. 
Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum.  American Journal of 
Physiology-Gastrointestinal and Liver Physiology, 271, G172-G183. 
ARUNACHALAM, K. D. 1999. Role of bifidobacteria in nutrition, medicine and technology. Nutrition Research, 19, 1559-1597.   252 
ASHBY, L. J., BEEZER, A. E. & BUCKTON, G. 1989. In vitro dissolution testing of oral controlled release preparations in the presence 
of artificial foodstuffs .1. Exploration of alternative methodology - microcalorimetry. International Journal of Pharmaceutics, 
51, 245-251. 
ASHRAF, R. & SHAH, N. P. 2011. Selective and differential enumerations of Lactobacillus delbrueckii subsp bulgaricus, Streptococcus 
thermophilus, Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium spp. in yoghurt  - A review. International 
Journal of Food Microbiology, 149, 194-208. 
AULTON, M. E. 2013. Aulton's Pharmaceutics: The Design and manufacture of medicines, Edinburgh, Churchill Livingstone. 
AURELI, P., FIORE, A., SCALFARO, C., CASALE, M. & FRANCIOSA, G. 2010. National survey outcomes on commercial probiotic 
food supplements in Italy. International Journal of Food Microbiology, 137, 265-273. 
BAINES, S. D., O'CONNOR, R., FREEMAN, J., FAWLEY,  W. N., HARMANUS, C., MASTRANTONIO, P., KUIJPER, E. J. & 
WILCOX, M. H. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. Journal of Antimicrobial 
Chemotherapy, 62, 1046-1052. 
BALDAN, R., CIGANA, C., TESTA, F., BIANCONI, I., DE SIMONE, M., PELLIN, D., DI SERIO, C., BRAGONZI, A. & CIRILLO, D. 
M. 2014. Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of Staphylococcus aureus in 
vitro and murine models of co-infection. Plos One, 9, e89614. 
BALDONI, D., HERMANN, H., FREI, R., TRAMPUZ,  A. & STEINHUBER, A. 2009. Performance of microcalorimetry for early 
detection of methicillin resistance in clinical isolates of Staphylococcus aureus. Journal of Clinical Microbiology, 47, 774-776. 
BANSAL, T. & GARG, S. 2008. Probiotics: From functional foods to pharmaceutical products. Current Pharmaceutical Biotechnology, 9, 
267-287. 
BAO, Y., ZHANG, Y., ZHANG, Y., LIU, Y., WANG, S., DONG, X., WANG, Y. & ZHANG, H. 2010. Screening of potential probiotic 
properties of Lactobacillus fermentum isolated from traditional dairy products. Food Control, 21, 695-701. 
BARBOSA, T. M., SERRA, C. R., LA RAGIONE, R. M., WOODWARD, M. J. & HENRIQUES, A. O. 2005. Screening for Bacillus 
isolates in the broiler gastrointestinal tract. Applied and Environmental Microbiology, 71, 968-978. 
BAREFOOT, S. F. & KLAENHAMMER, T. R.1983. Detection and activity of Lactacin B, a bacteriocin produced by Lactobacillus 
acidophilus Applied and Environmental Microbiology, 45,1808–1815. 
BARRETT, E., MATTARELLI, P., SIMPSON, P. J., O'TOOLE, P. W., FITZGERALD, G. F., ROSS, R. P. & STANTON, C. 2012. 
Culture Media for the detection and enumeration of bifidobacteria in food production. In: CORRY, J. E. L., CURTIS, G. D. W. 
& BAIRD, R. M. (eds.) Handbook of culture media for food and water microbiology, 3rd Edition. Cambridge: Royal Society of 
Chemistry. 
BARTLETT, J. G. 2002. Clinical practice. Antibiotic-associated diarrhea. New England Journal of Medicine, 346, 334-9. 
BARTLETT, J. G. 2010. Clostridium difficile: progress and challenges. Antimicrobial Therapeutics Reviews, 1213, 62-69. 
BARTLETT,  J.  G.,  CHANG,  T.  W.,  GURWITH,  M.,  GORBACH,  S.  L.  &  ONDERDONK,  A.  B.  1978.  Antibiotic-associated 
pseudomembranous colitis due to toxin-producing clostridia. The New England Journal of Medicine, 298, 531-4. 
BARTLETT, J. G., ONDERDONK, A. B., CISNEROS, R. L. & KASPER, D. L. 1977. Clindamycin-associated colitis due to a toxin-
producing species of Clostridium in hamsters. The Journal of Infectious Diseases, 136, 701-5. 
BARTOLONI, A., MANTELLA, A., GOLDSTEIN, B. P., DEI, R., BENEDETTI, M., SBARAGLI, S. & PARADISI, F. 2004. In-vitro 
activity of nisin against clinical isolates of Clostridium difficile. Journal of Chemotherapy, 16, 119-121.  
BARTSCH, S. M., UMSCHEID, C. A., FISHMAN, N. & LEE, B. Y. 2013. Is Fidaxomicin Worth the Cost? An Economic Analysis. 
Clinical Infectious Diseases, 57, 555-561. 
BATTLEY, E. H. 1960. Growth-reaction equations for saccharomyces-cerevisiae. Physiologia Plantarum, 13, 192-203. 
BAUER, M. P., NOTERMANS, D. W., VAN BENTHEM, B. H. B., BRAZIER, J. S., WILCOX, M. H., RUPNIK, M., MONNET, D. L., 
VAN DISSEL, J. T., KUIJPER, E. J. & GRP, E. S. 2011. Clostridium difficile infection in Europe: a hospital-based survey. 
Lancet, 377, 63-73. 
BAUMANN, D. P. & REINBOLD, G. W. 1966. Freezing of lactic cultures. Journal of Dairy Science, 49, 259-264. 
BAYNE-JONES,  S.  1929.  Bacterial  calorimetry  I.  General  considerations.  Description  of  differential  microcalorimeter.  Journal  of 
Bacteriology, 17, 105-122. 
BE'ER, A., ZHANG, H. P., FLORIN, E. L., PAYNE, S. M., BEN-JACOB, E. & SWINNEY, H. L. 2009. Deadly competition between 
sibling bacterial colonies. Proceedings of the National Academy of Sciences of the United States of America, 106, 428-433. 
BEAUBIEN,  A.,  KEITA,  L.  &  JOLICOEUR,  C.  1987.  Flow  microcalorimetry  investigation  of  the  influence  of  surfactants  on  a 
heterogeneous aerobic culture. Applied and Environmental Microbiology, 53, 2567-2573. 
BEEZER, A. E. 1980. Biological microcalorimetry. London: Academic press.   253 
BEEZER, A. E., NEWELL, R. D. & TYRRELL, H. J. V. 1976. Application of flow microcalorimetry to analytical problems - preparation, 
storage and assay of frozen inocula of Saccharomyces-cerevisiae. Journal of Applied Bacteriology, 41, 197-207. 
BEEZER, A. E., NEWELL, R. D. & TYRRELL, H. J. V. 1979. Characterization and metabolic studies of Saccharomyces-cerevisiae and 
Kluyveromyces-fragilis by flow micro-calorimetry. Antonie Van Leeuwenhoek Journal of Microbiology, 45, 55-63. 
BEGLEY, M., GAHAN, C. G. M. & HILL, C. 2005. The interaction between bacteria and bile. Fems Microbiology Reviews, 29, 625-651. 
BELAICH, A. & BELAICH, J. P. 1976. Microcalorimetric study of the anaerobic growth of Escherichia coli: measurements of the affinity 
of whole cells for various energy substrates. Journal of Bacteriology, 125, 19-24. 
BELAICH, J. P. & PRAT, H. 1963. Thermogenese et croissance de Pseudomonas lindneri en glucose limitant. Comptes Rendus Des 
Seances De La Societe De Biologie Et De Ses Filiales, 157, 316-322. 
BELAICH, J. P. 1962. These de specialite, University of Marseilles.  
BELAY, N. & RASOOLY, A. 2002. Staphylococcus aureus growth and enterotoxin A production in an anaerobic environment. Journal of 
Food Protection, 65, 199-204. 
BEN-AMOR, K., VERBAARSCHOT, P., BREEUWER, P., AKKEREMANS, A. D. L., DE VOS, W. M., ROMBOUTS, F. M. & ABEE, 
T. 2001. Use of flow cytometry and cell sorting for the assessment of the viability of bifidobacteria during bile salts stress. 
Abstracts of the General Meeting of the American Society for Microbiology, 101, 567-567. 
BENDALI, F., DURAND, A., HEBRAUD, M. & SADOUN, D. 2011. Lactobacillus paracasei subsp paracasei: an Algerian isolate with 
antibacterial activity against enteric pathogens and probiotic fitness. Journal of Food and Nutrition Research, 50, 139-149. 
BERMUDEZ-BRITO, M., PLAZA-DIAZ, J., MUNOZ-QUEZADA, S., GOMEZ-LLORENTE, C. & GIL, A. 2012. Probiotic mechanisms 
of action. Annals of Nutrition and Metabolism, 61, 160-174. 
BERNET, M. F., BRASSART, D., NEESER, J. R. & SERVIN, A. L. 1994. Lactobacillus-acidophilus la-1 binds to cultured human 
intestinal-cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut, 35, 483-489. 
BEST, E. L., FREEMAN, J. & WILCOX, M. H. 2012. Models for the study of Clostridium difficile infection. Gut Microbes, 3, 145-167. 
BHUNIA, A. K., JOHNSON, M. C. & RAY, B. 1988. Purification, characterization and antimicrobial spectrum of a bacteriocin produced 
by Pediococcus-acidilactici. Journal of Applied Bacteriology, 65, 261-268. 
BIK, E. M., ECKBURG, P. B., GILL, S. R., NELSON, K. E., PURDOM, E. A., FRANCOIS, F., PEREZ-PEREZ, G., BLASER, M. J. & 
RELMAN, D. A. 2006. Molecular analysis of the bacterial microbiota in the human stomach. Proceedings of the National 
Academy of Sciences of the United States of America, 103, 732-737. 
BINGHAM, S. A., PETT, S. & DAY, K. C. 1990. Non-starch polysaccharide intake of a representative sample of british adults. Journal of 
Human Nutrition and Dietetics, 3, 333-338. 
BISWAS, L., BISWAS, R., SCHLAG, M., BERTRAM, R. & GOTZ, F. 2009. Small-colony variant selection as a survival strategy for 
Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Applied and Environmental Microbiology, 75, 6910-6912. 
BJORKSTEN, B. 2006. The gut microbiota: a complex ecosystem. Clinical and Experimental Allergy, 36, 1215-1217. 
BLOSSOM, D. B. & MCDONALD, L. C. 2007. The challenges posed by reemerging Clostridium difficile infection. Clinical Infectious 
Diseases, 45, 222-227. 
BOHNHOFF, M., DRAKE, B. L. & MILLER, C. P. 1955. The effect of an antibiotic on the susceptibility of the mouse's intestinal tract to 
Salmonella infection. Antibiotics annual, 3, 453-5. 
BOIVINET, P. 1964. Thesis, University Aix-Marseille.  
BOLING, E. A., BLANCHAR.GC & RUSSELL, W. J. 1973. Bacterial identification by microcalorimetry. Nature, 241, 472-472. 
BONKAT, G., BRAISSANT, O., WIDMER, A. F., FREI, R., RIEKEN, M., WYLER, S., GASSER, T. C., WIRZ, D., DANIELS, A. U. & 
BACHMANN,  A. 2012. Rapid detection of urinary tract pathogens using microcalorimetry: principle, technique and first 
results. Bju International, 110, 892-897. 
BOUCHEMAL, K., AGNELY, F., KOFFI, A. & PONCHEL, G. 2009. A concise analysis of the effect of temperature and propanediol-1, 
2 on Pluronic F127 micellization using isothermal titration microcalorimetry. Journal of Colloid and Interface Science, 338, 
169-176. 
BOUFFARD, A. 1895. C. R. Hebdomadaires Seances Acad Sci, Paris, 121, 357.  
BOUZA,  E.  2012. Consequences  of  Clostridium difficile  infection: understanding  the healthcare  burden.  Clinical Microbiology and 
Infection, 18, 5-12. 
BOYD, M. A., ANTONIO, M. A. D. & HILLIER, S. L. 2005. Comparison of API 50 CH strips to whole-chromosomal DNA probes for 
identification of Lactobacillus species. Journal of Clinical Microbiology, 43, 5309-5311. 
BRACHKOVA, M. I., DUARTE, A. & PINTO, J. F. 2009. Evaluation of the viability of Lactobacillus spp. after the production of 
different solid dosage forms. Journal of Pharmaceutical Sciences, 98, 3329-3339.   254 
BRAISSANT,  O.,  BINDSCHEDLER,  S.,  CAILLEAU,  G.,  AUBRECHT,  R.,  KOVACIC,  L.  &  LEE,  N.  2010b.  Isothermal 
Microcalorimetry a Novel Tool for Non-Disruptive Analysis of Microbial Heat Production in Subsurface Ecosystems. Origins 
of Life and Evolution of Biospheres, 40, 561-562. 
BRAISSANT, O., BONKAT, G., WIRZ, D. & BACHMANN, A. 2013. Microbial growth and isothermal microcalorimetry: Growth 
models and their application to microcalorimetric data. Thermochimica Acta, 555, 64-71. 
BRAISSANT, O., WIRZ, D., GOEPFERT, B. & DANIELS, A. U. 2010c. Biomedical use of isothermal microcalorimeters. Sensors, 10, 
9369-9383. 
BRAISSANT,  O.,  WIRZ,  D.,  GOEPFERT,  B.  &  DANIELS,  A.  U.  2010d.  "The  heat  is  on":  Rapid  microcalorimetric  detection  of 
mycobacteria in culture. Tuberculosis, 90, 57-59. 
BRAISSANT,  O.,  WIRZ,  D.,  GOPFERT,  B.  &  DANIELS,  A.  U.  2010a.  Use  of  isothermal  microcalorimetry  to  monitor  microbial 
activities. Fems Microbiology Letters, 303, 1-8. 
BRANDL, K., PLITAS, G., MIHU, C. N., UBEDA, C., JIA, T., FLEISHER, M., SCHNABL, B., DEMATTEO, R. P. & PAMER, E. G. 
2008. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature, 455, 804-U8. 
BRAVO, D., BRAISSANT, O., SOLOKHINA, A., CLERC, M., DANIELS, A. U., VERRECCHIA, E. & JUNIER, P. 2011. Use of an 
isothermal microcalorimetry assay to characterize microbial oxalotrophic activity. Fems Microbiology Ecology, 78, 266-274. 
BRAZIER, J. S., RAYBOULD, R., PATEL, B., DUCKWORTH, G., PEARSON, A., CHARLETT, A., DUERDEN, B. I. & NETWORK, 
H. P. A. R. M. 2008. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English 
hospitals, 2007-08. Euro surveillance : European communicable disease bulletin, 13. 
BRIOUKHANOV, A. L., THAUER, R. K. & NETRUSOV, A. I. 2002. Catalase and superoxide dismutase in the cells of strictly anaerobic 
microorganisms. Mikrobiologiya, 71, 330-335. 
BRITISH  PHARMACOPOEIA.  2013.  Volume  V,  Appendix  XII  B.  Dissolution  ANNEX:  Recommendations  on  dissolution  testing; 
Appendix I A. General regeants: gastric juice, artificial. 
BRITTON, R. A. & YOUNG, V. B. 2012. Interaction between the intestinal microbiota and host in Clostridium difficile colonization 
resistance. Trends in Microbiology, 20, 313-319. 
BRITTON, R. A. & YOUNG, V. B. 2014. Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile. 
Gastroenterology, 146, 1547-1553. 
BROWN, P. O., PALMER, C., BIK, E. M., DIGIULIO, D. B. & RELMAN, D. A. 2007. Development of the human infant intestinal 
microbiota. Plos Biology, 5, 1556-1573. 
BSAC. 2013. BSAC methods for antimicrobial susceptibility testing. 1-87. 
BUJALANCE, C., JIMENEZ-VALERA, M., MORENO, E. & RUIZ-BRAVO, A. 2006. A selective differential medium for Lactobacillus 
plantarum. Journal of Microbiological Methods, 66, 572-575. 
BURKE, K. E. & LAMONT, J. T. 2013. Fecal transplantation for recurrent Clostridium difficile infection in older adults: A Review. 
Journal of the American Geriatrics Society, 61, 1394-1398. 
BURKE, K. E. & LAMONT, J. T. 2014. Clostridium difficile infection: A worldwide disease. Gut and Liver, 8, 1-6. 
BURNS, D. A. & MINTON, N. P. 2011. Sporulation studies in Clostridium difficile. Journal of Microbiological Methods, 87, 133-138. 
BURNS, D. A., HEAP, J. T. & MINTON, N. P. 2010. Clostridium difficile spore germination: an update. Research in Microbiology, 161, 
730-734. 
BUTLER,  R.  N.,  ZACHARAKIS,  B.,  MOORE,  D.,  CRAWFORD,  K.  &  DAVIDSON,  G.  2001.  Non-invasive  measurement  of  a 
fermentation pattern shift in infants during the first three months of life. Gastroenterology, 120, A266-A266. 
CABALLERO-FRANCO, C., KELLER, K., DE SIMONE, C. & CHADEE, K. 2007. The VSL#3 probiotic formula induces mucin gene 
expression and secretion in colonic epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 
292, G315-G322. 
CAMASCHELLA, P., MIGNOT, O., PIROVANO, F. & SOZZI, T. 1998. Method for differentiated enumeration of mixed cultures of 
thermophilic lactic acid bacteria and bifidobacteria by using only one culture medium. Lait, 78, 461-467. 
CARDELLE-COBAS, A., OLANO, A., CORZO, N., VILLAMIEL, M., COLLINS, M., KOLIDA, S. & RASTALL, R. A. 2012. In vitro 
fermentation of lactulose-derived oligosaccharides by mixed fecal microbiota. Journal of Agricultural and Food Chemistry, 60, 
2024-2032. 
CARMEN  COLLADO,  M.  &  HERNANDEZ,  M.  2007.  Identification  and  differentiation  of  Lactobacillus,  Streptococcus  and 
Bifidobacterium species in fermented milk products with bifidobacteria. Microbiological Research, 162, 86-92. 
CARROLL, C. K. 2013. Laboratory technical advances in the diagnosis of Clostridium difficile. In Tang, Y.W., Stratton, C. W. (eds.). 
Advanced Techniques in Diagnostic Microbiology. Springer Science+Business Media New York. 769-783.   255 
CARVALHO, A. S., SILVA, J., HO, P., TEIXEIRA, P., MALCATA, F. X. & GIBBS, P. 2004b. Relevant factors for the preparation of 
freeze-dried lactic acid bacteria. International Dairy Journal, 14, 835-847. 
CARVALHO, A. S., SILVA, J., HO, P., TEIXEIRA, P., MALCATA, F. X. & GIBBS, P. 2004a. Effects of various sugars added to growth 
and  drying  media  upon  thermotolerance  and  survival  throughout  storage  of  freeze-dried  lactobacillus  delbrueckii  ssp 
bulgaricus. Biotechnology Progress, 20, 248-254. 
CHAMPAGNE, C. P., GARDNER, N., BROCHU, E. & BEAULIEU, Y. 1991. The freeze-drying of lactic-acid bacteria - a review. 
Canadian  Institute  of  Food Science  and  Technology Journal-Journal  De  L  Institut  Canadien  De Science Et  Technologie 
Alimentaires, 24, 118-128. 
CHAMPAGNE, C. P., RAYMOND, Y., GONTHIER, J. & AUDET, P. 2009. Enumeration of the contaminating bacterial microbiota in 
unfermented pasteurized milks enriched with probiotic bacteria. Canadian Journal of Microbiology, 55, 410-418. 
CHAMPAGNE, C. P., ROSS, R. P., SAARELA, M., HANSEN, K. F. & CHARALAMPOPOULOS, D. 2011. Recommendations for the 
viability assessment of probiotics as concentrated cultures and in food matrices. International Journal of Food Microbiology, 
149, 185-193. 
CHAN, R. C. Y., REID, G., IRVIN, R. T., BRUCE, A. W. & COSTERTON, J. W. 1985. Competitive-exclusion of uropathogens from 
human uroepithelial cells by lactobacillus whole cells and cell-wall fragments. Infection and Immunity, 47, 84-89. 
CHANDRAMOULI, V., KAILASAPATHY, K., PEIRIS, P. & JONES, M. 2004. An improved method of microencapsulation and its 
evaluation to protect Lactobacillus spp. in simulated gastric conditions. Journal of Microbiological Methods, 56, 27-35. 
CHANDRAMOULI, V., KAILASAPATHY, K., PEIRIS, P. & JONES, M. 2004. An improved method of microencapsulation and its 
evaluation to protect Lactobacillus spp. in simulated gastric conditions. Journal of Microbiological Methods, 56, 27-35. 
CHAPMAN, C. M. C., GIBSON, G. R. & ROWLAND, I. 2011. Health benefits of probiotics: are mixtures more effective than single 
strains? European Journal of Nutrition, 50, 1-17. 
CHAPMAN, C. M. C., GIBSON, G. R. & ROWLAND, I. 2012. In vitro evaluation of single- and multi-strain probiotics: Inter-species 
inhibition between probiotic strains, and inhibition of pathogens. Anaerobe, 18, 405-413. 
CHAPMAN, C. M., GIBSON, G. R., TODD, S. & ROWLAND, I. 2013. Comparative in vitro inhibition of urinary tract pathogens by 
single- and multi-strain probiotics. European Journal of Nutrition, 52, 1669-77. 
CHARALAMPOPOULOS, D., PANDIELLA, S. S. & WEBB, C. 2003. Evaluation of the effect of malt, wheat and barley extracts on the 
viability of potentially probiotic lactic acid bacteria under acidic conditions. International Journal of Food Microbiology, 82, 
133-41. 
CHARTERIS, W. P., KELLY, P. M., MORELLI, L. & COLLINS, J. K. 1997. Selective detection, enumeration and identification of 
potentially probiotic Lactobacillus and Bifidobacterium species in mixed bacterial populations. International Journal of Food 
Microbiology, 35, 1-27. 
CHARTERIS, W. P., KELLY, P. M., MORELLI, L. & COLLINS, J. K. 1998. Development and application of an in vitro methodology to 
determine  the  transit  tolerance  of  potentially  probiotic  Lactobacillus  and  Bifidobacterium  species  in  the  upper  human 
gastrointestinal tract. Journal of Applied Microbiology, 84, 759-768. 
CHEIKHYOUSSEF,  A.,  POGORI,  N.,  CHEN,  W.  &  ZHANG,  H.  2008.  Antimicrobial  proteinaceous  compounds  obtained  from 
bifidobacteria: from production to their application. International Journal of Food Microbiology, 125, 215-222. 
CHEN, H.-Y., YAO, J., ZHOU, Y., CHEN, H.-L., WANG, F., GAI, N., ZHUANG, R.-S., CECCANTI, B., MASKOW, T. & ZARAY, G. 
2008. Investigation of the toxic effect of cadmium on Candida humicola and Bacillus subtilis using a microcalorimetric method. 
Journal of Hazardous Materials, 159, 465-470. 
CHEN, J. J., CAI, W. & FENG, Y. 2007a. Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. Clinical 
Nutrition, 26, 559-566. 
CHEN, X. Y., XU, J. J., SHUAI, J. B., CHEN, J. S., ZHANG, Z. F. & FANG, W. H. 2007b. The S-layer proteins of Lactobacillus 
crispatus strain ZJ001 is responsible for competitive exclusion against Escherichia coli O157: H7 and Salmonella typhimurium. 
International Journal of Food Microbiology, 115, 307-312. 
CHUNG, H. J., BANG, W. & DRAKE, M. A. 2006. Stress response of Escherichia coli. Comprehensive Reviews in Food Science and 
Food Safety, 5, 52-64. 
CLINICAL AND LABORATORY STANDARDS INSTITUTE. 2009. Performance standards for antimicrobial disk susceptibility tests. 
Wayne, PA: Clinical and Laboratory Standards Institute, Approved standard M2–A10. 
CLINICAL  AND  LABORATORY  STANDARDS  INSTITUTE. 2009. Performance standards for antimicrobial susceptibility testing. 
Wayne, PA: Clinical and Laboratory Standards Institute. Nineteenth informational supplement M100–S19.   256 
CLOSTRIDIUM DIFFICILE RIBOTYPING NETWORK (CDRN) for England and Northern Ireland 2011-13. [online]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/329156/C_difficile_ribotyping_network_CDRN
_report.pdf. [20 June 2014]. 
CLOUD, J. & KELLY, C. P. 2007. Update on Clostridium difficile associated disease. Current Opinion in Gastroenterology, 23, 4-9. 
COEURET, V., GUEGUEN, M. & VERNOUX, J. P. 2004a. Numbers and strains of lactobacilli in some probiotic products. International 
Journal of Food Microbiology, 97, 147-156. 
COHEN, L. E., SMITH, C. J., PISTER, J. D. & WELLS, R. F. 1974. Clindamycin (cleocin) colitis. American Journal of Roentgenology, 
121, 301-304. 
COLEMAN, N. S., MARCIANI,  L., BLACKSHAW, E., WRIGHT, J.,  PARKER, M., YANO, T., YAMAZAKI, S., CHAN, P. Q., 
WILDE, K., GOWLAND, P. A., PERKINS, A. C. & SPILLER, R. C. 2003. Effect of a novel 5-HT3 receptor agonist MKC-
733 on upper gastrointestinal motility in humans. Alimentary Pharmacology & Therapeutics, 18, 1039-1048. 
COLLADO,  M.  C.,  MORENO,  Y.,  HERNANDEZ,  E.,  COBO,  J.  M.  &  HERNANDEZ,  M.  2005.  Note.  In  vitro  viability  of 
Bifidobacterium strains isolated from commercial dairy products exposed to human gastrointestinal conditions. Food Science 
and Technology International, 11, 307-314. 
COLLINS, F. M. & CARTER, P. B. 1978. Growth of salmonellae in orally infected germfree mice. Infection and Immunity, 21, 41-47. 
COLLINS, M. D. & GIBSON, G. R. 1999. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the 
gut. American Journal of Clinical Nutrition, 69, 1052S-1057S. 
CONROY, M. E., SHI, H. N. & WALKER, W. A. 2009. The long-term health effects of neonatal microbial flora. Current Opinion in 
Allergy and Clinical Immunology, 9, 197-201. 
CONWAY, P. L., GORBACH, S. L. & GOLDIN, B. R. 1987. Survival of lactic-acid bacteria in the human stomach and adhesion to 
intestinal-cells. Journal of Dairy Science, 70, 1-12. 
COOK, M. T., TZORTZIS, G., CHARALAMPOPOULOS, D. & KHUTORYANSKIY, V. V. 2011. Production and evaluation of dry 
alginate-chitosan microcapsules as an enteric delivery vehicle for probiotic bacteria. Biomacromolecules, 12, 2834-2840. 
COOK, M. T., TZORTZIS, G., CHARALAMPOPOULOS, D. & KHUTORYANSKIY, V. V. 2012. Microencapsulation of probiotics for 
gastrointestinal delivery. Journal of Control Release, 162, 56-67. 
CORCORAN, B. M., ROSS, R. P., FITZGERALD, G. F. & STANTON, C. 2004. Comparative survival of probiotic lactobacilli spray-
dried in the presence of prebiotic substances. Journal of Applied Microbiology, 96, 1024-1039. 
COSTA, E., USALL, J., TEIXIDO, N., GARCIA, N. & VINAS, I. 2000. Effect of protective agents, rehydration media and initial cell 
concentration on viability of Pantoea agglomerans strain CPA-2 subjected to freeze-drying. Journal of Applied Microbiology, 
89, 793-800. 
COSTA, E., USALL, J., TEIXIDO, N., TORRES, R. & VINAS, I. 2002. Effect of package and storage conditions on viability and efficacy 
of the freeze-dried biocontrol agent Pantoea agglomerans strain CPA-2. Journal of Applied Microbiology, 92, 873-878. 
COTTER, P. D. & HILL, C. 2003. Surviving the acid test: Responses of gram-positive bacteria to low pH. Microbiology and Molecular 
Biology Reviews, 67, 429-453. 
COUPE, A. J., DAVIS, S. S. & WILDING, I. R. 1991. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy-
subjects. Pharmaceutical Research, 8, 360-364. 
COWMAN, R. A. & SPECK, M. L. 1965. Ultra-low temperature storage of lactic streptococci. Journal of Dairy Science, 48, 1531-1532. 
CROWE, J. H., CARPENTER, J. F. & CROWE, L. M. 1998. The role of vitrification in anhydrobiosis. Annual Review of Physiology, 60, 
73-103. 
CRUZ-GUERRERO, A., HERNANDEZ-SANCHEZ, H., RODRIGUEZ-SERRANO, G., GOMEZ-RUIZ, L., GARCIA-GARIBAY, M. & 
FIGUEROA-GONZALEZ,  I.  2014.  Commercial  probiotic  bacteria  and  prebiotic  carbohydrates:  a  fundamental  study  on 
prebiotics uptake, antimicrobials production and inhibition of pathogens. Journal of the Science of Food and Agriculture, 94, 
2246-52. 
CUI, J. H., GOH, J. S., KIM, P. H., CHOI, S. H. & LEE, B. J. 2000. Survival and stability of bifidobacteria loaded in alginate poly-l-lysine 
microparticles. International Journal of Pharmaceutics, 210, 51-59. 
CULLIGAN, E. P., HILL, C. & SLEATOR, R. D. 2009. Probiotics and gastrointestinal disease: successes, problems and future prospects. 
Gut Pathogens, 1,1-12. 
CUMMINGS, J. H. & MACFARLANE, G. T. 1991. The control and consequences of bacterial fermentation in the human colon. Journal 
of Applied Bacteriology, 70, 443-459. 
CUMMINGS, J. H. 1981. Short chain fatty acids in the human colon. Gut, 22, 763-79.   257 
CUMMINGS, J. H., GIBSON, G. R. & MACFARLANE, G. T. 1989. Quantitative estimates of fermentation in the hind gut of man. Acta 
Veterinaria Scandinavica, Supplements 86, 1989: Proceedings of the International Symposium on Comparative Aspects of the 
Physiology of Digestion in Ruminants and Hindgut Fermenters, 76-82. 
CYSTIC FIBROSIS FOUNDATION PATIENT REGISTRY: Annual Data Report 2012. [online]. Available from: http://www.cff.org. [21 
August 2014]. 
DAHAN,  A.  S.  &  AMIDON,  G.  L.  2008  Gastrointestinal  Dissolution  and  Absorption  of  Class  II  Drugs,  in  Drug  Bioavailability: 
Estimation of Solubility, Permeability, Absorption and Bioavailability, Volume 40, Second Edition (eds H. van de Waterbeemd 
and B. Testa), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527623860.ch3 
DASS, N. B., JOHN, A. K., BASSIL, A. K., CRUMBLEY, C. W., SHEHEE, W. R., MAURIO, F. P., MOORE, G. B. T., TAYLOR, C. 
M. & SANGER, G. J. 2007. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and 
GPR43 receptor activation. Neurogastroenterology and Motility, 19, 66-74. 
DAVEY, H. M. 2011. Life, death, and in-between: meanings and methods in microbiology. Applied and Environmental Microbiology, 77, 
5571-5576. 
DE KRAKER, M. E. A., WOLKEWITZ, M., DAVEY, P. G., GRUNDMANN, H. & GRP, B. S. 2011. Clinical impact of antimicrobial 
resistance in European hospitals: Excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus 
aureus bloodstream infections. Antimicrobial Agents and Chemotherapy, 55, 1598-1605. 
DE LA COCHETIERE, M. F., DURAND, T., LEPAGE, P., BOURREILLE, A., GALMICHE, J. P. & DORE, J. 2005. Resilience of the 
dominant human fecal microbiota upon short-course antibiotic challenge. Journal of Clinical Microbiology, 43, 5588-5592. 
DE MAN, J. C., ROGOSA, M. & SHARPE, M. E. 1960. A medium for the cultivation of lactobacilli. Journal of Applied Bacteriology, 23, 
130-135. 
DE PALMA, G., NADAL,  I., MEDINA, M., DONAT, E., RIBES-KONINCKX, C., CALABUIG, M. & SANZ, Y. 2010. Intestinal 
dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. Bmc Microbiology, 10, 63. 
DE VALDEZ, G. F., DE GIORI, G. S., DE RUIZ HOLGADO, A. P. & OLIVER, G. 1985a. Effect of the rehydration medium on the 
recovery of freeze-dried lactic-acid bacteria. Applied and Environmental Microbiology, 50, 1339-1341. 
DE VALDEZ, G. F., DE GIORI, G. S., HOLGADO, A. P. D. & OLIVER, G. 1985b. Rehydration conditions and viability of freeze-dried 
lactic-acid bacteria. Cryobiology, 22, 574-577. 
DE  VRESE,  M.  &  SCHREZENMEIR,  J.  2008.  Probiotics,  prebiotics,  and  synbiotics.  Advances  in  Biochemical 
Engeneering/Biotechnology, 111, 1-66. 
DEBAST, S. B., BAUER, M. P., KUIJPER, E. J. & COMM 2014. European society of clinical microbiology and infectious diseases: 
Update of the treatment guidance document for Clostridium difficile infection. Clinical Microbiology and Infection, 20, 1-26. 
DETHLEFSEN, L., ECKBURG, P. B., BIK, E. M. & RELMAN, D. A. 2006. Assembly of the human intestinal microbiota. Trends in 
Ecology & Evolution, 21, 517-523. 
DETHLEFSEN,  L., HUSE, S., SOGIN, M. L. & RELMAN, D. A. 2008a. The pervasive effects of an antibiotic on the human gut 
microbiota, as revealed by deep 16S rRNA Sequencing. Plos Biology, 6, 2383-2400. 
DETHLEFSEN, L., HUSE, S., SOGIN, M. L. & RELMAN, D. A. 2008b. The pervasive effects of an antibiotic on the human gut 
microbiota, as revealed by deep 16S rRNA sequencing. Plos Biology, 6, e280. 
DIAL, S., ALRASADI, K., MANOUKIAN, C., HUANG, A. & MENZIES, D. 2004. Risk of Clostridium difficile diarrhea among hospital 
inpatients prescribed proton pump inhibitors: cohort and case-control studies. Canadian Medical Association Journal, 171, 33-
38. 
DING, W. K. & SHAH, N. P. 2009. An improved method of microencapsulation of probiotic bacteria for their stability in acidic and bile 
conditions during storage. Journal of Food Science, 74, M53-M61. 
DORE, J. & CORTHIER, G. 2010. The human intestinal microbiota. Gastroentérologie clinique et biologique, 34, S7-S15. 
DRAGO, L., DE VECCHI, E., NICOLA, L., COLOMBO, A. & GISMONDO, M. R. 2004. Microbiological evaluation of commercial 
probiotic products available in Italy. Journal of Chemotherapy, 16, 463-467. 
DRAGO, L., GISMONDO, M. R., LOMBARDI, A., DEHAEN, C. & GOZZINI, L. 1997. Inhibition of in vitro growth of enteropathogens 
by new Lactobacillus isolates of human intestinal origin. Fems Microbiology Letters, 153, 455-463. 
DRAGO, L., RODIGHIERO, V., CELESTE, T., ROVETTO, L. & DE VECCHI, E. 2010. Microbiological evaluation of commercial 
probiotic products available in the USA in 2009. Journal of Chemotherapy, 22, 373-377. 
DRASAR,  B.  S.  &  SHINER,  M.  1969b.  Studies  on  the  intestinal  flora.  II.  Bacterial  flora  of  the  small  intestine  in  patients  with 
gastrointestinal disorders. Gut, 10, 812-819.   258 
DRASAR, B. S., SHINER, M. & MCLEOD, G. M. 1969a. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract 
in healthy and achlorhydric persons. Gastroenterology, 56, 71-9. 
DRESSMAN, J. B. 1986. Comparison of canine and human gastrointestinal physiology. Pharmaceutical Research, 3, 123-131. 
DRESSMAN, J. B., AMIDON, G. L., REPPAS, C. & SHAH, V. P. 1998. Dissolution testing as a prognostic tool for oral drug absorption: 
Immediate release dosage forms. Pharmaceutical Research, 15, 11-22. 
DRESSMAN,  J.  B.,  BERARDI,  R.  R.,  DERMENTZOGLOU,  L.  C.,  RUSSELL,  T.  L.,  SCHMALTZ,  S.  P.,  BARNETT,  J.  L.  & 
JARVENPAA, K. M. 1990. Upper gastrointestinal (GI) pH in young, healthy-men and women. Pharmaceutical Research, 7, 
756-761. 
DRUDY,  D.,  FANNING,  S.  &  KYNE,  L.  2007.  Toxin  A-negative,  toxin  B-positive  Clostridium  difficile.  International  Journal  of 
Infectious Diseases, 11, 5-10. 
DUBBERKE, E. R. & WERTHEIMER, A. I. 2009. Review of current literature on the economic burden of Clostridium difficile infection. 
Infection Control and Hospital Epidemiology, 30, 57-66. 
DUBEY, A. P., RAJESHWARI, K., CHAKRAVARTY, A. & FAMULARO, G. 2008. Use of VSL#3 in the treatment of rotavirus diarrhea 
in children. Journal of Clinical Gastroenterology, 42, S126-S129. 
DUBRUNFAUT, M. 1856. Note sur la chaleur at le travail méchanique produits par la fermentation vineuse.  C. R. Hebdomadaires 
Seances Acad. 42, 945-948.  
DUERDEN, B. I. 2011. Contribution of a government target to controlling Clostridium difficile in the NHS in England. Anaerobe, 17, 
175-179. 
DUNNE, C., MURPHY, L., FLYNN, S., O'MAHONY, L., O'HALLORAN, S., FEENEY, M., MORRISSEY, D., THORNTON, G., 
FITZGERALD, G., DALY, C., KIELY, B., QUIGLEY, E. M. M., O'SULLIVAN, G. C., SHANAHAN, F. & COLLINS, J. K. 
1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. 
Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology, 76, 279-292. 
DUTEAU,  N.  M.,  ROGERS,  J.  D.,  BARTHOLOMAY,  C.  T.  &  REARDON,  K.  F.  1998.  Species-specific  oligonucleotides  for 
enumeration of Pseudomonas putida F1, Burkholderia sp. strain JS150, and Bacillus subtilis ATCC 7003 in biodegradation 
experiments. Applied and Environmental Microbiology, 64, 4994-4999. 
EFENTAKIS, M. & DRESSMAN, J. B. 1998. Gastric juice as a dissolution medium: surface tension and ph. European Journal of Drug 
Metabolism and Pharmacokinetics, 23, 97– 102. 
EIDTMANN, A. & SCHAUZ, K. 1992. Cryopreservation of protoplasts from sporidia of ustilago-maydis. Mycological Research, 96, 318-
320. 
EL-NEZAMI,  H.,  MYKKANEN,  H.,  KANKAANPAA,  P.,  SALMINEN,  S.  &  AHOKAS,  J.  2000.  Ability  of  Lactobacillus  and 
Propionibacterium strains to remove aflatoxin B-1 from the chicken duodenum. Journal of Food Protection, 63, 549-552. 
ELLIOT, E. & TEVERSHAM, K. 2004. An evaluation of nine probiotics available in South Africa, August 2003. South African Medical 
Journal, 94, 121-124. 
ELMER, G. W., SURAWICZ, C. M. & MCFARLAND, L. V. 1996. Biotherapeutic agents - A neglected modality for the treatment and 
prevention of selected intestinal and vaginal infections. Jama-Journal of the American Medical Association, 275, 870-876. 
ENGLYST, H. N. & MACFARLANE, G. T. 1986. Breakdown of resistant and readily digestible starch by human gut bacteria. Journal of 
the Science of Food and Agriculture, 37, 699-706. 
ESCHBACH, M., SCHREIBER, K., TRUNK, K., BUER, J., JAHN, D. & SCHOBERT, M. 2004. Long-term anaerobic survival of the 
opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. Journal of Bacteriology, 186, 4596-604. 
EVALDSON, G., HEIMDAHL, A., KAGER, L. & NORD, C. E. 1982. The normal human anaerobic microflora. Scandinavian journal of 
infectious diseases. Supplementum, 35, 9-15. 
EVANS, D. F., PYE, G., BRAMLEY, R., CLARK, A. G., DYSON, T. J. & HARDCASTLE, J. D. 1988. Measurement of gastrointestinal 
pH profiles in normal ambulant human-subjects. Gut, 29, 1035-1041. 
EWASCHUK, J. B., DIAZ, H., MEDDINGS, L., DIEDERICHS, B., DMYTRASH, A., BACKER, J., LANGEN, M. L. V. & MADSEN, 
K. L. 2008. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. American Journal 
of Physiology-Gastrointestinal and Liver Physiology, 295, G1025-G1034. 
FALLANI, M., YOUNG, D., SCOTT, J., NORIN, E., AMARRI, S., ADAM, R., AGUILERA, M., KHANNA, S., GIL, A., EDWARDS, 
C. A., DORE, J. & TEAM, I. 2010. Intestinal microbiota of 6-week-old infants across Europe: Geographic influence beyond 
delivery mode, breast-feeding, and antibiotics. Journal of Pediatric Gastroenterology and Nutrition, 51, 77-84.   259 
FALONY, G., CALMEYN, T., LEROY, F. & DE VUYST, L. 2009. Coculture Fermentations of Bifidobacterium species and Bacteroides 
thetaiotaomicron reveal a mechanistic insight into the prebiotic effect of inulin-type fructans.  Applied and Environmental 
Microbiology, 75, 2312-2319. 
FAMULARO, G., DE SIMONE, C., MATTEUZI, D. & PIROVANO, F. 1999. Traditional and high potency probiotic preparations for 
oral bacteriotherapy. Biodrugs, 12, 455-470. 
FAN, D. D., WANG, L. H., SHANG, L. A., SHI, H. J., MA, X. X., MI, Y. & XU, K. Z. 2008. A microcalorimetric method for studying 
the biological effects of Mg2+ ion on recombinant Escherichia coli. Chemical and Biochemical Engineering Quarterly, 22, 
363-368. 
FAO/WHO, 2001. Joint FAO/WHO expert consultation and report of a joint evaluation of health and nutritional properties of probiotics in 
food including powder milk with live lactic acid bacteria on food additives. Córdoba, Argentina, 1-4 October 2001. [online]. 
Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. [12 November 2013] 
FDA, Guidance for Industry. 2000. Waiver of the in vivo bioavailability and bioequivalence studies for immediate-release solid oral 
dosage forms based on a biopharmaceutics classification system; U.S. Department of Health and Human, Food and Drug 
Administration (FDA), Center for Drug Evaluation and Research: Washington, DC, 1− 13. 
FEDORKA-CRAY, P. J., CRAY, W. C., ANDERSON, G. A., NICKERSON, K. W. 1988. Bacterial tolerance to 100% dimethylsulfoxide, 
Canadian Journal of Microbiology. 34, 688–689. 
FIELD, D., QUIGLEY, L., O'CONNOR, P. M., REA, M. C., DALY, K., COTTER, P. D., HILL, C. & ROSS, R. P. 2010. Studies with 
bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microbial Biotechnology, 3, 473-486. 
FINEGOLD, S. M. 1969. Intestinal bacteria  - role they play in normal physiology, pathologic physiology, and infection.  California 
Medicine, 110, 455-459. 
FLINT, H. J., BAYER, E. A., RINCON, M. T., LAMED, R. & WHITE, B. A. 2008. Polysaccharide utilization by gut bacteria: potential 
for new insights from genomic analysis. Nature Reviews Microbiology, 6, 121-131. 
FOLKERS, B. L., SCHURING, C., ESSMANN, M. & LARSEN, B. 2010. Quantitative real time PCR detection of Clostridium difficile 
growth inhibition by probiotic organisms. North American Journal of Medical Sciences, 2, 5-10. 
FOMIN, D. C., ALYCHEVA, I. S., VESELOVSKAYA, L. I., TATCHIN, S. M. 1973. Antibacterial properties of dimethylsulphoxide. 
Khimioterapia infektsiy i lekarstvennoy ustoychivosti patogennych mikroorganizmov, Moskva, 63–64. 
FONSECA, B. B., BELETTI, M. E., DA SILVA, M. S., DA SILVA, P. L., DUARTE, I. N. & ROSSI, D. A. 2010. Microbiota of the 
cecum,  ileum  morphometry,  pH  of  the  crop  and  performance  of  broiler  chickens  supplemented  with  probiotics.  Revista 
Brasileira De Zootecnia-Brazilian Journal of Animal Science, 39, 1756-1760. 
FORDTRAN, J. S. & WALSH, J. H. 1973. Gastric-acid secretion rate and buffer content of stomach after eating - results in normal 
subjects and in patients with duodenal-ulcer. Journal of Clinical Investigation, 52, 645-657. 
FORREST, W. W., WALKER, D. J. & HOPGOOD, M. F. 1961. Enthalpy changes associated with lactic fermentation of glucose. Journal 
of Bacteriology, 82, 685-690. 
FUJITA, T., MONK, P. R. & WADSO, I. 1978. Calorimetric identification of several strains of lactic-acid bacteria. Journal of Dairy 
Research, 45, 457-463. 
FULLER, R. 1989. Probiotics in man and animals. Journal of Applied Bacteriology, 66, 365-378. 
FULLER, R. 1991. Probiotics in human medicine. Gut, 32, 439-442. 
FURRIE, E., MACFARLANE, S., KENNEDY, A., CUMMINGS, J. H., WALSH, S. V., O'NEIL D, A. & MACFARLANE, G. T. 2005. 
Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative 
colitis: a randomised controlled pilot trial. Gut, 54, 242-9. 
GAISFORD, S. & O’NEILL, M. A.A. 2006. Pharmaceutical isothermal calorimetry. New York; London : Informa Healthcare.  
GAISFORD, S. 2012. Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals.  Advanced Drug 
Delivery Reviews, 64, 431-439. 
GAISFORD, S., BEEZER, A. E., BISHOP, A. H.,  WALKER, M. & PARSONS, D. 2009. An in vitro method for the quantitative 
determination of the antimicrobial efficacy of silver-containing wound dressings. International Journal of Pharmaceutics, 366, 
111-116. 
GARRITY, M. G., BELL, J. A. & LILBURN, T. 2005. In Bergey’s manual of systemic bacteriology, 2nd ed. Bergey’s manual trust, 
Springer Science+Business Media. Inc., 233 Spring Street: New York 2, 323-359. 
GERDING, D. N., MUTO, C. A. & OWENS, R. C. 2008a. Measures to control and prevent Clostridium difficile infection. Clinical 
Infectious Diseases, 46, S43-S49.   260 
GERDING, D. N., MUTO, C. A. & OWENS, R. C. 2008b. Treatment of Clostridium difficile infection. Clinical Infectious Diseases, 46, 
S32-S42. 
GERRITSEN, J., SMIDT, H., RIJKERS, G. T. & DE VOS, W. M. 2011. Intestinal microbiota in human health and disease: the impact of 
probiotics. Genes and Nutrition, 6, 209-240. 
GHERNA,  R.  L.  1981.  Preservation.  In:  GERHARDT,  P.,  MURRAY,  R.G.E., COSTILOW,  R.N.,  NESTER,  E.W.,  WOOD,  W.A., 
KRIEG, N.R. and PHILLIPS, G.B. 1980. Manual of Methods for General Bacteriology. ASM Press, Washington, DC. 208–
217. 
GHODDUSI, H. B., GRANDISON, M. A., GRANDISON, A. S. & TUOHY, K. M. 2007. In vitro study on gas generation and prebiotic 
effects of some carbohydrates and their mixtures. Anaerobe, 13, 193-199. 
GIANNELL, R. A., ZAMCHECK, N. & BROITMAN, S. A. 1972. Gastric-acid barrier to ingested microorganisms in man - studies in-
vivo and in-vitro. Gut, 13, 251-256. 
GIBSON, C. A., LANDERKI.GB & MORSE, P. M. 1966. Effects of additives on survival of lactic streptococci in frozen storage. Applied 
Microbiology, 14, 665-&. 
GIBSON,  G. R. & ROBERFROID, M. B. 1995. Dietary modulation of the human colonic microbiota  - introducing the concept of 
prebiotics. Journal of Nutrition, 125, 1401-1412. 
GIBSON, G. R. & WILLIAMS, C. M. 1999. Gut fermentation and health advantages: Myth or reality? British Journal of Nutrition, 81, 83-
84. 
GIBSON, G. R., MACFARLANE, G.T. 1995. Human colonic bacteria: role in nutrition, physiology and pathology. Boca Raton, FL: CRC 
Press. 
GIBSON, G. R., PROBERT, H. M., VAN LOO, J., RASTALL, R. A. & ROBERFROID, M. B. 2004. Dietary modulation of the human 
colonic microbiota: updating the concept of prebiotics. Nutrition Research Reviews, 17, 259-275. 
GIEL, J. L., SORG, J. A., SONENSHEIN, A. L. & ZHU, J. 2010. Metabolism of bile salts in mice influences spore germination in 
Clostridium difficile. Plos One, 5. 
GILLOR, O., ETZION, A. & RILEY, M. A. 2008. The dual role of bacteriocins as anti- and probiotics. Applied Microbiology and 
Biotechnology, 81, 591-606. 
GISMONDO, M. R., DRAGO, L. & LOMBARDI, A. 1999. Review of probiotics available to modify gastrointestinal flora. International 
Journal of Antimicrobial Agents, 12, 287-292. 
GIUBERTI, G., GALLO, A., MOSCHINI, M. & MASOERO, F. 2013. In vitro production of short-chain fatty acids from resistant starch 
by pig faecal inoculum. Animal, 7, 1446-1453. 
GOETZE, O., TREIER, R., FOX, M., STEINGOETTER, A., FRIED, M., BOESIGER, P. & SCHWIZER, W. 2009. The effect of gastric 
secretion  on  gastric  physiology  and  emptying  in  the  fasted  and  fed  state  assessed  by  magnetic  resonance  imaging. 
Neurogastroenterology and Motility, 21, 725-e42. 
GOLDENBERG, J. Z., MA, S. S., SAXTON, J. D., MARTZEN, M. R., VANDVIK, P. O., THORLUND, K., GUYATT, G. H. & 
JOHNSTON, B. C. 2013. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. 
Cochrane Database of Systematic Reviews, 5, CD006095. 
GOLDIN, B. R. & GORBACH, S. L. 1984. The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme-activity. 
American Journal of Clinical Nutrition, 39, 756-761. 
GOLDIN, B. R. 1998. Health benefits of probiotics. British Journal of Nutrition, 80, S203-S207. 
GOPAL, P. K., PRASAD, J., SMART, J. & GILL, H. S. 2001. In vitro adherence properties of Lactobacillus rhamnosus DR20 and 
Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. International 
Journal of Food Microbiology, 67, 207-216. 
GORBACH, S. L. 1971. Intestinal microflora. Gastroenterology, 60, 1110-1129. 
GORBACH, S. L., PLAUT, A. G., NAHAS, L., WEINSTEIN, L., SPANKNEBEL, G. & LEVITAN, R. 1967. Studies of intestinal 
microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology, 53, 856-67. 
GORDON, D. M. & O'BRIEN, C. L. 2006. Bacteriocin diversity and the frequency of multiple bacteriocin production in Escherichia coli. 
Microbiology, 152, 3239-3244. 
GORDON, H. A. & PESTI, L. 1971. The gnotobiotic animal as a tool in the study of host microbial relationships. Bacteriological reviews, 
35, 390-429. 
GORDON, J. I., TURNBAUGH, P. J., HAMADY, M., YATSUNENKO, T., CANTAREL, B. L., DUNCAN, A., LEY, R. E., SOGIN, M. 
L., JONES, W. J., ROE, B. A., AFFOURTIT, J. P., EGHOLM, M., HENRISSAT, B., HEATH, A. C. & KNIGHT, R. 2009. A 
core gut microbiome in obese and lean twins. Nature, 457, 480-484.   261 
GRACIAS, K. S. & MCKILLIP, J. L. 2004. A review of conventional detection and enumeration methods for pathogenic bacteria in food. 
Canadian Journal of Microbiology, 50, 883-890. 
GRANDY, G., MEDINA, M., SORIA, R., TERAN, C. G. & ARAYA, M. 2010. Probiotics in the treatment of acute rotavirus diarrhoea. A 
randomized,  double-blind,  controlled  trial  using  two  different  probiotic  preparations  in  Bolivian  children.  Bmc  Infectious 
Diseases, 10. 
GRANGER, D.N., BARROWMAN, J.A. & KVIETYS, P.R. 1985. Clinical gastrointestinal  physiology. WB. Saunders: Philadelphia. 
GRATTEPANCHE, F., LACROIX, C., AUDET, P. & LAPOINTE, G. 2005. Quantification by real-time PCR of Lactococcus lactis subsp 
cremoris in milk fermented by a mixed culture. Applied Microbiology and Biotechnology, 66, 414-421. 
GREEN,  P.  N.  &  WOODFORD,  S.  K.  1992.  Preservation  studies  on  some  obligately  methanotrophic  bacteria.  Letters  in  Applied 
Microbiology, 14, 158-162. 
GUARNER, F. & MALAGELADA, J. R. 2003a. Gut flora in health and disease. Lancet, 361, 512-519. 
GUARNER, F. & SCHAAFSMA, G. J. 1998. Probiotics. International Journal of Food Microbiology, 39, 237-238. 
GUINANE, C. M. & COTTER, P. D. 2013. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a 
hidden metabolic organ. Therapeutic Advances in Gastroenterology, 6, 295-308. 
GUO, B., HARSTALL, C., LOUIE, T., VAN ZANTEN, S. V. & DIELEMAN, L. A. 2012. Systematic review: faecal transplantation for 
the treatment of Clostridium difficile-associated disease. Alimentary Pharmacology & Therapeutics, 35, 865-875. 
GUO, H., YAO, J., CAI, M., QIAN, Y., GUO, Y., RICHNOW, H. H., BLAKE, R. E., DONI, S. & CECCANTI, B. 2012. Effects of 
petroleum contamination on soil microbial numbers, metabolic activity and urease activity. Chemosphere, 87, 1273-1280. 
GUSLANDI, M. 2007. Probiotic agents in the treatment of irritable bowel syndrome. Journal of International Medical Research, 35, 583-
589. 
HARRIGAN, W.F. 1998. Laboratory methods in food microbiology. Gulf Professional Publishing, Medical, 92-98. 
HARRISON, A. P. 1956. Causes of death of bacteria in frozen suspensions. Antonie Van Leeu Wenhoek Journal of Microbiology and 
Serology, 22, 407-418. 
HARTUNG, J. 1986. On the use of flow microcalorimetry in estimating the biological effect of adverse substances on Escherichia-coli .1. 
flow  microcalorimetric  assays  with  microorganisms  for  antibiotics  and  chemicals  (literature-review).  Zentralblatt  Fur 
Bakteriologie Mikrobiologie Und Hygiene Serie B-Umwelthygiene Krankenhaushygiene Arbeitshygiene Praventive Medizin, 
183, 36-46. 
HASLAM,  S.  C.,  KETLEY,  J.  M.,  MITCHELL,  T.  J.,  STEPHEN,  J.,  BURDON,  D.  W.  &  CANDY,  D.  C.  A.  1986.  Growth  of 
Clostridium-difficile and production of toxins A and B in complex and defined media. Journal of Medical Microbiology, 21, 
293-297. 
HASSAN, M., KJOS, M., NES, I. F., DIEP, D. B. & LOTFIPOUR, F. 2012. Natural antimicrobial peptides from bacteria: characteristics 
and potential applications to fight against antibiotic resistance. Journal of Applied Microbiology, 113, 723-736. 
HATAKKA, K., HOLMA, R., EL-NEZAMI, H., SUOMALAINEN, T., KUISMA, M., SAXELIN, M., POUSSA, T., MYKKANEN, H. & 
KORPELA, R. 2008. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. 
shermanii JS on potentially carcinogenic bacterial activity in human colon. International Journal of Food Microbiology, 128, 
406-10. 
HATAKKA, K., SAVILAHTI, E., PONKA, A., MEURMAN, J. H., POUSSA, T., NASE, L., SAXELIN, M. & KORPELA, R. 2001. 
Effect  of  long  term  consumption  of  probiotic  milk  on  infections  in  children  attending  day  care  centres:  double  blind, 
randomised trial. British Medical Journal, 322, 1327-1329. 
HAVENAAR, R. & HUIS IN'T VELD, J. H. J. 1992. Probiotics: A general view. The Lactic Acid Bacteria, Vol. 1; The lactic acid bacteria 
in health and disease, 151-170. 
HAYASHI, H., TAKAHASHI, R., NISHI, T., SAKAMOTO, M. & BENNO, Y. 2005. Molecular analysis of jejunal, ileal, caecal and 
recto-sigmoidal  human  colonic  microbiota  using  16S  rRNA  gene  libraries  and  terminal  restriction  fragment  length 
polymorphism. Journal of Medical Microbiology, 54, 1093-1101. 
HEALTH CANADA. Accepted claims about the nature of probiotic microorganisms in food. Health Canada. [online]. Available from: 
http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/probiotics_claims-allegations_probiotiques-eng.php%20(2009).  [30 
August 2014] 
HEALTH  PROTECTION  AGENCY.  Results  of  the  mandatory  Clostridium  difficile  reporting  scheme.  [online].  Available  from: 
http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/ 1195733750761. [12 June 2014] 
HEBUTERNE, X. 2003. Gut changes attributed to ageing: effects on intestinal microflora. Current Opinion in Clinical Nutrition and 
Metabolic Care, 6, 49-54.   262 
HECKLY, R. J. 1978. Preservation of microorganisms. Advances in Applied Microbiology, 24, 1–53. 
HEEG, D., BURNS, D. A., CARTMAN, S. T. & MINTON, N. P. 2012. Spores of Clostridium difficile clinical isolates display a diverse 
germination response to bile salts. Plos One, 7, e32381. 
HEGLER, F. & KAPPLER, A. 2010. Cryopreservation of anoxygenic phototrophic Fe(II)-oxidizing bacteria. Cryobiology, 61, 158-160. 
HEINE, W. 1996. The influence of different formulas on the intestinal microflora of infants. Monatsschrift Kinderheilkunde, 144, S169-
S173. 
HELL,  M.,  BERNHOFER,  C.,  STALZER,  P.,  KERN,  J.  M.  &  CLAASSEN,  E.  2013.  Probiotics in Clostridium difficile  infection: 
reviewing the need for a multistrain probiotic. Beneficial Microbes, 4, 39-51. 
HELLMIG, S., VON SCHÖNING, F., GADOW, C., KATSOULIS, S., HEDDERICH, J., FÖLSCH, U. R. & STÜBER, E. 2006. Gastric 
emptying time of fluids and solids in healthy subjects determined by 13C breath tests: influence of age, sex and body mass 
index. Journal of Gastroenterology and Hepatology, 21, 1832–1838. 
HENG, Z., CONGYI, Z., CUNXIN, W., JIBIN, W., CHAOJIANG, G., JIE, L. & YUWEN, L. 2005. Microcalorimetric study of virus 
infection - The effects of hyperthermia and alpha 1b recombinant homo interferon on the infection process of BHK-21 cells by 
foot and mouth virus. Journal of Thermal Analysis and Calorimetry, 79, 45-50. 
HERBEL, S. R., VAHJEN, W., WIELER, L. H. & GUENTHER, S. 2013. Timely approaches to identify probiotic species of the genus 
Lactobacillus. Gut Pathogens, 5, 27. 
HERNANDEZ GARCIA, A. 2011. Anhydrobiosis in bacteria: From physiology to applications. Journal of Biosciences, 36, 939-950. 
HERNANDEZ, D., CARDELL, E. & ZARATE, V. 2005. Antimicrobial activity of lactic acid bacteria isolated from Tenerife cheese: 
initial characterization of plantaricin TF711, a bacteriocin-like substance produced by Lactobacillus plantarum TF711. Journal 
of Applied Microbiology, 99, 77-84. 
HICKSON,  M.  2011.  Probiotics  in  the  prevention  of  antibiotic-associated  diarrhoea  and  Clostridium  difficile  infection.  Therapeutic 
Advances in Gastroenterology, 4, 185-97. 
HILL, C., GUARNER, F., REID, G., GIBSON, G. R., MERENSTEIN, D. J., POT, B., MORELLI, L., CANANI, R. B., FLINT, H. J., 
SALMINEN,  S.,  CALDER,  P.  C.  &  SANDERS,  M.  E.  2014.  Expert  consensus  document:  The  International  Scientific 
Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature 
reviews. Gastroenterology & Hepatology, 11, 506-14. 
HILL, M. J. & DRASAR, B. S. 1975. Normal colonic bacterial-flora. Gut, 16, 318-323. 
HILL, M. J. 1997. Intestinal flora and endogenous vitamin synthesis. European Journal of Cancer Prevention, 6, S43-S45. 
HOFFMAN, L. R., DEZIEL, E., D'ARGENIO, D. A., LEPINE, F., EMERSON, J., MCNAMARA, S., GIBSON, R. L., RAMSEY, B. W. 
&  MILLER,  S.  I.  2006.  Selection  for  Staphylococcus  aureus  small-colony  variants  due  to  growth  in  the  presence  of 
Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences of the United States of America, 103, 19890-19895. 
HOLDEMAN, L. V., GOOD, I. J. & MOORE, W. E. C. 1976. Human Fecal Flora - Variation in Bacterial Composition within Individuals 
and a Possible Effect of Emotional Stress. Applied and Environmental Microbiology, 31, 359-375. 
HOOKMAN,  P.  &  BARKIN,  J.  S.  2009.  Clostridium  difficile  associated  infection,  diarrhea  and  colitis.  World  Journal  of 
Gastroenterology, 15, 1554-1580. 
HOOPER, L. V. & GORDON, J. I. 2001. Commensal host-bacterial relationships in the gut. Science, 292, 1115-1118. 
HOOVER, D.G. & HARLANDER, S.K. 1993. Screening methods for detecting bacteriocin activity. In Hoover, D.G. & Steenscr, L.R. 
1993. Bacteriocins of lactic acid bacteria. Academic press, California, USA, 23-39. 
HOSKISSON, P. A. & HOBBS, G. 2005. Continuous culture - making a comeback? Microbiology-Sgm, 151, 3153-3159. 
HOWELL, M., WIRZ, D., DANIELS, A. U. & BRAISSANT, O. 2012. Application of a microcalorimetric method for determining drug 
susceptibility in mycobacterium species. Journal of Clinical Microbiology, 50, 16-20. 
HPA  Summary  points  on  Clostridium  difficile  Infection  (CDI).  2011.  [online].  Available  from: 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1278944283388. [21 July 2014]. 
HUANG, H., WEINTRAUB, A., FANG, H. & NORD, C. E. 2009. Antimicrobial resistance in Clostridium difficile. International Journal 
of Antimicrobial Agents, 34, 516-522. 
HUANG,  Y.  &  ADAMS,  M.  C.  2004.  In  vitro  assessment  of  the  upper  gastrointestinal  tolerance  of  potential  probiotic  dairy 
propionibacteria. International Journal of Food Microbiology, 91, 253-260. 
HUBALEK, Z. 2003. Protectants used in the cryopreservation of microorganisms. Cryobiology, 46, 205-29. 
HUGHES, S. A., SHEWRY, P. R., GIBSON, G. R., MCCLEARY, B. V. & RASTALL, R. A. 2008. In vitro fermentation of oat and barley 
derived beta-glucans by human faecal microbiota. Fems Microbiology Ecology, 64, 482-493.   263 
HURLEY, B. W. & NGUYEN, C. C. 2002. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Archives 
of Internal Medicine, 162, 2177-2184. 
HUTT, P., SHCHEPETOVA, J., LOIVUKENE, K., KULLISAAR, T. & MIKELSAAR, M. 2006. Antagonistic activity of probiotic 
lactobacilli and bifidobacteria against entero- and uropathogens. Journal of Applied Microbiology, 100, 1324-32. 
HWANG, S. W. 1966. Long-term preservation of fungus cultures with liquid nitrogen refrigeration. Applied Microbiology, 14, 784-788. 
IANNITTI, T. & PALMIERI, B. 2010. Therapeutical use of probiotic formulations in clinical practice. Clinical Nutrition, 29, 701-725. 
ILETT, K. F., TEE, L. B. G., REEVES, P. T. & MINCHIN, R. F. 1990. Metabolism of drugs and other xenobiotics in the gut lumen and 
wall. Pharmacology & Therapeutics, 46, 67-93. 
ISLAM, J., COHEN, J., RAJKUMAR, C. & LLEWELYN, M. J. 2012. Probiotics for the prevention and treatment of Clostridium difficile 
in older patients. Age Ageing, 41, 706-711. 
ISLAM, M. A., YUN, C. H., CHOI, Y. J. & CHO, C. S. 2010. Microencapsulation of live probiotic bacteria. Journal of Microbiology and 
Biotechnology, 20, 1367-1377. 
ISOLAURI, E., ARVOLA, T., SUTAS, Y., MOILANEN, E. & SALMINEN, S. 2000. Probiotics in the management of atopic eczema. 
Clinical and Experimental Allergy, 30, 1604-1610. 
IYER,  C.  &  KAILASAPATHY,  K.  2005.  Effect  of  co-encapsulation  of  probiotics  with  prebiotics  on  increasing  the  viability  of 
encapsulated bacteria under in vitro acidic and bile salt conditions and in yogurt. Journal of Food Science, 70, M18-M23. 
JACK, R. W., TAGG, J. R. & RAY, B. 1995. Bacteriocins of Gram-positive bacteria. Microbiological Reviews, 59, 171-200. 
JANTRATID, E., JANSSEN, N., REPPAS, C. & DRESSMAN, J. B. 2008. Dissolution media simulating conditions in the proximal 
human gastrointestinal tract: An update. Pharmaceutical Research, 25, 1663-1676. 
JARA, S., SANCHEZ, M., VERA, R., COFRE, J. & CASTRO, E. 2011. The inhibitory activity of Lactobacillus spp. isolated from breast 
milk on gastrointestinal pathogenic bacteria of nosocomial origin. Anaerobe, 17, 474-477. 
JENSEN, H., GRIMMER, S., NATERSTAD, K. & AXELSSON, L. 2012. In vitro testing of commercial and potential probiotic lactic acid 
bacteria. International Journal of Food Microbiology, 153, 216-222. 
JIMENEZDIAZ, R., RIOSSANCHEZ, R. M., DESMAZEAUD, M., RUIZBARBA, J. L. & PIARD, J. C. 1993. Plantaricins S and T, 2 
new  bacteriocins  produced  by  Lactobacillus-plantarum  lpco10  isolated  from  a  green  olive  fermentation.  Applied  and 
Environmental Microbiology, 59, 1416-1424. 
JOHANSSON, P. & WADSO, I. 1999a. Towards more specific information from isothermal microcalorimetric measurements on living 
systems. Journal of Thermal Analysis and Calorimetry, 57, 275-281. 
JOHANSSON,  P.  &  WADSO,  I.  1999b.  An  isothermal  microcalorimetric  titration/perfusion  vessel  equipped  with  electrodes  and 
spectrophotometer. Thermochimica Acta, 342, 19-29.  
JOHNSON, A. P. & WILCOX, M. H. 2012. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. Journal of 
Antimicrobial Chemotherapy, 67, 2788-2792. 
JORGENSEN, J. H. & FERRARO, M. J. 2000. Antimicrobial susceptibility testing: Special needs for fastidious organisms and difficult-
to-detect resistance mechanisms. Clinical Infectious Diseases, 30, 799-808. 
JORGENSEN, J. H. & FERRARO, M. J. 2009. Antimicrobial Susceptibility Testing: A review of general principles and contemporary 
practices. Clinical Infectious Diseases, 49, 1749-1755. 
JUMP, R. L. P., PULTZ, M. J. & DONSKEY, C. J. 2007. Vegetative Clostridium difficile survives in room air on moist surfaces and in 
gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C-
difficile-associated diarrhea? Antimicrobial Agents and Chemotherapy, 51, 2883-2887. 
KABANOVA, N., KAZARJAN, A., STULOVA, I. & VILU, R. 2009. Microcalorimetric study of growth of Lactococcus lactis IL1403 at 
different glucose concentrations in broth. Thermochimica Acta, 496, 87-92. 
KAILASAPATHY,  K.  &  CHIN,  J.  2000.  Survival  and  therapeutic  potential  of  probiotic  organisms  with  reference  to  Lactobacillus 
acidophilus and Bifidobacterium spp. Immunology & Cell Biology, 78, 80-88. 
KALAKOUTSKIAI, L.V & POZHARITSKA, L.M 1968. Calorimetric studies on germinating and quiescent conidia of Actinomyces 
streptomycini B-6. Journal of General and Applied Microbiology, 14, 209-212. 
KALANTZI, L., GOUMAS, K., KALIORAS, V., ABRAHAMSSON, B., DRESSMAN, J. B. & REPPAS, C. 2006. Characterization of 
the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharmaceutical 
Research, 23, 165-176. 
KALLIOMAKI, M., SALMINEN, S., ARVILOMMI, H., KERO, P., KOSKINEN, P. & ISOLAURI, E. 2001. Probiotics in primary 
prevention of atopic disease: a randomised placebo-controlled trial. Lancet, 357, 1076-1079.   264 
KANG, K. H., SHIN, H. J., PARK, Y. H., LEE, T. S., 1989. Studies on the antibacterial substances produced by lactic acid bacteria: 
purification and some properties of antibacterial substance ‘Bifilong’ produced by B. longum. Korean Dairy Science 1, 204–
216. 
KARLSSON, S., DUPUY, B., MUKHERJEE, K., NORIN, E., BURMAN, L. G. & AKERLUND, T. 2003. Expression of Clostridium 
difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infection and Immunity, 71, 1784-1793. 
KAWAI, Y., SAITOH, B., TAKAHASHI, O., KITAZAWA, H., SAITO, T., NAKAJIMA, H. & ITOH, T. 2000. Primary amino acid and 
DNA  sequences  of  gassericin  T,  a  lactacin  F-family  bacteriocin  produced  by  Lactobacillus  gasseri  SBT2055.  Bioscience 
Biotechnology and Biochemistry, 64, 2201-2208. 
KAWASE, K., SUZUKI, T., KIYOSAWA, I., OKONOGI, S., KAWASHIMA, T. & KUBOYAMA, M. (1983) Effects of composition of 
infant's formulas on the intestinal microflora of infants. Bifidobacteria Microflora 2: 25-31. 
KEITH, S. C. 1913. Factors influencing the survival of bacteria at temperatures in the vicinity of the freezing point of water. Science, 37, 
877-879. 
KELLY, C. P. & LAMONT, J. T. 2008. Clostridium difficile - More difficult than ever. New England Journal of Medicine, 359. 
KHAN, N. H., AHSAN, M., TAYLOR, W. D. & KOGURE, K. 2010. Culturability and survival of marine, freshwater and clinical 
Pseudomonas aeruginosa. Microbes and Environments, 25, 266-274. 
KIM, M. N., KIM, N., LEE, S. H., PARK, Y. S., HWANG, J. H., KIM, J. W., JEONG, S. H., LEE, D. H., KIM, J. S., JUNG, H. C. & 
SONG, I. S. 2008. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter, 13, 261-
268. 
KLUGE, S., HOFFMANN, M., BENNDORF, D., RAPP, E. & REICHL, U. 2012. Proteomic tracking and analysis of a bacterial mixed 
culture. Proteomics, 12, 1893-1901. 
KONG, W. J., WANG, J. B., JIN, C., ZHAO, Y. L., DAI, C. M., XIAO, X. H. & LI, Z. L. 2009. Effect of emodin on Candida albicans 
growth investigated by microcalorimetry combined with chemometric analysis. Applied Microbiology and Biotechnology, 83, 
1183-1190. 
KONG, W. J., XING, X. Y., XIAO, X. H., ZHAO, Y. L., WEI, J. H., WANG, J. B., YANG, R. C. & YANG, M. H. 2012. Effect of 
berberine on Escherichia coli, Bacillus subtilis, and their mixtures as determined  by isothermal microcalorimetry. Applied 
Microbiology and Biotechnology, 96, 503-510. 
KOS,  B.,  SUSKOVIC,  J.,  BEGANOVIC,  J.,  GJURACIC,  K.,  FRECE,  J.,  IANNACCONE,  C.  &  CANGANELLA,  F.  2008. 
Characterization of the three selected probiotic strains for the application in food industry. World Journal of Microbiology & 
Biotechnology, 24, 699-707. 
KOTSOU, M. G., MITSOU, E. K., OIKONOMOU, I. G. & KYRIACOU, A. A. 2008. In vitro assessment of probiotic properties of 
Lactobacillus strains from infant gut microflora. Food Biotechnology, 22, 1-17. 
KRAMER, M., OBERMAJER, N., MATIJASIC, B. B., ROGELJ, I. & KMETEC, V. 2009. Quantification of live and dead probiotic 
bacteria in lyophilised product by real-time PCR and by flow cytometry. Applied Microbiology and Biotechnology, 84, 1137-
1147. 
KUEHNE, S. A., COLLERY, M. M., KELLY, M. L., CARTMAN, S. T., COCKAYNE, A. & MINTON, N. P. 2014. Importance of Toxin 
A, Toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. Journal of Infectious Diseases, 209, 83-86. 
KUIJPER, E. J., BARBUT, F., BRAZIER, J. S., KLEINKAUF, N., ECKMANNS, T., LAMBERT, M. L., DRUDY, D., FITZPATRICK, 
F., WIUFF, C., BROWN, D. J., COIA, J. E., PITUCH, H., REICHERT, P., EVEN, J., MOSSONG, J., WIDMER, A. F., 
OLSEN, K. E., ALLERBERGER, F., NOTERMANS, D. W., DELMEE, M., COIGNARD, B., WILCOX, M., PATEL, B., 
FREI, R., NAGY, E., BOUZA, E., MARIN, M., AKERLUND, T., VIROLAINEN-JULKUNEN, A., LYYTIKAINEN, O., 
KOTILA,  S.,  INGEBRETSEN,  A.,  SMYTH,  B.,  ROONEY,  P.,  POXTON,  I.  R.  &  MONNET,  D.  L.  2008.  Update  of 
Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin, 13. 
KUIJPER, E. J., COIGNARD, B., TULL, P., ESGCD & ECDC 2006. Emergence of Clostridium difficile-associated disease in North 
America and Europe. Clinical Microbiology and Infection, 12, 2-18. 
KUMAGAI, H., KUMAGAE, S., MITANI, K. & ENDO, T. 2004. Effects of supplementary probiotics to two different diets on dry matter 
intake, daily gain, digestibility, ruminal pH, and fecal microbial populations and metabolites in ewes. Animal Science Journal, 
75, 219-224. 
KURTMANN, L., CARLSEN, C. U., RISBO, J. & SKIBSTED, L. H. 2009. Storage stability of freeze-dried Lactobacillus acidophilus 
(La-5) in relation to water activity and presence of oxygen and ascorbate. Cryobiology, 58, 175-180.   265 
LAGO RIVERO, N., LEGIDO SOTO, J. L., ARIAS SANTOS, I. & CASAS, L. M. 2013. Differentiation between Staphylococcus aureus 
and Staphylococcus epidermidis using microcalorimetry. International Journal of Thermophysics, 34, 1039-1048. 
LAGO RIVERO, N., LEGIDO, J. L., ARIAS SANTOS, I. & CASAS, L. M. 2012. Comparative study of microcalorimetric behavior of 
Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae. Polish Journal of Microbiology, 61, 199-204. 
LAGO, N., LEGIDO, J. L., PAZ ANDRADE, M. I., ARIAS, I. & CASAS, L. M. 2011. Microcalorimetric study on the growth and 
metabolism of Pseudomonas aeruginosa. Journal of Thermal Analysis and Calorimetry, 105, 651-655. 
LAMBERT, R., MARTIN, F. & VAGNE, M. 1968. Relationship between hydrogen ion and pepsin  - concentration in human gastric 
secretion. Digestion, 1, 65-77. 
LAMONT, J. T. 2002. Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies. Transactions of the 
American Clinical and Climatological Association, 113, 167-80; discussion 180-181. 
LAN, Y., WILLIAMS, B. A., VERSTEGEN, M. W. A., PATTERSON, R. & TANIMINGA, S. 2007. Soy oligosaccharides in vitro 
fermentation characteristics and its effect on caecal microorganisms of young broiler chickens.  Animal Feed Science and 
Technology, 133, 286-297. 
LANGWORTHY, D. E., METZ, K. A. & DAWES, S. M. 2002. Flow cytometric methods for the study of bacteria and protozoan parasites 
in environmental matrices. Abstracts of the General Meeting of the American Society for Microbiology, 102, 386. 
LARSEN, N., VOGENSEN, F. K., VAN DEN BERG, F. W. J., NIELSEN, D. S., ANDREASEN, A. S., PEDERSEN, B. K., ABU AL-
SOUD, W., SORENSEN, S. J., HANSEN, L. H. & JAKOBSEN, M. 2010. Gut microbiota in human adults with type 2 diabetes 
differs from non-diabetic adults. Plos One, 5. 
LARSON,  H.  E.,  PARRY,  J.  V.,  PRICE,  A.  B.,  DAVIES,  D.  R.,  DOLBY,  J.  &  TYRRELL,  D.  A.  1977.  Undescribed  toxin  in 
pseudomembranous colitis. British medical journal, 1, 1246-8. 
LAWLEY, T. D. & WALKER, A. W. 2013. Intestinal colonization resistance. Immunology, 138, 1-11. 
LEE, H. M. & LEE, Y. 2008. A differential medium for lactic acid-producing bacteria in a mixed culture. Letters in Applied Microbiology, 
46, 676-681. 
LEE,  Y.  J.,  YU,  W.  K.  &  HEO,  T.  R. 2003.  Identification  and  screening  for  antimicrobial activity  against Clostridium difficile  of 
Bifidobacterium and Lactobacillus species isolated from healthy infant faeces. International Journal of Antimicrobial Agents, 
21, 340-346. 
LEMA, M., WILLIAMS, L. & RAO, D. R. 2001. Reduction of fecal shedding of enterohemorrhagic Escherichia coli O157 : H7 in lambs 
by feeding microbial feed supplement. Small Ruminant Research, 39, 31-39. 
LESLIE, S. B., ISRAELI, E., LIGHTHART, B., CROWE, J. H. & CROWE, L. M. 1995. Trehalose and sucrose protect both membranes 
and proteins in intact bacteria during drying. Applied and Environmental Microbiology, 61, 3592-3597. 
LESMES, U., BEARDS, E. J., GIBSON, G. R., TUOHY, K. M. & SHIMONI, E. 2008. Effects of resistant starch type III polymorphs on 
human colon microbiota and short chain fatty acids in human gut models. Journal of Agricultural and Food Chemistry, 56, 
5415-5421. 
LEVISON, M. 1977. Factors influencing colonization of the gastrointestinal tract with Pseudomonas auruginosa. In Bergey’s manual of 
systemic bacteriology, 2nd ed. Bergey’s manual trust, Springer Science+Business Media. Inc., 233 Spring Street: New York 2, 
323-359. 
LEY, R. E., BACKHED, F., TURNBAUGH, P., LOZUPONE, C. A., KNIGHT, R. D. & GORDON, J.  I. 2005. Obesity alters gut 
microbial ecology. Proceedings of the National Academy of Sciences U S A, 102, 11070-11075. 
LEY, R. E., LOZUPONE, C. A., HAMADY, M., KNIGHT, R. & GORDON, J. I. 2008. Worlds within worlds: evolution of the vertebrate 
gut microbiota. Nature Reviews Microbiology, 6, 776-788. 
LEY, R. E., PETERSON, D. A. & GORDON, J. I. 2006a. Ecological and evolutionary forces shaping microbial diversity in the human 
intestine. Cell, 124, 837-48. 
LEY, R. E., TURNBAUGH, P. J., KLEIN, S. & GORDON, J. I. 2006b. Microbial ecology - Human gut microbes associated with obesity. 
Nature, 444, 1022-1023. 
LI, X., LIU, Y., WU, J. & QU, S. S. 2002. Action of the selenomorpholine compounds on the bacterium growth by microcalorimetry. 
Chinese Journal of Chemistry, 20, 829-833. 
LI, X., LIU, Y., ZHAO, R. M., WU, J., SHEN, X. S. & QU, S. S. 2000. Microcalorimetric study of Escherichia coli growth inhibited by 
the selenomorpholine complexes. Biological Trace Element Research, 75, 167-175. 
LIDDELL,  J.  2014.  Gut  bacteria  can  prevent  most  diseases  including  autoimmune  diseases.  [online].  Available  from: 
http://lifestyleclinic.co.za/auto-immune-diseases-2/ [18 September 2014]   266 
LIESACK, W. & STACKEBRANDT, E. 1992. Unculturable microbes detected by molecular sequences and probes. Biodiversity and 
Conservation, 1, 250-262. 
LILLY, D. M. & STILLWEL.RH 1965. Probiotics - Growth-promoting factors produced by microorganisms. Science, 147, 747-748. 
LIM, K. S., HUH, C. S., BAEK, Y. J. & KIM, H. U. 1995. A selective enumeration medium for bifidobacteria in fermented dairy-
products. Journal of Dairy Science, 78, 2108-2112. 
LIN, W. H., HWANG, C. F., CHEN, L. W. & TSEN, H. Y. 2006. Viable counts, characteristic evaluation for commercial lactic acid 
bacteria products. Food Microbiology, 23, 74-81. 
LINDAHL, A., UNGELL, A. L., KNUTSON, L. & LENNERNAS, H. 1997. Characterization of fluids from the stomach and proximal 
jejunum in men and women. Pharmaceutical Research, 14, 497-502. 
LINDENEG, O., MELLEMGAARD, K., FABRICIUS, J. & LUNDQUIST, F. 1964. Myocardial utilization of acetate, lactate and free 
fatty acids after ingestion of ethanol. Clinical Science, 27, 427-35. 
LINTON, A. H. 1983. Theory of antibiotic inhibition zone formation, disc sensitivity methods and MIC determinations. In Denver, A.D. & 
Quesnel, L.B. 1983. Antibiotic: Assessment of antimicrobial activity and resistance. Academic Press, Inc. London, 19-30. 
LIVNEY, Y. D. 2010. Milk proteins as vehicles for bioactives. Current Opinion in Colloid & Interface Science, 15, 73-83. 
LJUNGHOLM, K., WADSO, I. & MARDH, P. A. 1976. Microcalorimetric detection of growth of mycoplasmatales. Journal of General 
Microbiology, 96, 283-288. 
LONG, S. S. & SWENSON, R. M. 1977. Development of anaerobic fecal flora in healthy newborn infants. Journal of Pediatrics, 91, 298-
301. 
LOVELOCK, J. E. & BISHOP, M. W. H. 1959. Prevention of freezing damage to living cells by dimethyl sulphoxide. Nature, 183, 1394-
1395. 
LOVELOCK, J. E. 1953. The mechanism of the protective action of glycerol against haemolysis by freezing and thawing. Biochimica Et 
Biophysica Acta, 11, 28-36. 
LU, L. & WALKER, W. A. 2001. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium.  American 
Journal of Clinical Nutrition, 73, 1124S-1130S. 
LYERLY, D. M., KRIVAN, H. C. & WILKINS, T. D. 1988. Clostridium difficile: its disease and toxins. Clinical Microbiology Reviews, 
1, 1-18. 
LYRAS, D., O'CONNOR, J. R., HOWARTH, P. M., SAMBOL, S. P., CARTER, G. P., PHUMOONNA, T., POON, R., ADAMS, V., 
VEDANTAM, G., JOHNSON, S., GERDING, D. N. & ROOD, J. I. 2009. Toxin B is essential for virulence of Clostridium 
difficile. Nature, 458, 1176-1181. 
MACCONNACHIE, A. A., FOX, R., KENNEDY, D. R. & SEATON, R. A. 2009. Faecal transplant for recurrent Clostridium difficile-
associated diarrhoea: a UK case series. Qjm-an International Journal of Medicine, 102, 781-784. 
MACFARLANE, G. T. & MACFARLANE, S. 1997. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal 
bacteria. Scandinavian Journal of Gastroenterology Supplement, 222, 3-9. 
MACFARLANE, G. T., CUMMINGS, J. H. & ALLISON, C. 1986. Protein-degradation by human intestinal bacteria. Journal of General 
Microbiology, 132, 1647-1656. 
MACFARLANE,  G.  T.,  STEED,  H.  &  MACFARLANE,  S.  2008.  Bacterial  metabolism  and  health-related  effects  of  galacto-
oligosaccharides and other prebiotics. Journal of Applied Microbiology, 104, 305-344. 
MACFARLANE, S. & MACFARLANE, G. T. 2004. Bacterial diversity in the human gut. Advances in Applied Microbiology, 54, 261-
289. 
MACFARLANE,  S.,  MACFARLANE,  G.  T.  &  CUMMINGS,  J.  H.  2006.  Review  article:  prebiotics  in  the  gastrointestinal  tract. 
Alimentary Pharmacology & Therapeutics, 24, 701-714. 
MACHAN,  Z.  A.,  TAYLOR,  G.  W.,  PITT,  T.  L.,  COLE,  P.  J.  &  WILSON,  R.  1992.  2-Heptyl-4-hydroxyquinoline  N-oxide,  an 
antistaphylococcal agent produced by Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 30, 615-623. 
MACPHERSON, A. J. & HARRIS, N. L. 2004. Interactions between commensal intestinal bacteria and the immune system.  Nature 
Reviews Immunology, 4, 478-485. 
MACY, J. M. & PROBST, I. 1979. The biology of gastrointestinal bacteroides. Annual Review of Microbiology, 33, 561-594. 
MADIGAN, M. T., MARTINKO, J. M. & PARKER J. 1997. Clinical and diagnostic microbiology and immunology, Brock biology of 
microorganisms. Prentice Hall, International, Inc., Englewood Cliffs, N. J., 876–877. 
MAJAMAA, H. & ISOLAURI, E. 1997. Probiotics: A novel approach in the management of food allergy. Journal of Allergy and Clinical 
Immunology, 99, 179-185.   267 
MAJHENIC, A. C., VENEMA, K., ALLISON, G. E., MATIJASIC, B. B., ROGELJ, I. & KLAENHAMMER, T. R. 2004. DNA analysis 
of the genes encoding acidocin LF221 A and acidocin LF221 B, two bacteriocins produced by Lactobacillus gasseri LF221. 
Applied Microbiology and Biotechnology, 63, 705-14. 
MALAGELADA, J. R., LONGSTRETH, G. F., SUMMERSKILL, W. H. J. & GO, V. L. W. 1976. Measurement of gastric functions 
during digestion of ordinary solid meals in man. Gastroenterology, 70, 203-210. 
MALIN, M., VERRONEN, P., KORHONEN, H., SYVAOJA, E. L., SALMINEN, S., MYKKANEN, H., ARVILOMMI, H., EEROLA, E. 
& ISOLAURI, E. 1997. Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with 
juvenile chronic arthritis: Evaluation of effect on gut defence mechanisms. Inflammopharmacology, 5, 219-236. 
Mandatory  MRSA,  MSSA  and  E.  coli  bacteraemia  and  C.  difficile  infection  data,  2013/14.    [online].  Available  from: 
https://www.gov.uk/government/collections/clostridium-difficile-guidance-data-and-analysis. [10 July 2014] 
MARCIANI, L., GOWLAND, P. A., SPILLER, R. C., MANOJ, P., MOORE, R. J., YOUNG, P. & FILLERY-TRAVIS, A. J. 2001. Effect 
of  meal  viscosity  and  nutrients  on  satiety,  intragastric  dilution,  and  emptying  assessed  by  MRI.  American  Journal  of 
Physiology-Gastrointestinal and Liver Physiology, 280, G1227-G1233. 
MARELLI, G., PAPALEO, E. & FERRARI, A. 2004. Lactobacilli for prevention of urogenital infections: a review. European review for 
medical and pharmacological sciences, 8, 87-95. 
MAROO, S. & LAMONT, J. T. 2006. Recurrent Clostridium difficile. Gastroenterology, 130, 1311-1316. 
MARTINEZ, R. C., FRANCESCHINI, S. A., PATTA, M. C., QUINTANA, S. M., GOMES, B. C., DE MARTINIS, E. C. & REID, G. 
2009.  Improved  cure  of  bacterial  vaginosis  with  single  dose  of  tinidazole  (2  g),  Lactobacillus  rhamnosus  GR-1,  and 
Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Canadian Journal of Microbiology, 55, 133-
138. 
MARY, P., OCHIN, D. & TAILLIEZ, R. 1986. Growth status of rhizobia in relation to their tolerance to low  water activities and 
desiccation stresses. Soil Biology & Biochemistry, 18, 179-184. 
MASCO, L., CROCKAERT, C., VAN HOORDE, K., SWINGS, J. & HUYS, G. 2007. In vitro assessment of the gastrointestinal transit 
tolerance of taxonomic reference strains from human origin and probiotic product isolates of Bifidobacterium. Journal of Dairy 
Science, 90, 3572-3578. 
MASKOW, T., KEMP, R., BUCHHOLZ, F., SCHUBERT, T., KIESEL, B. & HARMS, H. 2010. What heat is telling us about microbial 
conversions in nature and technology: from chip- to megacalorimetry. Microbial Biotechnology, 3, 269-284. 
MASOOD, M. I., QADIR, M. I., SHIRAZI, J. H. & KHAN, I. U. 2011. Beneficial effects of lactic acid bacteria on human beings. Critical 
Reviews in Microbiology, 37, 91-98. 
MAUKONEN,  J.,  ALAKOMI,  H.-L.,  NOHYNEK,  L.,  HALLAMAA,  K.,  LEPPÄMÄKI,  S.,  MÄTTÖ,  J.  &  SAARELA,  M.  2006. 
Suitability  of  the  fluorescent techniques  for the  enumeration  of probiotic  bacteria in  commercial non-dairy  drinks  and  in 
pharmaceutical products. Food Research International, 39, 22-32. 
MAZUR, P., LEIBO, S. P. & CHU, E. H. Y. 1972. A two factor hypothesis of freezing injury. Experimental Cell Research, 71, 345-355. 
MCCONNELL, E. L., FADDA, H. M. & BASIT, A. W. 2008b. Gut instincts: explorations in intestinal physiology and drug delivery. 
International Journal of Pharmaceutics, 364, 213-226. 
MCCONNELL, E. L., SHORT, M. D. & BASIT, A. W. 2008a. An in vivo comparison of intestinal pH and bacteria as physiological 
trigger mechanisms for colonic targeting in man. Journal of Control Release, 130, 154-160. 
MCDANIEL, L. E. & BAILEY, E. G. 1968. Liquid nitrogen preservation of standard inoculum: gas-phase storage. Applied Microbiology, 
16, 912-916. 
MCDONALD, L. C., OWINGS, M. & JERNIGAN, D. B. 2006. Clostridium difficile infection in patients discharged from US short-stay 
hospitals, 1996-2003. Emerging Infectious Diseases, 12, 409-415. 
MCFARLAND,  L. V., SURAWICZ, C. M. & STAMM, W. E. 1990. Risk-factors for Clostridium-difficile carriage and C-difficile-
associated diarrhea in a cohort of hospitalized-patients. Journal of Infectious Diseases, 162, 678-684. 
MCFARLAND,  L.  V.,  SURAWICZ,  C.  M.,  RUBIN,  M.,  FEKETY,  R.,  ELMER,  G.  W.  &  GREENBERG,  R.  N.  1999.  Recurrent 
Clostridium difficile disease: Epidemiology and clinical characteristics. Infection Control and Hospital Epidemiology, 20, 43-
50. 
MCMASTER-BAXTER, N. L. & MUSHER, D. M. 2007. Clostridium difficile: Recent epidemiologic findings and advances in therapy. 
Pharmacotherapy, 27, 1029-1039. 
MEDSCAPE.  March  2014.  Clostridium  difficile  colitis.  [online].  Available  from:    http://emedicine.medscape.com/article/186458-
overview#aw2aab6b2b4 [Accessed on 7 May 2014]  
MERYMAN, H. T. 1971. Cryoprotective Agents. Cryobiology, 8, 173-183.   268 
MESSENS, W. & DE, V. L. 2002. Inhibitory substances produced by Lactobacilli isolated from sourdoughs--a review. International 
Journal of Food Microbiology, 72, 31-43. 
METCHNIKOFF, E. 1908. The microbes of intestinal putrefaction. Comptes Rendus Hebdomadaires Des Seances De L Academie Des 
Sciences, 147, 579-582. 
MEYERHOF, O. 1924. “Chemical dynamics in life phenomena”. Monograph, 110.  
MICHEL-BRIAND, Y. & BAYSSE, C. 2002. The pyocins of Pseudomonas aeruginosa. Biochimie, 84, 499-510. 
MINAMI,  Y.,  YAZAWA,  K.,  TAMURA,  Z.,  TANAKA,  T.  &  YAMAMOTO,  T.  1983.  Selectivity  of  utilization  of  galactosyl-
oligosaccharides by bifidobacteria. Chemical & Pharmaceutical Bulletin, 31, 1688-1691. 
MINELLI, E. B. & BENINI, A. 2008. Relationship between number of bacteria and their probiotic effects. Microbial Ecology in Health 
and Disease, 20, 180-183. 
MINISTERO DELLA SALUTE, Commissione unica per la nutrizione e la dietetica. Guidelines on probiotics and prebiotics. Ministero 
della Salute. [online]. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1016_allegato.pdf. [30 August 2014] 
MISHRA, C. & LAMBERT, J. 1996. Production of anti-microbial substances by probiotics. Asia Pacific journal of clinical nutrition, 5, 
20-24. 
MISHRA, V. & PRASAD, D. N. 2005. Application of in vitro methods for selection of Lactobacillus casei strains as potential probiotics. 
International Journal of Food Microbiology, 103, 109-115. 
MITSUOKA, T. 1984. The effect of nutrition on intestinal flora. Nahrung, 28, 619-625. 
MITTY, R. D. & LAMONT, J. T. 1994. Clostridium difficile diarrhea: pathogenesis, epidemiology, and treatment. The Gastroenterologist, 
2, 61-69. 
MOBERG, L. J. & SUGIYAMA, H. 1979. Microbial ecological basis of infant botulism as studied with germfree-mice. Infection and 
Immunity, 25, 653-657. 
MODABER, I. 1975. Clostridium-difficile. Acta Medica Iranica, 18, 111-128. 
MOKARRAM, R. R., MORTAZAVI, S. A., NAJAFI, M. B. H. & SHAHIDI, F. 2009. The influence of multi stage alginate coating on 
survivability of potential probiotic bacteria in simulated gastric and intestinal juice. Food Research International, 42, 1040-
1045. 
MOLL, W. M., UNGERECHTS, J., MARKLEIN, G. & SCHAAL, K. P. 1996. Comparison of BBL Crystal(R) ANR ID Kit and API rapid 
ID 32 A for identification of anaerobic bacteria. Zentralblatt Fur Bakteriologie-International Journal of Medical Microbiology 
Virology Parasitology and Infectious Diseases, 284, 329-347. 
MOLLY, K., VANDEWOESTYNE, M., DESMET, I. & VERSTRAETE, W. 1994. Validation of the simulator of the human intestinal 
microbial ecosystem (shime) reactor using microorganism-associated activities. Microbial Ecology in Health and Disease, 7, 
191-200. 
MONK, P. & WADSO, I. 1968. A flow micro reaction calorimeter. Acta Chemica Scandinavica, 22, 1842-1852. 
MONK, P. & WADSO, I. 1975. Use of microcalorimetry for bacterial classification. Journal of Applied Bacteriology, 38, 71-74. 
MONK, P. & WADSO, I. 1975. Use of microcalorimetry for bacterial classification. Journal of Applied Bacteriology, 38, 71-74. 
MONOD, J. 1949. The growth of bacterial cultures. Annual Review of Microbiology, 3, 371-394. 
MONOD, J. 1950. La technique de culture continue theorie et applications. Annales De L Institut Pasteur, 79, 390-410. 
MOORE, W. E. C. & HOLDEMAN, L. V. 1974. Human fecal flora - normal flora of 20 Japanese-Hawaiians. Applied Microbiology, 27, 
961-979. 
MOORE, W. E. C., CATO, E. P. & HOLDEMAN, L. V. 1969. Anaerobic bacteria of gastrointestinal flora and their occurrence in clinical 
infections. Journal of Infectious Diseases, 119, 641-649.  
MOORE, W. E. C., RYSER, M. & HOLDEMAN, L. V. 1975. Predominant kinds of bacteria in gastro intestinal contents. Abstracts of the 
Annual Meeting of the American Society for Microbiology, 75, 61. 
MORENO, Y., COLLADO, M. C., FERRUS, M. A., COBO, J. M., HERNANDEZ, E. & HERNANDEZ, M. 2006. Viability assessment 
of lactic acid bacteria in commercial dairy products stored at 4 degrees C using LIVE/DEAD (R) BacLight(TM) staining and 
conventional plate counts. International Journal of Food Science and Technology, 41, 275-280. 
MORGAN, C. A., HERMAN, N., WHITE, P. A. & VESEY, G. 2006. Preservation of micro-organisms by drying; A review. Journal of 
Microbiological Methods, 66, 183-193. 
MORGAN, T. D., BEEZER, A. E., MITCHELL, J. C. & BUNCH, A. W. 2001. A microcalorimetric comparison of the anti-Streptococcus 
mutans efficacy of plant extracts and antimicrobial agents in oral hygiene formulations. Journal of Applied Microbiology, 90, 
53-58.   269 
MOURA, P., BARATA, R., CARVALHEIRO, F., GIRIO, F., LOUREIRO-DIAS, M. C. & ESTEVES, M. P. 2007. In vitro fermentation 
of xylo-oligosaccharides from corn cobs autohydrolysis by Bifidobacterium and Lactobacillus strains. Lwt-Food Science and 
Technology, 40, 963-972. 
MUDIE, D. M., AMIDON, G. L. & AMIDON, G. E. 2010. Physiological parameters for oral delivery and in vitro testing. Molecular 
Pharmaceutics, 7, 1388-1405. 
MULLER,  J.  A.,  STANTON,  C.,  SYBESMA,  W.,  FITZGERALD,  G.  F.  &  ROSS,  R.  P. 2010. Reconstitution  conditions  for  dried 
probiotic powders represent a critical step in determining cell viability. Journal of Applied Microbiology, 108, 1369-1379. 
MUNOZ, P., GIANNELLA, M., ALCALA,  L., SARMIENTO, E., YANEZ, J. F., PALOMO, J., CATALAN, P., CARBONE, J. & 
BOUZA,  E.  2007.  Clostridium  diffidle-associated  diarrhea  in  heart  transplant  recipients:  Is  hypogammaglobulinemia  the 
answer? Journal of Heart and Lung Transplantation, 26, 907-914. 
MYLLYLUOMA, E., AHONEN, A. M., KORPELA, R., VAPAATALO, H. & KANKURI, E. 2008. Effects of multispecies probiotic 
combination on Helicobacter pylori infection in vitro. Clinical and Vaccine Immunology, 15, 1472-1482. 
NA, X. & KELLY, C. 2011. Probiotics in Clostridium difficile infection. Journal of Clinical Gastroenterology, 45 Suppl, S154-S158. 
NAABER, P., SMIDT, I., STSEPETOVA, J., BRILENE, T., ANNUK, H. & MIKELSAAR, M. 2004. Inhibition of Clostridium difficile 
strains by intestinal Lactobacillus species. Journal of Medical Microbiology, 53, 551-554. 
NAGARAJAN, K. & LOH, K. C. 2014. Molecular biology-based methods for quantification of bacteria in mixed culture: perspectives and 
limitations. Applied microbiology and biotechnology, 98, 6907-6919. 
NAGY, E., PETTERSON, M. & MARDH, P. A. 1991. Antibiosis between bacteria isolated from the vagina of women with and without 
signs of bacterial vaginosis. APMIS, 99, 739-744. 
NAJIM, H. N., MOHAMMED, A. Z., & SAAB KHUDHIR, Z. 2012. The antibacterial activity of bacteriocin produced by Lactobacillus 
acidophilus isolates against sensitive reference strain Lactobacillus acidophilus R0052 and its stability to different pH, heating 
and storage temperatures. Proceeding of the Eleventh Veterinary Scientific Conference, 274-279. 
NARANG,  A.,  KONOPKA,  A.  &  RAMKRISHNA,  D.  1997.  New  patterns  of  mixed-substrate  utilization  during  batch  growth  of 
Escherichia coli K12. Biotechnology and Bioengineering, 55, 747-757. 
NARAYANAPPA, D. 2008. Randomized double blinded controlled trial to evaluate the efficacy and safety of Bifilac in patients with 
acute viral diarrhea. Indian Journal of Pediatrics, 75, 709-713. 
NARUSZEWICZ, M., JOHANSSON, M. L., ZAPOLSKA-DOWNAR, D. & BUKOWSKA, H. 2002. Effect of Lactobacillus plantarum 
299v on cardiovascular disease risk factors in smokers. American Journal of Clinical Nutrition, 76, 1249-1255. 
NASH, T., POSTGATE, J. R. & HUNTER, J. R. 1963. Similar effects of various neutral solutes on survival of Aerobacter aerogenes and 
of red blood cells after freezing and thawing. Nature, 199, 1113. 
NEBRA, Y. & BLANCH, A. R. 1999. A new selective medium for Bifidobacterium spp. Appl Environ Microbiol, 65, 5173-5176. 
NERANDZIC, M. M., PULTZ, M. J. & DONSKEY, C. J. 2009. Examination of potential mechanisms to explain the association between 
proton pump inhibitors and Clostridium difficile infection. Antimicrobial Agents and Chemotherapy, 53, 4133-4137. 
NES,  I.  F.  2011.  History,  current  knowledge,  and  future  directions  on  bacteriocin  research  in  lactic  acid  bacteria.  Prokaryotic 
Antimicrobial Peptides: from Genes to Applications, 3-12. 
NEWELL, R. D. 1975. Ph.D. Thesis, University of London.  
NEWELL, R.D. 1980. The identification and characterization of microorganisms by microcalorimetry. In Beezer, A. E. 1980. Biological 
microcalorimetry. London: Academic press, 163-185. 
NG, S. C., HART, A. L., KAMM, M. A., STAGG, A. J. & KNIGHT, S. C. 2009. Mechanisms of action of probiotics: recent advances. 
Inflammatory Bowel Diseases, 15, 300-310. 
NICOLAIDES, E., GALIA, E., EFTHYMIOPOULOS, C., DRESSMAN, J. B. & REPPAS, C. 1999. Forecasting the in vivo performance 
of four low solubility drugs from their in vitro dissolution data. Pharmaceutical Research, 16, 1876-1882. 
NIH. September 2013. Colonoscopy. [online]. Available from: http://catalog.niddk.nih.gov/ImageLibrary/detail.cfm?id=1450 [Accessed 7 
May 2014]  
NING, X. Q., QIAO, W. W., ZHANG, L. & GAO, X. 2013. Applications of microcalorimetry in environmental sciences. Asian Journal of 
Chemistry, 25, 8838-8842. 
NOLETO, A. L. S., MALBURG, L. M. & BERGDOLL, M. S. 1987. Production of staphylococcal-enterotoxin in mixed cultures. Applied 
and Environmental Microbiology, 53, 2271-2274. 
NOVICK, A. & SZILARD, L. 1950. Description of the chemostat. Science, 112, 715-716. 
O'HARA, A. M. & SHANAHAN, F. 2006. The gut flora as a forgotten organ. Embo Reports, 7, 688-693.   270 
O'MAHONY,  F.  C.  &  PAPKOVSKY,  D.  B.  2006.  Rapid  high-throughput  assessment  of  aerobic  bacteria  in  complex  samples  by 
fluorescence-based oxygen respirometry. Applied and Environmental Microbiology, 72, 1279-1287. 
O'NEILL, M. A. A. & GAISFORD, S. 2011. Application and use of isothermal calorimetry in pharmaceutical development. International 
Journal of Pharmaceutics, 417, 83-93. 
O'NEILL, M., VINE, G. J., BEEZER, A. E., BISHOP, A. H., HADGRAFT, J., LABETOULLE, C., WALKER, M., BOWLER, P. G. 
2003.  Antimicrobial  properties  of  silver-containing  wound  dressings:  a  microcalorimetric  study.  International  Journal  of 
Pharmaceutics, 263, 61-68. 
O'TOOLE,  P.  W.  &  COONEY,  J.  C.  2008.  Probiotic  bacteria  influence  the  composition  and  function  of  the  intestinal  microbiota. 
Interdisciplinary perspectives on infectious diseases, 2008, 175285-175285. 
OATLEY, J. T., RARICK, M. D., JI, G. E. & LINZ, J. E. 2000. Binding of aflatoxin B-1 to bifidobacteria in vitro. Journal of Food 
Protection, 63, 1133-1136. 
OLIVARES,  M.,  DIAZ-ROPERO,  M.  P.,  MARTIN,  R.,  RODRIGUEZ,  J.  M.  &  XAUS,  J.  2006.  Antimicrobial  potential  of  four 
Lactobacillus strains isolated from breast milk. Journal of Applied Microbiology, 101, 72-79. 
OLIVEIRA, R. B. P., OLIVEIRA, A. D. L. & GLORIA, M. B. A. 2008. Screening of lactic acid bacteria from vacuum packaged beef for 
antimicrobial activity. Brazilian Journal of Microbiology, 39, 368-374. 
OLSSON,  C.  &  HOLMGREN,  S.  2001.  The  control  of  gut  motility.  Comparative  Biochemistry  and  Physiology  a-Molecular  and 
Integrative Physiology, 128, 481-503. 
OSBORNE, J. A. & LEE, D. 1975. Studies on conditions required for optimum recovery of Tetrahymena-pyriformis strain s (phenoset a) 
after freezing to and thawing from -196 C. Journal of Protozoology, 22, 233-237. 
OUWEHAND, A. C., SALMINEN, S. & ISOLAURI, E. 2002. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 
International Journal of General and Molecular Microbiology, 82, 279-289. 
OWENS, R. C. & AMBROSE, P. G. 2007. Amtimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modem 
antibiotic era. Diagnostic Microbiology and Infectious Disease, 57, 77S-83S. 
OZMEN, L. & LANGRISH, T. A. G. 2002. Comparison of glass transition temperature and sticky point temperature for skim milk 
powder. Drying Technology, 20, 1177-1192. 
PAIDHUNGAT, M. & SETLOW, P. 2000. Role of Ger proteins in nutrient and nonnutrient triggering of spore germination in Bacillus 
subtilis. Journal of Bacteriology, 182, 2513-2519. 
PAREDES-SABJA, D., BOND, C., CARMAN, R. J., SETLOW, P. & SARKER, M. R. 2008. Germination of spores of Clostridium 
difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology-
Sgm, 154, 2241-2250. 
PAREDES-SABJA, D., BOND, C., CARMAN, R. J., SETLOW, P. & SARKER, M. R. 2009. Germination of spores of Clostridium 
difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD) (vol 154, pg 
2241, 2008). Microbiology-Sgm, 155, 1376-1376. 
PAREDES-SABJA, D., SETLOW, P. & SARKER, M. R. 2011. Germination of spores of Bacillales and Clostridiales species: mechanisms 
and proteins involved. Trends in Microbiology, 19, 85-94. 
PAREDES-SABJA, D., SHEN, A. & SORG, J. A. 2014. Clostridium difficile spore biology: sporulation, germination, and spore structural 
proteins. Trends in Microbiology, xx, 1-11.  
PARKES, G. C., SANDERSON, J. D. & WHELAN, K. 2009. The mechanisms and efficacy of probiotics in the prevention of Clostridium 
difficile-associated diarrhoea. Lancet Infectious Diseases, 9, 237-244. 
PARVEZ, S., MALIK, K. A., KANG, S. A. & KIM, H. Y. 2006. Probiotics and their fermented food products are beneficial for health. 
Journal of Applied Microbiology, 100, 1171-1185. 
PATTANI, R., PALDA, V. A., HWANG, S. W. & SHAH, P. S. 2013. Probiotics for the prevention of antibiotic-associated diarrhea and 
Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med, 7, e56-67. 
PEDERSEN, P. B., VILMANN, P., BAR-SHALOM, D., MULLERTZ, A. & BALDURSDOTTIR, S. 2013. Characterization of fasted 
human gastric fluid for relevant rheological parameters and gastric lipase activities. European Journal of Pharmaceutics and 
Biopharmaceutics, 85, 958-965. 
PEDRETTI, S. 2013. Probiotic market: up or down? Nutrafoods, 12, N18-N19. 
PEI, Z. H., BINI, E. J., YANG, L. Y., ZHOU, M. S., FRANCOIS, F. & BLASER, M. J. 2004. Bacterial biota in the human distal 
esophagus. Proceedings of the National Academy of Sciences of the United States of America, 101, 4250-4255. 
PEPIN, J., ALARY, M. E., VALIQUETTE, L., RAICHE, E., RUEL, J., FULOP, K., GODIN, D. & BOURASSA, C. 2005. Increasing risk 
of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Diseases, 40, 1591-1597.   271 
PERESTELO, F. R., BLANCO, M. T., GUTIERREZ-NAVARRO, A. M. & FALCON, M. A. 1985. Growth inhibition of Staphylococcus-
aureus by a staphylolytic enzyme from Pseudomonas-aeruginosa. Microbios Letters, 30, 85-94. 
PEREZ, P. F., DORE, J., LECLERC, M., LEVENEZ, F., BENYACOUB, J., SERRANT, P., SEGURA-ROGGERO, I., SCHIFFRIN, E. J. 
&  DONNET-HUGHES,  A.  2007.  Bacterial  imprinting  of  the  neonatal  immune  system:  Lessons  from  maternal  cells? 
Pediatrics, 119, E724-E732. 
PETERSON, A. C., BLACK, J. J. & GUNDERSON, M. F. 1962. Staphylococci in competition .2. Effect of total numbers and proportion 
of Staphylococci in mixed cultures on growth in artificial culture medium. Applied Microbiology, 10, 23-30. 
PIARD, J. C. & DESMAZEAUD, M. 1991. Inhibiting factors produced by lactic-acid bacteria .1. oxygen metabolites and catabolism end-
products. Lait, 71, 525-541. 
PIARD, J. C. & DESMAZEAUD, M. 1992. Inhibiting factors produced by lactic-acid bacteria .2. bacteriocins and other antibacterial 
substances. Lait, 72, 113-142. 
PIDDOCK, L. J. V. 1990. Techniques used for the determination of antimicrobial resistance and sensitivity in bacteria. Journal of Applied 
Bacteriology, 68, 307-318. 
PILLAI, A. & NELSON, R. 2008. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database of 
Systematic Reviews, CD004611. 
PLOWMAN, J. & PECK, M. W. 2002. Use of a novel method to characterize the response of spores of non-proteolytic Clostridium 
botulinum types B, E and F to a wide range of germinants and conditions. Journal of Applied Microbiology, 92, 681-694. 
POCOCK, G., RICHARDS, C. D. & RICHARDS, D. A. 2006. The gastrointestinal system. In Human Physiology. Oxford University 
Press. 4
th edition, 579-623. 
POSTGATE, J. R. & HUNTER, J. R. 1961. Survival of frozen bacteria. Journal of General Microbiology, 26, 367-378. 
POSTGATE, J. R. 1976. Death in microbes and macrobes. In GRAY T. R. G. & POSTGATE J. R. (ed.), The survival of vegetative 
microbes. Cambridge University Press, Cambridge, United Kingdom. 
POXTON, I. R., MCCOUBREY, J. & BLAIR, G. 2001. The pathogenicity of Clostridium difficile. Clinical microbiology and infection, 7, 
421-7. 
PRAKASH, O., NIMONKAR, Y. & SHOUCHE, Y. S. 2013. Practice and prospects of microbial preservation. Fems Microbiology Letters, 
339, 1-9. 
PRAT, H. 1953. Observations on thermogenic bacteria. Revue Canadienne De Biologie, 12, 19-34. 
PRAT, H., CALVET, E. & FRICKER, J. 1946. Etude microcalorimetriques du development des cultures bacteriennes et de la germination 
des graines. Revue Canadienne de Biologie, 5, 247-250. 
PRESS, A. G., HAUPTMANN, I. A., HAUPTMANN, L., FUCHS, B., FUCHS, M., EWE, K. & RAMADORI, G. 1998. Gastrointestinal 
pH profiles in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 12, 673-678. 
PROBERT, H. M. & GIBSON, G. R. 2002. Investigating the prebiotic and gas-generating effects of selected carbohydrates on the human 
colonic microflora. Letters in Applied Microbiology, 35, 473-480. 
PROBERT, H. M., APAJALAHTI, J. H., RAUTONEN, N., STOWELL, J. & GIBSON, G. R. 2004. Polydextrose, lactitol, and fructo-
oligosaccharide  fermentation  by  colonic  bacteria  in  a  three-stage  continuous  culture  system.  Applied  and  Environmental 
Microbiology, 70, 4505-4511. 
PUBLIC HEALTH ENGLAND, 2013. Update guidance on the management and treatment of Clostridium difficile infection. Gov.UK 
[online]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_
treatment.pdf [15 September 2014] 
PUBLIC HEALTH ENGLAND, 2014. Annual Epidemiological Commentary: Mandatory MRSA, MSSA and E. coli bacteraemia and C. 
difficile infection data, 2013/14. [online]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/330529/HCAI_mandatory_surveillance_annual_
epidemiological_commentary_2013_14.pdf [15 September 2014] 
QUIGLEY, E. M. M. 2013. Gut bacteria in health and disease. Gastroenterology & Hepatology, 9, 560-569. 
RAINKIE, D. & KOLBER, M. R. 2013. Probiotics for the prevention of Clostridium difficile. Canadian Family Physician, 59, 957. 
RANADHEERA, C. S., EVANS, C. A., ADAMS, M. C. & BAINES, S. K. 2012. In vitro analysis of gastrointestinal tolerance and 
intestinal cell adhesion of probiotics in goat's milk ice cream and yogurt. Food Research International, 49, 619-625. 
RAY, B., JEZESKI, J. J. & BUSTA, F. F. 1971. Effect of rehydration on recovery, repair, and growth of injured freeze-dried Salmonella-
anatum. Applied Microbiology, 22, 184-189.   272 
REA,  M.  C.,  ALEMAYEHU,  D.,  ROSS,  R.  P.  &  HILL,  C.  2013.  Gut  solutions  to  a  gut  problem:  bacteriocins,  probiotics  and 
bacteriophage for control of Clostridium difficile infection. Journal of Medical Microbiology, 62, 1369-1378. 
REA, M. C., DOBSON, A., O'SULLIVAN, O., CRISPIE, F., FOUHY, F., COTTER, P. D., SHANAHAN, F., KIELY, B., HILL, C. & 
ROSS, R. P. 2011. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a 
model of the distal colon. Proceedings of the National Academy of Sciences of the United States of America, 108, 4639-4644. 
REA, M. C., SIT, C. S., CLAYTON, E., O'CONNOR, P. M., WHITTAL, R. M., ZHENG, J., VEDERAS, J. C., ROSS, R. P. & HILL, C. 
2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. 
Proceedings of the National Academy of Sciences of the United States of America, 107, 9352-9357. 
REID, G. 2001b. Probiotic agents to protect the urogenital tract against infection. American Journal of Clinical Nutrition, 73, 437S-443S. 
REID, G., BRUCE, A. W., MCGROARTY, J. A., CHENG, K. J. & COSTERTON, J. W. 1990. Is there a role for  Lactobacilli in 
prevention of urogenital and intestinal infections. Clinical Microbiology Reviews, 3, 335-344. 
REID, G., COOK, R. L. & BRUCE, A. W. 1987. Examination of strains of Lactobacilli for properties that may influence bacterial 
interference in the urinary-tract. Journal of Urology, 138, 330-335. 
REID, G., HOWARD, J. & GAN, B. S. 2001a. Can bacterial interference prevent infection? Trends in Microbiology, 9, 424-428. 
REIMER, L. & CARROLL, K. 2004. Procedure for the storage of microorganisms. In: Murray E., Baron, E., Pfaller, M., Tenover, F. & 
Yolken, R. Eds. Manual of Clinical Microbiology. ASM Press, Washington, DC 67–73. 
RESHEF, L., NIV, J. & SHAPIRO, B. 1967. Effect of propionate on lipogenesis in adipose tissue. Journal of Lipid Research, 8, 682-687. 
RHODES, J., BARNARDO, D. E., PHILLIPS, S. F., ROVELSTA.RA & HOFMANN, A. F. 1969. Increased reflux of bile into stomach in 
patients with gastric ulcer. Gastroenterology, 57, 241-252. 
RIEDELE, C. & REICHL, U. 2011. Interspecies effects in a ceftazidime-treated mixed culture of Pseudomonas aeruginosa, Burkholderia 
cepacia and Staphylococcus aureus: analysis at the single-species level. Journal of Antimicrobial Chemotherapy, 66, 138-145. 
RIFKIN, G. D., FEKETY, F. R. & SILVA, J., JR. 1977. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium 
sordellii antitoxin. Lancet, 2, 1103-1106. 
RILEY, M. A. & GORDON, D. M. 1992. A Survey of col plasmids in natural isolates of Escherichia-coli and an investigation into the 
stability of col-plasmid lineages. Journal of General Microbiology, 138, 1345-1352. 
RIO, M. E., ZAGO, L. B., GARCIA, H. & WINTER, L. 2002. Undernutrition affect live lactobacillus effect on respiratory tract infections 
in children from social risk areas. Archivos Latinoamericanos De Nutricion, 52, 29-34. 
RISHMAWI,  N.,  GHNEIM,  R.,  KATTAN,  R.,  GHNEIM,  R.,  ZOUGHBI,  M.,  ABU-DIAB,  A.,  TURKUMAN,  S.,  DAUODI,  R., 
SHOMALI, I., ISSA, A. E.-R., SIRIANI, I., MARZOUKA, H., SCHMID, I. & HINDIYEH, M. Y. 2007. Survival of fastidious 
and nonfastidious aerobic bacteria in three bacterial transport swab systems. Journal of Clinical Microbiology, 45, 1278-1283. 
ROBERFROID, M., GIBSON, G. R., HOYLES, L., MCCARTNEY, A. L., RASTALL, R., ROWLAND, I., WOLVERS, D., WATZL, B., 
SZAJEWSKA,  H.,  STAHL,  B.,  GUARNER,  F.,  RESPONDEK,  F.,  WHELAN,  K.,  COXAM,  V.,  DAVICCO,  M.  J., 
LEOTOING, L., WITTRANT, Y., DELZENNE, N. M., CANI, P. D., NEYRINCK, A. M. & MEHEUST, A. 2010. Prebiotic 
effects: metabolic and health benefits. British Journal of Nutrition, 104 Suppl 2, S1-63. 
ROEDIGER, W. E. & MOORE, A. 1981. Effect of short-chain fatty acid on sodium absorption in isolated human colon perfused through 
the vascular bed. Digestive Diseases and Sciences, 26, 100-106. 
ROEDIGER, W. E. W. 1980. Anaerobic-bacteria, the colon and colitis. Australian and New Zealand Journal of Surgery, 50, 73-75. 
ROGERS, A. M. & MONTVILLE, T. 1991. Improved agar diffusion assay for nisin quantification. Food Biotechnology, 5, 161-168. 
RONG, X. M., HUANG, Q. Y., JIANG, D. H., CAI, P. & LIANG, W. 2007. Isothermal microcalorimetry: A review of applications in soil 
and environmental sciences. Pedosphere, 17, 137-145. 
ROOS, Y. H. 2002. Importance of glass transition and water activity to spray drying and stability of dairy powders. Lait, 82, 475-484. 
ROSENFELDT,  V.,  BENFELDT,  E.,  NIELSEN,  S.  D.,  MICHAELSEN,  K.  F.,  JEPPESEN,  D.  L.,  VALERIUS,  N.  H.  & 
PAERREGAARD, A. 2003. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. Journal of Allergy and 
Clinical Immunology, 111, 389-395. 
ROSS, P. W. 1971. Quantitative studies on salivary flora. Journal of Clinical Pathology, 24, 717-720. 
ROSSI, M., AMARETTI, A. & RAIMONDI, S. 2011. Folate production by probiotic bacteria. Nutrients, 3, 118-134. 
ROUND, J. L. & MAZMANIAN, S. K. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nature 
Reviews Immunology, 9, 313-323. 
ROWLAND, I. R., MALLETT, A. K. & WISE, A. 1985. The effect of diet on the mammalian gut flora and its metabolic-activities. Crc 
Critical Reviews in Toxicology, 16, 31-103. 
RUBNER, M. 1903. Hyg Rundsch 13, 857.   273 
RUBNER, M. 1904. Archiv for Hygiene, 48, 260.  
RUBNER, M. 1906. Archiv for Hygiene, 57, 193-243.  
RUEGER, M., BENSCH, G., TUENGLER, R. & REICHL, U. 2012. A flow cytometric method for viability assessment of Staphylococcus 
aureus and Burkholderia cepacia in mixed culture. Cytometry Part A, 81A, 1055-1066. 
RUIZ, F. O., GERBALDO, G., ASURMENDI, P., PASCUAL, L. M., GIORDANO, W. & BARBERIS, I. L. 2009. Antimicrobial activity, 
inhibition of urogenital pathogens, and synergistic interactions between lactobacillus strains. Current Microbiology, 59, 497-
501. 
RUNGE, F. E. & HEGER, R. 2000. Use of microcalorimetry in monitoring stability studies. Example: Vitamin A esters.  Journal of 
Agricultural and Food Chemistry, 48, 47-55. 
RUPNIK, M., WILCOX, M. H. &  GERDING, D. N. 2009. Clostridium difficile infection: new developments in epidemiology and 
pathogenesis. Nature Reviews Microbiology, 7, 526-536. 
RUSSEL, M., YAO, J., CHEN, H., WANG, F., ZHOU, Y., ZHUANG, R., CHOI, M. M. F., CECCANTI, B., TREBSE, P. & GYULA, Z. 
2009. Biological and microcalorimetric studies of the toxic effect of organoarsenic(v) compounds to wild strain of Bacillus 
thuringiensis. Biological Trace Element Research, 131, 192-203. 
RUSSEL,  W.J.,  FARLING,  S.R.,  BLANCHARD,  G.C.  &  BOLING,  E.A.  1975.  “Interim  Review  of  Microbial  Identification  by 
Microcalorimetry in Microbiology-1975” (D. Schlessinger, ed.) American Society for Microbiology, Washington, D.C. 22-31. 
RYCROFT, C. E., JONES, M. R., GIBSON, G. R. & RASTALL, R. A. 2001. A comparative in vitro evaluation of the fermentation 
properties of prebiotic oligosaccharides. Journal of Applied Microbiology, 91, 878-887. 
SAARELA, M., HALLAMAA, K., MATTILA-SANDHOLM, T. & MATTO, J. 2003. The effect of lactose derivatives lactulose, lactitol 
and lactobionic acid on the functional and technological properties of potentially probiotic Lactobacillus strains. International 
Dairy Journal, 13, 291-302. 
SAARELA, M., MOGENSEN, G., FONDEN, R., MATTO, J. & MATTILA-SANDHOLM, T. 2000. Probiotic bacteria: safety, functional 
and technological properties. Journal of Biotechnology, 84, 197-215. 
SAAVEDRA, J. 2000. Probiotics and infectious diarrhea. American Journal of Gastroenterology, 95, S16-S18. 
SABIKHI, L., BABU, R., THOMPKINSON, D. K. & KAPILA, S. 2008. Resistance of microencapsulated lactobacillus acidophilus la1 to 
processing treatments and simulated gut conditions. Food and Bioprocess Technology, 3, 586-593. 
SACCARO, D. M., HIROTA, C. Y., TAMIME, A. & OLIVEIRA, M. N. 2011. Evaluation of different selective media for enumeration of 
probiotic micro-organisms in combination with yoghurt starter cultures in fermented milk. African Journal of Microbiology 
Research, 46, 3901-3906. 
SAHADEVA, R.P.K., LEONG, S.F., CHUA, K. H., TAN, C.H., CHAN, H.Y., TONG, E.V., WONG, S.Y.W. & CHAN, H.K. 2011. 
Survival of commercial probiotic strains to pH and bile.  International Food Research Journal, 18,1515-1522. 
SAID, J., DODOO, C. C., WALKER, M., PARSONS, D., STAPLETON, P., BEEZER, A. E. & GAISFORD, S. 2014. An in vitro test of 
the efficacy of silver-containing wound dressings against Staphylococcus aureus and Pseudomonas aeruginosa in simulated 
wound fluid. International Journal of Pharmaceutics, 462, 123-128.  
SALMINEN, S. J., GUEIMONDE, M. & ISOLAURI, E. 2005. Probiotics that modify disease risk. Journal of Nutrition, 135, 1294-1298. 
SALMINEN, S., VON WRIGHT, A., MORELLI, L., MARTEAU, P., BRASSART, D., DE VOS, W. M., FONDEN, R., SAXELIN, M., 
COLLINS,  K., MOGENSEN,  G., BIRKELAND, S. E. & MATTILA-SANDHOLM, T. 1998. Demonstration of  safety of 
probiotics -- a review. International Journal of Food Microbiology, 44, 93-106. 
SANDERS, M. E. & HUIS IN’T VELD, J. H. I. 1999. Bringing a probiotic-containing functional food to the market: microbiological, 
product,  regulatory  and  labeling  issues.  Antonie  Van  Leeuwenhoek  International  Journal  of  General  and  Molecular 
Microbiology, 76, 293-315. 
SANDERS, M. E. 1993. Summary of conclusions from a consensus panel of experts on health attributes of lactic cultures - significance to 
fluid milk-products containing cultures. Journal of Dairy Science, 76, 1819-1828. 
SANTIVARANGKNA, C., KULOZIK, U. & FOERST, P. 2007. Alternative drying processes for the industrial preservation of lactic acid 
starter cultures. Biotechnology Progress, 23, 302-315. 
SARKER, S. A. & GYR, K. 1992. Nonimmunological defense-mechanisms of the gut. Gut, 33, 987-993. 
SAULNIER, D. M., SPINLER, J. K., GIBSON, G. R. & VERSALOVIC, J. 2009. Mechanisms of probiosis and prebiosis: considerations 
for enhanced functional foods. Current Opinion in Biotechnology, 20, 135-141. 
SAVAGE, D. C. 1977. Microbial ecology of gastrointestinal-tract. Annual Review of Microbiology, 31, 107-133. 
SAVAGE, D. C. 1986. Gastrointestinal microflora in mammalian nutrition. Annual Review of Nutrition, 6, 155-178.   274 
SAVINI, M., CECCHINI, C., VERDENELLI, M. C., SILVI, S., ORPIANESI, C. & CRESCI, A. 2010. Pilot-scale production and viability 
analysis of freeze-dried probiotic bacteria using different protective agents. Nutrients, 2, 330-339. 
SAXELIN, M. 2008. Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European 
perspective. Clinical Infectious Diseases, 46 Suppl 2, S76-9; discussion S144-S151. 
SCHAARSCHMIDT, B. & LAMPRECHT,  I. 1978. Micro-calorimetric study of  yeast growth, utilization of different carbohydrates. 
Thermochimica Acta, 22, 333-338. 
SCHAEFFER, A. B. & FULTON, M. D. 1933. A simplified method of staining endospores. Science New York, N.Y., 77, 194-194. 
SCHAFFER, B. & LORINCZY, D. 2005. Isoperibol calorimetry as a tool to evaluate the impact of the ratio of exopolysaccharide-
producing microbes on the properties of sour cream. Journal of Thermal Analysis and Calorimetry, 82, 537-541. 
SCHAFFER, B., SZAKALY, S. & LORINCZY, D. 2004. Examination of the growth of probiotic culture combinations by the isoperibolic 
batch calorimetry. Thermochimica Acta, 415, 123-126. 
SCHELINE, R. R. 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacological Reviews, 25, 451-523. 
SCHEUTZ, F. & STROCKBINE, A. N. 2005. In Bergey’s manual of systemic bacteriology, 2nd ed. Bergey’s manual trust, Springer 
Science Business Media. Inc., 233 Spring Street: New York, 2, 607-625. 
SCHLEIFER, K. & BELL, A. J. 2009. In Bergey’s manual of systematic bacteriology, 2nd ed. Bergey’s manual trust, Springer Dordrecht 
Heidelberg: London New York 3, 392-400. 
SCHLEIFER, K. 2009. In Bergey’s manual of systematic bacteriology, 2nd ed. Bergey’s manual trust, Springer Dordrecht Heidelberg: 
London New York 3, 465-491. 
SCHMIDT, H. A., FRITZLAR, G., DOLLE, W. & GOEBELL, H. 1970. Histamine and insulin-stimulated acid and pepsin secretion in 
patients with duodenal ulcers and normal subjects. Deutsche Medizinische Wochenschrift, 95, 2011-2016. 
SCHMIDT, J. K., KONIG, B. & REICHL, U. 2007. Characterization of a three bacteria mixed culture in a chemostat: evaluation and 
application of a quantitative terminal-restriction fragment length polymorphism (T-RFLP) analysis for absolute and species 
specific cell enumeration. Biotechnology and Bioengeneering, 96, 738-756. 
 SCHMIDT,  J.  K.,  RIEDELE,  C.,  REGESTEIN,  L.,  RAUSENBERGER,  J.  &  REICHL,  U.  2011.  A  Novel  Concept  Combining 
Experimental  and  Mathematical  Analysis  for  the  Identification  of  Unknown  Interspecies  Effects  in  a  Mixed  Culture. 
Biotechnology and Bioengineering, 108, 1900-1911. 
SCHOSTER, A., KOKOTOVIC, B., PERMIN, A., PEDERSEN, P. D., DAL BELLO, F. & GUARDABASSI, L. 2013. In vitro inhibition 
of Clostridium difficile and Clostridium perfringens by commercial probiotic strains. Anaerobe, 20, 36-41. 
SCHWAN, A., SJOLIN, S., TROTTESTAM, U. & ARONSSON, B. 1984. Relapsing Clostridium difficile enterocolitis cured by rectal 
infusion of normal feces. Scandinavian Journal of Infectious Diseases, 16, 211-215. 
SCHWAN, C., STECHER, B., TZIVELEKIDIS, T., VAN HAM, M., ROHDE, M., HARDT, W.-D., WEHLAND, J. & AKTORIES, K. 
2009. Clostridium difficile  Toxin  CDT  Induces  Formation  of  Microtubule-Based  Protrusions  and  Increases  Adherence  of 
Bacteria. Plos Pathogens, 5. 
SCYTHES,  K.  D.,  LOUIE,  M.  &  SIMOR,  A.  E.  1996.  Evaluation  of  nutritive  capacities  of  10  broth  media.  Journal  of  Clinical 
Microbiology, 34, 1804-1807. 
SEDLACZE.L, CZERNIAW.E, RADZIEJE.J & ZABLOCKI, B. 1966. Thermogenesis and growth yield of Escherichia coli in media 
containing various nitrogen sources. Bulletin De L Academie Polonaise Des Sciences-Serie Des Sciences Biologiques, 14, 613. 
SEKIROV, I., RUSSELL, S. L., ANTUNES, L. C. & FINLAY, B. B. 2010. Gut microbiota in health and disease. Physiological Reviews, 
90, 859-904. 
SEKSIK, P. 2010. Gut microbiota and IBD. Gastroentérologie clinique et biologique, 34 Suppl 1, S44-S51. 
SEPOVA, H. K., DUBNICKOVA, M., BILKOVA, A., BUKOVSKY, M. & BEZAKOVA, L. 2011. Identification and biological activity 
of potential probiotic bacterium isolated from the stomach mucus of breast-fed lamb. Brazilian Journal of Microbiology, 42, 
1187-1195. 
SERVIN, A. L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. Fems Microbiology Reviews, 
28, 405-440. 
SETLOW, P. 2007. I will survive: DNA protection in bacterial spores. Trends in Microbiology, 15, 172-180. 
SGHIR, A., CHOW, J. M. & MACKIE, R. I. 1998. Continuous culture selection of bifidobacteria and lactobacilli from human faecal 
samples using fructooligosaccharide as selective substrate. Journal of Applied Microbiology, 85, 769-777. 
SHAH, N. P. 2000. Probiotic bacteria: Selective enumeration and survival in dairy foods. Journal of Dairy Science, 83, 894-907. 
SHAH, N. P. 2007. Functional cultures and health benefits. International Dairy Journal, 17, 1262-1277.   275 
SHEARER, C. 1921. On the amount of heat liberated by Bacillu coli when grown in the presence of free amino-acids.  Journal of 
Physiology-London, 55, 50-60. 
SIMIONE, F. P. & BROWN, E. M. 1991. ATCC preservation methods. Freezing and freeze drying. American Type Culture Collection, 
Rockville, Maryland. 
SIMONCIC,  Z.,  ZUPANCIC,  P.,  ROSKAR,  R.,  GARTNER,  A.,  KOGEJ,  K.  &  KMETEC,  V.  2007.  Use  of  microcalorimetry  in 
determination  of  stability  of  enalapril  maleate  and  enalapril  maleate  tablet  formulations.  International  Journal  of 
Pharmaceutics, 342, 145-151. 
SINHA, V. R. & KUMRIA, R. 2003. Microbially triggered drug delivery to the colon. European Journal of Pharmaceutical Sciences, 18, 
3-18. 
SMITH, E. A. & MACFARLANE, G. T. 1996. Enumeration of human colonic bacteria producing phenolic and indolic compounds: 
Effects  of  pH,  carbohydrate  availability  and  retention  time  on  dissimilatory  aromatic  amino  acid  metabolism.  Journal  of 
Applied Bacteriology, 81, 288-302. 
SMITH, K. 2013. Therapy: Probiotics do not reduce antibiotic-associated or Clostridium difficile diarrhoea in older hospitalized patients. 
Nature Reviews Gastroenterology & Hepatology, 10, 566. 
SOHIER, D., PAVAN, S., RIOU, A., COMBRISSON, J. & POSTOLLEC, F. 2014. Evolution of microbiological analytical methods for 
dairy industry needs. Frontiers in Microbiology, 5, 1-10. 
SOKOLNICKA, I. 2000. The effect of probiotics on the immune system. Pneumonologia i alergologia polska, 68, 471-477. 
SOKOLSKI, W. T., STAPERT, E. M. & FERRER, E. B. 1964. Liquid nitrogen freezing in microbiological assay systems. I. Preservation 
of Lactobacillus leichmannii for direct use in the vitamin B12 assay. Applied Microbiology, 12, 327-329. 
SONOIKE, K., MADA, M. & MUTAI, M. 1986. Selective agar medium for counting viable cells of bifidobacteria in fermented milk. 
Journal of the Food Hygienic Society of Japan, 27, 238-244. 
SORG,  J.  A.  &  SONENSHEIN,  A.  L.  2008.  Bile  salts  and  glycine  as  cogerminants  for  Clostridium  difficile  spores.  Journal  of 
Bacteriology, 190, 2505-2512. 
SOURABH,  A.,  KANWAR,  S.  S.  &  SHARMA,  O.  P.  2011.  Antagonistic  potential  of  indigenous  bacterial  probiotics  of  Western 
Himalayas against antibiotic-resistant bacterial pathogens. Current Science, 101, 1351-1356. 
SOUSA,  T.,  PATERSON,  R.,  MOORE,  V.,  CARLSSON,  A.,  ABRAHAMSSON,  B.  &  BASIT,  A.  W.  2008.  The  gastrointestinal 
microbiota as a site for the biotransformation of drugs. International Journal of Pharmaceutics, 363, 1-25. 
SPIEGELMAN, D., WHISSELL, G. & GREER, C. W. 2005. A survey of the methods for the characterization of microbial consortia and 
communities. Canadian Journal of Microbiology, 51, 355-386. 
STAPERT, E. M., SOKOLSKI, W. T., KANESHIRO, W. M. & COLE, R. J. 1964. Liquid nitrogen freezing in microbiological assay 
systems. II. Preservation of Sarcina Lutea for antibiotic assays. Journal of Bacteriology, 88, 532-533. 
STAPLES, B. R., PROSEN, E. J. & GOLDBERG, R. N. 1973. National Bureau of Standards NBSIR  Washington, D. C. 73-181. 
STECHER, B. & HARDT, W.-D. 2008. The role of microbiota in infectious disease. Trends in Microbiology, 16, 107-114. 
STECHER,  B.,  ROBBIANI,  R.,  WALKER,  A.  W.,  WESTENDORF,  A.  M.,  BARTHEL,  M.,  KREMER,  M.,  CHAFFRON,  S., 
MACPHERSON, A. J., BUER, J., PARKHILL, J., DOUGAN, G., VON MERING, C. & HARDT, W.-D. 2007. Salmonella 
enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. Plos Biology, 5, 2177-2189. 
STEER, T., CARPENTER, H., TUOHY, K. & GIBSON, G. R. 2000. Perspectives on the role of the human gut microbiota and its 
modulation by pro- and prebiotics. Nutrition Research Reviews, 13, 229-254. 
STEINGOETTER, A., FOX, M., TREIER, R., WEISHAUPT, D., MARINCEK, B., BOESIGER, P., FRIED, M.& SCHWIZER, W. 2006. 
Effects  of  posture  on  the  physiology  of  gastric  emptying:  a  magnetic  resonance  imaging  study.  Scandinavian  Journal of 
Gastroenterology, 41,1155–1164. 
STRINGER, S. C., WEBB, M. D. & PECK, M. W. 2011. Lag time variability in individual spores of Clostridium botulinum.  Food 
Microbiology, 28, 228-235. 
SUN, W. R. & GRIFFITHS, M. W. 2000. Survival of bifidobacteria in yogurt and simulated gastric juice following immobilization in 
gellan-xanthan beads. International Journal of Food Microbiology, 61, 17-25. 
SWIDSINSKI,  A.,  LOENING-BAUCKE,  V.,  VERSTRAELEN,  H.,  OSOWSKA,  S.  &  DOERFFEL,  Y.  2008.  Biostructure  of  fecal 
microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology, 135, 568-579. 
TABASCO, R., GARCIA-CAYUELA, T., PELAEZ, C. & REQUENA, T. 2009. Lactobacillus acidophilus La-5 increases lactacin B 
production when it senses live target bacteria. International Journal of Food Microbiology, 132, 109-116.   276 
TABASCO, R., PAARUP, T., JANER, C., PELAEZ, C. & REQUENA, T. 2007. Selective enumeration and identification of mixed 
cultures of Streptococcus thermophilus, Lactobacillus delbrueckii subsp bulgaricus, L-acidophilus, L-paracasei subsp paracasei 
and Bifidobacterium lactis in fermented milk. International Dairy Journal, 17, 1107-1114. 
TAN, A. M. & LU, J. H. 1999. Microcalorimetric study of antiviral effect of drug. Journal of Biochemical and Biophysical Methods, 38, 
225-228. 
TANG, X. L. & PIKAL, M. J. 2004. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharmaceutical Research, 
21, 191-200. 
TANGL, F. 1903. Articles on the energetic of ontogenesis. Second announcement - On the consumption of chemical energy during the 
development of bacteria cultures. Archiv Fur Die Gesamte Physiologie Des Menschen Und Der Tiere, 98, 475-489. 
TANNOCK, G. W. 2008. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunology, 1, S15-S18. 
TEDESCHI, R. & DE PAOLI, P. 2011. Collection and preservation of frozen microorganisms. Methods in Molecular Biology, 675, 313-
326. 
TEDESCO, F. J. 1981. Antibiotic-associated colitis--an abating enigma. Journal of clinical gastroenterology, 3, 221-224. 
TEIXEIRA,  P.,  CASTRO,  H.  &  KIRBY,  R.  1995.  Spray-drying  as  a  method  for  preparing  concentrated  cultures  of  Lactobacillus-
bulgaricus. Journal of Applied Bacteriology, 78, 456-462. 
TEJERO-SARINENA, S., BARLOW, J., COSTABILE, A., GIBSON, G. R. & ROWLAND, I. 2013. Antipathogenic activity of probiotics 
against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic 
mixtures or the specificity of single strains? Anaerobe, 24, 60-65. 
TEJERO-SARINENA,  S.,  BARLOW,  J.,  COSTABILE,  A.,  GIBSON,  G.  R.  &  ROWLAND,  I.  2012.  In  vitro  evaluation  of  the 
antimicrobial activity of a range of probiotics against pathogens: Evidence for the effects of organic acids. Anaerobe, 18, 530-
538. 
TEMMERMAN, R., POT, B., HUYS, G. & SWINGS, J. 2001. A quality analysis of commercial probiotic products. Meded Rijksuniv Gent 
Fak Landbouwkd Toegep Biol Wet, 66, 535, 537-542. 
TEMMERMAN,  R.,  SCHEIRLINCK,  I.,  HUYS,  G.  &  SWINGS,  J.  2003.  Culture-independent  analysis  of  probiotic  products  by 
denaturing gradient gel electrophoresis. Applied and Environmental Microbiology, 69, 220-226. 
TENNYSON, C. A. & FRIEDMAN, G. 2008. Microecology, obesity, and probiotics. Current Opinion in Endocrinology Diabetes and 
Obesity, 15, 422-427. 
TERROINE, E. F. & WURMSER, R. 1922. Energy of growth. I. Development of Aspergillus niger. Bulletin de la Société de Chimie 
Biologique, 4, 519.  
THADEPALLI, H., LOU, M. A., BACH, V. T., MATSUI, T. K. & MANDAL, A. K. 1979. Microflora of the human small-intestine. 
American Journal of Surgery, 138, 845-850. 
THAM, C. S.-C., PEH, K.-K., BHAT, R. & LIONG, M.-T. 2012. Probiotic properties of bifidobacteria and lactobacilli isolated from local 
dairy products. Annals of Microbiology, 62, 1079-1087. 
THARMARAJ, N. & SHAH, N. P. 2003. Selective enumeration of Lactobacillus delbrueckii ssp bulgaricus, Streptococcus thermophilus, 
Lactobacillus acidophilus, bifidobacteria, Lactobacillus casei, Lactobacillus rhamnosus, and propionibacteria. Journal of Dairy 
Science, 86, 2288-2296. 
THERMOMETRIC AB. 2002. Thermal Activity Monitor Technical Specifications. 
THOMPSON-CHAGOYAN, O. C., MALDONADO, J. & GIL, A. 2007. Colonization and impact of disease and other factors on intestinal 
microbiota. Digestive Diseases and Sciences, 52, 2069-2077. 
TIMMERMAN, H. M., KONING, C. J. M., MULDER, L., ROMBOUTS, F. M. & BEYNEN, A. C. 2004. Monostrain, multistrain and 
multispecies problotics - A comparison of functionality and efficacy. International Journal of Food Microbiology, 96, 219-233. 
TIRLONI, E., CATTANEO, P., RIPAMONTI, B., AGAZZI, A., BERSANI, C. & STELLA, S. 2014. In vitro evaluation of Lactobacillus 
animalis SB310, Lactobacillus paracasei subsp paracasei SB137 and their mixtures as potential bioprotective agents for raw 
meat. Food Control, 41, 63-68. 
TISSIER, H. 1906. Treatment of intestinal infection by way of transforming the bacterial flora of the intestine. Comptes Rendus Des 
Seances De La Societe De Biologie Et De Ses Filiales, 58, 359-361. 
TOBA, T., YOSHIOKA, E. & ITOH, T. 1991. Acidophilucin-a, a new heat-labile bacteriocin produced by lactobacillus-acidophilus lapt 
1060. Letters in Applied Microbiology, 12, 106-108. 
TOBA, T., YOSHIOKA, E. & ITOH, T. 1991. Potential of Lactobacillus-gasseri isolated from infant feces to produce bacteriocin. Letters 
in Applied Microbiology, 12, 228-231.   277 
TONNA, I. & WELSBY, P. D. 2005. Pathogenesis and treatment of Clostridium difficile infection. Postgraduate Medical Journal, 81, 
367-369. 
TRAMPUZ, A., SALZMANN, S., ANTHEAUME, J. & DANIELS, A. U. 2007. Microcalorimetry: a novel method for detection of 
microbial contamination in platelet products. Transfusion, 47, 1643-1650. 
TRANSPARENCY MARKET RESEARCH. August 2013. Probiotics Market – Global Industry Analysis, Market Size, Share, Trends, 
Analysis,  Growth  and  Forecast,  2012  –  2018.  [online].  Available  from: 
http://www.prweb.com/releases/2013/8/prweb11077944.htm [Accessed 4 January 2014] 
TREJO, F. M., MINNAARD, J., PEREZ, P. F. & DE ANTONI, G. L. 2006. Inhibition of Clostridium difficile growth and adhesion to 
enterocytes by Bifidobacterium supernatants. Anaerobe, 12, 186-193. 
TREJO, F. M., PEREZ, P. F. & DE ANTONI, G. L. 2010. Co-culture with potentially probiotic microorganisms antagonises virulence 
factors  of  Clostridium  difficile  in  vitro.  Antonie  Van  Leeuwenhoek  International  Journal  of  General  and  Molecular 
Microbiology, 98, 19-29. 
TSUTSAEVA,  A.  A.  &  VYSEKANTSEV,  I.  P. 1983.  The  infectivity  of  t-4  phage  frozen  to minus 196 celsius in the presence  of 
cryoprotectors. Mikrobiologiya, 52, 519-521. 
TURNBAUGH, P. J., HAMADY, M., YATSUNENKO, T., CANTAREL, B. L., DUNCAN, A., LEY, R. E., SOGIN, M. L., JONES, W. 
J., ROE, B. A., AFFOURTIT, J. P., EGHOLM, M., HENRISSAT, B., HEATH, A. C., KNIGHT, R. & GORDON, J. I. 2009. A 
core gut microbiome in obese and lean twins. Nature, 457, 480-484. 
TURSI, A., BRANDIMARTE, G., GIORGETTI, G. M., ELISEI, W. & AIELLO, F. 2007. Balsalazide and/or high-potency probiotic 
mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal 
of Colorectal Disease, 22, 1103-1108. 
UKAI, M., TOMURA, A. & ITO, M. 1976. Cholesterol synthesis in germfree and conventional rats. The Journal of Nutrition, 106, 1175-
1183. 
USP, 2008. The United States Pharmacopeia USP 31, the National Formulary NF 26. The United States Pharmacopeial Convention, Inc. 
Rockville. 
VAN DE WIELE, T., BOON, N., POSSEMIERS, S., JACOBS, H. & VERSTRAETE, W. 2004. Prebiotic effects of chicory inulin in the 
simulator of the human intestinal microbial ecosystem. Fems Microbiology Ecology, 51, 143-153. 
VAN DEN ABBEELE, P., VENEMA, K., VAN DE WIELE, T., VERSTRAETE, W. & POSSEMIERS, S. 2013. Different human gut 
models reveal the distinct fermentation patterns of arabinoxylan versus inulin. Journal of Agricultural and Food Chemistry, 61, 
9819-9827. 
VAN REENEN, C. A., DICKS, L. M. T. & CHIKINDAS, M. L. 1998. Isolation, purification and partial characterization of plantaricin 
423, a bacteriocin produced by Lactobacillus plantarum. Journal of Applied Microbiology, 84, 1131-1137. 
VANHOUTTE, T., HUYS, G., BRANDT, E. & SWINGS, J. 2004. Temporal stability analysis of the microbiota in human feces by 
denaturing  gradient  gel  electrophoresis  using  universal  and  group-specific  16S  rRNA  gene  primers.  Fems  Microbiology 
Ecology, 48, 437-446. 
VAUGHAN, E. E., CAPLICE, E., LOONEY, R., OROURKE, N., COVENEY, H., DALY, C. & FITZGERALD, G. F. 1994. Isolation 
from food sources, of lactic-acid bacteria that produced antimicrobials. Journal of Applied Bacteriology, 76, 118-123. 
VAZQUEZ, C., LAGO, N., LEGIDO, J. L., ARIAS, I., CASAS, L. M. & MATO, M. M. 2013. Microcalorimetric study of the growth of 
Enterococcus faecalis, Klebsiella pneumoniae and their mixtures in an enriched culture medium. Journal of Thermal Analysis 
and Calorimetry, 113, 1415-1420. 
VAZQUEZ,  C.,  LAGO,  N.,  MATO,  M.  M.,  CASAS,  L.  M.,  ESARTE,  L.,  LEGIDO,  J.  L.  &  ARIAS,  I.  2014.  Microcalorimetric 
performance of the growth in culture of Escherichia coli, Proteus mirabilis and their mixtures in different proportions. Journal 
of Thermal Analysis and Calorimetry, 116, 107-112. 
VEDANTAM, G., CLARK, A., CHU, M., MCQUADE, R., MALLOZZI, M. & VISWANATHAN, V. K. 2012. Clostridium difficile 
infection:  toxins  and  non-toxin  virulence  factors,  and their contributions  to  disease  establishment and host  response.  Gut 
Microbes, 3, 121-134. 
VEKEMAN, B., HOEFMAN, S., DE VOS, P., SPIECK, E. & HEYLEN, K. 2013. A generally applicable cryopreservation method for 
nitrite-oxidizing bacteria. Systematic and Applied Microbiology, 36, 579-584. 
VELDKAMP, H. & JANNASCH, H. W. 1972. Mixed culture studies with chemostat. Journal of Applied Chemistry and Biotechnology, 
22, 105-123.   278 
VENEMA, K., VAN NUENEN, M. H. M. C., VAN DEN HEUVEL, E. G., POOL, W. & VAN DER VOSSEN, J. M. B. M. 2003. The 
effect of lactulose on the composition of the intestinal microbiota and short-chain fatty acid production in human volunteers and 
a computer-controlled model of the proximal large intestine. Microbial Ecology in Health and Disease, 15, 94-105. 
VERTZONI, M., DRESSMAN, J., BUTLER, J., HEMPENSTALL, J. & REPPAS, C. 2005. Simulation of fasting gastric conditions and 
its importance for the in vivo dissolution of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics, 
60, 413-417. 
VERTZONI, M., PASTELLI, E., PSACHOULIAS, D., KALANTZI, L. & REPPAS, C. 2007. Estimation of intragastric solubility of 
drugs: In what medium? Pharmaceutical Research, 24, 909-917. 
VILELA, E. G., FERRARI, M. D. D., TORRES, H. O. D., PINTO, A. G., AGUIRRE, A. C. C., MARTINS, F. P., GOULART, E. M. A. & 
DA CUNHA, A. S. 2008. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease 
in remission. Scandinavian Journal of Gastroenterology, 43, 842-848. 
VINE,  G. J. & BISHOP, A. H. 2005. The analysis of microorganisms by microcalorimetry in the pharmaceutical industry.  Current 
Pharmaceutical Biotechnology, 6, 223-238. 
VISCIDI, R., WILLEY, S. & BARTLETT, J. G. 1981. Isolation rates and toxigenic potential of Clostridium difficile isolates from various 
patient populations. Gastroenterology, 81, 5-9. 
VON AH, U., WIRZ, D. & DANIELS, A. 2009. Isothermal microcalorimetry - a new method for MIC determinations: results for 12 
antibiotics and reference strains of E. coli and S. aureus. Bmc Microbiology, 9, 1-14. 
VON  AH,  U.,  WIRZ,  D.  &  DANIELS,  A.  U.  2008.  Rapid  differentiation  of  methicillin-susceptible  Staphylococcus  aureus  from 
methicillin-resistant S. aureus and MIC determinations by isothermal microcalorimetry. Journal of Clinical Microbiology, 46, 
2083-2087. 
VON STOCKAR, U. & BIROU, B. 1989. The heat generated by yeast cultures with a mixed metabolism in the transition between 
respiration and fermentation. Biotechnology and Bioengineering, 34, 86-101. 
VONBERG, R. P., REICHARDT, C., BEHNKE, M., SCHWAB, F., ZINDLER, S. & GASTMEIER, P. 2008. Costs of nosocomial 
Clostridium difficile-associated diarrhoea. Journal of Hospital Infection, 70, 15-20. 
VRIEZE, A., HOLLEMAN, F., ZOETENDAL, E. G., DE VOS, W. M., HOEKSTRA, J. B. & NIEUWDORP, M. 2010. The environment 
within: how gut microbiota may influence metabolism and body composition. Diabetologia, 53, 606-613. 
WADSO,  I.  &  GOLDBERG,  R.  N.  2001.  Standards  in  isothermal  microcalorimetry  (IUPAC  technical  report).  Pure  and  Applied 
Chemistry, 73, 1625-1639. 
WADSO, I. 2009. Characterization of microbial activity in soil by use of isothermal microcalorimetry. Journal of Thermal Analysis and 
Calorimetry, 95, 843-850. 
WADSO, L. & GALINDO, F. G. 2009. Isothermal calorimetry for biological applications in food science and technology. Food Control, 
20, 956-961. 
WADSO, L. 2010. Operational issues in isothermal calorimetry. Cement and Concrete Research, 40, 1129-1137. 
WADSO, L., LI, Y. J. & BJURMAN, J. 2004. Measurements on two mould fungi with a calorespirometric method. Thermochimica Acta, 
422, 63-68. 
WALKER, A. W. & LAWLEY, T. D. 2013. Therapeutic modulation of intestinal dysbiosis. Pharmacological Research, 69, 75-86. 
WANG, F., YAO, J., CHEN, H., ZHOU, Y., CHEN, Y., CHEN, H., GAI, N., ZHUANG, R., TIAN, L., MASKOW, T., CECCANTI, B., 
TREBSE, P. & ZARAY, G. 2009. Microcalorimetric measurements of the microbial activities of single- and mixed-species 
with trivalent iron in soil. Ecotoxicology and Environmental Safety, 72, 128-135. 
WANG, X. & GIBSON, G. R. 1993. Effects of the in-vitro fermentation of oligofructose and inulin by bacteria growing in the human 
large-intestine. Journal of Applied Bacteriology, 75, 373-380. 
WARD, L. J. H. & TIMMINS, M. J. 1999. Differentiation of Lactobacillus casei, Lactobacillus paracasei and Lactobacillus rhamnosus by 
polymerase chain reaction. Letters in Applied Microbiology, 29, 90-92. 
WARNY, M., PEPIN, J., FANG, A., KILLGORE, G., THOMPSON, A., BRAZIER, J., FROST, E. & MCDONALD, L. C. 2005. Toxin 
production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and 
Europe. Lancet, 366, 1079-84. 
WEESE, J. S. & MARTIN, H. 2011. Assessment of commercial probiotic bacterial contents and label accuracy. Canadian Veterinary 
Journal, 52, 43-46. 
WEESE, J. S. 2002. Microbiologic evaluation of commercial probiotics. Journal of the American Veterinary Medical Association, 220, 
794-797.   279 
WEST, P. A., HEWITT, J. H. & MURPHY, O. M. 1979. Influence of methods of collection and storage on the bacteriology of human-
milk. Journal of Applied Bacteriology, 46, 269-277. 
WHEELDON, L. J., WORTHINGTON, T., HILTON, A. C., ELLIOTT, T. S. J. & LAMBERT, P. A. 2008. Physical and chemical factors 
influencing the germination of Clostridium difficile spores. Journal of Applied Microbiology, 105, 2223-2230. 
WIEGEL, J. 2009. In Bergey’s manual of systematic bacteriology, 2nd ed. Bergey’s manual trust, Springer Dordrecht Heidelberg: London 
New York, 3, 736-772. 
WIJSMAN, M. R., HEREIJGERS, J. & DEGROOTE, J. 1989. Selective enumeration of bifidobacteria in fermented dairy-products. 
Netherlands Milk and Dairy Journal, 43, 395-405. 
WILLS R. 2012. In vitro assessment of the survivability of Lactobacillus casei DN-114 001 and Lactobacillus casei Shirota, within 
commercialised food matrices, in the upper gastrointestinal tract. The Plymouth Student Scientist, 5, 80-89. 
WILSON, K. H. 1983. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. Journal of 
Clinical Microbiology, 18, 1017-1019. 
WILSON, K. H., SHEAGREN, J. N. & FRETER, R. 1985. Population-dynamics of ingested clostridium-difficile in the gastrointestinal-
tract of the syrian-hamster. Journal of Infectious Diseases, 151, 355-361. 
WINKELMANN,  M.,  HUTTL,  R.  &  WOLF,  G.  2004.  Application  of  batch-calorimetry  for  the  investigation  of  microbial  activity. 
Thermochimica Acta, 415, 75-82. 
WISPLINGHOFF,  H.,  BISCHOFF,  T.,  TALLENT,  S.  M.,  SEIFERT,  H.,  WENZEL,  R.  P.  &  EDMOND,  M. B. 2004.  Nosocomial 
bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical 
Infectious Diseases, 39, 309-317. 
WLODARSKA, M., WILLING, B., KEENEY, K. M., MENENDEZ, A., BERGSTROM, K. S., GILL, N., RUSSELL, S. L., VALLANCE, 
B. A. & FINLAY, B. B. 2011. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated 
citrobacter rodentium-induced colitis. Infection and Immunity, 79, 1536-1545. 
WONG, J. M. W., DE SOUZA, R., KENDALL, C. W. C., EMAM, A. & JENKINS, D. J. A. 2006. Colonic health: fermentation and short 
chain fatty acids. Journal of Clinical Gastroenterology, 40, 235-243. 
XIE, C. L., TANG, H. K., SONG, Z. H., QU, S. S., LIAO, Y. T. & LIU, H. S. 1988. Microcalorimetric study of bacterial-growth. 
Thermochimica Acta, 123, 33-41. 
XING, X., ZHAO, Y., KONG, W., ZHONG, Y., YAN, D., ZHANG, P., HAN, Y., JIA, L., JIN, C. & XIAO, X. 2011. Application of 
microcalorimetry and chemometric analysis. Journal of Thermal Analysis and Calorimetry, 109, 381-385. 
XU, J. & GORDON, J. I. 2003. Honor thy symbionts. Proceedings of the National Academy of Sciences of the United States of America, 
100, 10452-10459. 
YADAV, V., GAISFORD, S., MERCHANT, H. A. & BASIT, A. W. 2013. Colonic bacterial metabolism of corticosteroids. International 
Journal of Pharmaceutics, 457, 268-274. 
YANG, L. N., XU, F., SUN, L. X., ZHAO, Z. B. & SONG, C. G. 2008. Microcalorimetric studies on the antimicrobial actions of different 
cephalosporins. Journal of Thermal Analysis and Calorimetry, 93, 417-421. 
YEUNG, P. S. M., SANDERS, M. E., KITTS, C. L., CANO, R. & TONG, P. S. 2002. Species-specific identification of commercial 
probiotic strains. Journal of Dairy Science, 85, 1039-1051. 
YILDIRIM,  Z.  &  JOHNSON,  M.  G.  1998.  Characterization  and  antimicrobial  spectrum  of  bifidocin  B,  a  bacteriocin  produced  by 
Bifidobacterium bifidum NCFB 1454. Journal of Food Protection, 61, 47-51. 
ZAHARIA, D. C., MUNTEAN, A. A., POPA, M. G., STERIADE, A. T., BALINT, O., MICUT, R., IFTENE, C., TOFOLEAN, I., POPA, 
V. T., BAICUS, C., BOGDAN, M. A. & POPA, M. I. 2013. Comparative analysis of Staphylococcus aureus and Escherichia 
coli microcalorimetric growth. Bmc Microbiology, 13. 
ZHANG, G., FAN, M., LI, Y., WANG, P. & LV, Q. 2012. Effect of growth phase, protective agents, rehydration media and stress 
pretreatments on viability of Oenococcus oeni subjected to freeze-drying. African Journal of Microbiology Research, 6, 1478-
1484. 
ZHANG, H., DIBAISE, J. K., ZUCCOLO, A., KUDRNA, D., BRAIDOTTI, M., YU, Y., PARAMESWARAN, P., CROWELL, M. D., 
WING, R., RITTMANN, B. E. & KRAJMALNIK-BROWN, R. 2009. Human gut microbiota in obesity and after gastric 
bypass. Proceedings of the National Academy of Sciences U S A, 106, 2365-2370. 
ZHANG,  J.,  ZHANG,  X.,  YONG,  Q.,  XU,  Y.  &  YU,  S.  2008.  In  vitro  fermentation  characterization  of  low  concentration  of 
xylooligosaccharides prepared from corncob xylan by Bifidobacterium adolescentis. Proceedings of International Conference 
on Pulping, Papermaking and Biotechnology 2008: Icppb '08, I, 707-711.   280 
ZHAO, G. & ZHANG, G. 2005. Effect of protective agents, freezing temperature, rehydration media on viability of malolactic bacteria 
subjected to freeze-drying. Journal of Applied Microbiology, 99, 333-338. 
ZHAO, R. M., LIU, Y., XIE, Z. X., SHEN, P. & QU, S. S. 2000. A microcalorimetric method for studying the biological effects of La3+ 
on Escherichia coli. Journal of Biochemical and Biophysical Methods, 46, 1-9. 
ZHOU,  J.,  TUN,  T.  N.,  HONG,  S.  H.,  MERCER-CHALMERS,  J.  D.,  LAABEI,  M.,  YOUNG,  A.  E.  &  JENKINS,  A.  T.  2011. 
Development of a prototype wound dressing technology which can detect and report colonization by pathogenic bacteria. 
Biosens Bioelectron, 30, 67-72. 
ZHU, H., HART, C. A., SALES, D. & ROBERTS, N. B. 2006. Bacterial killing in gastric juice--effect of pH and pepsin on Escherichia 
coli and Helicobacter pylori. Journal of Medical Microbiology, 55, 1265-70. 
ZHU, W. M., LIU, W. & WU, D. Q. 2000. Isolation and characterization of a new bacteriocin from Lactobacillus gasseri KT7. Journal of 
Applied Microbiology, 88, 877-886. 
ZHU, Y., XIAO,  L., SHEN, D. & HAO, Y. 2010. Competition between yogurt probiotics and periodontal pathogens in vitro.  Acta 
Odontologica Scandinavica, 68, 261-268. 
ZOETENDAL, E. G., AKKERMANS, A. D. & DE VOS, W. M. 1998. Temperature gradient gel electrophoresis analysis of 16S rRNA 
from  human  fecal  samples  reveals  stable  and  host-specific  communities  of  active  bacteria.  Applied  and  Environmental 
Microbiology, 64, 3854-3859. 
ZOETENDAL, E. G., AKKERMANS, A. D. L., AKKERMANS-VAN VLIET, W. M., DE VISSER, J. A. G. M. & DE VOS, W. M. 2001. 
The  host  genotype  affects  the  bacterial  community  in  the  human  gastrointestinal  tract.  Microbial  Ecology in  Health and 
Disease, 13, 129-134. 
ZOETENDAL, E. G., VAUGHAN, E. E. & DE VOS, W. M. 2006. A microbial world within us. Molecular Microbiology, 59, 1639-1650. 